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The first section of this thesis describes the solid phase peptide synthesis of scotophobin, 
a small peptide thought to be responsible for the transference of a learned response between 
mammals, and several related peptides.  The synthetic peptides were tested against an array of G 
protein-coupled receptors.  Although interesting activity was observed, these studies failed to 
provide closure to the storied past of scotophobin.  We were able to demonstrate that the small 
peptide possesses in vitro activity. 
The second section describes the optimization of the thiol-mediated epoxide opening and 
intramolecular aldol reaction of epoxyketones.  This methodology provided access to a variety of 
densely functionalized bicyclo[3.3.1]non-3-en-2-ones in moderate to good yield (64-88%).  The 
newly synthesized bicyclo[3.3.1]non-3-en-2-ones were shown by a ChemGPS-NP analysis to 
occupy novel regions of chemical space.  In addition, they exhibited moderate activity in several 
assays.  
The third section describes our efforts toward the total synthesis of chrysophaentin A.  
Although the synthesis of the natural product has yet to be achieved, the convergent synthesis of 
the monomeric C1-C16 tetraphenol of chrysophaentin A was completed in 10 steps (longest linear 
sequence) and 24% overall yield.  The collaborative biological evaluation of two monomeric 
chrysophaentin A fragments revealed that they retained the potent antimicrobial activity of the 
parent natural product.  
The final section of this thesis describes the synthesis of three peptide-like inhibitors as 
well as several non-peptidic small-molecule inhibitors of botulinum neurotoxin serotype A light 
chain (BoNT/A LC).  In collaborative work, all three peptidic inhibitors were found to possess 
sub-µM activity.  X-ray crystallography was used to document the binding mode of one of the 
peptidic inhibitors on BoNT/A LC. 
Syntheses of Peptidic, Natural Product-inspired, and 
Heterocyclic Molecules as Biological Probes 
 
 Jared T. Hammill, PhD 
University of Pittsburgh, 2012
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1.0  THE SYNTHESIS OF SCOTOPHOBIN AND ANALOGOUS PEPTIDES VIA 
MICROWAVE ASSISTED SOLID PHASE PEPTIDE SYNTHESIS 
1.1 INTRODUCTION 
Peptides play a pivotal role in the fundamental physiological and biochemical functions of 
life, making them crucial to biological, medical, and pharmaceutical research; as such, they have 
been a major focus of synthetic chemistry for over a century.
1
 The first coupling of two amino 
acids was reported by Emil Fischer in 1901; however, the paucity of amino-protecting groups 
prohibited the synthesis of longer sequences.
2
 Over the course of the next fifty years, 
advancements in protecting groups and coupling agents led to synthesis of longer and more 
complicated peptides.  In 1954, du Vigneaud successfully synthesized the disulfide containing 
neurohypophysial nonapeptide hormone, oxytocin (Figure 1), an effort for which he later received 
the Nobel prize (1955).
3
   
 
 
Figure 1. Chemical structure of oxytocin. 
 
 The solution phase synthesis of oxytocin and larger peptides consisted of a series of 
repetitive coupling and deprotection steps, which required isolation and purification of each 
intermediate.  These endeavors proved to be both labor and time intensive.  In addition, solubility 
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and aggregation problems of growing peptide chains led to reduced coupling efficiency in the 
synthesis of longer peptides.  In 1963, Merrifield addressed some of these problems by reporting 
a new method for peptide synthesis, which employed the use of an insoluble support (Scheme 1).
4
    
 
 
Scheme 1. Merrifield's solid phase peptide synthesis 
 
Merrifield found that a chloromethylated copolymer of styrene and divinylbenzene 
possessed the requisite solubility and porous gel structure, which allowed penetration of reagents, 
especially in the presence of swelling solvents.  The copolymer (1.1) could be functionalized via a 
SN2 displacement of chloride with the corresponding triethylammonium salt of the first 
carbobenzyloxy (Cbz)-protected amino acid.  The amino protecting group was removed in the 
presence of hydrogen bromide (10% in glacial acetic acid) and converted to the free base (1.2) 
with triethylamine.  The free amine was then coupled to the subsequent amino acid using N,N-
dicyclohexylcarbodiimide (DCC) in DMF.
5
  The unwanted byproducts were effectively removed 
via thorough washing of the polymer, and the residual unreacted amine (1.3) was acetylated with 
acetic anhydride to reduce the level of free amine to <0.1%.  The process of coupling and 
deprotection was repeated until the full-length peptide was bound to the polymer, at which point 
cleavage from the resin was accomplished by saponification.  Purification of the peptide was 
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accomplished via chromatography on a Dowex 50-X4 column using a pyridinium acetate buffer 
(0.1 M, pH=4.0).
4
   
Solid phase peptide synthesis (SPPS) offers several important advantages over solution 
phase synthesis.  A large excess of activated amino acid and high reaction concentration allow the 
coupling to proceed more rapidly and nearly to completion.  Since excess reagents are removed 
by simple filtration and washing steps, SPPS eliminates the need for isolation and purification of 
intermediates.  In addition, due the ease of purification, reaction vessels have been developed 
such that the entire synthesis can be completed in the same vessel without the need for transfer, 
saving both time and material.   
Despite its advantages, SPPS presented some interesting challenges in the form of 
undesired side reactions during its infancy.  In addition, SPPS still suffered from epimerization 
problems. Activation of the acid can be accomplished through a variety of pathways (e.g., 
conversion to the acid halide, (mixed) anhydride, or activated ester).
6,7
  The increased acidity and 
electrophilicity of the activated amino acid however, promote both enolization and oxazolone 
formation (Scheme 2), which are the two most common causes of epimerization in peptide 
synthesis.
8
  Although a variety of coupling reagents and additives have been described to 
minimize epimerization and oxazolone formation,
6,7
 they have yet to be completely eliminated 
from peptide synthesis. 
 
 
Scheme 2. Common mechanisms of epimerization of an activated amino acid 
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A major breakthrough in peptide synthesis was the evolution of protecting groups.  One 
year after reporting his first protocol for SPPS, Merrifield introduced the use of the tert-
butoxycarbonyl (Boc)/Cbz protecting group scheme in a revised procedure.
9
  First introduced by 
the Carpino group in 1957,
10
 the Boc functionality served as an ideal temporary protecting group 
for the N-terminal amine.  N-Boc protected peptides allow for deacylation to occur under milder 
conditions (e.g., neat TFA), and thus decrease the loss of peptide from the resin.
9
  More 
permanent protection of side-chain functionality is accomplished using Cbz protecting groups, 
which are cleaved in the presence of stronger acids (e.g., anhydrous hydrofluoric acid).   
By incorporation of milder deprotection steps, changing the coupling solvent from THF 
to DMF, and altering the cleavage conditions, Merrifield’s revised protocol eliminated the need 
for the acetylation step, thereby dramatically decreasing the total reaction time for one cycle from 
over 24 h to 4 h with improved yields.
9,11,12
  These advancements allowed him to synthesize the 
octapeptide Bradykinin in an overall 68% yield in only 8 days.
11
  This was a substantial 
improvement, considering that only 10 years earlier, the synthesis of a nonapeptide was 
considered worthy of a Nobel prize. 
Although the Boc/Cbz protecting scheme was widely used to synthesize a number of 
peptides, it requires the use of HF.  Due to the extreme toxicity of HF as well as the requirement 
for HF-resistant equipment (e.g., polytetrafluoroethylene-lined) this method was and continues to 
be limited to specialists in the field.   
In 1970, Carpino et al. described the use of the 9-fluorenylmethoxycarbonyl (Fmoc) 
functionality as an acid stable amino protecting group which could be readily removed in the 
presence of mild base.
13
  This led to its incorporation into SPPS in 1978.
14
  The use of the 
orthogonal Fmoc/t-Bu protecting scheme allows for cleavage of the temporary Fmoc group under 
mild base conditions (20% piperidine in DMF).  In contrast, removal of the acid labile t-Bu 
protecting groups and cleavage from the resin can be accomplished simultaneously in the 
presence of TFA.   The main advantage of the Fmoc/t-Bu protecting scheme is that the orthogonal 
protecting groups are removed by different mechanisms; thus a milder acid may be used in the 
final deprotection step.
15
  Due to the mild reagents used, the Fmoc/t-Bu protecting scheme is 
more broadly applicable and has become the method of choice for most non-specialized 
laboratories.   
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Another major advancement in SPPS was the use of the microwave.  Microwaves first 
appeared in the organic synthesis literature around 1986, with the pioneering work of Gedye
16
 and 
Giguere
17
 who reported comparable or better yields and significantly reduced reaction times 
compared to conventional thermal conditions.  These early works were carried out in domestic 
kitchen microwave ovens.  Over the course of the last 30 years, laboratory-grade microwaves 
have become commercially available.  This new generation of single-mode microwave reactors 
provide built-in direct temperature control, magnetic stirring, and software for temperature and 
pressure control, which minimize the formation of local hot spots and has made the microwave a 
more viable option for a wide range of organic reactions.
18
   
It was not until 1991 that Wang et al. described the first use of microwave irradiation to 
increase the efficiency and reduce the reaction times associated with SPPS.
19,20
  This initial 
protocol proved to be difficult to reproduce as it called for the use of a modified commercial 
microwave.
20
 Today, commercially available microwave reactors, specifically designed for 
peptide synthesis, allow for the reaction times of coupling and deprotection steps to be reduced to 
mere minutes.  In addition, microwave irradiation reduces the amount of aggregation within the 
growing peptide chain, increasing the yields in longer sequences.  
 Although the use of microwaves have led to a significant improvement in the synthesis of 
milligram quantities of peptides, its viability for large-scale production of peptides remains 
unproven. One of the major challenges facing process scale-up of microwave technology is the 
transfer of heat to and from larger reaction vessels.  The penetration depth of microwave 
irradiation, although dependent on the dielectric properties of the solvent, is usually only a few 
centimeters.
21
  As such, reaction vessels exceeding 500 mL require larger microwaves with more 
sophisticated cooling systems, which introduce added size, complexity, and cost to reactors.  In 
addition, the efficiency of converting electricity into microwave power can be relatively low 
(70% or less) as well as the expense of the large excess of reagents, and resins generally used in 
SPPS, makes the use of microwaves less attractive for large scale preparation of peptides.  
Microwave assisted SPPS also suffers from some more general challenges associated with 
solid-phase synthesis. While solid-phase synthesis methods are now considered well developed, a 
number of significant challenges still remain.  Variability in the characteristics of the resin used, 
as well as the substitution levels and distribution of the sites for attachment of the peptide, can 
dramatically affect both the coupling and deprotection steps.
22
  Therefore, improved methods of 
synthesis and characterization of different resins are imperative to improving the reproducibility 
of SPPS.  Furthermore, although several techniques to monitor the coupling and deprotection 
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steps during SPPS have been described, most are implemented qualitatively and suffer the 
requirement for irreversible consumption of material.  This inevitably leads either to loss of 
peptide-resin during testing or the potential for incomplete reactions, which lead to the formation 
of deletion peptides and truncated sequences that complicate final product purification.  In 
addition, the inability to isolate and purify intermediates and potential for several residue or 
sequence-specific side reactions (i.e., diketopiperazine or aspartimide formation) further 
complicate the final purification process and can make the preparation of high-purity samples 
very challenging.  Thus, although solid-phase peptide synthesis has evolved tremendously in the 
past 40 years, and the incorporation of microwaves has elevated it even further, it is clear a 
number of challenges still remain. 
1.2 SYNTHESIS OF SCOTOPHOBIN AND RELATED ANALOGUES 
The concept of memory transfer, or that a memory could be transferred from one 
organism to another, has been of great interest to scientists for decades.  The first step towards the 
realization of this concept is to develop an understanding of how the brain stores information.  In 
the 1950’s, several theories emerged pertaining to the mechanism by which the brain processes 
and stores the rich variety of experiences we incur during the course of our lifetime.
23
  One of the 
first detailed theories was proposed by Katz and Halstead.
24
  They recognized several pieces of 
empirical evidence: neuronal membranes contain proteins, neurons have a high rate of protein 
synthesis, some protein denaturants stimulate neurons, specifically arranged proteins have the 
potential to conduct electricty, and finally that protein content is lower in people with mental 
disorders.
24
  This empirical data led Katz and Halstead to conclude that proteins played a pivotal 
role in both axonal conduction and memory storage.  Their theory postulated that neuronal 
proteins are arranged in rough lattices that, when induced by a stimulus, could undergo 
conformational changes which elicit downstream neurotransmitter release.  Trans-synaptic 
transmission of these proteins establishes new neural networks and thus creates a “memory” of 
the stimulus.  The theory also postulated that each new experience causes certain neurons to 
synthesize a novel protein, which acts as a template for self-replication.  These new proteins can 
aggregate to form lattices each with a unique pattern of activation and propagation leading to the 
creation of new neural networks.
25
  Although the emipirical evidence in hand at the time would 
  7 
seem to support this hypothesis, the scarcity of methods for further evaluation and testing 
required the development of new experimental techniques.   
In 1962, McConnell provided empirical evidence in the form of a memory transfer 
experiment.  In this experiment, he classically conditioned planaria, pulverized them and fed them 
to a second batch of planaria, which “subsequently showed a saving upon learning the same task” 
as compared to a control group.
25
  However, this and other planarian experiments faced two major 
points of criticism:  there was insufficient evidence to support the hypothesis that invertabrates 
could in fact learn, and no group had demonstrated specificity in their memory transfer 
experiments.
25
  It was not until 1965 that the first examples of memory transfer in mammals 
appeared in the literature.  Four different reports were published in 1965;
26-29
 in three of the four 
reports RNA was hypothesized to be the transfer unit, while in the study conducted by Unger and 
Oceaguera-Navarro a small peptide was hypothesized to conduct the transfer.
29
  Being versed in 
stimulation-induced changes in protein structure and function in nerve proteins, Unger was most 
likely familiar with the hypotheses put forth by Katz and Halstead and very interested in 
contributing to the new memory transfer paradigm.  
Unger’s early work in this area focused on the transfer of morphine tolerance in rats.25 
bThis initial success led him to attempt the transfer of a learned behavior, giving rise to to his 
1965 Nature publication
29
 and fueling his interest in the subject.  In this publication, Unger and 
Oceaguera-Navarro conditioned the startle response of rats by repeatedly exposing them to a loud 
noise.  After several days of habituation, the rats’ brains were removed, homogenized, and 
injected intra-peritoneally into mice.  These mice exhibited significantly faster habituation to the 
same noise as compared to a control group injected with the brains of untrained rats.  The most 
important aspect of this work was that in direct contrast to the three other groups publishing 
memory transfer papers that year, Unger and Oceaguera-Navarro indentified the transfer unit to 
be a protein.  The authors demonstrated that the transfer effect was eliminated by incubating the 
brain homogenate in chymotrypsin, and it persisted when the brain homogenate was incubated in 
ribonuclease, clearly supporting the hypothesis that a protein or peptide, not RNA, was 
responsible for the transfer effect.
29
  This and the other results published in 1965 prompted a 
flurry of attempts to repeat the memory transfer experiments.  The majority of these attempts 
however, were met with very little success.   
One of the main criticisms in this field was always the lack of specificity.  Thus Unger, in 
a set of follow-up startle experiments, showed that mice receiving extracts from loud noise 
habituated rats showed faster habituation only to the sound and not to an air-puff, whereas the 
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opposite was true for those mice receiving the extracts of air-puff habituated rats.
25
  These studies 
were quickly followed by two papers, one of which presented his theory on the molecular basis 
for memory and a second, which became the most well-known publication of his career.   
In the first paper, Unger outlined his theory, which stated that when a pre-synaptic neuron 
fired it released a “connector” assumed to be a small peptide.30  This peptide was then taken up by 
a nearby post-synaptic neuron establishing a unique connection between the two neurons and thus 
establishing a new neural network.  Repeated connections between the neurons could strengthen 
the signaling pathway and each neural network in the brain (sensory, motor, etc.) had its own 
“connector”.   If these connections were uniquely involved in specific behaviors, it follows that 
certain molecules could be specific to these circuits.  Therefore, these molecules could essentially 
act as a code for the circuit and by extension the specific behavior. 
The second paper, which Unger published in 1968 provided experimental evidence to 
support his hypothesis.
31
 Unger reported another set of memory transfer experiments, this time 
using a previously described
32
 dark avoidance task.  In this experiemtent, rats were placed in a 
two-compartment apparatus (Scheme 3).  One compartment remained illuminated while the other 
remained in darkness.   
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Scheme 3. Cartoon representation of Unger's transfer experiment 
 
Upon entering the dark compartment, the rats received an electric shock, causing them to 
return to the lighted compartment.  This training was repeated five times a day, for a varying 
number days until the rats spent significantly less time in the dark compartment.  Once “trained”, 
the rats’ brains were removed, homogenized, and subjected to various extractions before being 
intra-peritoneally injected into mice.   Upon entering the same two-compartment apparatus, the 
mice that received extracts from the brains of trained rats spent significantly less time in the dark 
compartment than mice receiving extracts from the brain of an untrained rat.
29
  In addition, the 
authors investigated the chemical composition of the extracts and identified a small peptide as 
being responsible for the transfer effect.  This was an astounding feat since at the time the origin 
of the transfer effect was being debated at the macroscopic level between peptides and RNA.  
Meanwhile, Unger had not only provided empirical evidence supporting his hypothesis that 
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peptides were the transfer unit, he went further to propose that a single peptide was responsible.  
This result received much attention in both the scientific and public communties as evident by a 
Time magazing article describing Unger and his work.
25
   
Over the course of the next several years, a number of attempts to reproduce Unger’s 
results were published with mostly negative or inconclusive outcome.  However, approximately 
five years after his initial study, Unger revealed the identity of his peptide to be a pentadecamer, 
which he named scotophobin (derived from the ancient greek terms skotos and phobos meaning 
fear and darkness).
25
  Subsequently, several isolation, characterization, and synthetic studies led 
to the confirmation of the final pentadecamer structure (Figure 2).   
 
 
Figure 2. Structure of scotophobin 
  
Unger willingly provided samples of the peptide to a variety of groups for testing with 
mixed results in different animal models.
33-35
  Scotophobin has been synthesized both by 
traditional solution phase organic chemistry and utilizing Merrifield’s SPPS techniques.  
Problems with reproducibility caused the topic, which had thrived in the 50’s-70’s, to quickly 
vanish.  The last study involving scotophobin was published in 1979, one year after Unger’s 
death.   In a 1978 article,
36
  Irwin, a former co-worker and colleague, observed “in the long run it 
was not confusion over the biochemical identity of the transfer factors…which most damaged the 
crediblility of the transfer paradigm, but simply the unreliability of the phenomen.”  
Later, in a 1986 scientific correspondence published in Science, Irwin noted the sequence 
homology scotophobin shares with several known neuropeptides or their precursors (Table 1).  In 
particular, scotophobin shares sequence homology with MSEL-neurophysin, which is known to 
be associated with two hormones, oxytocin and vasopressin.
37
  Oxytocin and vasopressin are 
associated with female reproduction and the body’s retention of water, respectively.  
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Table 1. Comparison of sequence homology between scotophobin and several known neuroactive peptides. 
 
*Numbers in parentheses give the number of residues along polypeptide chain from amino terminal end. “NH2” 
indicates an amino terminal end.  Bold amino acids indicate sequence homology with scotophobin. 
 
Interestingly, the pentadecamer scotophobin has an amino-terminal peptide triplet that is 
identical to the enkephalins. The enkephalins are naturally occuring pentameric peptides known 
as endogenous opiods, which have potent painkilling effects and are released by neurons in the 
central nervous system and by the cells in the adrenal medulla.
38
  Sequence homology is also 
observed with β-lipotropin, which is part of a family of closely related peptides that exert 
modulatory effects on the neuromuscular function, including important components of motor 
pathways.
39
  Interestingly, Irwin notes that there appears to be an evolutionary relationship 
between substance P precursor and scotophobin, as judged by the stability of the sequence 
similiarity under simulated evolutionary change.
40
  Substance P is an important element in pain 
perception, and has been associated with the regulation of mood disorders, anxiety, and stress.
41
  
It is interesting to note the sequence homology scotophobin shares with these particular 
neuropeptides. Considering scotophobin is associated with rats that were trained by undergoing 
an extended and stressful training, including footshock, one could expect certain structural 
similiarites with related known neuropeptides and their precursor fragments associated with the 
processing of information concerning pain in the nervous system.  In light of the observed 
sequence homology and the now widely accepted view that certain neuropeptides play imporant 
roles as neurotransmitters and as modulators of brain function and behavior,
40
 our group decided 
to reassess scotophobin’s potential as a neuroactive peptide.  
Considering the major advancements in peptide synthesis, purification and 
characterization since the final experiments with scotophobin in 1979,
25
 we felt that we would be 
able to provide peptide samples of superior quality.  Furthermore, by testing the synthetic 
scotophobin and anaologous portions of known neuroactive peptides against an array of G-protein 
coupled receptors (GPCRs,) through a collaboration with Dr. Bryan Roth and the NIMH 
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Psychoactive Drug Screening Program at the University of North Carolina at Chapel Hill, we 
hoped to avoid the irreproducibility problems exhibited in various animal models. 
G-protein coupled receptors (GPCRs) are the largest family of cell-surface receptors, and 
transduce signals mediated by a wide variety of both endogenous and exogenous signalling 
molecules, including peptides, to mediate alterations of intracellular function.
42
  These receptors 
control key physiological functions, including neurotransmission, hormone and enzyme release 
from endocrine and exocrine glands, cardiac and smooth muscle contraction, and nociception, or 
perception of a painful stimulus to name a few.
43
  GPCRs have also been associated with the 
modulation of anxiolytic activity.  Thus, one would expect scotophobin, a molecule proposed to 
be responsible for the transferrence of a conditioned response to an extended stressful and painful 
training, could stimulate one or more GPCRs.   
1.3 FIRST GENERATION APPROACH TOWARDS SCOTOPHOBIN 
Initial attempts to synthesize scotophobin utilized manual microwave assisted solid phase 
peptide synthesis conditions previously optimized by a former post-doctoral researcher, Dr. 
Abhisek Banerjee.  These conditions exploited the use of Fmoc protected amino acids, Rink 
amide SS resin
44
 (Figure 3), and the combination of PyBOP
45
 and HOBt
46
 for activation of the 
acid.  Cleavage from the resin was accomplished using a modified version of Reagent K
47
 (89.5% 
TFA, 3.0% thioanisole, 2.5% phenol, 0.5% H2O, 4% triisopropylsilane) and after work-up the 
crude peptides were purified by preparative RP HPLC. Using these conditions, scotophobin was 
successfully synthesized, as confirmed by Edman degradation; unfortunately this method of 
preparation resulted in an unacceptable 3% overall yield.  Therefore, further optimization of the 
synthesis was required.  
 
 
Figure 3. Rink amide resin (polystyrene (1% cross-linked with DVB) shown as gray sphere).44 
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SPPS consists of three different types of reactions: deprotection, coupling, and 
cleavage/global deprotection (Scheme 4).  As most publications describe the use of a 20% 
piperidine solution in DMF for the deprotection of the Fmoc protecting group,
47
 we focused on 
the optimization of the  coupling and cleavage/global deprotection steps. 
 
 
Scheme 4. Cartoon representation of SPPS 
1.3.1 Optimization of the Coupling Reaction 
In SPPS, the preferred reagents for the in situ activation of a carboxylic acid are either 
phosphonium based salts such as PyBOP
45
 and PyAOP
48
, or uronium/aminium based salts such as 
HATU
49
 or HBTU
49
 (Figure 4).
15,47
   In addition, the use of additives such as HOBt or HOAt is 
known to enhance reactivity while decreasing the rate of epimerization via formation of the 
OBt/OAt ester, which stabilize the approach of the amine via H-bonding.
6,7
 
Since the application of Dr. Banerjee’s conditions, utilizing PyBOP, in the presence of 
HOBt, provided an unacceptable yield, the use of the more active PyBrOP
50
 was investigated.  
However, due to its reportedly higher rate of epimerization,
6
 HOBt was added to the reaction 
mixture, most likely leading to the in situ formation of PyBOP.  Gratifyingly, the use of PyBrOP 
and HOBt increased the overall yield  to 10%, but still left room for improvement.   In 1999, the 
Goodman group described a new coupling reagent: 3-(diethoxyphosphoryloxy)-1,2,3-
benzotriazin-4-(3H)-one (DEPBT) (Figure 4).
51
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Figure 4. Commonly used activating reagents and additives. 
 
 In this initial report, Goodman et al. demonstrated the superiority of DEPBT as compared to 
PyBrOP, HATU, and HBTU in racemization studies, while exhibiting comparable or improved 
yields.
51
  Thus, employing DEPBT as the activating agent, in the absence of additives, increased 
the overall yield to 25% (Table 2).  Satisfied with an almost 10-fold improvement in overall yield, 
DEPBT was used as the activating agent in all subsequent couplings.   
 
Table 2. Screen of activating agents for synthesis of scotophobin.a 
 
aAll syntheses were completed using 3.5 equiv of both the coupling reagent and the additive. Final deprotection was 
accomplished via stirring in a modified version of Reagent K (89.5% TFA, 3.0% thioanisole, 2.5% phenol, 0.5% 
H2O, 4% triisopropylsilane) for 2 h at rt. The crude peptides were purified via RP HPLC. *Yields are determined 
assuming the initial loading of the resin to be 0.7 mmol/g. 
 
1.3.1.1 Synthesis of the Goodman Reagent 
 
Although initially purchased from a commercial vendor, the Goodman reagent was 
subsequently synthesized according to a known protocol (Scheme 5).
51
  The commercially 
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available methyl anthranilate was treated with hydroxylamine hydrochloride and sodium 
hydroxide in methanol/water to afford hydroxamic acid 1.4 in 77% yield.  Treatment of 1.4 with 
sodium nitrite and hydrochloric acid in water provided 3-hydroxy-1,2,3-benzotriazin-4 (3H)-one 
(1.5) in 82% yield.  1.5 was subsequently converted to DEPBT (1.6) in the presence of ethyl 
chlorophosphate and triethylamine in CH2Cl2 in 77% yield.  
 
 
Scheme 5. Synthesis of the Goodman reagent 
 
1.3.2 Optimization of Cleavage and Global Deprotection 
Next, attention was directed toward the optimization of the cleavage and global 
deprotection steps.  The treatment of a peptidyl resin with a cleavage cocktail is not one simple 
reaction, but a series of competing reactions.  Unless suitable reagents and reaction conditions are 
selected the peptide will be irreversibly modified or damaged.  The overall nature of the cleavage 
cocktail is dependent on the linker.  The Rink Amide SS resin requires the use of high 
concentration TFA solutions.  Cleavages in these solutions lead to the formation of carbonium 
ions and other reactive intermediates.  Hence, the appropriate mixture of scavengers is critical for 
the minimization of undesired side reactions, and has been shown to have a large effect on the 
purity of the isolated peptides.
52
  A variety of widely used TFA cleavage cocktails were 
investigated (Table 3).
47,52
  In addition, Dr. Banerjee’s optimized cocktail, herein referred to as 
Reagent A, was examined.  This cocktail is a modified version of Reagent K and possess a 
slightly different ratio of reagents, as well as the exclusion of the malodorous 1,2-ethanedithiol 
(1,2-EDT), and addition of triisopropylsilane (TIS), which has been shown to be especially useful 
in the presence of more sensitive peptides.
53
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Scotophobin was synthesized according to the Fmoc/t-Bu protecting scheme and utilizing 
DEPBT as the activating agent.  Following the final deprotection of the Fmoc group, the resin 
was dried, split into four batches, and subjected to a specific cleavage cocktail for 2 h at rt.  
Purification was accomplished via RP HPLC and yields were determined assuming a 
homogenous peptide distribution on the resin (Table 3). 
  
Table 3. Optimization of cleavage/global deprotection conditions and composition of the cocktails exploreda 
 
aRows correspond to the ratio of components.  Peptide sythesis was accomplished using DEPBT (3.5 equiv) as the 
activating agent.  Following the final deprotection of the Fmoc group, the resin was dried, split into four batches, and 
subjected to the specific cleavage cocktail for 2 h at rt. Purification was accomplished via RP HPLC. *Yields are 
determined assuming the peptide is homogenously dispersed on the resin and an initial loading of 0.7 mmol/g. 
*Reagent A refers to a modified version of the Reagent K, which was optimized by Dr. Banerjee.  
 
Examination of the data revealed that Reagent A gave superior yields.  Although, 
significant improvement in isolated yield was observed, examination of the HPLC traces (Figure 
5) following cleavage/global deprotection revealed a large number of side products or deletion 
sequences.  Thus, the coupling and deprotection reactions were not proceeding smoothly and 
further optimization was required. 
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Figure 5.  HPLC traces of crude peptide resulting from the evaluation of the different cleavage cocktails using a 
linear gradient of 30-80% buffer B in A (A: water containing 0.1% TFA, B: acetonitrile containing 0.1% TFA) over 
45 min with UV detection at 220 nm at a flow rate of 2 mL/min. 
 
1.3.3 Final Optimization 
After optimizing the coupling and cleavage/global deprotection steps, focus turned to the 
refinement of the microwave conditions.  The microwave conditions used to this point had been 
optimized by Dr. Banerjee for the solid phase synthesis of hybrid molecules containing both a 
trimeric peptide and a spiroketal modified steroid.
54
  Although these conditions afforded high 
yields during the synthesis of the hybrid molecules, the low yield observed for the synthesis of the 
pentadecameric scotophobin, suggested further refinement was needed.  After a series of 
discussions with Dr. Kazi Islam of the Peptide Synthesis Core of the Clinical and Translational 
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Science Institute of the University of Pittsburgh, the use of a new set of microwave conditions, 
which had proven successful in his laboratory, were investigated.  
These new conditions involved modification of both the coupling and deprotection 
reactions.  Starting from the the previously optimized microwave conditions (40 W, 70 ºC, 5 
min), it was discovered that decreasing the wattage to 25 W significantly reduced the propensity 
for temperature spikes during the course of the reaction.  Thus, the formation of unwanted side-
products was diminished.  However, in order to maintain coupling efficiency, the reaction 
temperature was increased to 80 ºC.  The wattage for the deprotection step was also reduced from 
50 W to 35 W in an effort to decrease potential epimerization and other side reactions which can 
take place under the basic deprotection conditions.  However, as with the coupling, in order to 
ensure complete deprotection the temperature was increased from  50 ºC to 78 ºC.  
 The composition of final cleavage cocktail was also further refined.  An examination of 
the literature revealed that the presence of sulfur containing residues can lead to the formation of  
disulfide bonds or sulfoxides.
52
  Thus, in an effort to make Reagent A more generally applicable, 
it was slightly modified to include 1,2-EDT.
52
  Therefore, the final cleavage cocktail consisted of 
TFA (87.5%), PhSCH3 (3.5%), 1,2-EDT (2%), PhOH (3.5%), H2O (2%), and TIS (1%). 
Applying the fully optimized conditions to the synthesis of scotophobin, the crude peptide 
was obtained in considerably higher purity (Figure 6).  It should be noted that direct comparison 
of the HPLC traces is not possible, as the two runs were performed under different conditions.  
The fully optimized procedure required a more shallow gradient to obtain a significant degree of 
separation.   
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Figure 6. Comparison of crude peptide purity when using the unoptimized microwave conditions and Reagent A 
(left) and the fully optimized procedure (right).  Note: direct comparisons cannot be made since analyses used 
slightly different conditions: Left conditions: a gradient from 30% Organic (0.1% TFA in CH3CN) and 70% Aqueous 
(0.1% TFA in H2O) to 80% Organic (0.1% TFA in CH3CN) and 20% Aqueous (0.1% TFA in H2O) over 45 minutes. 
Right: a gradient from 30% Organic (0.1% TFA in CH3CN) and 70% Aqueous (0.1% TFA in H2O) to 60% Organic 
(0.1% TFA in CH3CN) and 40% Aqueous (0.1% TFA in H2O) over 60 minutes. 
 
Scotophobin, and fragments of both β-lipotropin and substance P precursor were 
synthesized using the optimized SPPS conditions (Table 4).  In addition, a fourth analogue 
composed of residues 8-15 of scotophobin was synthesized to aid in characterization as well as to 
help identify the active portion of scotophobin.  The structure of the newly synthesized peptides 
was confirmed by 1D and 2D NMR experiments as well as HRMS analysis. 
 
Table 4. Synthesis of scotophobin and related analogues. 
 
aAll peptide synthesis was completed on 0.100 mmol scale. bYields were determined assuming an initial loading of 
0.7 mmol/g. 
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Scheme 6. Synthesis of scotphobin (SDNNQQGKSAQQGGY, JTH-NB72-40) 
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Scheme 7. Synthesis of substance P precursor fragment (SDTKHRKHSLQGHGY, JTH-NB72-41) 
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Scheme 8. Synthesis of β-lipotropin fragment (VLPTQSKESTMFGGY, JTH-NB72-42) 
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Scheme 9. Synthesis of residues 8-15 of scotophobin (KSAQQGGY, JTH-NB72-60) 
1.4 BIOLOGICAL RESULTS 
Approximately 10 mg of scotophobin and the other analogues (Table 4) were sent to our 
collaborator Dr. Bryan Roth of the Pharmacology department at the University of North Carolina 
School of Medicine.  Each compound was screened for radioligand binding inhibition of 
approximately 50 different G-protein coupled receptors (GPCRs).  The primary assays were 
conducted at 10 µM and the data represents a mean percent inhibition of radioligand binding 
(N=4 determination) for compound tested at the receptor subtypes.  Radioligand binding 
inhibition is considered significant in primary assays exhibiting 50% or greater inhibition of 
radioligand binding to the receptor.  If significant binding inhibition was observed during the 
primary assay, a second, dose-response radioligand binding inhibition assay was used to 
determine the substrate’s binding affinity (Ki).  Although each peptide was tested against 
  24 
approximately 50 GPCRs, only results that exhibited significant radioligand binding inhibition in 
primary assays will be discussed herein. 
 The portion of the substance P precursor peptide (JTH-NB72-41) exhibited no activity 
against any of the screened receptors.  The portion of β-lipotropin, JTH-NB72-42, exhibited 56% 
inhibition of radioligand binding to the kappa opioid receptor at 10 µM.  The kappa opioid 
receptors are widely distributed throughout the brain, spinal cord, and in pain neurons and are 
associated primarily with nociception, or perception of a painful stimulus.
55
  A secondary assay 
confirmed its activity and determined JTH-NB72-42’s Ki to be 2.7 µM (Figure 7).  In addition, 
JTH-NB72-42 exhibited 54% inhibition of radioligand binding to the opioid Sigma 2 receptor at 
10 µM.  The function of the sigma receptors are not yet clearly defined, however, they have been 
shown to be involved in neurotransmitter release, modulation of neurotransmitter receptor 
function, learning and memory processes, and regulation of movement and posture.
56
 A 
secondary binding assay revealed that JTH-NB72-42 possessed a Ki of 6.7 µM (Figure 7).   
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Figure 7. Secondary radioligand binding inhibition assay results for JTH-NB72-42 (shown in red).57 
 
In a primary assay, synthetic scotophobin (JTH-NB72-40) exhibited 76% inhibition of 
radioligand binding to the serotonin (5-hydroxytryptamine) receptor 5-HT1A at 10 µM.  5-HT1A is 
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known to be expressed in regions of the brain (e.g., cerebral cortex, hippocampus, amygdala, etc.) 
that are associated with the limbic system and are known to support a variety of functions 
including emotion, behavior, and memory.
55
  In addition, agonists of the 5-HT1A receptor (i.e., 
buspirone, flesinoxan, etc.) have been shown to exhibit anxiolytic and antidepressant activity.
55
  
A secondary binding assay however, revealed that the Ki of synthetic scotophobin was in fact 
greater than 10 µM (Figure 8).   
 In another primary assay, JTH-NB72-40 exhibited 67% inhibition of radioligand binding to 
the adrenergic Alpha1D receptor at 10 µM.  The adrenergic receptors mediate the diverse effects 
of the neurotransmitters of the sympathetic nervous system, norepinephrine, and epinephrine, at 
virtually all sites throughout the body.
55
  Specifically, the Alpha1D receptor is associated with 
smooth muscle contraction.  A secondary assay revealed confirmed this activity and revealed 
synthetic scotophobin possessed a sub-micromolar Ki of 0.7 µM (Figure 8).  
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Figure 8. Secondary radioligand binding inhibition assay results for JTH-NB72-40 (shown in red).58  
 
Interestingly, the truncated version of scotophobin (JTH-NB72-60) also demonstrated 
inhibitory activity against 5-HT1A in a primary binding assay (69% inhibition of radioligand 
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binding at 10 µM).  Once again, a secondary assay revealed that JTH-NB72-60 possessed a Ki 
greater than 10 µM (Figure 9).  JTH-NB72-60 exhibited 62% inhibition of radioligand binding to 
the kappa opioid receptor at 10 µM.  The secondary assay however, revealed JTH-NB72-60’s Ki 
to be greater than 10 µM (Figure 9). 
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Figure 9. Secondary radioligand binding inhibition assay results for JTH-NB72-60 (shown in red).59  
 
In addition to screening their binding affinities, both JTH-NB72-40 and JTH-NB72-60 
were screened for agonist/antagonist activity at 10 µM against several metabotropic glutamate 
receptors (mGluRs) (Table 5).  The reported results for each compound are calculated for agonists 
as the percent of maximal activity (as obtained with maximal agonist concentrations) and for 
antagonist as the percent of inhibition of receptor activity (in presence of an EC50 concentration of 
the agonist).  mGluRs are generally involved in the tuning of glutamatergic synapses, GABA-
ergic, dopaminergic, and serotonergic synapses.  As such, these receptors are common targets for 
therapeutic drugs associated with anxiety, pain, ischaemia, Parkinson’s disease, epilepsy, and 
schizophrenia.   
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Both JTH-NB72-40 and JTH-NB72-60 exhibited antagonistic activity of mGluR5 (68% 
and 67% inhibition respectively), which is associated with increasing neuronal excitability, pain 
sensitivity, anxiolytic activity, and even nootropic (cognitive enhancing) effects.
55,60
  JTH-NB72-
60 also exhibited agonistic activity of mGluR6, which is exclusively located in a single cell type 
of the retina.  The receptor is responsible for the hyperpolarization of the these cells in the dark, 
when glutamate is released from the rod or cone photoreceptor.
55
  Most intriguingly, both JTH-
NB72-40 and JTH-NB72-60 exhibited antagonist activity against mGluR8 (74% and 76% 
inhibition respectively).  Recently activation of mGluR8 has been shown to provide powerful 
inhibitory control of synaptic transmission within the lateral amygdala, with the ability to reduce 
activity in such a way that the expression and the acquisition of a learned fear become strongly 
impaired in vivo.
61
  
 
Table 5. Agonist/antagonist activity of JTH-NB72-40 and JTH-NB72-60 against several metabotropic glutamate 
receptors at 10 µM.62  
 
The reported results for each compound are calculated for agonists as the percent of maximal activity (as obtained 
with maximal agonist concentrations) and for antagonist as the percent of inhibition of receptor activity (in presence 
of an EC50 concentration of the agonist). 
1.5 CONCLUSIONS 
Starting from the previously optimized conditions, improvement of the coupling and 
cleavage/global deprotection steps, as well as refinement of the microwave irradiation conditions 
led to almost a 10-fold improvement in overall yield of the pentadecameric scotophobin as well as 
a dramatic increase in crude peptide purity.  The optimized protocol was successfully applied to 
the synthesis of scotophobin as well as several other analogues.  Through a collaboration with Dr. 
Byran Roth’s lab and the NIMH Psychoactive Drug Screening Program, these compounds were 
tested for radioligand binding inhibition against an array of GPCRs as well as agonist/antagonist 
modulation of several mGluRs.  
  28 
Considering scotophobin’s association with rats that have undergone an extended and 
stressful training, including footshock, one might expect the observed activity in relation to 
known modulators of anxiolytic and antidepressant activity.  In addition, the activity observed 
with modulators of pain sensitivity and even receptors specifically associated with the acquisition 
of a learned fear is very intriguing.  Although the data does not confirm the hypothesis that the 
transfer of a learned response exhibited in Unger’s studies was a result of the administration 
scotophobin, it demonstrates that a pure synthetic sample of scotophobin does possess in vitro 
neuropeptidic activity.   
1.6 EXPERIMENTAL 
N,N-Diisopropylethylamine was sequentially distilled from ninhydrin then KOH and 
stored under argon.   Piperidine was distilled from CaH2 and stored under argon.  Phenol was 
purified by dissolving the solid in diethyl ether, washing with a saturated aqueous solution of 
NaHCO3 (3x), extracting with aqueous NaOH (0.1 M) (3x), acidifying with 0.1 N HCl, extracting 
with Et2O (3x), concentrating under reduced pressure, and the dry solid was stored under argon. 
N,N-dimethylformamide was purchased from Alfa Aesar as anhydrous and amine free in 4 L 
quantities and stored in 1 L amber bottles (dried overnight in an oven at 140 ºC) over activated 4 
Å molecular sieves and under argon.  Trifluoroacetic acid (biochemical grade, 99.5+% pure) was 
purchased from Alfa Aesar and used as received.  Methanol (HPLC grade), water (HPLC grade), 
and thioanisole (99% purity) were purchased from Aldrich and used as received.  
Triisopropylsilane (99% pure) was purchased from Acros and used as received.  1,2-ethanedithiol 
(>98% pure) was purchased from Fluka and used as received.  All natural Fmoc-protected amino 
acids and 3-(diethoxy-phosphoryloxy)-3H-benzo[d][1,2,3] triazin-4-one were purchased from 
either Peptides International or Advanced Automated Peptide Protein Technologies (AAPPTEC) 
and used as received.  Unnatural Fmoc protected amino acids and Rink Amide Resin SS, 100-200 
mesh, 1% DVB (catalogue #: SA5030) were purchased from Advanced Chemtech and used as 
received.  BD Falcon BlueMax 50 mL Graduated tubes and 25 mm syringe filters with a 0.45 µm 
nylon frit were purchased from Fischer Scientific.   
The Fmoc-solid phase peptide syntheses were performed on a CEM Discover manual 
microwave peptide synthesizer fitted with a fiber-optic temperature probe.  Solid phase peptide 
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syntheses were performed in a 25 mL polypropylene reaction vessel.  The 25 mL polypropylene 
reaction vessel was constructed by inserting a Teflon ring (0.4 mm height, 2.1 mm outer diameter, 
1.8 mm inner diameter) into a capped 25 mL SPE reservoir purchased from Grace Davison 
Discovery Science (Catalogue #: 210425) containing a frit purchased from Grace Davison 
Discovery Science (Catalogue #: 211416) (Figure 10).  
 
 
Figure 10. Diagram of assembled 25 mL polypropylene reaction vessel. 
 
Preparative reverse phase HPLC purifications were performed on a Gilson HPLC system 
with 220 and 254 nm UV detection, using a Phenomenex Luna 5µ C18(2) 100 Å, AX (75 x 30.0 
mm) column at a flow rate of 10 mL/min.  Unless otherwise noted, all preparative runs used 
linear gradients of 30-60% buffer B in A (A: water containing 0.1% TFA, B: CH3CN containing 
0.1% TFA) over 30 min.  Analytical HPLC traces of final products were performed on a Gilson 
HPLC system with 220 and 254 nm UV detection, using a Varian Microsorb 100-3 C18 (100 x 
4.6 mm) column at a flow rate of 0.7 mL/min.  Unless otherwise noted, all analytical runs used 
linear gradients of 30-100% buffer B in A (A: water containing 0.1% TFA, B: MeOH) over 70 
min.  CD Spectra were recorded on a Jasco J-815 Circular Dichroism Spectrometer.  Unless 
otherwise noted, all CD spectra were recorded in MeOH at a concentration of 0.5 mmol, at 298 K, 
over a range of 300-200 nm, at a scan rate of 50 nm/min.  Mass spectra were obtained using an 
ABI 4800 MALDI TOF/TOF instrument with 2,5-dihydroxybenzoic acid as the matrix in the 
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positive ion mode.  Lyophilization was accomplished using a Labconco FreeZone 4.5 liter 
benchtop freeze dry system.   
Proton and carbon NMR spectra were recorded using a Bruker Avance spectrometer at 
600 MHz/150 MHz (
1
H NMR/
13
C NMR) in D2O (298 K), unless otherwise noted.  Chemical 
shifts (δ) are reported in parts per million (ppm) using MeOH solvent peaks as an internal 
reference (referenced to 3.34 ppm (
1
H) and 49.5 ppm (
13
C)).  
1
H NMR data are reported as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, qd = quartet of 
doublets), coupling constants (J) in Hertz (Hz), and integration.  
13
C NMR spectra were obtained 
using a proton-decoupled pulse sequence with d1 of 6 sec, and are tabulated by observed peak. 
A stock solution of the coupling base was prepared by dissolving DIPEA (1.74 mL, 1.00 
mmol) in DMF (5.00 mL) to give a 0.148 M solution.  A stock solution of the Fmoc-cleavage 
base was prepared by dissolving piperidine (1.00 mL, 10.1 mmol) in DMF (4.00 mL) to give a 
2.02 M solution.  A stock solution of the resin cleavage cocktail was prepared by combining TFA 
(5.07 g, 44.5 mmol), PhSCH3 (0.210 g, 1.69 mmol), PhOH (0.215 g, 2.28 mmol), TIPSH (0.0620 
g, 0.392 mmol), 1,2-EDT (0.135 g, 1.43 mmol) and H2O (0.100 g, 5.56 mmol).  All stock 
solutions were freshly prepared prior to use.   
1.6.1 General Procedure A: Solid Phase Peptide Synthesis.   
To a polypropylene reaction vessel (25 mL) charged with a Teflon stir bar (10 x 3 mm) 
was added the Rink Amide resin (0.143 g, 0.100 mmol, loading 0.700 mmol/g, 1.00 equiv). The 
resin was washed with MeOH (2 x 5 mL), CH2Cl2 (3 x 10 mL) and DMF (3 x 10 mL), suspended 
in CH2Cl2 (5 mL) and allowed to swell at room temperature for 20 min.  The resin was filtered 
and washed with DMF (3 x 10 mL). The reaction vessel was fitted with the fiber optic 
temperature probe and the Fmoc group was cleaved by heating the resin in the Fmoc-cleavage 
base stock solution (1 mL) in the microwave (35 W, 78 ºC, 3 min).  The resin was filtered and 
washed with DMF (3 x 10 mL), CH2Cl2 (3 x 10 mL) and DMF (3 x 10 mL).  The first Fmoc 
protected amino acid was coupled to the resin by heating in a pre-mixed solution of amino acid 
(0.350 mmol, 3.50 equiv), DEPBT (0.105 g, 0.350 mmol, 3.50 equiv), DMF (0.800 mL), and 
Fmoc-coupling base stock solution (0.750 mL) in the microwave (25 W, 80 ºC, 5 min).  The resin 
was filtered and washed with DMF (3 x 10 mL), CH2Cl2 (3 x 10 mL) and DMF (3 x 10 mL).  The 
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Fmoc group was cleaved by heating the resin in Fmoc-cleavage base stock solution (1 mL) in the 
microwave (35 W, 78 ºC, 3 min).  The resin was filtered and washed with DMF (3 x 10 mL), 
CH2Cl2 (3 x 10 mL) and DMF (3 x 10 mL).  The second Fmoc protected amino acid was coupled 
to the resin by heating in a pre-mixed solution of amino acid (0.350 mmol, 3.50 equiv), DEPBT 
(0.105 g, 0.350 mmol, 3.50 equiv), DMF (0.800 mL), and Fmoc-coupling base stock solution 
(0.750 mL) in the microwave (25 W, 80 ºC, 5 min).  This process of Fmoc cleavage and amino 
acid coupling was repeated for each additional amino acid.  After the final Fmoc cleavage, the 
resin was washed with DMF (30 mL) and CH2Cl2 (20 mL).  The protecting groups were cleaved 
by treatment of the dry resin with the resin cleavage cocktail stock solution (2.50 mL) for 2 h at 
room temperature with vigorous stirring.  The resin was filtered and rinsed with the remaining 
resin cleavage cocktail stock solution (1.50 mL) and TFA (1.50 mL), collecting the filtrate and 
rinses in a BD Falcon tube (50 mL).  The sample was concentrated to a heterogeneous mixture 
(approximately 0.2 mL) under a stream of argon for 30 min.  Cold diethyl ether (45 mL) was 
added to precipitate the crude peptide.  The sample was centrifuged (3200 rpm, -8 ºC, 15 min) 
and the supernatant was discarded.  The crude peptide was transferred to a scintillation vial (20 
mL) with approximately 5 mL of a mixture of H2O/CH3CN (9:1) and lyophilized overnight.  The 
crude peptide was dissolved in H2O containing 0.1% TFA (5.00 mL) and filtered through a 0.45 
µm nylon syringe filter.  The filtrate was purified by preparative RP HPLC.  
1.6.2 SPPS Experimental Procedures 
 
 
SDNNQQGKSAQQGGY (JTH-NB72-40).  Prepared according to general procedure A 
utilizing the following amino acid sequence: Fmoc-L-Tyr(tBu)-OH (0.161 g, 0.350 mmol, 3.50 
equiv), Fmoc-L-Gly-OH (0.104 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Gly-OH (0.104 g, 0.350 
mmol, 3.50 equiv), Fmoc-L-Gln(Trt)-OH (0.214 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Gln(Trt)-
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OH (0.214 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ala-OH (0.115 g, 0.350 mmol, 3.50 equiv), 
Fmoc-L-Ser(tBu)-OH (0.134 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Lys(Boc)-OH (0.164 g, 0.350 
mmol, 3.50 equiv), Fmoc-L-Gly-OH (0.104 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Gln(Trt)-OH 
(0.214 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Gln(Trt)-OH (0.214 g, 0.350 mmol, 3.50 equiv), 
Fmoc-L-Asn(OtBu)-OH (0.209 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Asn(OtBu)-OH (0.209 g, 
0.350 mmol, 3.50 equiv), Fmoc-L-Asp(OtBu)-OH (0.144 g, 0.350 mmol, 3.50 equiv), Fmoc-L-
Ser(tBu)-OH (0.134 g, 0.350 mmol, 3.50 equiv).   JTH-NB72-40 (0.0342 g, 22%) was obtained 
as a white powder.  The sample was subjected to HPLC purification twice using a linear gradient 
of 30-60% buffer B in A (A: water containing 0.1% TFA, B: MeOH) over 30 min. The product 
was characterized by 
1
H NMR (Table 6); 
13
C NMR (Table 6); COSY; HMBC; HMQC; HLC RT 
4.3 min, HRMS (MALDI
+
) m/z calcd for C62H97N23O26 [M+H]
+
 1580.7053, Found 1580.7041.  
 
Table 6. 
1H and 13C NMR Data for JTH-NB72-40 (700 MHz/176 MHz) in D2O (298 K) with MeOH as an internal 
reference (referenced to 3.34 ppm (1H) and 49.5 ppm (13C)). 
Residue 
# 
Amino Acid 
(N->C) Resonance 1H δ [ppm] 
13C δ 
[ppm] 
1 Serine CO  168.5 
  CαH 4.18 (t, J = 4.8 Hz, 1 H) 55.1 
   3.90 (dd, J = 5.6, 11.6 Hz, 1 H)  
  CβH 3.85 (dd, J = 5.0, 11.6 Hz, 1 H) 60.8 
2 Aspartic Acid CO  174.8 
  CαH 4.81-4.74 (m, 1 H) 50.3 
  CβH 2.89 (dd, J = 5.8, 12.9 Hz, 2 H) 35.9 
  Cγ  172.9 
3 Asparagine CO  175.1 
  CαH 4.71 (dd, J = 6.0, 12.1 Hz, 1 H) 51.3 
  CβH 2.87-2.82 (m, 2 H) 36.4 
  Cγ  174.0 
4 Asparagine CO  175.0 
  CαH 4.70 (dd, J = 6.5, 11.4 Hz, 1 H) 51.3 
  CβH 2.81-2.73 (m, 2 H) 36.4 
  Cγ  173.3 
5 Glutamine CO  174.4 
  CαH 4.34-4.29 (m, 1 H) 53.9 
  CβH 2.05-1.94 (m, 2 H) 27.2 
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  CγH 2.36 (dt, J = 15.6, 7.6 Hz, 2 H) 31.7 
  Cδ  178.4 
6 Glutamine CO  174.4 
  CαH 4.34-4.29 (m, 1 H) 53.9 
  CβH 2.19-2.05 (m, 2 H) 27.2 
  CγH 2.36 (dt, J = 15.6, 7.6 Hz, 2 H) 31.7 
  Cδ  178.4 
7 Glycine CO  171.7 
  CαH 4.01-3.98 (m, 2 H) 43.0 
8 Lysine CO  174.7 
  CαH 4.38-4.34 (m, 1 H) 54.2 
  CβH 
1.89-1.80 (m, 1 H), 
31 1.79-1.71 (m, 1 H) 
  CγH 1.49-1.41 (m, 2 H) 22.7 
  CδH 1.70-1.61 (m, 2 H) 26.9 
  CεH 2.97 (app t, J = 7.0 Hz, 2 H) 39.8 
9 Serine CO  172.5 
  CαH 4.43 (t, J = 5.3 Hz, 1 H) 56.3 
  CβH 4.01-3.92 (m, 2 H) 61.7 
10 Alanine CO  175.8 
  CαH 4.30 (q, J = 5.7 Hz, 1 H) 50.8 
  CβH 1.38 (d, J = 7.2 Hz, 3 H) 16.9 
11 Glutamine CO  174.4 
  CαH 4.34-4.29 (m, 1 H) 53.9 
  CβH 2.05-1.94 (m, 2 H) 27.2 
  CγH 2.36 (dt, J = 15.6, 7.6 Hz, 2 H) 31.7 
  Cδ  178.4 
12 Glutamine CO  174.4 
  CαH 4.34-4.29 (m, 1 H) 53.9 
  CβH 2.19-2.05 (m, 2 H) 27.2 
  CγH 2.36 (dt, J = 15.6, 7.6 Hz, 2 H) 31.7 
  Cδ  178.4 
13 Glycine CO  172.4 
  CαH 3.97-3.92 (m, 2 H) 43.2 
14 Glycine CO  172.4 
  34 
  CαH 3.87 (s, 2 H) 43.2 
15 Tyrosine CO  176.5 
  CαH 4.52 (dd, J = 5.9, 8.8 Hz, 1 H) 55.5 
   
3.09 (dd, J = 5.8, 14.1 Hz, 1 
H),  
  CβH 2.92 (dd, J = 9.0, 14.1 Hz, 1 H) 36.8 
  Cγ  128.9 
  CδH 7.14 (d, J = 8.4 Hz, 2 H) 131.2 
  CεH 6.83 (d, J = 8.4 Hz, 2 H) 116.1 
  Cζ  155.1 
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Figure 11. CD Spectrum of JTH-NB72-40 (0.5 mmol) in MeOH 
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Figure 12. Analytical HPLC trace of JTH-NB72-40 using a linear gradient of 30-50% buffer B in A (A: water 
containing 0.1% TFA, B: MeOH) over 20 min with UV detection at 220 nm at a flow rate of 0.5 mL/min. 
 
 
 
SDTKHRKHSLQGHGY (JTH-NB72-41).  Prepared according to general procedure A utilizing 
the following amino acid sequence: Fmoc-L-Tyr(tBu)-OH (0.161 g, 0.350 mmol, 3.50 equiv), 
Fmoc-L-Gly-OH (0.104 g, 0.350 mmol, 3.50 equiv), Fmoc-L-His(Trt)-OH (0.217 g, 0.350 mmol, 
3.50 equiv), Fmoc-L-Gly-OH (0.104 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Gln(Trt)-OH (0.214 g, 
0.350 mmol, 3.50 equiv), Fmoc-L-Leu-OH (0.124 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ser(tBu)-
OH (0.134 g, 0.350 mmol, 3.50 equiv), Fmoc-L-His(Trt)-OH (0.217 g, 0.350 mmol, 3.50 equiv), 
Fmoc-L-Lys(Boc)-OH (0.164 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Arg(Pbf)-OH (0.227 g, 0.350 
mmol, 3.50 equiv), Fmoc-L-His(Trt)-OH (0.217 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Lys(Boc)-
OH (0.164 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Thr(tBu)-OH (0.139 g, 0.350 mmol, 3.50 equiv), 
Fmoc-L-Asp(OtBu)-OH (0.144 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ser(tBu)-OH (0.134 g, 0.350 
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mmol, 3.50 equiv).  JTH-NB72-41 (0.0191 g, 11%) was obtained as colorless to white crystals. 
The sample was subjected to HPLC purification twice using a linear gradient of 30-60% buffer B 
in A (A: water containing 0.1% TFA, B: MeOH) over 30 min. The product was characterized by 
1
H NMR (Table 7); 
13
C NMR (Table 7); DEPT-135; COSY; HMBC; HMQC; HPLC RT 5.5 min. 
HRMS (MALDI
+
) m/z calcd for C74H116N28O22 [M+Na]
 +
 1749.8897, Found 1749.8827. 
 
Table 7. 
1H and 13C NMR Data for JTH-NB72-41 (700 MHz/150 MHz) in D2O (298 K) with MeOH as an internal 
reference (referenced to 3.34 ppm (1H) and 49.5 ppm (13C)). 
Residue 
# 
Amino 
Acid  
(N->C) Resonance 1H δ [ppm] 
13C δ 
[ppm] 
1 Serine CO  168.5 
  CαH 4.19 (t, J = 4.9 Hz, 1 H) 55.0 
  CβH 3.88-3.79 (m, 2 H) 60.8 
2 
Aspartic 
Acid CO  173.1 
  CαH 4.88 (t, J = 6.7 Hz, 1 H) 50.8 
  CβH 
2.96-2.91 (m, 1 H), 
36.3 2.90-2.85 (m, 1 H) 
  Cγ  175.0 
3 Threonine CO  172.1 
  CαH 4.27 (d, J = 4.7 Hz, 1 H) 60.0 
  CβH 4.21-4.16 (m, 1 H) 67.4 
  CγH 1.17 (d, J = 6.4 Hz, 3 H) 19.5 
4 Lysine CO  174.3 
  CαH 4.24 (dd, J = 5.9, 8.3 Hz, 1 H) 53.2 
  CβH 1.78-1.69 (m, 2 H) 30.5 
  CγH 1.48-1.39 (m, 2 H) 22.8 
  CδH 1.69-1.54 (m, 2 H) 26.8 
  CεH 3.00-2.93 (m, 2 H) 39.7 
5 Histidine CO  172.4 
  CαH 4.73-4.68 (m, 1 H) 53.0 
  CβH 
3.31-3.22 (m, 1 H), 
27.0 3.18-3.11 (m, 1 H) 
  Cγ  128.9 
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  CδH 7.29 (s, 1 H) 117.9 
  CεH 8.62 (d, J = 1.2 Hz, 1 H) 134.1 
6 Arginine CO  174.0 
  CαH 4.31 (app dd, J = 8.1, 14.1 Hz, 1 H) 54.4 
  CβH 1.85-1.77 (m, 2 H) 29.0 
  CγH 1.69-1.54 (m, 2 H) 22.8 
  CδH 3.22-3.15 (m, 2 H) 41.1 
  Cε  157.3 
7 Lysine CO  174.3 
  CαH 4.31 (dd, J = 8.1, 14.1 Hz, 1 H) 53.8 
  CβH 1.78-1.69 (m, 2 H) 31.0 
  CγH 1.39-1.30 (m, 2 H) 22.8 
  CδH 1.69-1.54 (m, 2 H) 26.9 
  CεH 3.00-2.93 (m, 2 H) 39.8 
8 Histidine CO  172.7 
  CαH 4.73-4.68 (m, 1 H) 53.1 
  CβH 
3.31-3.22 (m, 1 H), 
27.4 3.18-3.11 (m, 1 H) 
  Cγ  129.0 
  CδH 7.30 (s, 1 H) 117.9 
  CεH 8.63 (d, J = 1.1 Hz, 1 H) 134.1 
9 Serine CO  175.1 
  CαH 4.43 (t, J = 5.7 Hz, 1 H) 56.0 
  CβH 4.03-3.96 (m, 2 H) 61.7 
10 Leucine CO  172.0 
  CαH 4.36 (dd, J = 5.2, 9.4 Hz, 1 H) 54.3 
  CβH 1.78-1.69 (m, 2 H) 40.1 
  CγH 1.69-1.54 (m, 1 H) 25.0 
  CδH 
0.89 (d, J = 5.8 Hz, 3 H), 22.8, 
21.3 0.84 (d, J = 5.8 Hz, 3 H) 
11 Glutamine CO  174.2 
  CαH 4.31 (dd, J = 8.1, 14.1 Hz, 1 H) 53.9 
  CβH 
2.08 (dt, J = 13.5, 7.4 Hz, 1 H), 
27.4 1.96 (dt, J = 7.4, 15.8, Hz, 1 H) 
  CγH 2.33 (t, J = 7.5 Hz, 2 H) 31.6 
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  Cδ  178.4 
12 Glycine CO  171.6 
  CαH 3.86 (s, 2 H) 43.0 
13 Histidine CO  172.3 
  CαH 4.67 (dd, J = 5.7, 8.5 Hz, 1 H) 52.8 
  CβH 
3.31-3.22 (m, 1 H), 
27.0 3.18-3.11 (m, 1 H) 
  Cγ  128.8 
  CδH 7.26 (s, 1 H) 117.9 
  CεH 8.61 (d, J = 1.2 Hz, 1 H) 134.1 
14 Glycine CO  171.8 
  CαH 3.93-3.89 (m, 2 H) 43.0 
15 Tyrosine CO  176.4 
  CαH 4.53 (dd, J = 5.9, 8.7 Hz, 1 H) 55.5 
  CβH 
3.08 (dd, J = 5.8, 14.1 Hz, 1 H), 
36.9 2.91 (dd, J = 8.9, 14.1 Hz, 1 H) 
  Cγ  129.0 
  CδH 7.12 (d, J = 8.4 Hz, 2 H) 131.2 
  CεH 6.81 (d, J = 8.5 Hz, 2 H) 116.0 
  Cζ  155.0 
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Figure 13. CD spectrum of JTH-NB72-41 (0.5 mmol) in MeOH 
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Figure 14. Analytical HPLC trace of JTH-NB72-41 using a linear gradient of 30-100% buffer B in A (A: water 
containing 0.1% TFA, B: MeOH) over 70 min with UV detection at 220 nm at a flow rate of 0.7 mL/min. 
 
 
VLPTQSKESTMFGGY (JTH-NB72-42).  Prepared according to general procedure A utilizing 
the following amino acid sequence: Fmoc-L-Tyr(tBu)-OH (0.161 g, 0.350 mmol, 3.50 equiv), 
Fmoc-L-Gly-OH (0.104 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Gly-OH (0.104 g, 0.350 mmol, 3.50 
equiv), Fmoc-L-Phe-OH (0.136 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Met-OH (0.130 g, 0.350 
mmol, 3.50 equiv), Fmoc-L-Thr(tBu)-OH (0.139 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ser(tBu)-
OH (0.134 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Glu(tBu)-OH (0.149 g, 0.350 mmol, 3.50 equiv), 
Fmoc-L-Lys(Boc)-OH (0.164 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ser(tBu)-OH (0.134 g, 0.350 
mmol, 3.50 equiv), Fmoc-L-Gln(Trt)-OH (0.214 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Thr(tBu)-
OH (0.139 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Pro-OH (0.118 g, 0.350 mmol, 3.50 equiv), 
Fmoc-L-Leu-OH (0.124 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Val-OH (0.119 g, 0.350 mmol, 3.50 
equiv).  JTH-NB72-42 (0.0140 g, 9%) was obtained as a white powder. The sample was 
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subjected to HPLC purification twice using a linear gradient of 30-70% buffer B in A (A: water 
containing 0.1% TFA, B: MeOH) over 40 min.  The product was characterized by 
1
H NMR 
(Table 8); 
13
C NMR (Table 8); DEPT-135; COSY; HMBC; HMQC; HPLC RT 18.7 min, HRMS 
(MALDI
+
) m/z calcd for C73H114N18O23S [M+H]
+
 1643.8103, Found 1643.8116. 
 
Table 8. 
1H and 13C NMR Data for JTH-NB72-42 (600 MHz/150 MHz) in D2O (298 K) with MeOH as an internal 
reference (referenced to 3.34 ppm (1H) and 49.5 ppm (13C)). 
Residue 
# 
Amino Acid 
(N->C) Resonance 1H δ [ppm] 
13C δ 
[ppm] 
1 Valine CO  169.9 
  CαH 3.83-3.78 (m, 1 H) 58.8 
  CβH 2.20 (qd, J = 6.8, 13.6 Hz, 1 H) 30.8 
  CγH 
1.01 (d, J = 6.9 Hz, 3 H), 18.3, 
17.4 1.00 (d, J = 6.9 Hz, 3 H) 
2 Leucine CO  172.6 
  CαH 4.69 (dd, J = 10.2 Hz, 1 H) 51.1 
  CβH 1.64-1.56 (m, 2 H) 39.7 
  CγH 1.74-1.67 (m, 1 H) 25.0 
  CδH 0.94 (app t, J = 6.3 Hz, 6 H) 
23.0, 
21.1 
3 Proline CO  174.9 
  CαH 4.50 (dd, J = 6.0, 8.1 Hz, 1 H) 61.1 
  CβH 
2.34-2.29 (m, 1 H), 
30.0 1.93-1.88 (m, 1 H) 
  CγH 2.05 (td, J = 7.4, 14.7, 2 H) 25.4 
  CδH 
3.94-3.91 (m, 1 H), 
48.6 3.69 (td, J = 7.0, 9.5 Hz, 1 H) 
4 Threonine CO  172.5 
  CαH 4.26 (d, J = 4.8 Hz, 1 H) 59.9 
  CβH 4.21-4.16 (m, 1 H) 67.4 
  CγH 1.16 (d, J = 6.4 Hz, 3 H) 19.5 
5 Glutamic acid CO  173.8 
  CαH 4.41-4.38 (m, 1 H) 53.6 
  CβH 2.16-2.08 (m, 2 H) 26.7 
  CγH 2.48 (t, J = 7.5 Hz, 1 H), 30.9 
  43 
2.48 (d, J = 7.1 Hz, 1 H) 
  Cδ  177.8 
6 Serine CO  173.1 
  CαH 4.42 (t, J = 5.7 Hz, 1 H) 56.3 
  CβH 3.86-3.83 (m, 2 H) 61.5 
7 Lysine CO  174.2 
  CαH 4.33-4.30 (m, 1 H) 54.5 
  CβH 
1.89-1.83 (m, 1 H), 
30.8 1.79-1.74 (m, 1 H) 
  CγH 1.51-1.35 (m, 2 H) 22.7 
  CδH 1.70-1.65 (m, 2 H) 26.8 
  CεH 2.98 (t, J = 7.5 Hz, 2 H) 39.8 
8 Glutamine CO  176.3 
  CαH 4.41-4.38 (m, 1 H) 53.6 
  CβH 2.02-1.97 (m, 2 H) 27.4 
  CγH 2.39-2.34 (m, 2 H) 31.7 
  Cδ  178.3 
9 Serine CO  174.6 
  CαH 4.46 (t, J = 5.5 Hz, 1 H) 56.5 
  CβH 3.91-3.88 (m, 2 H) 61.7 
10 Threonine CO  172.8 
  CαH 4.33-4.30 (m, 1 H) 59.9 
  CβH 4.25-4.21 (m, 1 H) 67.6 
  CγH 1.22 (d, J = 6.4 Hz, 3 H) 19.6 
11 Methionine CO  174.9 
  CαH 4.38 (dd, J = 5.6, 8.8 Hz, 1 H) 54.5 
  CβH 1.96-1.91 (m, 2 H) 30.7 
  CγH 
2.46-2.40 (m, 1 H), 
29.7 2.35-2.29 (m, 1 H) 
  CδH 2.02 (s, 3 H) 14.7 
12 Phenylalanine CO  174.2 
  CαH 4.63 (dd, J = 7.3, 8.3 Hz, 1 H) 55.7 
   
3.17 (dd, J = 6.8, 13.9 Hz, 1 
H),  
  CβH 3.04 (dd, J = 8.8, 13.9 Hz, 1 H) 37.3 
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  Cγ  127.8 
  CδH 7.26 (d, J = 7.1 Hz, 2 H) 129.8 
  CεH 7.34 (t, J = 7.6 Hz, 2 H) 129.4 
  CζH 7.26-7.23 (m, 1 H) 136.9 
13 Glycine CO  172.3 
  CαH 3.88 (s, 2 H) 43.2 
14 Glycine CO  171.5 
  CαH 3.82 (d, J = 6.0 Hz, 2 H) 42.9 
15 Tyrosine CO  176.3 
  CαH 4.53 (dd, J = 5.8, 9.0 Hz, 1 H) 55.5 
   
3.11 (dd, J = 5.7, 14.1 Hz, 1 
H),  
  CβH 2.92 (dd, J = 9.1, 14.1 Hz, 1 H) 36.8 
  Cγ  128.9 
  CδH 7.16 (d, J = 8.4 Hz, 2 H) 131.2 
  CεH 6.85 (d, J = 8.4 Hz, 2 H) 116.1 
  Cζ  155.1 
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Figure 15. CD spectrum of JTH-NB72-42 (0.5 mmol) in MeOH 
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Figure 16. Analytical HPLC trace of JTH-NB72-42 using a linear gradient of 30-100% buffer B in A (A: water 
containing 0.1% TFA, B: MeOH) over 70 min with UV detection at 220 nm at a flow rate of 0.7 mL/min. 
 
 
 
KSAQQGGY (JTH-NB72-60).  Unlike the other syntheses presented, DEPBT used in this 
sequence was not purchased but synthesized according to literature protocols.
51
 JTH-NB72-60 
was prepared according to general procedure A utilizing the following amino acid sequence: 
Fmoc-L-Tyr(tBu)-OH (0.161 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Gly-OH (0.104 g, 0.350 mmol, 
3.50 equiv), Fmoc-L-Gly-OH (0.104 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Gln(Trt)-OH (0.214 g, 
0.350 mmol, 3.50 equiv), Fmoc-L-Gln(Trt)-OH (0.214 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ala-
OH (0.115 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ser(tBu)-OH (0.134 g, 0.350 mmol, 3.50 equiv), 
Fmoc-L-Lys(Boc)-OH (0.164 g, 0.350 mmol, 3.50 equiv).  JTH-NB72-60 (0.0465 g, 56%) was 
obtained as colorless to white crystals: The sample was subjected to HPLC purification using a 
linear gradient of 30-50% buffer B in A (A: water containing 0.1% TFA, B: MeOH) over 20 min.  
The product was characterized by 
1
H NMR (Table 9); 
13
C NMR (Table 9); DEPT-135; COSY; 
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HMBC; HMQC; HPLC RT 4.8 min, HRMS (MALDI
+
) m/z calcd for C35H56N12O12 [M+Na]
+
 
859.4039, Found 859.4034. 
 
Table 9. 
1H and 13C NMR Data for JTH-NB72-60 (600 MHz/150 MHz) in D2O (298 K) with MeOH as an internal 
reference (referenced to 3.34 ppm (1H) and 49.5 ppm (13C)). 
Residue 
# 
Amino 
Acid  
(N->C) Resonance 1H δ [ppm] 
13C δ 
[ppm] 
1 Lysine CO  170.4 
  CαH 4.08 (t, J = 6.6 Hz, 1 H) 53.4 
  CβH 1.96-1.86 (m, 2 H) 31.0 
  CγH 1.47 (dt, J = 7.6, 16.3 Hz, 2 H) 21.8 
  CδH 
1.70 (app td, J = 7.6, 15.2 Hz, 2 
H) 27.0 
  CεH 2.99 (t, J = 7.6 Hz, 2 H) 39.6 
2 Serine CO  171.7 
  CαH 
4.51 (app dd, J = 5.5, 10.1 Hz, 1 
H) 55.9 
  CβH 3.89 (dd, J = 5.9, 8.9 Hz, 2 H) 61.8 
3 Alanine CO  175.6 
  CαH 4.33-4.29 (m, 1 H) 50.6 
  CβH 1.39 (t, J = 9.9 Hz, 3 H) 17.0 
4 Glutamine CO  174.3 
  CαH 4.29 (dd, J = 6.5, 9.1 Hz, 1 H) 53.9 
  CβH 2.04-1.95 (m, 2 H) 27.3 
  CγH 2.35 (dt, J = 15.3, 7.6 Hz, 2 H) 31.7 
  Cδ  178.4 
5 Glutamine CO  173.9 
  CαH 4.34 (dd, J = 5.4, 8.9 Hz, 1 H) 53.8 
  CβH 2.14-2.05 (m, 2 H) 27.3 
  CγH 2.35 (dt, J = 15.3, 7.6 Hz, 2 H) 31.6 
  CδH  178.4 
6 Glycine CO  172.6 
  CαH 3.95 (d, J = 11.0 Hz, 2 H), 43.1 
7 Glycine CO  172.4 
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  CαH 3.86 (s, 2 H) 42.9 
8 Tyrosine CO  176.4 
  CαH 
4.51 (app dd, J = 5.5, 10.1 Hz, 1 
H) 55.5 
  CβH 
3.09 (dd, J = 5.8, 14.1 Hz, 1 H), 
36.8 2.91 (dd, J = 8.9, 14.1 Hz, 1 H) 
  Cγ  128.9 
  CδH 7.14 (d, J = 8.4 Hz, 2 H) 131.4 
  CεH 6.83 (d, J = 8.4 Hz, 2 H) 116.0 
  CζH  155.0 
 
 
Figure 17. CD spectrum of JTH-NB72-60 (0.5 mmol) in MeOH 
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Figure 18. Analytical HPLC trace of JTH-NB72-60 using a linear gradient of 30-50% buffer B in A (A: water 
containing 0.1% TFA, B: MeOH) over 20 min with UV detection at 220 nm at a flow rate of 0.5 mL/min. 
 
 
2-Amino-N-hydroxybenzamide (1.4).
63
 To a stirred solution of NaOH (24.0 g, 0.600 mol, 4 
equiv) in H2O (150 mL) at 0 ºC was slowly added hydroxylamine hydrochloride (20.8 g, 0.300 
mol, 2 equiv).  To the resulting solution was added methyl anthranilate (22.6 g, 0.150 mol, 1 
equiv), followed by methanol (200 mL). The mixture was allowed to stir for 2 d under TLC 
control, and concentrated under reduced pressure until the sodium salt of the hydroxamic acid 
began to precipitate (~50 mL).  The salt was filtered and washed with cold water. The pH of the 
filtrate was adjusted to 6 with conc. HCl and the free hydroxamic acid was precipitated. The 
precipitate was filtered, washed with cold water, the volume of the resulting filtrate was reduced 
in vacuo, the pH adjusted to 6 and the precipitate filtered. This process was repeated until no 
more precipitate was obtained to give 1.4 (17.6 g, 77%) as small white crystals: 
1
H NMR (300 
MHz, DMSO-d6) 10.91 (bs, 1 H), 8.83 (s, 1 H), 7.30 (dd, 1 H, J = 1.5, 8.1 Hz), 7.12 (dt, 1 H, J = 
1.5, 7.2 Hz), 6.69 (dd, 1 H, J = 1.2, 8.4 Hz), 6.47 (dt, 1 H, J = 1.2, 7.8 Hz), 6.22 (bs, 2 H); 
13
C 
NMR (75 MHz, DMSO-d6) 167.0, 149.3, 131.6, 127.5, 116.2, 114.7, 113.1.  
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3-Hydroxybenzo-1,2,3-triazin-4(3H)-one (1.5).
63
 A solution of 1.4 (10.5 g, 69.0 mmol, 1 equiv) 
in conc. HCl (18 mL) was diluted with H2O (200 mL) and cooled to 0 ºC.   A pre-cooled (0 ºC) 
solution of NaNO2 (5.21 g, 75.6 mmol, 1.1 equiv) in H2O (6.25 mL) was added slowly to the 
mixture at 0 ºC.  The resulting heterogeneous solution was allowed to stir at room temperature for 
2 h.  The precipitate was filtered and recrystallized from boiling ethanol to give 1.5 (9.26 g, 82%) 
as white crystals: 
1
H NMR (300 MHz, DMSO-d6); 12.9 (s, 1 H), 8.28 (d, 1 H, J = 3.6 Hz), 8.23 
(d, 1 H, J = 3.5 Hz), 8.09 (t, 1 H, J = 3.3 Hz), 7.93 (t, 1 H, J = 3.3 Hz); 
13
C NMR (75 MHz, 
DMSO-d6) 151.1, 143.9, 135.1, 132.5, 128.1, 124.8, 121.2. 
 
 
3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (1.6).
51
 To a solution of 1.5 (2.00 g, 
12.3 mmol, 1 equiv) and triethylamine (1.71 mL, 12.3 mmol, 1 equiv) in CH2Cl2 (11.3 mL) at 0 
ºC was added a solution of freshly distilled diethyl chlorophosphate (2.02 mL, 14.0 mmol, 1.1 
equiv) in CH2Cl2 (5.6 mL) was added dropwise over 1 h.  The reaction was allowed to warm to rt 
and stirred for 3 h. The resulting heterogeneous mixture was filtered, and the filtrate was 
concentrated under reduced pressure.  The resulting crude material was dissolved in EtOAc (30 
mL), washed with water (x2), brine, dried (MgSO4), and concentrated under reduced pressure.  
The resulting solid was recrystallized from EtOAc/hexanes to give 1.6 (2.74 g, 74%) as colorless 
to white crystals: Mp=73-73.5 ºC; 
1
H (600 MHz, CDCl3) 8.38 (d, 1 H, J = 7.8 Hz), 8.22 (d, 1 H, J 
= 8.4 Hz), 8.00 (t, 1 H, J = 8.4 Hz), 7.84 (t, 1 H, 7.8 Hz) 4.57-4.47 (m, 4 H), 1.47 (t, 6 H, J = 3.6 
Hz). 
  51 
2.0  LIBRARY SYNTHESIS OF BICYCLO[3.3.1]NONANES 
2.1 INTRODUCTION 
Aranorosin was isolated from the fermentation broth of the fungal strain 
Pseudoarachniotus roseus by Fehlhaber et al. in 1988.
64,65
  It was found to possess antibiotic, 
antifungal, and antitumor properties.
64
  Aranorosin’s structure was assigned through extensive 
NMR studies and confirmed by synthesis in several groups, including our own.
64-67
  One of the 
most intriguing structural features of aranorosin is the syn orientation of the two epoxide oxygens 
and the spiro-ether oxygen.  Aranorosin exists as a mixture of two epimeric hemiacetals, with the 
major isomer (Figure 19) orienting the amide and hydroxyl groups in a syn fashion comprising 
75% of the mixture.   At the time of our group’s synthesis, the stereochemistry at the C(6) 
position had not been determined.  
 
 
Figure 19. Major epimer of aranorosin 
 
 Our synthesis was successfully completed in 1993
66
 and featured an elegant method to set 
the all syn oxygenation.  A stereoselective addition of benzyloxy methyl lithium (BOMLi) to bis-
α,β-unsaturated ketone 2.1, followed by a Henbest epoxidation, directed by the newly formed 
tertiary alcohol 2.2, gave the desired syn oxygenated product 2.3 in 46% yield (Scheme 10).
66
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Scheme 10. Key synthetic step in the Wipf group’s synthesis of aranorosin 
 
 An important aspect that had to be considered in the addition reaction was the -facial 
selectivity of the nucleophile as it approached the dienone.  Gratifyingly, addition of the BOMLi 
nucleophile occurred in a 5:1 ratio favoring the desired attack to the -face of the ketone 
(Scheme 11).  In subsequent work by Wipf and Kim, it was determined that the selectivity 
resulted from dipolar control.  Hyperconjugative orbital stabilization in the transition state and 
orbital distortion effects appeared to be of secondary importance.
68
  After addition of BOMLi, a 
Henbest epoxidation, in the presence of Kishi’s radical inhibitor,69 provided only the all syn-
diepoxide (2.3).   It was hypothesized that the observed selectivity during the epoxidation arises 
from a kinetic resolution.  The steric congestion experienced by the peracid during its approach 
to the -face of the dienone (2.2) (Scheme 11) caused the rate of α-face epoxidation to be slow 
enough that this reaction pathway was essentially inoperable under the reaction conditions.  
Therefore, although the reaction was performed on a crude mixture of isomeric addition 
products, only the desired syn-diepoxide 2.3 was isolated.  
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Scheme 11. Kinetic resolution resulting from steric congestion during the Henbest epoxidation 
 
The authors did not report a crystal structure for 2.2, but the relative stereochemistry of 
the product was supported by a weak (<1%) NOE between the BOM methylene protons and the 
methylene protons of the 5-membered spirocyclic ring (Figure 20).  In addition, further support 
was derived from comparison to a model system in which a methyl Grignard reagent was used 
and a larger NOE (3%) was observed (Figure 20).
70
  
 
 
Figure 20. NOE correlations used to assign the relative stereochemistry of the epoxidation product 
 
With the desired diepoxide 2.3 in hand, the synthesis continued via acylation with the 
unsaturated fatty acid side chain, followed by several functional group manipulations which led 
to both the natural product aranorosin and its epimer at the C(6′)  position.  Having successfully 
synthesized the target molecule and assigned the absolute stereochemistry of the remote C(6′)  
stereocenter, our group sought to explore the natural product’s reactivity toward biologically 
relevant nucleophiles.  
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Aranorosin possesses two characteristic segments: the oxaspiro[5.4]decane moiety and 
the unsaturated fatty acid chain.  One could envision that both segments contain multiple sites 
that are susceptible to nucleophilic attack (Figure 21).   Many examples demonstrate the 
potential reactivity between sulfhydryl groups from natural sources (e.g., glutathione, cysteine) 
and ,-unsaturated ketone functional groups of biologically active natural compounds.71-73  
Thus, Michael addition to the unsaturated fatty acid chain is likely to occur.  In addition, 
Sharpless has done extensive studies of epoxide opening with thiol nucleophiles.
74,75
  Therefore, 
it became apparent that the compound may be readily intercepted by a thiol nucleophile such as 
glutathione or a cysteine.  
 
 
Figure 21. Potential sites of nucleophilic attack 
 
Due to the large number of reactive sites, our group chose first to explore the reactivity of 
the oxaspiro[5.4]decane core of aranorosin, using the saturated side chain model system (2.4).  
This model removed the potential for Michael additions while allowing more rapid access to test 
material.  Diepoxyketone 2.4 was treated with several nucleophiles containing either 
nucleophilic sulfur or nitrogen atoms.  Interestingly, no reaction was observed with nitrogen 
containing nucleophiles such as dibenzylamine, pyrrole, or guanosine.
70
  However, in the 
presence of sodium thiophenoxide, a substitute for glutathione, a novel reaction pathway led to 
the formation of bicyclo[3.3.1]nonane 2.5 (Scheme 12).  The structure of the 
bicyclo[3.3.1]nonane 2.5 was rigorously elucidated via 1D and 2D NMR experiments.
70,76
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Scheme 12. Addition/rearrangement to access the bicyclo[3.3.1]nonane scaffold 
 
Subsequent in situ NMR studies of ketone 2.6 revealed the initial conversion of the 
carbonyl carbon (200.9 ppm) to a hemithioacetal (80.5 ppm), followed by conversion to the bis-
α,β-unsaturated ketone 2.7 (178.9 ppm) (Scheme 13).76   Therefore, the first step is most likely 
the attack of the thiol nucleophile at the carbonyl group followed by a 1,2-migration and 
elimination.  
 
 
Scheme 13. In situ NMR studies to gain mechanistic insight into the addition/rearrangement pathway 
 
A hypothetical reaction mechanism was proposed (Scheme 14) in which an initial 
nucleophilic attack of thiophenol at the ketone 2.8, followed by an irreversible 1,2-migration 
leads to opening of the epoxide.  This sequence can be repeated to open the other epoxide and 
provide 2.9.  Sequential dehydration provided 2.10, which underwent a base-catalyzed 
intramolecular aldol reaction to the lactol/aldehyde to furnish the bicyclo[3.3.1]nonane 2.11 
(Scheme 14).
76
   The intramolecular aldol reaction proceeded stereoselectively and only one 
diastereomer was observed.
77
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Scheme 14. Proposed mechanism for the conversion of the spirocyclic diepoxyketone to the bicyclo[3.3.1]nonane 
scaffold 
 
Based on this and similar results in closely related model systems, a new general 
reactivity pattern for the addition of thiol nucleophiles to diepoxyketones was elucidated.
76
  Our 
group hypothesized that the intramolecular aldol reaction, which occurs in the lactol/aldehyde 
scaffold, could provide access to interesting derivatives, with stable carbon-sulfur linkages, for 
the diversity-oriented synthesis of libraries of bicyclic ring systems.  
The National Institutes of Health have launched an ambitious Molecular Libraries 
Program whose goal is to enhance chemical biology efforts through high throughput screening.  
Our group has been interested in the development of new methodologies that can be applied to 
the syntheses of focused libraries of underrepresented chemotypes in the NIH libraries.
78
  One of 
the most important question that must be addressed before undertaking the synthesis of a focus 
library is how to design small-molecules possessing new structures and properties while 
populating the biologically relevant regions of chemical space.
78
  One solution is to design 
natural product-like libraries. 
Natural products have had a profound impact on both chemical biology and drug 
discovery.  Over the last 70 years, out of the 155 small molecules approved for the treatment of 
cancer in humans, 47% were either natural products or derived from natural products.
79
   Natural 
product-like libraries can be filed into three categories: 1) libraries based on the core scaffold of 
an individual natural product, 2) libraries based on structural motifs that are found across an 
entire class of natural products, and 3) libraries that more generally mimic the structural 
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characteristics of natural products.
80
 Our strategy focused on using the novel 
addition/rearrangement methodology discovered during our study of aranorosin to synthesize a 
small library of highly functionalized bicyclo[3.3.1]nonanes which resemble the core of the 
interesting natural products gymnastatins F
81
 and Q (Figure 22).
82
 
Gymnastatins F and Q were isolated from the extract of the Halichondria sponge-derived 
fungus Gymnascella dankaliensis.  Their relative configurations have been established on the 
basis of spectroscopic analyses using 1D and 2D NMR techniques.  Both gymnastatin F and Q 
were found to exhibit potent growth inhibition against murine P388 lymphocytic leukemia and 
human cancer cell lines.
81
  Furthermore, gymnastatin Q showed appreciable growth inhibition 
against BSY-1 (breast) and MKN7 (stomach) human cancer cell lines.
82
 
 
 
Figure 22. Structure of gymnastatin F and gymnastatin Q 
   
 We envisioned that our new reaction pathway could be utilized to offer intriguing 
analogues that possess the functionalized bicyclo[3.3.1]nonane core present in these natural 
products.  By using a variety of thionucleophiles, and different acylating agents, diversity can be 
introduced at both the nitrogen and the carbon-sulfur linkages (Figure 23).   
 
 
Figure 23. Diversification points of the bicyclo[3.3.1]nonane scaffold 
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2.2 LIBRARY SYNTHESIS OF BICYCLO[3.3.1]NONANES  
2.2.1 First Generation Approach 
A retrosynthetic analysis of the functionalized scaffold is illustrated in Scheme 15.   The 
diversified bicyclo[3.3.1]nonane scaffold 2.12 is accessed via the addition/rearrangement 
reaction from key intermediate 2.13, followed by Boc removal and acylation.  The use of 
different acylating as well as different thionucleophiles provides two points of diversification. 
The key intermediate 2.13 is closely related to an intermediate in the previously described 
synthesis of aranorosin (vide supra).
66
  Therefore, in an analogous fashion the all syn 
oxygenation present in 2.14 will be set using addition of the BOMLi nucleophile to the 
corresponding dienone 2.1, followed by a Henbest epoxidation.  The dienone 2.1 can be readily 
accessed from Cbz-L-tyrosine 2.15 via oxidative cyclization methodology and a subsequent 
second Cbz protection.   
 
 
Scheme 15. Retrosynthetic analysis of the diversified bicyclo[3.3.1]nonane scaffold 
 
The synthetic route commenced with a scalable protection of L-tyrosine (2.16) with Cbz-
Cl in a basic H2O/THF medium to provide the protected amino acid 2.15 in quantitative yield.  In 
a very scalable process (25 g), the Cbz-protected L-tyrosine was converted to the desired 
spirocycle 2.17 via an oxidative cyclization in the presence of iodobenzene diacetate (PIDA).  
Bis-protection of the amine with a second Cbz group proceeded to give 2.1 in good yield (88%) 
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in the presence of a catalytic amount of DMAP and Cbz2O (2.18).  Cbz2O (2.18) was readily 
accessed on a 60 g scale in 97% yield via deprotonation of benzyl alcohol with NaH, trapping of 
the alkoxide with CO2, followed by trapping of the resulting carbonate with Cbz-Cl.  With the 
protected bis-α,β-unsaturated ketone 2.1 in hand, the key reaction to set the diepoxy function was 
investigated.   
 
 
Scheme 16. Synthesis of 2.1 
 
Preparation of benzyloxymethyl stannane 2.20 (BOMSn(Bu)3) was accomplished using a 
known procedure (Scheme 17).
83
  Generation of a zinc-copper couple, followed by formation of 
iodomethylzinc iodide and transmetalation to tin provided iodomethylstannane 2.19 in 71% 
yield.  Deprotonation of benzyl alcohol followed by SN2 displacement of the iodide provided the 
desired benzyloxymethyl stannane 2.20 in 89% yield.   
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Scheme 17. Synthesis of BOMSnBu3 
 
Benzyloxymethyl lithium (BOMLi) was prepared in situ from the corresponding stannane 
with n-BuLi in THF at -78 ºC and rapidly cannulated into a pre-cooled (-78 ºC) solution of 
dienone 2.1 in THF.   Due to the instability of the intermediate bis-allylic alcohol, the product 
was only partially purified and directly subjected to bis-epoxidation.  Henbest epoxidation, 
directed by the newly formed tertiary alcohol, in the presence of m-CPBA and Kishi’s radical 
inhibitor
69
 in CCl4 provided the desired diepoxy spirolactone 2.3 in 31% yield as a single 
diastereomer.   
 
 
Scheme 18. First generation approach to the key intermediate 2.3 
 
Although the relative stereochemistry of diepoxy lactone 2.3 was previously assigned via 
a weak NOE correlation and comparison to model systems,
70,76
 the configuration could be 
unambiguously determined via single crystal X-ray analysis (Figure 24).  
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Figure 24. X-ray structure of diepoxy spirolactone 2.3 generated using the Mercury software package.84 
 
After confirming the relative stereochemistry of the desired diepoxy spirolactone 2.3, the 
Cbz protecting groups were cleaved using Pd/C with 1,4-cyclohexadiene as a source of hydrogen 
in a 1:1 mixture of MeOH/THF.  Protection of the resulting crude amine with Boc2O proved to 
be a very low yielding process due to difficulties in purifying the desired product 2.14.   
 
 
Scheme 19. Attempted deprotection/reprotection of bisepoxy spirolactone 
 
In order to improve the possibility for a large scale production of the desired diepoxy 
ketone 2.14, the protecting group scheme was altered so that the complete deprotection and 
reprotection of the amine was no longer required.   
2.2.2 Second Generation Approach 
Starting from the dienone 2.21, protection with Boc2O proceeded smoothly in the 
presence of a catalytic amount of DMAP to give the desired bis-protected dienone 2.22 in 94% 
yield on 10 g scale.  Gratifyingly, the addition/diepoxidation reaction of the Boc/Cbz-protected 
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spirolactone 2.22 proceeded at -100 ºC to give 2.23 as a single diastereomer in an improved 47% 
yield.  Selective Cbz removal in the presence of Pd/C with 1,4-cyclohexadiene in a 1:1 mixture 
of THF/MeOH provided the protected diepoxy spirolactone 2.14 in 90% yield. 
 
 
Scheme 20. Revised protection scheme to access diepoxy spirolactone 
 
 Upon scale-up of the route outlined in Scheme 20, it became apparent that the preparation 
of BOMSnBu3 (2.20, Scheme 17) was experimentally challenging.  A brief survey of the 
literature revealed that a more scalable procedure had been described.
85
  Utilizing this new 
procedure BOMSnBu3 2.20 was prepared in one step in 67% yield (Scheme 21).  
 
 
Scheme 21. Improved synthesis of BOMSnBu3 
 
With the diepoxy spirolactone 2.14 in hand, partial lactone reduction in the presence of 
sodium borohydride and cerium trichloride, benzyl removal with Pd/C and vigorously bubbling 
H2, and diol cleavage with sodium periodate provided the desired key intermediate 2.13 in 54% 
yield over 3 steps (Scheme 22).   
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Scheme 22. Preparation of key intermediate 2.13 
 
Replacement of the saturated alkyl side chain used in the previous study (Scheme 12) with 
a Boc group significantly decreased the yield of the thiol-mediated rearrangement.  Using the 
reported procedure,
70
 a solution of spirolactone 2.13 was treated with NaH (10 equiv) and 
thiophenol (5 equiv) in THF to afford the desired product 2.24 in 41% yield.  
 
 
Scheme 23. Preparation of bicyclic amide 2.26 
 
The partially purified bicyclo[3.3.1]nonane 2.24 was deprotected in the presence of TFA 
in CH2Cl2.  A subsequent solvent swap, conversion to the free base with DIPEA, and addition of 
freshly distilled acetyl chloride afforded the acetylated bicyclo[3.3.1]nonane 2.26 along with an 
intractable impurity in a modest 66% yield.  
It soon became clear that the addition/rearrangement sequence would need to be re-
optimized in order to increase the yield.  A solvent screen revealed that THF gave the highest, 
though still unacceptable, yield of 36% and the product always contained an intractable impurity 
(Table 10).  In polar solvents such acetonitrile, a decrease in yield to 23% was observed.  
Significant decomposition was observed in DMF and only 5% of the desired product was 
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isolated after purification.  In 1,2-DME, the substrate quickly decomposed.  In the non-polar 
solvent toluene, only 12% of the desired product was isolated due to the poor solubility of the 
substrate.  Since THF produced the highest yield, the order of addition was explored in this 
solvent.  Variation of addition sequence had little effect on the quantity of isolated product.  In 
order to optimize the addition/rearrangement reaction a more readily accessible diepoxy ketone 
was needed. 
 
Table 10. Solvent screen for addition/rearrangement reaction 
 
 
2.2.3 Attempts to Directly Epoxidize Dienone 2.14 
 Next, the preparation of 2.27 by direct epoxidation of 2.22 was explored.  Due to the 
electronic withdrawing nature of dienone 2.14, it was expected that electrophilic epoxidizing 
agents such as m-CPBA would not react. The Weitz-Scheffer epoxidation however, utilizing 
alkaline H2O2, is known to epoxidize α,β-unsaturated ketones and has been well documented in 
the literature
86
 along with several asymmetric versions.
87
  A brief screening of basic epoxidation 
conditions provided only decomposition products (Table 11).  This was surprising because other 
groups had utilized this methodology in the synthesis of aranorosin.
67,88
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Table 11. Attempts at direct bisepoxidization of dienone 2.22 
 
 
In 1993, the McKillop group demonstrated the selective epoxidation of the lactol 
containing either a Boc or a Cbz amino protecting group in moderate yields, using the ethereal 
oxygen as a directing group.
67
  The only example of epoxidation of a spirolactone came from 
Rama Rao’s group, who clearly stated the epoxidation proved to be quite difficult.89  The authors 
found that treatment of the dienone spirolactone 2.28 with potassium carbonate and hydrogen 
peroxide in methanol at 0 ºC followed by acidification and careful quenching of excess peroxide 
with triphenylphosphine, and lactonization in the presence of DCC led to a mixture of epoxides 
(Scheme 24).  They suggested the smaller acetyl amino protecting group was interfering with the 
directing ability of the newly formed tertiary alcohol.  Upon switching to the full-length 
unsaturated fatty acid side chain, they were able to successfully arrive at the desired bis-epoxy 
dienone in a very modest 27% yield.  
 
 
Scheme 24. Rama Rao's bisepoxidation in his synthesis of aranorosin 
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2.2.4 Model System Investigations 
In order to simplify the synthesis of the bisepoxy ketone 2.14, the preparation of a 
derivative lacking the amino functionality was explored.  During the course of their investigation 
of the synthesis of aranorosin, the McKillop group synthesized such a substrate.
90,91
  Following 
this protocol, oxidative addition of MeOH in the presence of PIDA to p-methoxy phenol 
provided the desired quinone monoketal 2.29 in quantitative yield on 12 g scale (Scheme 25).  In 
situ generation of butenylmagnesium bromide followed by addition to quinone monoacetal 2.29, 
a solvent swap, and ketal hydrolysis, provided the desired bis-α,β-unsaturated ketone 2.30 in a 
very scalable process. Conversion of dienone 2.30 to the diepoxide 2.31 proceeded in slightly 
lower yields than reported (cf. 80%) to arrive at the desired syn oxygenated diepoxy ketone 2.31 
in 72% yield.  Ozonolysis in CH2Cl2 at -78 ºC followed by stirring in an excess of DMS for 
several days to ensure decomposition of the unusually stable ozonide intermediate provided the 
desired model system 2.32 in 76% yield as a 1:1 mixture of lactols as determined by 
1
H NMR. 
 
 
Scheme 25. Access to bisepoxy ketone model system 
 
With a sufficient quantity of lactol 2.32 in hand, optimization of the 
addition/rearrangement reaction was performed.  Under the previously reported conditions, 
spirolactol 2.32 was treated with thiophenol (5 equiv) and sodium hydride (10 equiv) in THF.  
Surprising, only 28% of the desired compound 2.33 was isolated (Table 12, entry 1).  An 
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increase in the equivalents of thiophenol and an initial survey of different orders of addition 
revealed no improvement in the reaction (Table 12, entry 2).  Upon decresing the temperature to 
-78 ºC, no increase in yield was observed.  Next, a number of bases, ranging in strengths, were 
investigated.  In the presence of n-BuLi, decomposition of the reaction mixture was observed, 
thus it was hypothesized a milder base may be necessary to effect the transformation.  In the 
presence of triethylamine, an intractable mixture was formed.  Na2CO3, which was previously 
reported to effect the desired reaction in the system containing a saturated alkyl chain,
76
 also led 
to the formation of a complex mixture. Switching to K2CO3, the yield increased to 72% in 8 h at 
rt (Table 12, entry 7).  
Next, the use of different solvents were investigated. The poor results exhibited by DMF, 
1,2-DME, and toluene during the initial solvent screen (Table 10, vide supra) deterred their 
further use.  The use of the polar protic solvent methanol, led to decomposition of the starting 
material.  It was later determined that the starting material decomposes in methanol in the 
absence of the other reagents, likely due to the nucleophilicity of methanol.  
1
H NMR analysis of 
the starting material after stirring overnight in methanol revealed a mixture of Michael addition 
products consistent with previous reports.  The use of the polar aprotic solvent acetonitrile led to 
the formation of the product in 40% yield.  Moving to more non-polar aprotic solvents provided 
markedly better results.  Although the use of diethyl ether increased the isolated yield of 2.33 to 
80% it noticeably slowed down the reaction.   Methylene chloride was found to be the optimal 
solvent screened and provided the desired product in 84% yield in only 5 h at room temperature. 
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Table 12. Optimization of addition/rearrangement reaction 
 
aThe range of yields listed reperesent the result obtained from all possible orders of addition. bThe reaction 
immediately turned black upon the addition of base. cThe reagents were added at 0 ºC and the reaction mixture was 
allowed to warm to rt.  dThe bisepoxy ketone starting material decomposed in MeOH. 
 
Next, the effect of the counter cation on the carbonate base was screened.  Both 
ammonium and calcium carbonate significantly reduced the rate of the reaction and after stirring 
overnight at room temperature none of the desired product was observed.  Lithium carbonate 
provided bicyclo[3.3.1]non-3-en-2-one 2.33 in 24% yield.  The use of cesium carbonate 
decreased the reaction time and afforded 86% of the desired product (2.33) in only 2 h (Table 12, 
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entry 15).  The equivalents of thiol and base were also examined.  Using 2 equivalents of both 
base and thiol decreased the yield to 70%.  A slight excess of thiophenol (3 equiv) and base (5 
equiv) gave an 83% yield.  Heating the reaction mixture in CH2Cl2 at reflux led to formation of 
the desired product in only 15 min in 70% yield.  This result prompted the exploration of 
microwave conditions.  Initially, 100 ºC for 5 min in CH2Cl2 led to decomposition.  After 
decreasing the temperate to 80 ºC, the reaction was complete in 1 min and provided the desired 
product in 83% yield; however, two unidentified side products were detected by TLC.  
Decreasing the reaction temperature further to 60 ºC led to a slight increase in reaction time to 
two minutes but provided the desired product in a reproducibly higher yield and cleaner 
conversion (Table 12; entry 20).  As observed previously, using stoichiometric amounts of thiol 
led to a slight decrease in yield (82%).  
Satisfied with both the optimized room temperature and microwave conditions we 
focused on expanding the scope of the reaction.  Specifically the use of aryl thiols containing 
electron donating, electron withdrawing, and sterically demanding susbstitution were evaluated 
under both the room temperature and microwave irradiation conditions.  The electron donating p-
methyl, t-butyl, and methoxy substitutions were well tolerated, affording the desired bicyles in 
good yields (entries 1-3, Table 13).  Electon withdrawing susbstitutents such as an o-bromo, m-
fluoro, and p-trifluoromethyl groups also proved efficient, affording the corresponding 
bicyclo[3.3.1]nonenones in good yields (entries 5-7, Table 13).  The use of 2-naphthyl 
thiophenol resulted in a slightly lower yield (57%); however, this decrease in yield can partly be 
explained by the reduced solubility of both the starting material and the product in 
dichloromethane (entry 8, Table 13).  Gratifyingly, microwave irradiation successfully afforded 
the desired bicycles in 2 min at 60 ºC in comparable yields to the thermal process.  Most notably, 
the lowest yielding naphthyl derivative (2.40) performed well under microwave conditions to 
provide the desired product in 74% yield. 
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Table 13. Scope and limitations of the addition/rearrangement reaction 
 
aYields in parentheses correspond to microwave yields using R-SH (3 equiv), Cs2CO3 (5 equiv), in CH2Cl2 in the 
microwave for 2 min at 60 ºC.  All yields are for isolated product. bProduct contains a minor intractable aromatic 
impurity.78 
     
Unambiguous structure determination of bicyclo[3.3.1]non-3-en-2-one 2.37 was 
accomplished by X-ray crystallography (Figure 25).  NMR analysis of 2.37, revealed a single 
diastereomer was observed, which was determined by X-ray analysis to be the diastereomer 
placing the hydroxyl substituents on the chair in an equatorial orientation.  Semi-empirical 
calculations (PM3) using the Spartan molecular modeling software
92
 revealed the observed 
equatorial diastereomer to be ~1.1 kcal/mol higher in energy than the axial diastereomer (Figure 
25).  Thus, the reaction does not appear to be under thermodynamic control.  
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Figure 25. (A) X-ray structure of o-bromo-bicyclo[3.3.1]nonane 2.37 generated using the Mercury software 
package.84 (B) Structures of both the equatorial and axial diastereomers used for molecular modeling calculations 
 
Next, a combination of 
13
C and 
1
H NMR studies were used to refine our previous 
mechanistic hypothesis (Scheme 14).76  In situ 
13
C NMR studies conducted with spirolactol 2.32 
revealed that upon incubation with thiophenol (3 equiv) in DMSO-d6, reversible nucleophilic 
attack of thiophenol at the carbonyl carbon (200.0 ppm) occurred leading to formation of all four 
possible diastereomeric O,S-acetals (80.4, 79.8, 79.1, 78.9 ppm).  Upon the addition of Cs2CO3 
(5 equiv), these thioacetals were converted to the ,-unsaturated carbonyl (191.1 ppm) 
corresponding to the bicyclo[3.3.1]non-3-en-2-one product 2.33.  In addition, monitoring the 
reaction by 
1
H NMR revealed the accumulation of a defined intermediate prior to product 
formation.  Upon the addition of base complete disappearance of the lactol hydrogen at C4 (5.76 
ppm) and two of the epoxide hydrogens (3.40-3.36 ppm) from 2.32 were observed.  However, 
prior to formation of bicyclo[3.3.1]non-3-en-2-one 2.33 (indicated by the alkene hydrogen at C7 
of 2.33, 5.96 ppm), an intermediate containing a doublet of doublets ultimately assigned to the 
C11 hydrogen of B (3.34 ppm) was observed.  In order to confirm the identify of intermediate B, 
spirolactol 2.32 was subjected to the optimized room temperature conditions and quenched after 
only 5 min to afford epoxyketone B in 18% yield along with 53% yield of 2.33.  As expected, 
upon resubmission of B to the reaction conditions, bicyclo[3.3.1]non-3-en-2-one 2.33 was 
formed in a comparable 77% yield.  Based on these NMR studies, we refined our previously 
proposed mechanistic hypothesis (Scheme 14).  Our refined mechanistic hypothesis (Scheme 26) 
postulates that after initial reversible addition of thiophenol, the resulting thioacetal undergoes an 
irreversible 1,2-migration to open the epoxide and afford intermediate A.  Next, prior to the 
addition of a second equivalent of thiophenol, a base catalyzed intramolecular aldol reaction with 
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the hemiacetal proceeds to give intermediate B which, upon addition of a second equivalent of 
thiophenol and elimination, affords the observed bicyclo[3.3.1]non-3-en-2-one product 2.33.  
 
 
Scheme 26. Proposed mechanism for the ring-opening and intermolecular aldol reaction of diepoxyketone 2.32 with 
thiophenol. Reproduced with permission from ref.78 
 
Having refined our mechanistic hypothesis and shown that aryl thiols containing electron 
donating, electron withdrawing, and sterically demanding substituents are well-tolerated we 
focused on expanding the scope of the reaction to include heterocyclic and alkyl thiols (Table 
14).  Although six different heterocyclic thiols were subjected to the optimized room temperature 
reaction conditions, none of the desired bicyclo[3.3.1]non-3-en-2-ones were observed (entries 1-
6, Table 14).  In all of the heterocyclic thiol examples only complex mixtures containing either 
recovered heterocyclic thiol and several unidentified products or complete decomposition was 
observed.  These results suggest that the addition/rearrangement reaction is intolerant of the 
tertiary Lewis basic amine functionality.  This result was also observed during our optimization 
studies (Table 12).  The use of triethylamine, a base of similar strength to the carbonate bases, 
provided a complex mixture like those observed during the screen of heterocyclic thiols.   
Investigating the use of alkyl thiols for the addition/rearrangement reaction also provided 
none of the desired bicyclo[3.3.1]non-3-en-2-one products (entries 7-11, Table 14).  The use of 
isopropyl 3-mercaptopropionate in the presence of cesium carbonate afforded an unexpected 
major product that was tentatively assigned by 
1
H NMR to be addition of the thiol to both 
epoxides as well as the lactol to give 2.41 in 32% yield.  Unfortunately, subjecting the reaction 
mixture to elongated reaction times or heating afforded only a complex mixture of products.  
One plausible explanation for the limited success of the alkyl thiols is that their decreased acidity 
may require the use of a stronger base.  Under the optimized conditions the aryl thiols (pka ~ 7) 
should be completely deprotonated by cesium carbonate (pka ~ 10) while the alkyl thiols (pka ~ 
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18) remain almost entirely protonated.  This hypothesis is supported by our initial optimization 
studies (Table 12) that demonstrated the use of a number of bases, ranging in strength provided 
markedly different results.  
 
Table 14. Attempt to expand the reaction scope to include heterocyclic and alkyl thiols 
 
 
Next, the use of non-sulfur nucleophiles was investigated (Table 15).  The use of three 
equivalents of a thioamide, phenol, or an aniline in the presence of base at room temperature 
proved inefficient and none of the corresponding bicyclo[3.3.1]non-3-en-2-ones were isolated.  
The use of aniline led to a product tentatively assigned by 
1
H NMR to be 2.42.  Although 
opening of both epoxides was observed, elimination and intramolecular aldol reaction did not 
proceed and 2.42 was isolated in 45% yield.   
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Table 15. Attempt to expand the reaction scope to include non-thiol nucleophiles 
 
 
Finally, in an attempt to synthesize the chlorinated core of the gymnastatins (Figure 22), 
focus was directed towards the use of chloride as a nucleophile (Figure 26).  Stirring 2.32 with 
an excess (10 equiv) of lithium chloride (LiCl) in either CH2Cl2 or THF at room temperature 
overnight afforded only recovered starting material.  The addition of either titanium tetrachloride 
or trifluoroacetic acid to a mixture of LiCl and 2.32 in THF led to complete consumption of the 
starting material, however only a complex mixture of unidentified products was observed.  The 
use of either tetrabutylammonium chloride or hydrochloric acid as a chloride source returned, 
after stirring overnight with 2.32 in THF, only recovered starting material.  These experiments 
suggest that the decreased nucleophilicity of the chloride relative to the thiolate requires the use 
of either Lewis or Bronsted acid catalysis to obtain reactivity with 2.32.  Unfortunately, these 
harsher conditions resulted in the formation of a complex mixture of products.  Thus, further 
experimentation with chloride nucleophiles was not pursued.  
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Figure 26. Attempt to use a chloride to elicit the addition/rearrangement reaction 
 
Unfortunately, heterocyclic thiols, alkyl thiols, and several other non-sulfur nucleophiles 
all proved to be ineffective substrates for the desired addition/rearrangement reaction under the 
optimized conditions.  Although the lack of success observed with heterocyclic thiols was 
attributed to the presence of Lewis basic amine functionalities, the ineffectiveness of the alkyl 
thiols and non-sulfur nucleophiles is more likely a result of differences in their nucleophilic 
properties.  Mechanistic studies have revealed that the reaction likely proceeds via initial attack 
of the thiol at the ketone to generate an intermediate hemithioacetal that undergoes an 
irreversible 1,2-migration to open the epoxide.
94
 
Next, several epoxy ketone cores were prepared and evaluated in the 
addition/rearrangement reaction (Scheme 27, Scheme 28, and Scheme 29).  First, the use of a 
naphthyl derivative 2.47 was explored (Scheme 27).  Oxidative addition of methanol to 4-
methoxy-1-napthol in the presence of PIDA afforded acetal 2.44 in 85% yield.  In situ generation 
of butenylmagnesium bromide followed by addition to quinone monoacetal 2.44, a solvent swap, 
and ketal hydrolysis, provided the desired α,β-unsaturated ketone 2.45 in 40% over two steps.  
Epoxidation of enone 2.45 in the presence of hydrogen peroxide and sodium hydroxide afforded 
the syn oxygenated epoxy ketone 2.46 in 75% yield.  Ozonolysis in CH2Cl2 at -78 ºC followed by 
stirring in an excess of DMS provided the desired naphthyl derivative 2.47 in quantitative yield 
as a 1:1 mixture of lactols as determined by 
1
H NMR.  Gratifyingly, subjection of epoxy-ketone 
2.47 to the optimized conditions with thiophenol gave bicyclo[3.3.1]non-3-en-2-one 2.48 in 80% 
yield. 
  76 
 
 
Scheme 27. Synthesis of naphthyl derivative 2.48 
 
 Next, the effect of substitution of the enone was examined (Scheme 28).  Oxidative 
addition of methanol to 3-methyl phenol gave 2.49, which after addition of butenyl magnesium 
bromide and acetal deprotection provided bis-,-unsaturated ketone 2.50 in 37% yield over 
three steps.  Epoxidation and ozonylosis of 2.50 proceeded smoothly to afford diepoxy 
spirolactol 2.52 in 68% yield (two steps).  Interestingly, reaction of 2.52 with thiophenol in the 
presence of base afforded the tricyclic epoxide 2.53 in 53% yield.  Even under forcing 
microwave conditions (10 equiv of thiophenol, 10 equiv of base, 80 ºC, 3 h) none of the expected 
bicyclo[3.3.1]non-3-en-2-one was observed.  The presence of the axial methyl group is likely to 
sterically destabilize the transition state of the epoxide opening process.  The observed stability 
of the epoxide in the presence of a large excess of nucleophile is promising for the potential use 
of more rigid epoxy-ketones in biological assays.   
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Scheme 28. Synthesis and addition/rearrangement of 2.52  
 
Finally, an attempt to extend the methodology to the formation of bicyclo[3.4.1]dec-3-en-
2-ones proved unsuccessful (Scheme 29).  In situ generation of the pentenylmagnesium bromide 
followed by addition to quinone monoketal 2.29 and ketal hydrolysis furnished 2.54 in 55% yield 
(two steps).  Diepoxidation and ozonolysis proceeded smoothly to give a 10:1 mixture of 
spirolactol 2.56a and aldehyde 2.56b as determined by 
1
H NMR.  Subjection of 2.56 to 
thiophenol and base afforded, after silica get chromatography, an intractable mixture of products 
containing a major product and several unidentified by-products; however none of the desired 
bicycle 2.57 (as indicated by the characteristic alkene proton at 6 ppm) was observed.  
1
H NMR 
analysis of the intractable mixture revealed that the major product contained protons 
corresponding to the incorporation of thiophenol (7-8 ppm) and a proton corresponding to an 
intact lactol (5.5 ppm).  Therefore, it appears that although thiophenoxide addition occurred, 
intramolecular aldol reaction to form the seven-membered ring did not.  The absence of 
intramolecular aldol product is most likely a result of the less favorable formation of the seven-
membered ring as compared to six-membered ring formation.
93
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Scheme 29. Attempt to synthesize the 7-membered ring variant 2.57 
 
Having demonstrated the scope and limitations of the addition/rearrangement and 
successfully preparing eleven new bicyclo[3.3.1]non-3-en-2-ones, we sought to compare the new 
products to the bicyclo[3.3.1]non-3-en-2-ones currently contained in the Molecular Libraries 
Small Molecule Repository (MLSMR) library (1907 compounds).  
Through a collaboration with Dr. Beratan and coworkers at Duke University, the 
molecular diversity of the newly synthesized structures were analyzed using the ChemGPS-NP
94
 
map of chemical space.  ChemGPS-NP is a software program that provides a coordinate system 
designed for exploration of biologically relevant compounds.  It uses principle component 
analysis derived from the physiochemical properties of known bioactive natural products.  The 
first four principles components account for roughly 77% of data variance.  Principal Component 
1 (PC1) represents size, shape and polarizability of a compound.  PC2 corresponds to aromatic 
and conjugative properties, PC3 describes lipophilicity, polarity, and H-bond capacity, and PC4 
expresses the flexibility and rigidity of a molecule.
94
  
Figure 27 illustrates a comparison of the polarity/lipophilicity and aromatic character of 
the newly synthesized bicyclo[3.3.1]non-3-en-2-ones (blue circles) and the bicyclononanes 
already present in the MLSMR (crosses).  From Figure 27 it is clear that the newly synthesized 
bicyclo[3.3.1]non-3-en-2-ones occupy a novel region of the MLSMR chemical space.  This 
novel space is primarily derived from the high levels of aromaticity and low lipophilicity relative 
to the bicyclononanes currently present in the MLSMR library.  The increased aromaticity is 
derived from the aryl thiols, in particular the naphthyl derivate 2.40 shown as number 15 in 
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Figure 27 is far outside the previously prepared bicyclononanes.  The low lipophilicity of the 
compounds is derived from the densely hydroxylated core the derivatives.  This is demonstrated 
by the yellow boxes in Figure 27, which represent the newly synthesized compounds lacking 
hydroxyl groups.   
 
 
Figure 27. ChemGPS-NP coordinates of the synthesized bicyclononanes (in blue) and bicyclononanes in the 
MLSMR library (X's).  Also shown are the new products lacking hydroxyl groups (yellow boxes).  Figure 
reproduced with permission from ref.78 
 
Figure 28 (a) is a graph of PC4 and PC1, which represent the two principle components 
for molecular flexibility and size, respectively, and also compares the newly synthesized 
bicycle[3.3.1]non-3-en-2-ones (blue boxes) to the bicyclononanes already in the MLSMR library 
(crosses).  It is clear from Figure 28 (a) that the new compounds are not significantly different in 
molecular size relative to the previously prepared bicyclononanes; however, some of the newly 
prepared analogues are slightly larger than previously prepared compounds.  In addition, the 
newly prepared analogues are generally less flexible than the previously prepared compounds.  
The relatively high polarity and structural rigidity of the new compounds are potentially 
attractive for their biological activity and make them less likely to exhibit non-specific ligand-
receptor interactions.  
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Figure 28. ChemGPS-NP coordinates of the bicyclo[3.3.1]non-3-en-2-ones (blue boxes) in the MLMSR library 
(crosses). (a) Graph of PC1 and PC4, which represent the principle component dervied from molecular size and 
flexability respectively. (b) Graph of PC5 and PC6 which represent the principle components dervied from 
electronegativity and electropositive atom content, respectively.  Figure was reproduced with permission for ref.78 
 
Figure 28 (b) is a graph of PC6 and PC5 which represent the principle components 
corresponding to electronegativity and electropositive atomic content respectively.  Again this 
graph is a comparison of newly synthesized compounds (blue boxes) and those already in the 
MLSMR library (crosses).  Figure 28 (b) illustrates that the new compounds are clustered around 
the origin of the PC6 axis and occupy the relatively empty negative PC5 axis.   
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In addition, the physiochemical descriptors of the newly synthesized bicyclo[3.3.1]non-3-
en-2-ones were evaluated using the OpenEye toolkit as well as ChemAxon (Table 16).  All but 
two of the new prepared bicyclic compounds obey Lipinski’s rule of 5.95  As these rules were 
generated to roughly correlate to the efficiency of drug transport across membranes, the fact that 
all compounds are well below the required <5 hydrogen bond donors (HBD) and <10 hydrogen 
bond acceptors (HBA) bodes well for their potential biological activity.  In addition, most of the 
new compounds exhibit XlogP’s <5, indicating low lipophilicity and promising bioavailability.    
 
Table 16. Selected physiochemical properties of the newly synthesized bicyclo[3.3.1]non-3-en-2-ones 
 
 
  The present ChemGPS-NP analysis demonstrates how the densely hydroxylated core 
and large aromatic character of the natural-product like bicyclo[3.3.1]non-3-en-2-ones allows 
them to access new regions of biologically relevant chemical space.  The combination of ease of 
synthesis, limited flexibility, hydrophilic nature, and promising physiochemical properties 
suggests these compounds may be potential leads for the development of bioactive compounds.
78
   
The newly synthesized bicyclo[3.3.1]non-3-en-2-ones were submitted to the MLSMR in 
50+ mg quantities.  Since their submission, seven of the eleven newly synthesized 
bicyclo[3.3.1]non-3-en-2-ones have been evaluated in 58 different biological assays.  The parent 
bicyclo[3.3.1]non-3-en-2-one, 2.33, exhibited 33±2.6% (N = 3) inhibition at 4 µM in a 
luminescence-based high throughput assay for inhibitors of the interaction of the lipase co-
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activator protein, abhydrolase domain containing 5 (ABHD5), with perilipin-5 (MDLDP; 
PLIN5).
96
  ABHD5 is a protein that activates an enzyme, adipose triglyceride, which plays a role 
in breaking down triglycerides.
96
   Structural comparison of 2.33 to some of the most potent 
interaction inhibitors (100% inhibition at 4 µM) reported in PubChem
97
 reveals that while a 
diverse set of structures have exhibited activity in this assay, 2.33 contains an unrepresented 
structure (Figure 29).  A counterscreen for selective interaction inhibition of ABHD5 revealed 
2.33 exhibited 43±2.5% (N = 3) inhibition at 4 µM of hepatocyte nuclear factor 4 dimerization 
(HNF4).
96
  HNF4 is a member of the nuclear receptor superfamily and binds DNA exclusively as 
a homodimer.  Dimerization controls important aspects of receptor function, such as DNA 
binding, protein stability, ligand binding and interactions with co-activators.
96
      
 
 
Figure 29. Structure of 2.33 and the most potent inhibitors of the interaction of the lipase co-activator protein, 
abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MDLDP; PLIN5).96   
 
  83 
Bicyclo[3.3.1]non-3-en-2-one 2.35 exhibited 99% inhibition of ataxin-2 (ATXN2) 
protein expression at 25 µM in a quantitative high-throughput screen (qHTS).
96
  The 
overexpression of ATXN2 is associated with a multi-system neurodegenerative disease leading 
to progressive ataxia (loss of voluntary coordination of muscle movement) and later lose of 
function in other neuronal systems.
96
  Once again, while a diverse set of structures have 
exhibited activity in this assay, the newly synthesized bicyclo[3.3.1]non-3-en-2-one is novel 
(Figure 30).   
 
 
Figure 30. Structure of 2.35 and some of the most potent inhibitors of ataxin-2 protein (ATXN2) expression.97 
 
In addition, 2.35 exhibited 73% inhibition at 3 µM in a fluorescence-based cell-based 
high-throughput assay to identify antagonists of the human trace amine associated receptor 1 
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(TAAR1).
96
    TAAR1 is a G protein-coupled receptor activated by trace amines, which has been 
shown to modulate the activity of neurotransmitters such as dopamine and γ-amino butyric acid 
and alterations in their brain levels are associated with schizophrenia and depression.
96
  As a 
result, TAAR1 is an interesting target for the development of ligands to probe the role of this 
receptor in CNS function and disease.
96
  While a diverse set of structures have exhibited activity 
in this assay, 2.35 contains a novel structure (Figure 31).  
 
 
Figure 31. Structure of 2.35 and some other potent antagonists of the human trace amine associated receptor 1 
(TAAR1).97 
 
A counterscreen for selective antagonists of TAAR1 revealed 2.35 exhibited 33±2.3% (N 
= 3) inhibition at 3 µM in a fluorescence-based cell-based high throughput assay to identify 
antagonists of the G-protein alpha subunit, G-alpha-16 (Ga16).
96
  Ga16 has been shown to play a 
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role in the formation of blood cellular components and its down-regulation is associated with 
leukemia.
96
 
2.3 CONCLUSIONS 
The successful preparation of a single member of the fully functionalized 
bicyclo[3.3.1]non-3-en-2-one core containing the amino functionality presented here provides a 
proof of principle for the creation of a natural product-like small library based on this scaffold.  
Completion of the synthesis of a model system allowed rapid access to a precursor that was used 
to rigorously optimize conditions for the addition/rearrangement reaction.  Two optimized 
procedures were realized.  A more broadly applicable procedure at room temperature in CH2Cl2 
provided the desired products in 1.5 h in 57-87% yield, and microwave conditions in CH2Cl2 
shortened the reaction time to 2 min at 60 ºC to provide the desired products in 64-88% yield.   
Both sets of conditions were shown to tolerate electron-donating, electron-withdrawing, 
and sterically demanding substituents as well as several epoxy ketone starting materials.  In situ 
NMR studies allowed for the refinement of our mechanistic hypothesis.  The limitations of the 
methodology were explored and although a number of aryl thiols were converted, the use of 
heterocyclic and alkyl thiols as well as other non-sulfur based nucleophiles was unsuccessful.  In 
addition, attempts to synthesize a bicyclo[3.4.1]decenone were unsuccessful.   
The newly synthesized bicyclo[3.3.1]non-3-en-2-ones were shown via ChemGPS-NP 
analysis to occupy novel regions of chemical space when compared to the bicyclononanes 
currently present in the MLSMR.  The unique hydrophilicity of the new analogues coupled with 
their structural rigidity and promising physiochemical properties make them prime candidates for 
lead compounds with decreased potential for non-specific binding.  All of the newly synthesized 
compounds have passed quality control and have been submitted to the MLMSR in 50+ mg 
quantities for biological evaluation.   
Seven of the eleven compounds submitted to the MLMSR were tested for activity in 58 
different assays.  Two of the bicyclo[3.3.1]non-3-en-2-ones, 2.33 and 2.35, exhibited activity.  
Although neither compound proved to be the most potent inhibitor evaluated in these assays, 
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structural comparison to some of the most potent inhibitors revealed that the newly synthesized 
bicyclo[3.3.1]non-3-en-2-ones were structurally novel.  These assays, in combination with the 
ChemGPS analysis, demonstrate that the goal of synthesizing a small natural product-like focus 
library containing a biologically relevant and currently underrepresented scaffold in the NIH 
libraries has been achieved. 
2.4 EXPERIMENTAL 
 
General. All moisture sensitive reactions were performed using syringe-septum techniques 
under an atmosphere of either dry N2 or dry argon unless otherwise noted. All glassware was 
dried in an oven at 140 ºC for a minimum of 6 h or flame-dried under an atmosphere of dry 
nitrogen prior to use. Reactions carried out at -78 ºC employed a CO2(s)/acetone bath. Diethyl 
ether and tetrahydrofuran were dried by distillation over sodium/benzophenone under an argon 
atmosphere. Dry methylene chloride was purified by filtration through an activated alumina 
column. Methylene chloride was degassed using the freeze/pump/thaw method (3x). Methanol 
was stored over molecular sieves (3Å).  Deuterated chloroform was stored over anhydrous 
potassium carbonate. Reactions were monitored by TLC analysis (pre-coated silica gel 60 F254 
plates, 250 µm layer thickness) and visualized by using UV lamp (254 nm) or by staining with 
either Vaughn’s reagent (4.8 g of (NH4)6Mo7O24•4 H2O and 0.2 g of Ce(SO4)2 in 100 mL of a 3.5 
N H2SO4) or a potassium permanganate solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL 
of a 0.1% NaOH solution). Flash column chromatography was performed with 40-63 µm silica 
gel (Silicycle). Microwave reactions were performed on a Biotage Initiator microwave reactor. 
Infrared spectra were measured on a Smiths Detection IdentifyIR FT-IR spectrometer (ATR). 
Unless otherwise indicated, all NMR data were collected at room temperature in CDCl3 on a 
300, 500, 600, or 700 MHz Bruker instrument. Chemical shifts (δ) are reported in parts per 
million (ppm) with internal CHCl3 ( 7.26 ppm for 
1
H and 77.00 ppm for 
13
C), internal acetone 
( 2.05 ppm for 1H and 29.85 ppm for 13C), or internal DMSO ( 2.50 ppm for 1H and 39.52 for 
13
C) as the reference. 
1
H NMR data are reported as follows: chemical shift, multiplicity (s = 
singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of 
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doublets, dt = doublet of triplets, td = triplet of doublets, qd = quartet of doublets, sep = septet), 
integration, and coupling constant(s) (J) in Hertz (Hz).  HRMS analyses were obtained using 
either a Q-TOF Ultima API, Micromass UK Limited (ESI) or a VG Autospec, FISIONS 
instrument (EI). 
2.4.1 General Procedure A: Addition/Rearrangement to Afford the Bicyclo[3.3.1]non-3-
en-2-one Scaffold.  
To a stirred solution of 2.32 (0.0500 g, 0.252 mmol, 1 equiv) in dry, degassed CH2Cl2 (12 
mL) was added Cs2CO3 (0.411 g, 1.26 mmol, 5 equiv) and the thiol nucleophile (0.757 mmol, 3 
equiv). The reaction mixture was allowed to stir at room temperature for 1-2 h, diluted with 
EtOAc (40 mL), and washed with brine. The organic layer was separated and the aqueous layer 
was extracted with EtOAc (2 x 10 mL).  The combined organic layers were washed with brine, 
dried (MgSO4), filtered, and concentrated under reduced pressure. The crude mixture was 
dissolved in CH2Cl2 and purified by chromatography on SiO2.   
2.4.2 General Procedure B: Microwave Assisted Addition/Rearrangement to Afford the 
Bicyclo[3.3.1]non-3-en-2-one Scaffold. 
 To a stirred solution of 2.32 (0.0100 g, 0.0505 mmol, 1 equiv) in dry, degassed CH2Cl2 
(2 mL) was added Cs2CO3 (0.0822 g, 0.252 mmol, 5 equiv) and the thiol nucleophile (0.151 
mmol, 3 equiv). The reaction mixture was heated in the microwave reactor for 2 min at 60 ºC, 
diluted with CH2Cl2 (10 mL), and washed with brine. The organic layer was separated and the 
aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic layers were washed 
with brine, dried (MgSO4), filtered, and concentrated under reduced pressure. The crude mixture 
was dissolved in CH2Cl2 and purified by chromatography on SiO2. 
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(3S)-3-[(Benzyloxycarbonyl)amino]-1-oxaspiro[4.5]deca-7,10-diene-2,8-dione (2.17).
70
 To a 
stirred solution of iodobenzene diacetate  (75.0 g, 228 mmol, 1.20 equiv) in MeCN/i-PrOH (3:1, 
500 mL) was added a solution of 2.15 (60.0 g, 190 mmol, 1 equiv) in MeCN/i-PrOH (3:1, 400 
mL) dropwise over 2 h.  After the addition was complete, the mixture was allowed to stir at rt for 
4 h open to the air, quenched with a saturated aqueous solution of NaHCO3 (400 mL), and 
extracted with EtOAc (3 x 300 mL).  The combined organic layers washed with a saturated 
aqueous solution of NaHCO3, brine, dried (MgSO4), filtered, and concentrated under reduced 
pressure.  The crude residue was dissolved in EtOAc/hexanes (4:1, 300 mL) and passed through 
a pad of SiO2.  The resulting solution was concentrated and purified by chromatography on SiO2  
(EtOAc/hexanes, 1:4-1:1) to give 2.17 (24.0 g, 41%) as yellow powder: Rf 0.43 (EtOAc/hexanes, 
1:1); Mp 104-106 °C (EtOAc); [α]D -25.6 (c 1.04, CH2Cl2); IR (neat) 3336, 3034, 2971, 2935, 
1761, 1711, 1675, 1634, 1258, 1211 cm
-1
; 
1
H NMR (700 MHz, CDCl3) δ 7.32 (s, 5 H), 6.86 (s, 2 
H), 6.24 (app t, 2 H, J = 11.9 Hz), 5.91 (d, 1 H, J = 4.9 Hz), 5.11 (d, 1 H, J = 12.6 Hz), 5.08 (d, 1 
H, J = 12.6 Hz), 4.64 (d, 1 H, J = 8.4 Hz), 2.2263 (t, 1 H, J = 11.2 Hz), 2.48 (t, 1 H, J = 11.9 Hz); 
13
C NMR (176 MHz, CDCl3) δ 184.0, 173.5, 155.9, 146.0, 144.1, 135.6, 129.6, 129.0, 128.5, 
128.4, 128.1, 76.1, 67.5, 50.3, 37.9;  HRMS (ESI
+
) m/z calcd for C17H15NO 313.0950, found 
313.0946. 
 
 
 (3S)-3-[Bis(benzyloxycarbonyl)amino]-1-oxaspiro[4.5]deca-7,10-diene-2,8-dione (2.1).
70
 
  89 
To a stirred solution of 2.17 (8.90 g, 28.4 mmol, 1 equiv) in MeCN (90 mL) was added DMAP 
(1.04 g, 8.52 mmol, 0.3 equiv) and Cbz2O (2.18) (32.5 g, 114 mmol, 4 equiv) in ten portions at 5 
min intervals.  The reaction mixture was allowed to stir at rt for 2 h, diluted with EtOAc (50 
mL), washed with water and brine (x2), dried (MgSO4), filtered, and concentrated under reduced 
pressure.  The crude residue was purified by chromatography on SiO2 (EtOAc/hexanes, 1:5 to 
1:3) to give 2.1 (10.8 g, 85%) as white powder: Rf 0.66 (EtOAc/hexanes, 1:1); Mp 113-116 ºC 
(CHCl3); [α]D -46.2 (c 1.02, CH2Cl2); IR (neat) 3060, 3032, 2982, 2973, 2953, 2894, 1772, 1709, 
1670, 1629, 1297, 1226, 1187, 752, 695 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 7.43-7.27 (m, 10 
H), 6.81 (dd, 1 H, J = 3.1, 10.1 Hz), 6.47 (dd, 1 H, J = 3.1, 10.1 Hz), 6.21 (dd, 1 H, J = 1.9, 10.1 
Hz), 6.14 (dd, 1 H, J = 1.9, 10.1 Hz), 5.52 (t, 1 H, J = 10.2 Hz), 5.28 (d, 2 H, J = 12.0 Hz), 5.23 
(d, 2 H, J = 12.0 Hz), 2.57 (dd, 2 H, J = 2.0, 10.2 Hz); 
13
C NMR (75 MHz, CDCl3)  183.9, 
171.4, 152.3, 146.0, 144.8, 134.0, 129.0, 128.7, 128.6, 128.5, 128.5, 75.5, 70.0, 54.3, 35.2; 
HRMS (ESI
+
) m/z calcd for C25H21NO7Na 470.1216, found 470.1231. 
 
 
Dibenzyl Carbonate (2.18).
70
   NaH (60% in mineral oil; 12.0 g, 300 mmol, 1.3 equiv) was 
washed with dry hexanes (30 mL), dried under vacuum, and resuspended in THF (60 mL).  A 
solution of benzyl alcohol (25.0 g, 231 mmol, 1 equiv) in dry THF (450 mL) was added, via an 
addition funnel to the NaH slurry over 30 min.  The reaction mixture was heated at reflux for 2 h 
and then cooled to 0 °C in an ice bath.  Dry CO2 was bubbled through the vigorously stirred 
solution for 1 h at 0 °C.  To this very viscous slurry was added benzyl chloroformate (33.0 mL, 
231 mmol, 1 equiv) dropwise via an addition funnel over 20 min.  The reaction mixture was 
allowed to warm to rt, stirred for an additional 3 h, diluted with H2O (200 mL), and extracted 
with Et2O (2 x 100 mL).  The combined organic layers were washed with brine, dried (Na2SO4), 
filtered, and concentrated under reduced pressure.  The resulting oil was washed with hexanes, 
placed under vacuum for several minutes, and allowed to crystallize for 2 d to give 2.18 (64.5 g, 
98%) as white solid (Note: yield was determined from NMR which showed THF and hexanes, 
which, using the molar ratio, were subtracted from the mass of the crude material): Mp 23 °C; 
1
H 
NMR (300 MHz, CDCl3) δ 7.42 (s, 10 H), 5.28 (s, 4 H); 
13
C NMR (75 MHz, CDCl3) δ 148.2, 
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133.6, 128.8, 128.5, 128.5, 71.1. 
 
 
1
st
 Generation approach to tri-n-butyliodomethylstannane (2.19).
98
  In a 100 mL, three-neck, 
round bottomed flask, cupric acetate monohydrate (0.0400 g 0.200 mmol, 1 equiv) was dissolved 
in glacial acetic acid (4 mL) by heating in an oil bath. To the resulting greenish blue solution was 
added granular zinc (2.60 g, 40 mg atom, 1 equiv) and this mixture was stirred for 2 min while 
heating was continued. The acetic acid was decanted from the settled dark brown Cu/Zinc 
couple; a second batch of glacial acetic acid (4 mL) was added, stirred with heating for 2 min, 
and decanted.  The metal couple was cooled to room temperature, washed with dry Et2O (2 x 8 
mL), and dried under an argon stream.  After the addition of dry THF (7 mL), the reaction was 
initiated with several drops of diiodomethane.  Upon appearance of a purple color, an additional 
portion of dry THF (13 mL) was added to the flask and a solution of diiodomethane (10.8 g, 40.2 
mmol, 2 equiv) in THF (7 mL) was added dropwise at a rate which allowed the reaction mixture 
to maintain a temperature of ca. 40 °C.  The stirring was continued for the first hour without 
heating but during the last two hours the temperature was maintained with an oil bath.  The 
resulting dark purple slurry was cannulated to another 100 mL round-bottom flask through a 
glass filter.  To the very pale yellow ICH2ZnI solution was added tributyltin chloride (90%; 6.60 
mL, 21.2 mmol, 1 equiv) dropwise over 10 min and the mixture was stirred for 26 h.  The yellow 
reaction mixture was diluted with hexanes (150 mL), washed with water and brine, dried 
(MgSO4), filtered, and concentrated under reduced pressure to give a pale yellow oil.  The crude 
oil was purified by chromatography on SiO2 (hexanes) to give 2.19 (6.20 g, 68%) as a colorless 
oil:  Rf 0.87 (hexanes); 
1
H NMR (300 MHz, CDCl3) δ 1.95 (s, 2 H), 1.59-1.48 (m, 6 H), 1.39-
1.27 (m, 6 H), 1.01-0.89 (m, 15 H). 
 
 
1
st
 Generation approach to benzyloxymethyl tri-n-butylstannane (2.20).
98
  To a slurry of 
NaH (60% in mineral oil; 0.746 g, 18.6 mmol, 1.4 equiv) in dry THF (35 mL) was added 
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dropwise at rt benzyl alcohol (1.72 mL, 18.6 mmol, 1.25 equiv).  The reaction mixture was 
allowed to stir until H2 evolution subsided (~15 min).  To the resulting stirred solution was added 
2.19 (6.20 g, 14.4 mmol, 1 equiv) in one portion and the mixture was stirred at rt for 64 h, diluted 
with hexanes (100 mL), washed with water and brine, dried (MgSO4), filtered, and concentrated 
under reduced pressure.  The resulting pale yellow oil was purified by chromatography on Si2O 
(EtOAc/hexanes 0:1 to 1:50) to give 2.20 (4.86 g, 89%) as a colorless oil: 
1
H NMR (300 MHz, 
CDCl3) δ 7.33 (s, 5 H) 4.45 (s, 2 H), 3.78 (t, 2 H, J = 7.8 Hz), 1.60-1.40 (m, 6 H), 1.39-1.27 (m, 
6 H), 0.97-0.89 (m, 15 H); 
13
C NMR (75 Hz, CDCl3) δ 138.9, 128.2, 127.5, 127.3, 77.2, 61.5, 
29.1, 27.3, 13.7, 9.0.  
 
 
2
nd
 Generation approach to benzyloxymethyl tri-n-butylstannane (2.20).
85
  To a stirred 
solution of freshly distilled diisopropylamine (3.20 mL, 22.7 mmol, 1.1 equiv) in dry THF (40 
mL) was added dropwise n-BuLi (1.6 M in hexanes; 12.9 mL, 20.6 mmol, 1 equiv) at -78 °C.  
After addition, the reaction mixture was allowed to warm to 0 °C for 30 min and Bu3SnH (5.56 
mL, 20.6 mmol, 1 equiv) was added.  The resulting greenish solution was stirred at 0 °C for 30 
min and then cooled to -78 °C.  Freshly distilled chloromethyl benzyl ether (2.86 mL, 20.6 
mmol, 1 equiv) was added and the solution was allowed to stirred for 30 min at -78 °C.  The 
reaction mixture was allowed to warm to rt and stir for 6 h, diluted with hexanes (50 mL), 
washed with brine (x2), dried (MgSO4), filtered, and concentrated under reduced pressure to give 
a yellow oil.  The crude oil was purified by chromatography on SiO2 (hexanes/CH2Cl2, 8:2) to 
give 2.20 (5.66 g, 67%) as a colorless oil:  
1
H NMR (300 MHz, CDCl3) δ 7.33 (s, 5 H) 4.45 (s, 2 
H), 3.78 (t, 2 H, J = 7.80 Hz), 1.60-1.40 (m, 6 H), 1.39-1.27 (m, 6 H), 0.97-0.89 (m, 15 H); 
13
C 
NMR (75 MHz, CDCl3) δ 138.9, 128.2, 127.5, 127.3, 77.2, 61.5, 29.1, 27.3, 13.7, 9.0. 
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 (3S,5S,6S,7R,8S,9S,10R)-3-[Bis(benzyloxycarbonyl)amino]-8-[(benzyloxy)-methyl]-
6,7:9,10-diepoxy-8-hydroxy-1-oxaspiro[4.5]decan-2-one (2.3).
70
  To a stirred solution of 2.20 
(1.38 g, 3.35 mmol, 1.5 equiv) in dry THF (15 mL) was added n-BuLi (1.6 M in hexanes; 2.10 
mL, 3.35 mmol, 1.5 equiv) dropwise at -78 °C.  After 10 min, the deep yellow solution was 
cooled to -100 °C and rapidly cannulated to a pre-cooled (-100 °C) solution of 2.1 (1.00 g, 2.24 
mmol, 1 equiv) in dry THF (10 mL).   After 10 min, the mixture was quenched at -78 °C with 
NaHCO3 (5% aqueous solution; 30 mL) under vigorous stirring, allowed to warm to rt and 
extracted with EtOAc (3 x 60 mL).  The combined organic layers were washed with brine, dried 
(Na2SO4), filtered, and concentrated under reduced pressure to give a yellow-green oil.  Upon 
addition of hexanes (5 mL) to the oily residue, two immiscible layers formed.  The top layer was 
decanted, the remaining oil was diluted with CCl4 (20 mL) and m-CPBA (1.75 g, 9.61 mmol, 4.3 
equiv) and 3-tert-butyl-4-hydroxy-5-methylphenylsulfide (0.721 g, 2.01 mmol, 0.9 equiv) were 
added.  The resulting slurry was heated at 70 °C for 3 h, at which point the solvent was removed 
under reduced pressure.  The crude residue was dissolved in CH2Cl2 (5 mL) and purified by 
chromatography on SiO2 (EtOAc/hexanes 1:5 to 1:1) to give 2.3 (0.300 g, 23%) as a white 
powder: Rf 0.16 (EtOAc/hexanes, 1:1); Mp 163-164 °C (CHCl3); [α]D -18.6 (c 1.00, CH2Cl2); IR 
(neat) 3513, 3060, 3030, 2965, 2855, 1781, 1729, 1688, 1339, 1231, 1120, 941, 760, 749, 697 
cm
-1
; 
1
H NMR (300 MHz, CDCl3)  7.36-7.3 (s, 10 H), 7.22-7.20 (m, 5 H), 5.30, 5.23 (AB, 2 H, 
J = 12.0 Hz), 5.27 (m, 1 H), 4.50, 4.44 (AB, 1 H, J = 11.0 Hz), 3.62, 3.56 (AB, 2 H, 9.0 Hz), 
3.25 (dt, 2 H, J = 1.2, 3.9 Hz), 3.15 (dd, 1 H, J = 2.7, 4.2 Hz), 3.07 (dd, 1 H, J = 3.0, 3.9 Hz), 
2.26 (dd, 1 H, J = 10.8, 13.8 Hz), 1.94 (dd, 1 H, J = 10.2, 14.1 Hz); 
13
C NMR (176 MHz, CDCl3) 
 171.6, 152.4, 136.8 , 134.2, 128.8, 128.7, 128.5, 128.5, 128.4, 128.3, 79.2, 74.1, 72.7, 69.9, 
68.7, 59.1, 59.1, 58.7, 58.6, 54.0, 32.4; HRMS (ESI
+
) m/z calcd for C33H31NO10Na 624.1846, 
found 624.1831. 
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1
st
 Generation approach to (3S,5S,6S,7R,8S,9S,10R)-3-[(tert-butoxy-carbonyl)amino]-8-
[(benzyloxy)-methyl]-6,7:9,10-diepoxy-8-hydroxy-1-oxaspiro[4.5]decan-2-one (2.14).
70
  To a 
stirred solution of 2.3 (0.150 g, 0.255 mmol, 1 equiv) in dry THF/absolute MeOH (1:1, 12 mL) 
was added 1,4-cyclohexadiene (0.938 mL, 9.91 mmol, 38.8 equiv) and Pd/C (10% w/w; 0.160 
g).  The reaction mixture was stirred at rt for 2 h, filtered through Celite and di-tert-butyl 
dicarbonate (0.167 g, 0.766 mmol, 3 equiv) was added to the filtrate.  The mixture was stirred at 
rt for 30 min.  The solvent was removed under reduced pressure and the crude residue was 
purified by chromatography on SiO2 (EtOAc/hexanes, 1:1) to give 2.14 (0.0406 g, 38%) as a 
white solid: 
1
H NMR  (300 MHz, CDCl3) δ 7.48 (s, 5 H), 5.72 (bs, 1 H), 4.68 (s, 3 H), 3.75 (s, 2 
H), 3.58-3.47 (m, 4 H), 2.68 (t, 1 H, J = 11.0 Hz), 2.27 (dd, 1 H, J = 11.0 Hz), 1.61 (s, 9 H).  For 
full characterization see 2
nd
 generation approach. 
 
 
2
nd
 Generation approach to (3S,5S,6S,7R,8S,9S,10R)-3-[(tert-butoxycarbonyl)amino]-8-
[(benzyloxy)-methyl]-6,7:9,10-diepoxy-8-hydroxy-1-oxaspiro[4.5]decan-2-one (2.14).
70
  To a 
stirred solution of 2.23 (0.430 g, 0.758 mmol, 1 equiv) in dry THF/absolute MeOH (1:1, 40 mL) 
was added 1,4-cyclohexadiene (3.13 mL, 33.1 mmol, 43.7 equiv) and Pd/C (10% w/w; 0.100 g).  
The reaction mixture was allowed to stir at rt for 2 h, an additional batch of Pd/C (10% w/w; 
0.200 g) was added, and the mixture was allowed to stir at rt for an additional 5 h, filtered 
through Celite and purified by chromatography on SiO2 (deactivated with Et3N, EtOAc/hexanes, 
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1:1) to give 2.14 (0.234 g, 72%) as a white foam: Rf 0.58 (EtOAc/hexanes, 3:1); [α]D +0.9 (c 
1.05, CH2Cl2); IR (neat) 3457, 3063, 2976, 2905, 1783, 1692, 1597, 1531, 1464, 1326, 1155, 
1080, 989, 700 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 7.39-7.28 (m, 5 H), 5.21 (bs, 1 H), 4.56 (d, 1 
H, J = 11.4 Hz), 4.51 (d, 1 H, J = 11.4 Hz), 4.41 (q, 1 H, J = 10.0 Hz), 3.63 (d, 1 H, J = 9.3 Hz), 
3.59 (d, 1 H, J = 9.3 Hz), 3.42-3.38 (m, 1 H), 3.30-3.27 (m, 3 H), 3.10 (bs, 1H), 2.59 (dd, 1 H, J 
= 10.2 Hz, 13.8 Hz), 2.06 (app t, 1 H, J = 12 Hz), 1.47 (s, 9 H); 
13
C NMR (75 MHz, CDCl3)  
173.8, 155.1, 136.9, 128.6, 128.3, 128.2, 80.9, 79.5, 74.1, 72.7, 68.5, 59.4, 59.3, 59.3, 58.0, 49.8, 
35.3, 28.3; HRMS (ESI
+
) m/z calcd for C22H27NO8Na 456.1634, found 456.1612. 
 
 
 (3S)-3-[(Benzyloxycarbonyl)-(tert-butoxycarbonyl)amino]-1-oxaspiro[4.5]deca-7,10-diene-
2,8-dione (2.22).  To a stirred solution of 2.21 (7.84 g, 25.0 mmol, 1 equiv) in dry MeCN (125 
mL) was added DMAP (0.917 g, 7.51 mmol, 1 equiv), followed by Boc2O (6.55 g, 30.0 mmol, 
1.2 equiv) in two portions at a 30 min interval.  The resulting solution was allowed to stir at rt for 
45 min, and concentrated under reduced pressure.  The crude residue was dissolved in 
EtOAc/hexanes (3:1), passed through a plug of SiO2, and concentrated under reduced pressure to 
give 2.22 (9.73 g, 94%) as a white solid: Rf 0.40 (EtOAc/hexanes, 1:2); Mp 60-63 °C (EtOAc); 
[α]D -26.7 (c 0.99, CH2Cl2); IR 2976, 2935, 1785, 1731, 1694, 1671, 1634, 1347, 1226, 1142, 
1107 cm
-1
; 
1
H NMR (300 MHz, CDCl3)  7.35-7.27 (m, 5 H), 6.84 (dd, 1 H, J = 10.2 Hz), 6.69 
(dd, 1 H, J = 3.2, 10.2 Hz), 6.15 (dd, 1 H, J = 3.2, 10.2 Hz), 6.12 (dd, 1 H, J = 1.8, 3.4 Hz), 5.42 
(t, 1 H, J = 10.2 Hz), 5.19 (d, 1 H, J = 11.9 Hz), 5.13 (d, 1 H,  J = 11.9 Hz), 2.61-2.45 ( m, 2 H), 
1.38 (s, 9 H); 
13
C NMR (75 MHz, CDCl3)  183.8, 171.6, 152.5, 150.7, 146.1, 145.0, 134.1, 
128.7, 128.5, 128.4, 128.3, 128.1, 84.9, 75.3, 69.4, 53.8, 35.1, 27.5; ESI-MS m/z 436.5 [M+Na]
+
 
314.5 ([M-Boc]
+
). 
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 (3S,5S,6S,7R,8S,9S,10R)-3-[(tert-Butoxycarbonyl)(benzyloxycarbonyl)amino]-8-
[(benzyloxy)-methyl]-6,7:9,10-diepoxy-8-hydroxy-1-oxaspiro[4.5]decan-2-one (2.23).
70
  To a 
stirred solution of 2.20 (1.49 g, 3.63 mmol, 1.5 equiv) in dry, degassed THF (10 mL) was added 
dropwise at -78 °C of n-BuLi (2.27 mL, 1.6 M in hexanes; 3.63 mmol, 1.5 equiv).  After 20 min, 
the deep yellow solution was cooled to -105 °C and rapidly cannulated to a pre-cooled (-105 °C) 
solution of the 2.22 (1.00 g, 2.42 mmol, 1 equiv) in dry, degassed THF (15 mL).  After 45 min, 
the reaction was quenched at -105 °C with NaHCO3 (3% aqueous solution; 15 mL) under 
vigorous stirring.  The mixture was allowed to warm to rt and extracted with EtOAc (3 x 40 mL).  
The combined organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated 
under reduced pressure to give an oil.  Upon addition of hexanes (2 mL) to the oily residue, two 
immiscible layers formed.  The top layer was decanted, the remaining oil was diluted with 
degassed CCl4 (15 mL), and m-CPBA (2.20 g, 12.1 mmol, 5 equiv) and 3-tert-butyl-4-hydroxy-
5-methylphenylsulfide (0.867 g, 2.42 mmol, 1 equiv) were added to the stirred solution.  The 
resulting slurry was heated at 70 °C for 3 h, diluted with EtOAc (40 mL), and the solvent was 
removed under reduced pressure.  The crude residue was dissolved in CH2Cl2, loaded onto SiO2 
and purified by chromatography on SiO2 (deactivated with Et3N; EtOAc/hexanes 4:1 to 2:1 to 
1:1 to 1:2) to give 2.23 (0.798 g, 58%) as a colorless foam: Rf 0.16 (EtOAc/hexanes, 1:1); [α]D -
6.6 (c 0.68, CH2Cl2); IR (neat) 1787, 1731, 1696, 1349, 1230, 937, 698 cm
-1
; 
1
H NMR (300 
MHz, CDCl3) δ 7.42-7.35 (m, 5 H), 7.30-7.23 (m, 5 H), 5.26 (d, 1 H, J = 11.7 Hz), 5.22 (t, 1 H, J 
= 9.6 Hz), 5.20 (d, 1 H, J = 12 Hz), 4.52 (d, 1 H, J = 11.1 Hz), 4.47 (d, 1 H, J = 11.1 Hz), 3.62 
(d, 1 H, J = 9.3 Hz), 3.58 (d, 1 H, J = 9.3 Hz), 3.31-3.24 (m, 3 H), 3.21 (dd, 1 H, J = 2.7, 3.9 
Hz), 2.30 (dd, 1 H, J = 10.5, 13.8 Hz), 2.03 (dd, 1 H,  J = 10.2, 13.8 Hz), 1.45 (s, 9 H); 
13
C NMR 
(125 MHz, CDCl3) δ 171.9, 152.8, 151.0, 136.9, 134.5, 128.8, 128.8, 128.7, 128.5, 128.5, 128.3, 
85.1, 79.0, 77.3, 74.1, 72.8, 69.7, 68.7, 59.1, 59.1, 58.9, 58.7, 53.7, 32.6, 30.9, 27.9; HRMS 
(ESI
+
) m/z calcd. for C30H33NO10Na 590.2002, found 590.2019. 
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(2R,3S,5S,6S,7R,9S,10R)-3-[(tert-Butoxycarbonyl)amino]-6,7:9,10-diepoxy-2-hydroxy-1-
oxaspiro[4.5]decan-8-one (2.13).
70
  A solution of 2.14 (0.160 g, 0.369 mmol, 1 equiv) and 
CeCl3-7H2O (0.459 g, 1.85 mmol, 5 equiv) in EtOH/H2O (2:1, 13 mL) was stirred for 10 min at 
rt until all solids had completely dissolved.  The mixture was cooled to -25 ºC, treated with 
NaBH4 (0.084 g, 2.21 mmol, 6 equiv) in three portions at 30 min intervals, allowed to stir at -25 
°C for an additional 30 min and quenched with several drops of acetone. The reaction mixture 
was diluted with EtOAc (150 mL), washed with brine, dried (MgSO4), filtered, and concentrated 
under reduced pressure.  The crude residue was dissolved in MeOH/THF (1:1, 16 mL) and of 
Pd/C (300 mg, 10% w/w) was added to the stirred solution.  The reaction vessel was evacuated 
and back filled with H2 three times.  H2 was vigorously bubbled through the solution at rt 
overnight.   The mixture was filtered through a pad of Celite and concentrated under reduced 
pressure.  The resulting yellow residue was dissolved in MeOH/THF (1:1, 10 mL) and a solution 
of NaIO4 (0.395 g, 1.85 mmol, 5 equiv) in H2O (2 mL) was added.  After 1.5 h, a second solution 
of NaIO4 (0.250 g) in H2O (1 mL) was added to the reaction mixture.  After an additional 1 h at 
rt, the reaction mixture was diluted with EtOAc (20 mL), washed with brine, dried (MgSO4), 
filtered, and concentrated under reduced pressure.  The crude residue was dissolved in CH2Cl2 (3 
mL) purified by chromatography on SiO2 (deactivated with Et3N, EtOAc/hexanes, 1:1) to give 
2.13 (0.0624 g, 54%) as a colorless film: Rf 0.78; [α]D +2.3 (c 0.60, CH2Cl2); IR (CDCl3) 3388, 
2976, 1700, 1508, 1364, 1243, 1161, 1006, 926, 790 cm
-1
; 
1
H NMR (600 MHz, CDCl3) δ 5.59 (s, 
1 H), 5.15 (d, 1 H, J = 8.4 Hz), 4.59 (s, 1 H), 4.42 (s, 1 H), 3.68 (s, 1 H), 3.50 (s, 1 H), 3.43 (s, 2 
H), 2.53 (t, 1 H, J = 11.4 Hz), 2.03 (t, 1 H, J = 12.0 Hz), 1.44 (s, 9 H); 
13
C NMR (150 MHz, 
CDCl3) δ 198.3, 155.3, 96.4, 80.3, 78.6, 64.2, 62.9, 55.8, 55.5, 53.2, 35.9, 28.3; HRMS (ESI
+
) 
m/z calcd for C14H19NO7Na 336.1059, found 336.1060. 
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tert-Butyl-(1S,2S,3R,5S)-2,5,9-trihydroxy-8-oxo-1,7-bis(phenylthio)bicyclo[3.3.1]non-6-en-
3-ylcarbamate (2.24).  To a stirred solution of 2.13 (0.025 g, 0.0803 mmol, 1 equiv) in dry THF 
(3 mL) was added NaH (60% dispersion in mineral oil; 0.00963 g, 0.241 mmol, 3 equiv) and 
thiophenol (0.0442 g, 0.402 mmol, 5 equiv).  The reaction mixture was allowed to stir at rt for 2 
h, diluted with EtOAc (10 mL), washed with H2O and brine, dried (Mg2SO4), filtered, and 
concentrated under reduced pressure.  The residue was purified by chromatography on SiO2 
(EtOAc/hexane 1:5 to 1:1) to give 2.24 (0.0171 g, 41%) as a colorless film: Rf 0.26 
(EtOAc/hexane, 1:1); 
1
H NMR (300 MHz, CDCl3) δ 7.59-7.27 (m, 10 H), 6.01 (s, 1 H), 4.59 (s, 
1 H), 3.60 (bs, 1 H), 3.50 (bs, 1 H), 3.26 (s, 1 H), 3.24 (s, 1 H), 3.20 (s, 1 H), 3.13 (d, 1 H, J = 
3.9 Hz), 2.14 (bs, 1 H), 1.70 (s, 1 H), 1.26 (s, 1H); 
13
C (75 MHz, CDCl3) δ 189.0, 171.2, 155.7, 
142.4, 139.6, 137.9, 134.8, 133.3, 132.1, 130.6, 129.9, 129.7, 129.5, 129.2, 126.4, 124.4, 123.6, 
80.3, 75.7, 72.3, 72.0, 69.8, 51.0, 36.5, 29.7, 28.3. 
 
 
Acetyl-(1S,2S,3R,5S)-2,5,9-trihydroxy-8-oxo-1,7-bis(phenylthio)bicyclo[3.3.1]non-6-en-3-
ylcarbamate (2.26).  To a stirred solution of 2.24 (0.0182 g, 0.0353 mmol, 1 equiv) in CH2Cl2 
(0.3 mL) was added trifluoroacetic acid (0.026 mL, 0.353 mmol, 10 equiv) and the mixture was 
allowed to stir at rt for 2.5 h.  The solvent was removed with purging N2.  To the crude TFA salt 
(0.014 g, 0.0337 mmol, 1 equiv) was added DIPEA (0.234 mL, 1.15 mmol, 40 equiv) and the 
reaction mixture was allowed to stir for 10 min, and heated with a solution of freshly distilled 
acetyl chloride (0.00317 g, 0.0404 mmol, 1.2 equiv) in CH2Cl2 (0.060 mL).  The mixture was 
allowed to stir at rt for 30 min, concentrated in a stream of N2, washed with citric acid (1 M 
aqueous solution) (2 x10 mL), saturated aqueous NaHCO3 (2 x 10 mL), brine, dried (Na2SO4), 
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filtered, and concentrated under reduced pressure.  The crude residue was purified by 
chromatography on SiO2 (MeOH/ CH2Cl2, 3:97) to give 2.26 (0.0102 g, 66%) as a colorless film: 
Rf 0.62 (CH2Cl2/MeOH, 9:1); 
1
H NMR (700 MHz, CDCl3) δ 7.60-7.27 (m, 10 H), 6.00 (s, 1 H), 
5.69 (s, 1 H), 3.90 (s, 2 H), 3.49 (s, 1 H), 3.28 (s, 1 H), 3.21 (d, 1 H, J = 9.8 Hz), 2.09 (dd, 1 H, J 
= 4.2, 12.6 Hz), 1.96 (s, 3 H), 1.34 (t, 1 H, J = 12.6 Hz); 
13
C NMR (176 MHz, CDCl3) δ 189.3, 
171.4, 142.3, 138.1, 134.8, 130.49, 130.0, 129.5, 129.2, 126.8, 123.5, 77.8, 75.7, 73.4, 72.2, 71.9.  
 
 
4,4-Dimethoxycyclohexa-2,5-dienone (2.29).
91,99
  To a stirred solution of 4-methoxyphenol 
(10.0 g, 80.6 mmol, 1 equiv) in dry MeOH (200 mL) at 0 °C under a nitrogen atmosphere was 
added phenyliodonium diacetate (PIDA; 25.9 g, 80.6 mmol, 1 equiv), and the resulting solution 
was stirred for 45 min. After 45 min, the mixture was quenched with a saturated aqueous 
solution of NaHCO3 (300 mL) and extracted with Et2O (3x). The combined organic layers were 
washed with brine, dried (MgSO4), filtered, and concentrated under reduced pressure. The 
reaction mixture was purified by chromatography on SiO2 (deactivated with 0.1% Et3N; 
EtOAc/hexanes 1:5 to 1:1) to give 2.29 (12.3 g, 99%) as a colorless oil: Rf 0.41 (EtOAc/hexanes, 
1:3); IR (neat) 2991, 2941, 2830, 1685, 1671, 1636, 1178, 1105, 1083, 1059, 1034, 1034, 958, 
853 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 6.84-6.79 (m, 2 H), 6.29-6.24 (m, 2 H), 3.37 (s, 6 H); 
13
C NMR (75 Hz, CDCl3) δ 185.1, 143.2, 130.0, 92.4, 50.4; HRMS (EI
+
) m/z calcd for C8H10O3 
154.0630, found 154.0628. 
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4-(But-3-enyl)-4-hydroxycyclohexa-2,5-dienone (2.30).
91
  To a dry, 100 mL, three-necked, 
round-bottom flask equipped with an addition funnel and reflux condenser was added 
magnesium turnings (2.27 g, 93.4 mmol, 1.2 equiv) and a crystal of iodine.  Heat (Bunsen burner 
flame) was applied to the stirred turnings until a purple gas coated the interior of the flask. The 
sample was allowed to cool under argon and suspended in dry THF (30 mL). To the stirred 
solution was added via an addition funnel a solution of 4-bromo-1-butene (9.48 mL, 93.4 mmol, 
1.2 equiv) in dry THF (10 mL) at a rate so that the solution maintained a gentle reflux. After the 
addition was complete, the reaction mixture was allowed to stir at reflux for 45 min, cooled to rt 
and cannulated over 30 min into a pre-cooled (-78 ºC) solution of 2.29 (12.0 g, 77.8 mmol, 1 
equiv) in dry THF (150 mL). The reaction mixture was allowed to stir at -78 ºC for 3 h and 
quenched with a saturated aqueous solution of NH4Cl, warmed to rt, and extracted with EtOAc 
(3 x 150 mL). The combined organic layers were washed with brine, dried (MgSO4) and 
concentrated under reduced pressure. The resulting oil was diluted with H2O/acetone (1:1, 500 
mL) and glacial acetic acid (50 mL) was added. The reaction mixture was allowed to stir at rt for 
3 h, and extracted with EtOAc (3 x 150 mL). The combined organic layers were washed with 
brine, dried (MgSO4), filtered, and concentrated under reduced pressure to give a yellow oil 
which was purified by chromatography on SiO2 (EtOAc/hexanes, 1:3) to give 2.30 (7.05 g, 43%) 
as a volatile pale yellow oil: Rf 0.24 (EtOAc/hexanes, 1:3); IR (neat) 3339, 3276, 2937, 1662, 
1606, 1396, 1052, 1018, 991, 859, 716 cm
-1
; 
1
H NMR (300 MHz, CDCl3)  6.86-6.81 (m, 2 H), 
6.21-6.16 (m, 2 H), 5.77 (dddd, 1 H, J = 6.3, 6.3, 10.2, 16.5 Hz), 5.06-4.96 (m, 2 H), 2.52 (s, 1 
H), 2.09-2.01 (m, 2 H), 1.88-1.83 (m, 2 H); 
13
C NMR (75 MHz, CDCl3) δ 185.5, 150.9, 137.1, 
128.4, 115.4, 69.8, 38.8, 27.8. HRMS (EI
+
) m/z calcd for C10H12O2 164.0837, found 164.0829. 
 
 
4-(But-3-enyl)-4-hydroxycyclohexa-2,5-dioxirane (2.31).
91
  To a stirred solution of enone 2.30 
(4.25 g, 25.9 mmol, 1 equiv) in methanol (100 mL) and 30 % aq. hydrogen peroxide (7.93 mL, 
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77.6 mmol, 3 equiv) at 0 ºC was added 6 M NaOH (2.16 mL, 7.00 mmol, 0.5 equiv) dropwise. 
The reaction mixture was allowed to stir at 0 ºC for 2 h, poured onto DI water and thoroughly 
extracted with EtOAc (7 x 100 mL). The combined organic layers were washed with brine, 
poured onto activated 4 Å molecular sieves, and allowed to stir at rt for 3 h. The mixture was 
filtered and concentrated under reduced pressure to give 2.31 (3.68 g, 72%) as an off-white solid: 
Rf 0.62 (EtOAc/ CH2Cl2, 1:1); IR (neat) 3459, 3028, 2976, 2940, 1702, 1366, 1328, 1239, 1090, 
1060, 1025, 926, 917 cm
-1
; 
1
H NMR (300 MHz, CDCl3)  5.79 (ddd, 1 H, J = 6.6, 10.2, 16.8 
Hz), 5.09-5.01 (m, 2 H), 3.50 (s, 4 H), 3.03 (s, 1 H), 2.27-2.15 (m, 2 H), 1.96-1.90 (m, 2 H); 
13
C 
NMR (75 MHz, CDCl3) δ 198.9, 136.7, 115.9, 68.9, 63.9, 57.0, 35.6, 26.9. HRMS (ESI
+
) m/z 
calcd for C10H12O4 196.0736, found 196.0726. 
 
 
1-Oxaspiro[4.5.]deca-6,9-diepoxy-2,8-lactol (2.32).
91
  A solution of 2.31 (1.00 g, 5.10 mmol, 1 
equiv) in CH2Cl2 (30 mL) was cooled to -78 ºC. Ozone was passed through the stirred solution 
for 3.5 h followed by purging with N2 before the dropwise addition of DMS (7.54 mL, 102 
mmol, 20 equiv) at -78 ºC. The reaction mixture was allowed to stir at -78 ºC for 1 h and then 
allowed to warm to rt and stirred at rt for 3 d. The solvent was removed under reduced pressure. 
The crude product was purified by chromatography on SiO2 (EtOAc) to give 2.32 (0.962 g, 95%) 
as an off-white solid: Rf 0.45 (EtOAc); Mp 164-166 ºC; IR (neat) 3369, 3440, 2965, 1722, 1459, 
1431, 1349, 1243, 1202, 1038, 976, 919 cm
-1
; 
1
H NMR (500 MHz, acetone-d6)  5.69 (d, 1 H, J 
= 1.8 Hz), 5.53 (bs, 1 H), 3.62 (t, 1 H, J = 2.4 Hz), 3.49 (t, 1 H, J = 2.1 Hz), 3.35 (t, 1 H, J = 2.4 
Hz), 3.31 (t, 1 H, J = 2.4 Hz), 2.35-2.27 (m, 1 H), 2.19-2.11 (m, 2 H), 2.05-2.00 (m, 1 H); 
13
C 
NMR (125 MHz, acetone-d6) δ 200.5, 100.6, 80.3, 65.2, 63.6, 56.1, 55.9, 33.9, 31.1; HRMS 
(EI
+
) m/z calcd for C9H10O5 198.0528, found 198.0523. 
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(1S,8R,9S)-5,8,9-Trihydroxy-1,3-bis(phenylthio)bicyclo[3.3.1]non-3-en-2-one (2.33). 
Prepared according to general procedure A utilizing 2.32 (0.025 g, 0.126 mmol, 1 equiv), 
Cs2CO3 (0.205 g, 0.631 mmol, 5 equiv), and thiophenol (0.039 mL, 0.38 mmol, 3 equiv). The 
crude mixture was purified by chromatography on SiO2 (EtOAc/hexanes 1:2 to 1:1) to give 2.33 
(0.0416 g, 83%) as a white solid: Rf 0.33 (EtOAc/hexanes, 1:1); Mp 185-188 ºC; IR (neat) 3502, 
3335, 3051, 2945, 2879, 1666, 1590, 1472, 1439, 1310, 1228, 1100, 1032, 954, 738, 689 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  7.52-7.51 (m, 2 H), 7.46-7.41 (m, 5 H), 7.33-7.32 (m, 3 H), 5.96 
(d, 1 H, J = 0.9 Hz), 3.85-3.83 (m, 1 H), 3.48 (s, 1 H), 3.32 (s, 1 H), 3.24 (s, 1 H) 2.27 (s, 1 H), 
2.06-2.03 (m, 1 H), 1.89 (dd, 1 H, J = 1.5, 6.6 Hz), 1.76 (dt, 1 H, J = 2.1, 8.1 Hz), 1.67 (s, 1 H), 
1.38 (dq, 1 H, J = 3.0, 8.1 Hz); 
13
C NMR (125 MHz, CDCl3) δ 193.0, 143.3, 141.9, 134.9, 133.4, 
133.1, 130.1, 129.9, 129.5, 129.2, 128.4, 73.0, 69.9, 63.4, 58.4, 33.3, 29.1; HRMS (EI
+
) m/z 
calcd for C21H20O4S2 400.0803, found 400.0822. 
 
 
(1S,8R,9S)-5,8,9-Trihydroxy-1,3-bis(phenylthio)bicyclo[3.3.1]non-3-en-2-one (2.33). 
Prepared according to general procedure B utilizing 2.32 (0.0100 g, 0.0505 mmol, 1 equiv), 
Cs2CO3 (0.0822 g, 0.252 mmol, 5 equiv) and thiophenol (0.015 mL, 0.151 mmol, 3 equiv). The 
crude reaction mixture was purified by chromatography on SiO2 (EtOAc/hexanes 1:2 to 1:1) to 
give 2.33 (0.0178 g, 88%) as a white solid: Rf 0.33 (EtOAc/hexanes, 1:1); 
1
H NMR (300 MHz, 
acetone-d6) δ 7.79-7.75 (m, 2 H), 7.52-7.39 (m, 8 H), 5.99 (d, 1 H, J = 2.4 Hz), 4.65 (bs, 1 H), 
4.52 (bs, 1 H), 4.02 (d, 1 H, J = 1.8 Hz), 3.42-3.37 (m, 1 H), 3.19, (s, 1 H), 2.00-1.94 (m, 1 H), 
1.62-1.54 (m, 1 H), 1.51-1.34 (m, 2 H). For full characterization see directly preceding 
experimental. 
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(1S,8R,9S)-5,8,9-Trihydroxy-1,3-bis(p-tolylthio)bicyclo[3.3.1]non-3-en-2-one (2.34).  
Prepared according to general procedure A utilizing 2.32 (0.0500, 0.252 mmol, 1 equiv), Cs2CO3 
(0.411 g, 1.26 mmol, 5 equiv), and p-thiocresol (0.0940 mL, 0.757 mmol, 3 equiv). The crude 
reaction mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 1:1) to give 2.34 
(0.078.6 g, 73%) as a white solid: Rf 0.29 (EtOAc/hexanes, 1:1); Mp 191-193 ºC; IR (neat) 3496, 
3345, 3060, 2942, 1664, 1578, 1472, 1420, 1314, 1217, 1100, 1031, 868, 731 cm
-1
; 
1
H NMR 
(300 MHz, acetone-d6) δ 7.64-7.62 (m, 2 H), 7.40-7.38 (m, 2 H), 7.28 (d, 2 H, J = 8.1 Hz), 7.23 
(d, 2 H, J = 8.1 Hz), 5.84 (d, 1 H, J = 2.4 Hz), 4.44 (bs, 1 H), 3.99 (s, 1 H), 3.37 (dd, 1 H, J = 6.0, 
10.8 Hz), 3.17 (d, 1 H, J = 2.4 Hz), 2.36 (s, 3 H), 2.35 (s, 3 H), 1.99-1.92 (m, 1 H), 1.58-1.51 (m, 
1 H), 1.48-1.32 (m, 2 H); 
13
C NMR (75 MHz, acetone-d6) δ 190.9, 143.1, 140.8, 140.0, 139.9, 
139.1, 135.6, 131.4, 130.6, 128.1, 126.1, 77.5, 75.8, 74.2, 69.2, 31.4, 28.4, 21.2, 21.2; HRMS 
(EI
+
) m/z calcd for C23H24O4S2 428.1116, found 428.1101
 
 
 
(1S,8R,9S)-5,8,9-Trihydroxy-1,3-bis(p-tolylthio)bicyclo[3.3.1]non-3-en-2-one (2.34). 
Prepared corresponding to general procedure B utilizing 2.32 (0.0100 g, 0.0505 mmol, 1 equiv), 
Cs2CO3 (0.0822 g, 0.252 mmol, 5 equiv) and p-thiocresol (0.0188 g, 0.151 mmol, 3 equiv). The 
crude reaction mixture was purified by chromatography on SiO2 (EtOAc/hexanes 1:2 to 1:1) to 
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give 2.34 (0.0160 g, 74%) as a white solid: Rf 0.29 (EtOAc/hexanes, 1:1); 
1
H NMR (300 MHz, 
acetone-d6) δ 7.63 (dm, 2 H, J = 8.1 Hz), 7.39 (dm, 2 H, J = 8.1 Hz), 7.28 (d, 2 H, J = 8.1 Hz), 
7.23 (d, 2 H, J = 8.1 Hz), 5.84 (d, 1 H, J = 2.4 Hz), 4.59 (bs, 1 H), 4.44 (d, 1 H, J = 3.0 Hz), 3.99 
(d, 1 H, J = 2.1 Hz), 3.39-3.34 (m, 1 H), 3.17 (s, 1 H), 2.36 (s, 3 H), 2.35 (s, 3 H), 1.99-1.92 (m, 
1 H), 1.58-1.51 (m, 1 H), 1.48-1.32 (m, 2 H). For full characterization see directly preceding 
experimental. 
 
 
(1S,8R,9S)-1,3-Bis(4-tert-butylphenylthio)-5,8,9-trihydroxybicyclo[3.3.1]non-3-en-2-one 
(2.35).  Prepared according to general procedure A utilizing 2.32 (0.0500, 0.252 mmol, 1 equiv), 
Cs2CO3 (0.411 g, 1.26 mmol, 5 equiv), and 4-tert-butylthiophenol, (0.13 mL, 0.76 mmol, 3 
equiv). The crude reaction mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 
5:1 to 3:1) to give 2.35 (0.0935 g, 72%) as a white solid: Rf 0.86 (EtOAc/hexanes, 1:1); Mp 203-
207 ºC; IR (neat): 3475, 2956, 2902, 2866, 1674, 1591, 1489, 1265, 1099, 1034, 1012, 831, 729 
cm
-1
; 
1
H NMR (300 MHz, acetone-d6) δ 7.71-7.69 (m, 1 H), 7.68-7.67 (m, 1 H), 7.52-7.41 (m, 6 
H), 5.94 (d, 1 H, J = 2.4 Hz), 4.62 (bs, 1 H), 4.48 (bs, 1 H), 4.04 (d, 1 H, J = 1.8 Hz), 3.40 (dd, 1 
H, J = 6.0, 11. 1 Hz), 3.19 (d, 1 H, J = 2.1 Hz), 2.01-1.93 (m, 1 H), 1.61-1.54 (m, 1 H), 1.49-1.35 
(m, 2 H), 1.33 (s, 9 H), 1.32 (s, 9 H); 
13
C NMR (75 MHz, acetone-d6) δ 190.9, 153.7, 152.8, 
143.8, 139.5, 138.9, 134.9, 128.4, 127.6, 126.9, 126.1, 77.7, 75.8, 74.2, 69.3, 35.3, 28.3; HRMS 
(EI+) m/z calcd for C29H36O4S2 512.2055, found 512.2076. 
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(1S,8R,9S)-1,3-Bis(4-tert-butylphenylthio)-5,8,9-trihydroxybicyclo[3.3.1]non-3-en-2-one 
(2.35).  Prepared corresponding to general procedure B utilizing 2.32 (0.0100 g, 0.0505 mmol, 1 
equiv), Cs2CO3 (0.0822 g, 0.252 mmol, 5 equiv) and 4-tert-butyl-thiophenol (0.026 mL, 0.15 
mmol, 3 equiv).  The crude reaction mixture was purified by chromatography on SiO2 
(EtOAc/hexanes 1:5 to 1:2) to give 2.35 (0.0218 g, 84%) as an off-white solid: Rf 0.86 
(EtOAc/hexanes, 1:1); 
1
H NMR (300 MHz, acetone-d6) δ 7.70-7.67 (m, 2 H), 7.52-7.41 (m, 6 H), 
5.94 (d, 1 H, J = 2.4 Hz), 4.47 (bs, 1 H), 4.04 (bs, 1 H), 3.40 (dd, 1 H, J = 5.7, 10. 8 Hz), 3.19 (d, 
1 H, J = 2.7 Hz), 2.01-1.93 (m, 1 H), 1.61-1.54 (m, 1 H), 1.49-1.35 (m, 2 H), 1.33 (s, 9 H), 1.32 
(s, 9 H).  For full characterization see directly preceding experimental. 
 
 
(1S,8R,9S)-5,8,9-Trihydroxy-1,3-bis(4-methoxyphenylthio)bicyclo[3.3.1]non-3-en-2-one 
(2.36).  Prepared according to general procedure A utilizing 2.32 (0.0500, 0.252 mmol, 1 equiv), 
Cs2CO3 (0.411 g, 1.26 mmol, 5 equiv), and 4-methoxythiophenol (0.093 mL, 0.76 mmol, 3 
equiv). The crude reaction mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 
1:1) to give 2.36 (0.0857 g, 74%) as a white solid. Rf 0.29 (EtOAc/hexanes, 1:1); Mp 105-107 
ºC; IR (neat) 3487, 2937, 2911, 2903, 1670, 1588, 1491, 1285, 1243, 1172, 1101, 1025, 950, 829 
cm
-1
; 
1
H NMR (300 MHz, acetone-d6) δ 7.69-7.65 (m, 2 H), 7.45-7.42 (m, 2 H), 7.06-7.02 (m, 2 
H), 6.99-6.95 (m, 2 H), 5.70 (d, 1 H, J = 2.4 Hz), 4.55 (bs, 1 H), 4.37 (s, 1 H), 3.97 (d, 1 H J = 
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2.1 Hz), 3.85 (s, 3 H), 3.83 (s, 3 H), 3.36 (dd, 1 H, J = 6.0, 10.8 Hz), 3.15 (s, 1 H), 1.98-1.91 (m, 
1 H), 1.56-1.50 (m, 1 H), 1.46-1.32 (m, 2 H); 
13
C NMR (75 MHz, acetone-d6) δ 191.1, 162.0, 
161.7, 141.7, 140.9, 140.5, 137.9, 121.4, 119.9, 116.3, 115.4, 77.4, 75.8, 74.1, 69.1, 55.8, 55.7, 
31.5, 28.3; HRMS (EI
+
) m/z calcd for C23H24O6S2 460.1014, found 460.1009. 
 
 
(1S,8R,9S)-5,8,9-Trihydroxy-1,3-bis(4-methoxyphenylthio)bicyclo[3.3.1]non-3-en-2-one 
(2.36).  Prepared according to general procedure B utilizing 2.32 (0.0100 g, 0.0505 mmol, 1 
equiv), Cs2CO3 (0.0822 g, 0.252 mmol, 5 equiv) and 4-methoxythiophenol (0.019 mL, 0.15 
mmol, 3 equiv).  The crude mixture was purified by chromatography on SiO2 (EtOAc/hexanes 
1:5 to 1:2) to give 2.36 (0.0186 g, 80%) as a white solid: Rf 0.29 (EtOAc/hexanes, 1:1); 
1
H NMR 
(300 MHz, acetone-d6) δ 7.66 (dm, 2 H, J = 8.7 Hz), 7.43 (dm, 2 H, J = 9.0 Hz), 7.04 (dm, 2 H, 
9.0 Hz), 6.96 (dm, 2 H, J = 8.7 Hz), 5.69 (d, 1 H, J = 2.4 Hz), 4.38 (bs, 1 H), 3.98 (d, 1 H, J = 2.1 
Hz), 3.85 (s, 3 H), 3.83 (s, 3 H), 3.35 (dd, 1 H, J = 6.0, 10.8 Hz), 3.15 (d, 1 H, J = 2.4 Hz), 1.98-
1.91 (m, 1 H), 1.56-1.50 (m, 1 H), 1.46-1.32 (m, 2 H).  For full characterization see directly 
preceding experimental. 
 
 
(1S,8R,9S)-1,3-Bis(2-bromophenylthio)-5,8,9-trihydroxybicyclo[3.3.1]non-3-en-2-one (2.37). 
Prepared according to general procedure A utilizing 2.32 (0.0500, 0.252 mmol, 1 equiv), Cs2CO3 
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(0.411 g, 1.26 mmol, 5 equiv), and 2-bromobenzenethiol (0.091 mL, 0.76 mmol, 3 equiv). The 
crude reaction mixture was purified by chromatography on SiO2 (EtOAc/hexanes 1:3 to 1:1) to 
give 2.37 (0.121 g, 87%) as a white solid. A small portion was recrystallized (acetone/Et2O) to 
give colorless crystals for x-ray analysis: Rf 0.28 (EtOAc/hexanes, 1:1); Mp 171-173 ºC; IR 
(neat) 3427, 3468, 2937, 2883, 2868, 1659, 1599, 1446, 1420, 1331, 1272, 1248, 1110, 1019, 
954, 760, 732 cm
-1
; 
1
H NMR (300 MHz, acetone-d6) δ 8.06 (dd, 1 H, J = 2.4, 7.2 Hz), 7.79 (dd, 1 
H, 2.1, 7.2 Hz), 7.75 (dd, 1 H, J = 0.9, 8.1 Hz), 7.56 (dd, 1 H, J = 1.5, 7.8 Hz), 7.45-7.29 (m, 4 
H), 6.19 (d, 1 H, J = 2.7 Hz), 4.86 (bs, 1 H), 4.63 (s, 1 H), 3.79 (d, 1 H, J = 2.1 Hz), 3.47 (dd, 1 
H, J = 5.7, 10.2 Hz), 3.43 (d, 1 H, J = 2.1 Hz), 1.74-1.55 (m, 4 H); 
13
C NMR (75 MHz, acetone-
d6) δ 190.0, 148.5, 141.6, 135.8, 135.6, 134.5, 134.4, 134.3, 133.2, 132.4, 131.5, 130.8, 129.6, 
129.1, 127.6, 78.1, 76.2, 70.0, 69.9, 31.3, 28.4; HRMS (ESI+) m/z calcd for C21H18O4NaS2Br2 
578.8911, found 578.8945. 
 
 
(1S,8R,9S)-1,3-Bis(2-bromophenylthio)-5,8,9-trihydroxybicyclo[3.3.1]non-3-en-2-one (2.37). 
Prepared according to general procedure B utilizing 2.32 (0.0100 g, 0.0505 mmol, 1 equiv), 
Cs2CO3 (0.0822 g, 0.252 mmol, 5 equiv) and 2-bromothiophenol (0.018 mL, 0.15 mmol, 3 
equiv). The crude reaction mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 
2:1 to 1:1) to give 2.37 (0.0233 g, 83%) as a white solid: Rf 0.28 (EtOAc/hexanes, 1:1); 
1
H NMR 
(300 MHz, acetone-d6) δ 8.06 (dd, 1 H, J = 2.4, 7.2 Hz), 7.79 (dd, 1 H, 2.1, 7.2 Hz), 7.75 (dd, 1 
H, J = 0.9, 8.1 Hz), 7.56 (dd, 1 H, J = 1.5, 7.8 Hz), 7.45-7.29 (m, 4 H), 6.19 (d, 1 H, J = 2.4 Hz), 
4.86 (bs, 1 H), 4.69 (bs, 1 H), 3.80 (s, 1 H), 3.48 (dd, 1 H, J = 5.7, 10.2 Hz), 3.43 (d, 1 H, J = 2.4 
Hz), 2.04-2.00 (m, 1 H), 1.74-1.55 (m, 3 H).  For full characterization see directly preceding 
experimental. 
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(1S,8R,9S)-1,3-Bis(3-fluorophenylthio)-5,8,9-trihydroxybicyclo[3.3.1]non-3-en-2-one (2.38). 
Prepared according to general procedure A utilizing 2.32 (0.0500, 0.252 mmol, 1 equiv), Cs2CO3 
(0.411 g, 1.26 mmol, 5 equiv), and 3-fluorothiophenol (0.064 mL, 0.76 mmol, 3 equiv). The 
crude reaction mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 1:1) to give 
2.38 (0.110 g, 74%) as a white solid: Rf 0.46 (EtOAc/hexanes, 1:1); Mp 190-192 ºC; IR (neat) 
3349, 3345, 3060, 2942, 2918, 1664, 1578, 1472, 1420, 1472, 1314, 1217, 1155, 1099, 868, 731 
cm
-1
; 
1
H NMR (300 MHz, acetone-d6) δ 7.63-7.56 (m, 2 H), 7.51-7.41 (m, 2 H), 7.30-7.21 (m, 3 
H), 7.16-7.09 (m, 1 H), 6.39 (d, 1 H, J = 2.4 Hz), 4.76 (bs, 1 H), 4.19 (s, 1 H), 3.48 (dd, 1 H, J = 
6.0, 11.1 Hz), 3.29 (d, 1 H, 2.4 Hz), 2.06-1.98 (m, 1 H), 1.72-1.63 (m, 1 H), 1.58-1.42 (m, 2 H); 
13
C NMR (75 MHz, acetone-d6) δ 190.3, 165.1 (d, J = 48.8 Hz), 161.8 (d, J = 48.8 Hz), 149.3, 
137.0, 135.9 (d, J = 8.3 Hz), 135.2 (d, J = 3.0 Hz), 132.3 (d, J = 7.5 Hz), 132.0 (d, J = 9.0 Hz), 
131.3 (d, J = 8.3 Hz), 129.1 (d, J = 3.0 Hz), 125.5 (d, J = 21.0 Hz), 119.7 (d, J = 22.5 Hz), 117.6 
(d, J = 21.0 Hz), 115.7 (d, J = 21.0 Hz), 77.8, 76.0, 74.7, 69.4, 31.2, 28.6; HRMS (EI
+
) m/z calcd 
for C21H19F2O4S2 436.0615, found 436.0633. 
 
 
(1S,8R,9S)-1,3-Bis(3-fluorophenylthio)-5,8,9-trihydroxybicyclo[3.3.1]non-3-en-2-one (2.38).  
Prepared according to general procedure B utilizing 2.32 (0.0100 g, 0.0505 mmol, 1 equiv), 
Cs2CO3 (0.0822 g, 0.252 mmol, 5 equiv) and 3-fluorthiophenol (0.013 mL, 0.15 mmol, 3 equiv). 
The crude reaction mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 1:1) to 
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give 2.38 (0.017 g, 77%) as a white solid: Rf 0.46 (EtOAc/hexanes, 1:1); 
1
H NMR (300 MHz, 
acetone-d6) δ 7.63-7.56 (m, 2 H), 7.49-7.42 (m, 2 H), 7.30-7.22 (m, 3 H), 7.16-7.10 (m, 1 H), 
6.38 (d, 1 H, J = 2.4 Hz), 4.76 (bs, 1 H), 4.19 (s, 1 H), 3.49 (dd, 1 H, J = 6.0, 10.8 Hz), 3.29 (d, 1 
H, 2.4 Hz), 2.02-1.98 (m, 1 H), 1.72-1.63 (m, 1 H), 1.58-1.42 (m, 2 H).  For full characterization 
see directly preceding experimental. 
 
 
(1S,8R,9S)-5,8,9-Trihydroxy-1,3-bis(4-(trifluoromethyl)phenylthio)bicyclo[3.3.1]non-3-en-
2-one (2.39).  Prepared according to general procedure A utilizing 2.32 (0.0500, 0.252 mmol, 1 
equiv), Cs2CO3 (0.411 g, 1.26 mmol, 5 equiv), and 4-trifluoromethylthiophenol (0.135 g, 0.757 
mmol, 3 equiv). The crude reaction mixture was purified by chromatography on SiO2 
(EtOAc/hexane, 1:1) to give 2.39 (0.100 g, 74%) as a foam: Rf 0.21 (EtOAc/hexanes, 1:1); Mp 
145-148 ºC IR (neat) 3498, 1685, 1604, 1319, 1163, 1120, 1103, 1062, 1013, 839 cm
-1
; 
1
H NMR 
(300 MHz, acetone-d6) δ 8.00 (d, 2 H, J = 8.1 Hz), 7.74 (d, 2 H, J = 8.1 Hz), 7.69 (d, 2 H, J = 8.4 
Hz), 7.60 (d, 2 H, J = 8.4 Hz), 6.69 (d, 1 H, J = 2.7 Hz), 4.84 (bs, 1 H), 4.28 (s, 1 H), 3.54 (dd, 1 
H, J = 5.7, 10.5 Hz), 3.32 (d, 1 H, J = 2.4 Hz), 2.03-1.96 (m, 1 H), 1.80-1.47 (m, 3 H);
 13
C NMR 
(75 MHz, acetone-d6) δ 190.0, 152.8, 139.6, 135.8, 135.4, 131.9, 126.8 (q, J = 3.75 Hz), 126.4 
(q, J = 3.75 Hz), 78.0, 76.0, 75.0, 69.6, 31.0, 28.8. HRMS (ESI+) m/z calcd for C23H18O4F6NaS2 
559.0448, found 559.0490. 
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(1S,8R,9S)-5,8,9-Trihydroxy-1,3-bis(4-(trifluoromethyl)phenylthio)bicyclo[3.3.1]non-3-en-
2-one (2.39).  Prepared according to general procedure B utilizing 2.32 (0.0100 g, 0.0505 mmol, 
1 equiv), Cs2CO3 (0.0822 g, 0.252 mmol, 5 equiv) and 4-trifluoromethylthiophenol (0.0207 g, 
0.151 mmol, 3 equiv).  The crude reaction mixture was purified by chromatograph on SiO2 
(EtOAc/hexanes, 1:1) to give 2.39 (0.0191 g, 71%) as a yellow film: Rf 0.21 (EtOAc/hexanes, 
1:1); 
1
H NMR (300 MHz, acetone-d6) δ 8.00 (d, 1 H, J = 8.1 Hz), 7.75 (d, 1 H, J = 8.1 Hz), 7.68 
(d, 1 H, J = 8.4 Hz), 7.60 (d, 1 H, J = 8.4 Hz) 6.69 (d, 1 H, J = 2.7 Hz), 4.28 (s, 1 H), 3.53 (dd, 1 
H, J = 5.7, 10.5 Hz), 2.03-1.96 (m, 1 H), 1.80-1.47 (m, 3 H).  For full characterization see 
directly preceding experimental. 
 
 
(1S,8R,9S)-5,8,9-Trihydroxy-1,3-bis(naphthalen-2-ylthio)bicyclo[3.3.1]non-3-en-2-one 
(2.40).  Prepared according to general procedure A utilizing 2.32 (0.0250, 0.126 mmol, 1 equiv), 
Cs2CO3 (0.206 g, 0.631 mmol, 5 equiv), and napthalene-2-thiol (0.0606 g, 0.378 mmol, 3 equiv).  
The crude reaction mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 1:1) to 
give 2.40 (0.0357 g, 57%) as a white solid: Rf 0.44 (EtOAc/hexanes, 1:1); Mp 230-233 ºC; IR 
(neat) 2509, 3351, 3047, 2984, 2871, 1662, 1584, 1129, 1099, 1032, 954, 857, 820, 745 cm
-1
; 
1
H 
NMR (300 MHz, DMSO-d6) δ 8.39 (s, 1 H), 8.09 (s, 1 H), 8.00-7.88 (m, 6 H), 7.83 (d, 1 H, J = 
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8.4 Hz), 7.59-7.57 (m, 4 H), 7.49 (d, 1 H, J = 8.1 Hz), 6.05 (d, 1 H, J = 1.8 Hz), 5.62 (d, 1 H, J = 
3.6 Hz), 5.51 (s, 1 H), 5.22 (d, 1 H, J = 3.9 Hz), 3.03 (s, 1 H), 1.83-1.81 (m, 1 H), 1.46-1.38 (m, 
2 H), 1.22-1.14 (m, 1 H); 
13
C NMR (75 MHz, DMSO-d6) δ 190.7, 146.7, 138.5, 136.0, 134.6, 
133.5, 132.9, 132.4, 132.3, 129.8, 129.3, 128.7, 128.0, 127.9, 127.7, 127.6, 127.2, 127.0, 126.9, 
126.5, 76.6, 74.7, 74.0, 68.1, 30.6, 28.4; HRMS (ESI+) m/z calcd for C29H24O4NaS2 523.1014, 
found 523.1017. 
 
 
(1S,8R,9S)-5,8,9-Trihydroxy-1,3-bis(naphthalen-2-ylthio)bicyclo[3.3.1]non-3-en-2-one 
(2.40).  Prepared according to general procedure B utilizing 2.32 (0.0100 g, 0.0505 mmol, 1 
equiv), Cs2CO3 (0.0822 g, 0.252 mmol, 5 equiv) and napthalene-2-thiol (0.0242 g, 0.151 mmol, 
3 equiv).  The crude reaction mixture was purified by chromatograph on SiO2 (EtOAc/hexanes, 
1:1) to give 2.40 (0.0186 g, 74%) as a yellow film: Rf 0.44 (EtOAc/hexanes, 1:1); 
1
H NMR (300 
MHz, DMSO-d6) δ 8.39 (s, 1 H), 8.09 (s, 1 H), 8.00-7.88 (m, 6 H), 7.83 (d, 1 H, J = 8.4 Hz), 
7.59-7.57 (m, 4 H), 7.49 (dd, 1 H, J = 1.5, 8.1 Hz), 6.05 (d, 1 H, J = 2.1 Hz), 5.62 (d, 1 H, J = 3.9 
Hz), 5.51 (s, 1 H), 5.22 (d, 1 H, J = 3.6 Hz), 3.35-3.30 (m, 1 H), 3.03 (m, 1 H), 1.83-1.81 (m, 1 
H), 1.46-1.38 (m, 2 H), 1.22-1.14 (m, 1 H).  For full characterization see directly preceding 
experimental. 
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(1R,2R,4S,6S,7R,10S)-1,7,10-Trihydroxy-6-(phenylthio)-3-oxatricyclo[4.3.1.0
2,4
]decan-5-one 
(B).  To a stirred solution of 2.32 (0.250 g, 1.27 mmol, 1 equiv) in CH2Cl2 (25 mL) was added 
thiophenol (0.391 mL, 3.82 mmol, 3 equiv) and Cs2CO3 (3.46 g, 6.37 mmol, 5 equiv). The 
reaction mixture was allowed to stir at rt for 5 min then quenched with a saturated aqueous 
solution of NH4Cl and extracted with EtOAc (3x). The combined organic layers were washed 
with brine, dried (MgSO4), filtered, and concentrated under reduced pressure. The crude mixture 
was purified by chromatography on SiO2 (EtOAc/hexanes, 1:1) to give B (0.070 g, 18%) as a 
colorless film: Rf 0.45 (EtOAc); IR (CDCl3) 3465, 2943, 2877, 1709, 1274, 1437, 1326, 1111, 
1085, 1025, 904, 729, 703 cm
-1
; 
1
H NMR (300 MHz, CDCl3)  7.64 (d, 2 H, J = 7.5 Hz), 7.50-
7.36 (m, 3 H), 3.69 (d, 1 H, J = 3.3 Hz), 3.62 (d, 1 H, J = 2.1 Hz), 3.47 (d, 2 H, J = 4.2 Hz), 3.36 
(s, 1 H), 3.32 (s, 1 H), 2.92 (d, 1 H, J = 12.3 Hz), 2.14-2.07 (m, 2 H), 1.50-1.38 (m, 2 H); 
13
C 
NMR (75 MHz, CDCl3)  198.3, 138.2, 130.4, 129.3, 126.0, 73.6, 71.7, 70.7, 70.6, 60.8, 56.6, 
29.9, 27.7; HRMS (EI
+
) m/z calcd for C15H16O5S 308.0718, found 308.0713. 
 
 
Diisopropyl-3,3'-(((1S,5S,8R,9S)-5,8,9-trihydroxy-2-oxobicyclo[3.3.1]non-3-ene-1,3-
diyl)bis(sulfanediyl))dipropanoate (2.41).  To a stirred solution of 2.32 (0.0500 g, 0.252 mmol, 
1 equiv) in dry CH2Cl2 (12 mL) was added Cs2CO3 (0.411 g, 0.757 mmol, 5 equiv) and isopropyl 
3-mercaptopropionate (0.112 g, 0.757 mmol, 3 equiv).  The reaction mixture was allowed to stir 
at rt for 3 h.  The reaction mixture was diluted with EtOAc, washed with brine, and the aqueous 
layer was extracted with EtOAc (x 2).  The combined organic layers were washed with brine, 
dried (MgSO4), filtered, and concentrated under reduced pressure.  The reaction mixture was 
purified by chromatography on SiO2 (EtOAc/hexanes 3:1 to 1:1) to give 2.41 (0.050 g, 32%) as a 
yellowish film: Rf 0.54 (EtOAc/hexanes, 1:1), 
1
H NMR (300 MHz, Acetone-d6) δ 6.40 (d, 1 H, J 
= 2.1 Hz), 4.96 (sep, 3 H, J = 6.3 Hz), 4.66 (s, 1 H), 4.47 (m, 1 H), 3.43 (d, 1 H, J = 2.1 Hz), 3.26 
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(ddd, 1 H, J = 6.3, 7.2, 18.3 Hz), 3.10-2.8 (m, 7 H), 2.75-2.48 (m, 7 H), 2.19 (dt, 1 H, J = 4.2, 
13.2), 1.97 (dq, 1 H, J = 15.0, 2.1 Hz), 1.72 (ddd, 1 H, J = 1.8, 4.8, 13.2 Hz), 1.53-1.41 (m, 1 H), 
1.22 (d, 6 H, J = 6.0 Hz), 1.21 (d, 12 H, J = 6.3 Hz); 
13
C NMR (75 MHz, Acetone-d6) δ 195.2, 
172.5, 171.7, 171.3, 145.3, 136.7, 75.3, 69.4, 68.8, 63.2, 35.6, 34.6, 34.0, 31.5, 28.2, 26.3, 26.0, 
22.0. 
 
 
(5r,7R,9S)-2,7,9-Trihydroxy-6,10-bis(phenylamino)-1-oxaspiro[4.5]decan-8-one (2.42).  To a 
stirred solution of 2.32 (0.0200 g, 0.101 mmol, 1 equiv) in CH3CN (0.5 mL) was added aniline 
(0.030 mL, 0.30 mmol, 3 equiv) and ZnCl2 (0.00687 g, 0.05 equiv).  The reaction mixture was 
allowed to stir at rt for 24 h, diluted with EtOAc, washed with brine, dried (MgSO4), filtered, and 
concentrated under reduced pressure.  The crude mixture was purified by chromatography on 
SiO2 (EtOAc/hexanes, 3:1 to 1:1) to give 2.42 (0.0174 g, 45%) as a 1:1 mixture of diastereomers: 
Rf 0.27 (EtOAc/hexanes);
 1
H NMR (300 MHz, CDCl3) δ 7.21 (t, 2 H, J = 6.0 Hz), 6.86 (d, 2 H, J 
= 6.0 Hz), 6.81 (t, 1 H, J = 6.0 Hz), 5.81 (d, 1 H, J = 3.0 Hz), 4.33 (bs, 1 H), 3.67 (s, 1 H), 3.57 
(s, 1 H), 3.54 (s, 1 H), 3.48 (s, 1 H), 3.44 (s, 2 H), 3.39 (s, 2 H), 2.49-2.43 (m, 1 H), 2.36-2.02 
(m, 4 H); 
13
C NMR (75 MHz, CDCl3) δ 199.3, 145.3, 129.3, 119.5, 114.5, 99.9, 88.0, 79.9, 64.3, 
33.0, 29.7.  Only NMR data for the major diastereomers is shown. 
 
 
4,4-Dimethoxynaphthalen-1(4H)-one (2.44).
15
  To a stirred solution of 4-methoxynapthol (5.00 
g, 28.7 mmol, 1 equiv) in MeOH (150 mL) was added PIDA (11.1 g, 34.4 mmol, 1.2 equiv), and 
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the resulting solution was stirred at rt for 1 h. The mixture was quenched with a saturated 
aqueous solution of NaHCO3 and extracted with CH2Cl2 (3x). The combined organic layers were 
dried (MgSO4), filtered, and concentrated under reduced pressure. The crude mixture was 
purified by chromatography on SiO2 (deactivated with 0.1% Et3N; EtOAc/hexanes, 1:3) to give 
2.44 (5.00 g, 85%) as a blue semi-solid: Rf 0.52 (EtOAc/hexanes, 1:3); IR (CDCl3) 2935, 2827, 
1668, 1629, 1597, 1455, 1297, 1056, 974, 764 cm
-1
; 
1
H NMR (300 MHz, CDCl3) 8.01 (d, 1 H, J 
= 7.5 Hz), 7.67 (d, 1 H, J = 7.2 Hz), 7.59 (t, 1 H, J = 8.1 Hz), 7.43 (t, 1 H, J = 8.1 Hz), 6.88 (d, 1 
H, J = 10.5 Hz), 6.53 (d, 1 H, J = 10.5 Hz), 3.13 (s, 6 H); 
13
C NMR (75 Hz, CDCl3) δ 183.6, 
144.0, 139.5, 133.3, 132.4, 131.4, 129.1, 126.5, 126.1, 94.8, 51.0; HRMS (ESI
+
) m/z calcd for 
C12H13O3 [M+H]
+
 205.0865, found 205.0870. 
 
 
4-(But-3-enyl)-4-hydroxynaphthalen-1(4H)-one (2.45).  To a dry, 250 mL round-bottom flask 
equipped with an addition funnel was added magnesium turnings (0.714 g, 29.4 mmol, 1.2 
equiv) and a crystal of iodine. Heat (Bunsen burner flame) was applied to the stirred turnings 
until a purple gas coated the interior of the flask. The sample was allowed to cool under argon 
and suspended in dry ether (20 mL). To the stirred solution was added via an addition funnel a 
solution of 4-bromo-1-butene (2.98 mL, 29.4 mmol, 1.2 equiv) in dry ether (20 mL). The 
reaction mixture was allowed to stir at reflux for 1 h, allowed to cool to rt, and a solution of 2.44 
(5.00 g, 24.5 mmol, 1 equiv) in dry ether (40 mL) was added and quantitatively transferred with 
dry ether (20 mL). The heterogeneous reaction mixture was allowed to stir at rt for 15 min, 
cooled to 0 ºC, quenched with a saturated aqueous solution of NH4Cl and extracted with ether 
(x3). The combined organic layers were washed with brine, dried (MgSO4), filtered, and 
concentrated under reduced pressure.  The crude oil was suspended in acetone/water (1:1, 200 
mL) and glacial acetic acid (14 mL) was added. The reaction mixture was allowed to stir at 0 ºC 
for 2 h and extracted with Et2O (x2). The combined organic layers were washed with a saturated 
aqueous solution of NaHCO3, brine, dried (MgSO4), filtered, and concentrated under reduced 
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pressure. The crude mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 1:10 to 
5:1 to 1:1) to give 2.45 (2.09 g, 40%) as a yellow oil: Rf 0.68 (EtOAc/hexanes, 1:1); IR (CDCl3) 
3407, 3066, 2937, 1657, 1597, 1456, 1297, 1150, 1051, 1014, 911, 762 cm
-1
; 
1
H NMR (300 
MHz, CDCl3) δ 7.99 (d, 1 H, J = 7.8 Hz), 7.70 (d, 1 H, J = 7.5 Hz), 7.60 (t, 1 H, 6.6 Hz), 7.40 (t, 
1 H, 8.1 Hz), 6.92 (d, 1 H, J = 10.2 Hz), 6.31 (d, 1 H, J = 10.2 Hz), 5.62 (dddd, 1 H, J = 6.3, 6.3, 
10.5, 12.6 Hz), 4.91-4.85 (m, 2 H), 2.81 (s, 1 H), 2.12-1.96 (m, 2 H), 1.96-1.82 (m, 1 H), 1.58-
1.45 (m, 1 H); 
13
C NMR (75 Hz, CDCl3) δ 184.6, 151.9, 146.0, 137.0, 133.4, 130.2, 128.4, 
128.1, 126.3, 126.1, 115.0, 71.0, 42.0, 28.1; HRMS (ESI
+
) m/z calcd for C14H14O2Na 237.0891, 
found 237.0900 
 
 
(1aS,7S,7aR)-7-(But-3-enyl)-7-hydroxy-7,7a-dihydronaphtho[2,3-b]oxiren-2(1aH)-one 
(2.46).  To a stirred solution of 2.45 (1.90 g, 8.87 mmol, 1 equiv) and 30% aq. hydrogen 
peroxide (2.72 mL, 1.3 mmol, 3 equiv) in methanol (80 mL) at 0 ºC was added 6 M NaOH (0.74 
mL, 4.4 mmol, 0.5 equiv) dropwise. The reaction mixture was allowed to stir at 0 ºC for 2 h, 
poured onto a saturated aqueous NH4Cl solution and extracted with EtOAc (x2). The combined 
organic layers were checked for peroxides, dried (MgSO4), filtered, and concentrated under 
reduced pressure to give 2.46 (1.53 g, 75%) as a light green powder: Rf 0.73 (EtOAc/hexanes, 
1:1); Mp 76-78 ºC; IR (neat) 3437, 3004, 2953, 1675, 1597, 1452, 1334, 1293, 1062, 1010, 868, 
773, 742 cm
-1
; 
1
H NMR (300 MHz, CDCl3)  7.86-7.83 (m, 1 H), 7.69-7.62 (m, 2 H), 7.42 (td, 1 
H, J = 2.7, 6.0 Hz) 5.71-5.58 (m, 1 H), 4.94-4.87 (m, 2 H), 3.79 (d, 1 H, J = 4.2 Hz), 3.75 (d, 1 
H, J = 4.2 Hz), 2.75 (s, 1 H), 1.98-1.81 (m, 4 H); 
13
C NMR (75 MHz, CDCl3) δ 193.5, 143.3, 
136.9, 134.4, 128.5, 128.3, 126.7, 126.6, 115.2, 72.4, 58.8, 55.5, 40.6, 27.4; HRMS (EI
+
) m/z 
calcd for C14H14O3Na 253.0841, found 253.0862. 
 
  115 
 
(1a’R,2S,7a’S)-5-Hydroxy-4,5-dihydro-1a’H,3H-spiro[furan-2,2’-naphtho[2,3-b]oxiren]-
7’(7a’H)-one (2.47).  A solution of 2.46 (1.10 g, 4.99 mmol, 1 equiv) in CH2Cl2 (40 mL) was 
cooled to -78 ºC. Ozone was passed through the stirred solution for 1.5 h, which was then purged 
with N2 before the dropwise addition of DMS (7.39 mL, 99.9 mmol, 20 equiv) at -78 ºC. The 
reaction mixture was allowed to stir at -78 ºC for 1 h and then allowed to warm to rt and stirred 
at rt for 3 d. The solvent was removed under reduced pressure and the crude mixture was purified 
by chromatography on SiO2 (EtOAc/hexanes, 1:2 to 1:1) to give 2.47 (1.18 g, 100% yield) as a 
2:1 mixture of diastereomers as an off-white solid: Rf 0.43 (EtOAc/hexanes, 1:1); IR (CDCl3) 
3446, 2984, 1685, 1599, 1456, 1338, 1297, 1047, 1027, 986, 755, 732 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3)  7.84 (d, 1 H, J = 7.5 Hz), 7.63 (d, 1 H, J = 9.0 Hz), 7.44-7.38 (m, 2 H), 6.02 (d, 1 H, J 
= 3.5 Hz), 4.04 (d, 1 H, J = 4.2 Hz), 3.79 (bs, 1 H), 3.74 (d, 1 H, J = 4.5 Hz),  2.55-2.45 (m, 1 H), 
2.22-2.08 (m, 2 H), 1.77 (ddd, 1 H, J = 3.0, 8.1, 11.4 Hz); 
13
C NMR (75 Hz, CDCl3) δ 194.2, 
142.8, 134.4, 128.3, 127.2, 126.5, 125.2, 100.3, 82.8, 58.4, 54.1, 35.8, 32.0; HRMS (EI
+
) m/z 
calcd for C13H12O4 232.0736, found 232.0735. NMR data is for the major diastereomer only. 
 
 
(5R,8S,9R,11R)-5,8,11-Trihydroxy-9-(phenylthio)-6,7,8,9-tetrahydro-5,9-
methanobenzo[8]annulen-10(5H)-one (2.48).  To a stirred solution of 2.47 (0.0500 g, 0.215 
mmol, 1 equiv) in dry CH2Cl2 (5 mL) was added Cs2CO3 (0.351 g, 1.08 mmol, 5 equiv) and 
thiophenol (0.066 mL, 0.646 mmol, 3 equiv). The reaction was allowed to stir at rt for 1 h. The 
crude mixture was diluted with CH2Cl2 (4 mL), washed with brine, dried (MgSO4), filtered, and 
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concentrated under reduced pressure. The residue was purified by chromatography on SiO2 
(EtOAc/hexanes, 10:1 to 1:1) to give 2.48 (59.0 mg, 80% yield) as a white solid. A small portion 
was recrystallized (acetone/Et2O) to give colorless crystals for x-ray analysis: Rf 0.32 
(EtOAc/hexanes, 1:1); Mp 180-182 ºC; IR (CDCl3) 3489, 1675, 1597, 1286, 1271, 1228, 1055, 
1027, 760, 767 cm
-1
; 
1
H NMR (300 MHz, Acetone-d6)  7.92 (d, 1 H, J = 7.8 Hz), 7.80 (d, 2 H, J 
= 7.8 Hz), 7.75 (s, 1 H), 7.71 (t, 1 H, J = 6.9 Hz), 7.54-7.42 (m, 4 H), 4.62 (bs, 1 H), 4.49 (s, 1 
H), 4.04 (s, 1 H), 3.52 (dd, 1 H, J = 5.7, 11.7 Hz), 3.42 (s, 1 H), 1.89-1.83 (m, 1 H), 1.72-1.57 
(m, 2 H), 0.99 (dq, 1 H, J = 5.7, 12.3 Hz); 
13
C NMR (75 MHz, Acetone-d6) δ 193.9, 146.8, 
139.2, 135.4, 133.5, 130.6, 129.9, 129.9, 128.2, 127.3, 125.8, 77.5, 75.2, 74.6, 69.8, 35.1, 28.6; 
HRMS (EI
+
) m/z calcd for C19H18O4S 342.0926, found 342.0925. 
 
 
4,4-Dimethoxy-3-methylcyclohexa-2,5-dienone (2.49).
14
  To a stirred solution of m-cresol 
(9.67 mL, 92.5 mmol, 1 equiv) in MeOH (300 mL) at 0 ºC was added PIDA (44.7 g, 139 mmol, 
1.5 equiv). The reaction mixture was allowed to warm to rt and stirred for 1 h. At this point, an 
additional batch of PIDA (20.0 g, 64 mmol, 0.7 equiv) was added. The mixture was allowed to 
stir at rt for an additional 1 h, and quenched with a saturated aqueous solution of Na2CO3, and 
extracted with Et2O (x2). The combined organic layers were washed with brine, dried (Na2SO4), 
filtered, and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (deactivated with 0.1% Et3N; EtOAc/hexanes, 1:4) to give 2.49 (13.1 g, 
85% yield) as a yellow oil: Rf 0.38 (EtOAc/hexanes, 1:3); IR (CDCl3) 2937, 1674, 1640, 1616, 
1439, 1385, 1107, 1057, 965 cm
-1
; 
1
H NMR (300 MHz, CDCl3)  6.62 (d, 1 H, J = 10.2 Hz), 
6.23 (dd, 1 H, J = 1.8, 10.5 Hz), 6.06 (s, 1 H), 3.08 (s, 6 H), 1.78 (s, 3 H); 
13
C NMR (75 MHz, 
CDCl3) δ 184.5, 155.6, 143.5, 131.9, 129.4, 95.0, 50.6, 16.3; HRMS (EI
+
) m/z calcd for C9H12O3 
168.0786, found 168.0785. 
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4-(But-3-en-1-yl)-4-hydroxy-3-methylcyclohexa-2,5-dienone (2.50).  To a dry, 25 mL round-
bottom flask equipped with an addition funnel was added magnesium turnings (0.0305 g, 1.26 
mmol, 1.2 equiv) and a crystal of iodine. Heat (Bunsen burner flame) was applied to the stirred 
turnings until a purple gas coated the interior of the flask. The sample was allowed to cool under 
argon and suspended in dry ether (6 mL). To the stirred solution was added via an addition 
funnel a solution of 4-bromo-1-butene (0.13 mL, 1.26 mmol, 1.2 equiv) in dry ether (2 mL). The 
reaction mixture was allowed to stir at reflux for 40 min, allowed to cool to rt, and a solution of 
2.49 (0.176 g, 1.05 mmol, 1 equiv) in dry ether (3 mL) was added. The heterogeneous mixture 
was allowed to stir at rt for 15 min, cooled to 0 ºC and quenched with a saturated aqueous 
solution of NH4Cl and extracted with Et2O (x3). The combined organic layers were washed with 
brine, dried (MgSO4), filtered, and concentrated under reduced pressure. The crude amber oil 
was suspended in acetone/water (1:1, 20 mL) and glacial acetic acid (1.4 mL) was added. The 
reaction mixture was allowed to stir at 0 ºC for 4 h and extracted with Et2O (x2). The combined 
organic layers were washed with a saturated aqueous solution of NaHCO3, brine, dried (MgSO4), 
filtered, and concentrated under reduced pressure. The crude mixture was purified by 
chromatography on SiO2 (EtOAc/hexanes, 1:5 to 1:3) to give 2.50 (0.0813 g, 44%) as a yellow 
oil: Rf 0.35 (EtOAc/hexanes, 1:2); IR (CDCl3) 3420, 2920, 1666, 1633, 1446, 1431, 1394, 1375, 
1243, 1049, 1001, 893 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 6.76 (dd, 1 H, J = 3.0, 10.2 Hz), 6.57 
(s, 1 H), 6.07 (d, 1 H, J = 9.9 Hz), 5.71 (dddd, 1 H, J = 6.0, 6.0, 10.2, 16.5 Hz), 4.98-4.90 (m, 2 
H), 3.34 (s, 1 H) 2.00-1.92 (m, 2 H), 1.80 (s, 3 H), 1.80-1.74 (m, 2 H); 
13
C NMR (75 Hz, CDCl3) 
δ 186.6, 151.4, 147.0, 137.3, 134.5, 127.8, 115.0, 69.8, 38.8, 27.8, 15.5; HRMS (EI+) m/z calcd 
for C11H14O2 178.0994, found 178.0994.  
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(1R,3S,5R,6S,7S)-6-(But-3-en-1-yl)-6-hydroxy-5-methyl-4,8-dioxatricyclo[5.1.0.0]octan-2-
one (2.51).  To a stirred solution of 2.50 (1.00 g, 5.61 mmol, 1 equiv) and 30 % aq. hydrogen 
peroxide (5.73 mL, 56.1 mmol, 10 equiv) in methanol 50 mL at rt was added 6 M NaOH (0.935 
mL, 5.61 mmol, 1 equiv) dropwise. After 5 h, the reaction mixture was quenched with a 
saturated aqueous NH4Cl solution and extracted with EtOAc (x2). The combined organic layers 
were checked for peroxides, dried (MgSO4), filtered, and concentrated under reduced pressure. 
The crude residue was purified by chromatography on SiO2 (EtOAc/hexanes, 1:2) to give 2.51 
(0.800 g, 68% yield) as a pale yellow oil: Rf 0.66 (EtOAc/hexanes, 1:1); IR (CDCl3) 3483, 2976, 
2933, 2859, 1705, 1640, 1437, 1159, 1085, 1023, 919, 841 cm
-1
; 
1
H NMR (700 MHz, CDCl3)  
5.78 (dddd, 1 H, J = 6.3, 6.3, 10.5, 12.6 Hz), 5.06-5.01 (m, 2 H), 3.51 (d, 1 H, J = 4.2 Hz), 3.49 
(t, 1 H, J = 4.2 Hz), 3.29 (d, 1 H, J = 3.5 Hz), 2.94 (bs, 1 H), 2.17-2.08 (m, 2 H), 1.96-1.89 (m, 2 
H), 1.43 (s, 3 H); 
13
C NMR (176 Hz, CDCl3) δ 199.9, 136.6, 116.0, 70.3, 69.0, 63.8, 62.3, 57.2, 
35.6, 27.1, 15.7; HRMS (ESI
+
) m/z calcd for C11H14O4Na 233.0790, found 233.0797.  
 
 
(1'R,2S,3'S,5'R,7'S)-5-Hydroxy-1'-methyldihydro-3H-4',8'-dioxaspiro[furan-2,2'-
tricyclo[5.1.0.0
3,5
]octan]-6'-one (2.52).  A solution of 2.51 (0.0700 g, 0.333 mmol, 1 equiv) in 
CH2Cl2 (3 mL) was cooled to -78ºC. Ozone was passed through the stirred solution for 1.5 h, 
which was then purged with N2 before the dropwise addition of DMS (0.49 mL, 6.7 mmol, 20 
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equiv) at -78 ºC. The reaction mixture was stirred at -78 ºC for 1 h and then allowed to warm to 
rt and stirred for 3 d. The solvent was removed under reduced pressure and the crude mixture 
was purified by chromatography on SiO2 (EtOAc/hexanes, 1:1) to give 2.52 (0.0710 g, 100% 
yield) as a colorless oil and as a 1:1 mixture of lactols: Rf 0.22 (EtOAc/hexanes, 1:1), IR (CDCl3) 
3496, 2976, 1705, 1442, 1457, 1204, 1159, 1094, 1034, 982, 915, 868, 795 cm
-1
; 
1
H NMR (300 
MHz, CDCl3)  5.82 (s, 1 H), 4.44 (bs, 1 H), 3.69 (t, 0.5 H, J = 3.6 Hz), 3.55 (d, 0.5 H, J = 3.3 
Hz), 3.44-3.38 (m, 1.5 H), 3.21 (d, 0.5 H, J = 3.3 Hz), 2.37-1.95 (m, 4 H), 1.37 (s, 3 H) ; 
13
C 
NMR (75 Hz, CDCl3) δ 200.1 (200.1), 99.8 (99.8), 79.6, (79.6), 70.6, (69.0), 64.3, (62.7), 61.1, 
(60.7), 55.9, (55.5), 33.0, (33.0), 30.5, (30.4), 15.5, (15.5); HRMS (EI
+
) m/z calcd for C10H12O5 
212.0685, found 212.0680. 
13
C NMR data for the diastereomer are listed in parenthesis. 
 
 
(1S,2R,4S,6S,7R,10S)-1,7,10-Trihydroxy-10-methyl-6-(phenylthio)-3-
oxatricyclo[4.3.1.0
2,4
]decan-5-one (2.53).  To a stirred solution of 2.52 (0.0500 g, 0.236 mmol, 
1 equiv) in dry CH2Cl2 (2 mL) was added Cs2CO3 (0.384 g, 1.18 mmol, 5 equiv) and thiophenol 
(0.072 mL, 0.707 mmol, 3 equiv).  The reaction was stirred at rt for 2 h. The crude mixture was 
diluted with EtOAc, and washed with brine. The aqueous layer was extracted with EtOAc (x2), 
the organic layers were combined, washed with brine, dried (MgSO4), filtered, and concentrated 
under reduced pressure. The crude mixture was purified by chromatography on SiO2 
(EtOAc/hexanes, 1:3 to 1:1) to give 2.53 (0.0400 g, 53% yield) as a colorless film: Rf 0.29 
(EtOAc/hexanes, 1:1); IR (CDCl3) 3476, 2933, 2877, 1720, 1437, 1426, 1360, 1113, 1081, 1032, 
752, 729 cm
-1
; 
1
H NMR (300 MHz, CDCl3)  7.65 (t, 1 H, J = 1.8 Hz), 7.63 (d, 1 H, J = 1.5 Hz), 
7.48-7.35 (m, 3 H), 3.48-3.47 (m, 1 H), 3.42 (app t, 2 H, J = 2.4 Hz), 3.33 (dd, 1 H, J = 5.4, 11.7 
Hz), 2.92 (dd, 1 H, J = 2.4 Hz, 12.3 Hz), 2.18-2.02 (m, 2 H), 1.54 (s, 3 H), 1.51-1.25 (m, 2 H); 
13
C NMR (75 MHz, CDCl3) δ 199.0, 138.2, 130.2, 129.2, 126.4, 73.9, 72.1, 70.6, 70.6, 67.2, 
62.3, 29.6, 27.6, 14.8; HRMS (EI
+
) m/z calcd for C16H18O5S 322.0875, found 322.0880. 
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4-Hydroxy-4-(pent-4-enyl)cyclohexa-2,5-dienone (2.54).  To a dry, 25 mL, two-necked, round-
bottom flask equipped with an addition funnel was added magnesium turnings (0.341 g, 14.0 
mmol, 1.2 equiv) and a crystal of iodine. Heat (Bunsen burner flame) was applied to the stirred 
turnings until a purple gas coated the interior of the flask. The sample was allowed to cool under 
argon and suspended in THF (4 mL). To the stirred solution was added via an addition funnel a 
solution of 5-bromo-1-pentene (1.7 mL, 14 mmol, 1.2 equiv) in THF (8 mL). The reaction 
mixture was allowed to stir at ca. 40 ºC for 1 h, allowed to cool to rt, and added via dropwise 
addition to a solution of 2.29 (1.80 g, 11.7 mmol, 1 equiv) in THF (20 mL) at -78 ºC. The 
reaction mixture was allowed to stir at -78 ºC for 1 h and quenched with a saturated aqueous 
solution of NH4Cl, warmed to rt, and extracted with EtOAc (x3). The combined organic layers 
were washed with brine, dried (MgSO4) and concentrated under reduced pressure. The crude 
residue was suspended in acetone/water (1:1, 100 mL), glacial acetic acid (10 mL) was added, 
and the reaction mixture was allowed to stir at rt for 2 h. The reaction mixture was concentrated 
under reduced pressure. The remaining aqueous layer was extracted with EtOAc (x3) and the 
combined organic layers were washed with brine, dried (MgSO4), and concentrated under 
reduced pressure. The crude residue was purified by chromatography on SiO2 (EtOAc/hexanes, 
1:5 to 1:3) to give 2.54 (1.14 g, 55% yield) as a yellow oil: Rf 0.2 (EtOAc/hexanes, 1:3); IR 
(neat) 3403, 2935, 2860, 1664, 1619, 1392, 1267, 1169, 1004, 859, 710 cm
-1
; 
1
H NMR (300 
MHz, CDCl3) δ 6.84-6.79 (m, 2 H), 6.19-6.14 (m, 2 H), 5.73 (dddd, 1 H, J = 6.6, 6.6, 10.2, 16.8 
Hz), 5.02-4.94 (m, 2 H), 2.43 (s, 1 H), 2.04 (q, 2 H, J = 7.2 Hz), 1.78-1.73 (m, 2 H), 1.40-1.29 
(m, 2 H); 
13
C NMR (75 MHz, CDCl3) δ 185.7, 151.3, 137.7, 128.2, 115.3, 69.9, 39.1, 33.6, 22.8; 
HRMS (ESI
+
) m/z calcd for C11H14O2K 217.0631, found 217.0639. 
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5-(Pent-4-enyl)-4-hydroxycyclohexa-2,5-dioxirane (2.55).  To a stirred solution of 2.54 (1.00 
g, 5.61 mmol, 1 equiv) and 30 % aq. hydrogen peroxide (1.72 mL, 16.8 mmol, 3 equiv) in 
methanol (50 mL) at 0 ºC was added 6 M NaOH (0.467 mL, 2.81 mmol, 0.5 equiv) dropwise. 
The reaction mixture was allowed to stir at 0 ºC for 2 h, poured onto a saturated aqueous NH4Cl 
solution and extracted with EtOAc (x3). The combined organic layers were washed with brine, 
poured onto activated 4 Å molecular sieves, and allowed to stir at rt for 3 h. The mixture was 
filtered and concentrated under reduced pressure to give 2.55 (1.05 g, 89% yield) as a yellow oil: 
Rf 0.43 (EtOAc/hexanes, 1:1); IR (neat) 3481, 2935, 1702, 1638, 1435, 1435, 1239, 1084, 995, 
926, 887, 788 cm
-1
; 
1
H NMR (300 MHz, CDCl3)  5.75 (dddd, 1 H, J = 6.6, 6.6, 10.2, 13.5 Hz), 
5.05-4.99 (m, 2 H), 3.50 (s, 4 H), 3.09 (s, 1 H), 2.11 (q, 2 H, J = 6.9 Hz), 1.84-1.78 (m, 2 H), 
1.53-1.42 (m, 2 H); 
13
C NMR (75 MHz, CDCl3) δ 199.0, 137.2, 115.8, 69.0, 64.0, 57.0, 35.8, 
33.7, 21.9; HRMS (ESI
+
) m/z calcd for C11H14O4Na 233.0790, found 233.0785. 
 
 
(1'R,2s,3'S,5'R,7'S)-6-Hydroxytetrahydro-4',8'-dioxaspiro[pyran-2,2'-
tricyclo[5.1.0.0
3,5
]octan]-6'-one (2.56).  A solution of 2.55 (0.92 g, 4.38 mmol, 1 equiv) in 
CH2Cl2 (22 mL) was cooled to -78 ºC.  Ozone was passed through the stirred solution for 2 h, 
which was then purged with N2 before the dropwise addition of DMS (6.47 mL, 87.5 mmol, 20 
equiv) at -78 ºC. The reaction mixture was allowed to stir at -78 ºC for 1 h and then allowed to 
warm to rt and stirred at rt for 3 d. The solvent was removed under reduced pressure. The crude 
product was purified by chromatography on SiO2 (EtOAc/hexanes, 1:2 to 1:1) to give 2.56 
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(0.803 g, 86% yield) as a 10:1 mixture of the open and closed forms of the lactol, as an off-white 
solid: Rf 0.25 (EtOAc/hexanes, 1:1); Mp 112-115 ºC; IR (CDCl3) 3424, 2961, 2913, 1698, 1442, 
1251, 1101, 1010, 988, 956, 902, 868, 788 cm
-1
; 
1
H NMR (600 MHz, CDCl3)  5.60 (s, 1 H), 
4.32 (bs, 1 H), 4.17 (t, 1 H, J = 4.2 Hz), 3.50 (t, 1 H, J = 3.6 Hz), 3.42-3.40 (m, 2 H), 2.14-2.06 
(m, 1 H), 1.85-1.81 (m, 2 H), 1.79-1.71 (m, 3 H); 
13
C NMR (151 Hz, acetone-d6) δ 199.1, 91.9, 
69.7, 64.0,  62.9, 56.2, 55.5, 29.5, 29.3, 13.8; HRMS (EI
+
) m/z calcd for C10H12O5 212.0685, 
found 212.0691. Only the major lactol diastereomer is listed. 
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3.0  EFFORTS TOWARD THE TOTAL SYNTHESIS OF CHRYSOPHAENTIN A 
3.1 INTRODUCTION 
Infectious diseases, which include bacterial infections, are the leading cause of death 
worldwide.
100
  The Center for Disease Control estimates that each year more than 90,000 people 
die in the United States from hospital acquired bacterial infections alone.
101
  The discovery, 
development, and clinical exploitation of antibiotics like penicillin, tetracycline and vancomycin 
were some of the greatest medical advances of the twentieth century.  The development of drug-
resistant bacterial strains however, documented as early as the 1930s, continues to pose a 
significant challenge.
102
  Since 1962, only three new classes of antibiotics have been approved 
for clinical use (an oxazolidinone, a cyclic lipopeptide, and a pleuromutilin derivative), and most 
“new” antibiotics are simply variants of older products.101-103  Almost all of the approved 
antimicrobial drugs target one of four processes: cell wall synthesis, protein synthesis, DNA 
synthesis, or interruption of folic acid synthesis.
103
  In addition, the long-term use of a single 
antibiotic (>10 days) promotes the growth of bacteria that are not only resistant to that antibiotic 
but also to other structurally unrelated antibiotics.  Finally, while resistance in bacteria strains 
may appear rapidly, even in the absence of a selecting antibiotic they are slow to be lost, 
reflecting the minimal survival cost to the emerging resistance.
102
  The increase in multi-drug 
resistance, coupled with constantly emerging novel pathogens and potential bioterrorism, have 
created an urgent need for new antibiotics with novel mechanisms of action. 
Bacterial cell division is an essential process that has yet to be targeted by a clinically 
approved antibiotic.  Filamenting temperature-sensitive mutant Z (FtsZ) is an essential protein to 
bacterial cell division that is highly conserved in the bacterial kingdom and absent in the 
mitochondria of higher eukaryotes. Studies in E. coli, have shown that bacterial cell division 
takes place via a sequential protein assembly pathway: FtsZ > FtsA, Zap A, Zip A > FtsE, FtsX > 
  124 
FtsK > FtsQ > FtsB, FtsL > FtsW > FtsI > FtsN > AmiC > EnvC.
103
  FtsZ, after guanosine 5’-
triphosphate (GTP) dependent polymerization, forms the contractile Z-ring.  Upon moving to the 
mid-cell, FtsZ recruits other proteins, which gather to produce the new cell wall and septal ring.  
Contraction of the septal ring eventually leads to completion of the cell division (Figure 32).  
Therefore, the development of a small-molecule inhibitor of the FtsZ protein could provide a 
new antibiotic with a novel mechanism of action.   
 
 
Figure 32. Cartoon representation of bacterial cell division and ribbon representation of the FtsZ protein adapted 
from PDB structure 3VPA.104 
 
FtsZ is a structural homologue of the mammalian -tubulin.  Similar to tubulin, FtsZ is a 
GTPase that polymerizes to generate dynamic structures that resemble microtubule 
protofilaments.  GTP hydrolysis destabilizes the polymer, and once all of the GTP is converted 
to GDP the polymer completely dissembles into its individual monomers.
105
 The successful 
targeting of -tubulin in the treatment of cancer may suggest that the protein superfamily is a 
viable target for small-molecule modulation.  In addition, targeting cell-division proteins, which 
are externally located, removes the need to optimize any small molecule inhibitors for entry into 
the cytoplasm.  Although FtsZ and human tubulin share many structural and functional 
properties, none of the classical tubulin inhibitors exhibit significant inhibition of FtsZ 
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polymerization or GTPase activity in vitro.  Thus, differentiation between inhibition of the two 
pathways should be plausible.
103
  
Several natural products have been isolated which modulate the activity of FtsZ 
polymerization (Figure 33).  Viriditoxin, isolated from the venom of the prairie rattlesnake 
(Crotalus viridis),
106
 was shown to inhibit FtsZ polymerization and concomitant GTPase 
inhibition with IC50 values of 8.2 µg/mL and 7.0 µg/mL respectively.
107
  Dichamanetin and 2’’’-
hydroxy-5’’-benzylisouvarinol-B (HBB), isolated independently by Hufford and Anam from U. 
chamae and X. afticana respectively and synthesized in the Shaw laboratory, exhibited FtsZ 
inhibition with IC50 values of 12.5 and 8.3 µM respectively.
108-110
 Another natural product, 
sanguinarine, induced cell filamentation in both Gram-positive and Gram-negative bacteria and 
was shown to act by inhibiting cytokinesis by perturbing formation of the Z-ring.
111
 In addition 
to these natural products several small molecule modulators of the FtsZ protein have been 
reported (Figure 34). 
 
 
Figure 33. Natural product inhibitors of FtsZ 
 
In 2004, RayChaudhuri and co-workers at Harvard reported the results of their efforts to 
identify small molecule inhibitors of the FtsZ protein.  A screen of 18,320 compounds led to the 
isolation of five small molecules, which inhibited the polymerization-GTP hydrolysis-
depolymerization cycle of FtsZ through distinct mechanisms.
105
  Zantrin 4 and Zantrin 2 (Figure 
34) exhibited FtsZ inhibition with IC50 values of 25 µM and 10 µM respectively against several 
bacterial cell lines.  Further mechanism of action studies revealed that while Zantrin 4 and 
Zantrin 2 acted by destabilizing polymer formation, other members of the five compounds acted 
by stabilization of the FtsZ assembly.
105
   Each of the five identified inhibitors was structurally 
unrelated to GTP or each other.  This study demonstrated that inhibition of cell division could be 
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achieved by either the stabilization or destabilization of the FtsZ assembly similar to the 
orthogonality between vinblastine and Taxol inhibition of microtubule function. 
Czaplewski and co-workers at Begbroke Science Park in the United Kingdom, also 
seeking to identify small molecule inhibitors of cell division, developed a new cell-based 
microtiter plate assay to screen for inhibitors of cell division.
112
  Using the very weak inhibitor  
3-methoxybenzamide as a lead compound, they screened approximately 105,000 compounds.   
From this screen a new lead compound, PC170942, was identified and shown to inhibit the FtsZ 
protein in a dose-dependent manner with an IC50 of 10 µM.
112
  Several years and rounds of SAR 
later they identified the significantly more potent PC190723 that exhibited antibacterial activity 
against several bacterial cell lines as well as inhibited FtsZ with an IC50 value of 0.1 µM.
113
  
White and co-workers at the Southern Research Institute (SRI) have spent the last 30 years 
designing and preparing inhibitors of tubulin polymerization.  Interestingly, a screen of over 200 
compounds developed in their labs resulted in the identification of SRI-3072.  SRI-3072 was 
shown to specifically target FtsZ with an IC50 of 52 µM without inhibition of mammalian tubulin 
polymerization.
114
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Figure 34. Small molecule inhibitors of FtsZ 
 
The molecules discussed here comprise only a subset of the small molecule inhibitors of 
bacterial cell division that target the FtsZ protein.  Examination of their structures reveals that a 
wide array of electronically and structurally diverse small molecules can be used to modulate the 
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FtsZ pathway in an orthogonal manner to FtsZ’s eukaryotic homologue -tubulin.  These results 
coupled with the potential to modulate FtsZ via both stabilization and destabilization, and 
success of -tubulin modulating therapies all serve to validate FtsZ modulation as a potential 
antimicrobial target. 
Recently, Dr. Bewley and co-workers at the National Institutes of Health isolated eight 
new FtsZ modulating antimicrobial natural products, chrysophaentins A-H (Figure 35).
115
  The 
chrysophaentins were isolated from the marine chrysophyte alga Chrysophaeum taylori and are 
structurally characterized by the presence of two polyoxygenated, polyhalogentaed ,’-
diarylbutene units connected by two ether bonds.  While each member of the family exhibited 
antimicrobial activity, chrysophaentin A proved the most potent.  Chrysophaentin A showed 
activity in resistant strains including methicillin-resistant Staphylococcus aureus (MIC50 =1.5  
0.7 µg/mL), multidrug resistant S. aureus (1.4  0.4 µg/mL), and vancomycin-resistant 
Enterococcus faecium (2.9  0.8 µg/mL).115  Limited access to the natural product led to a need 
for synthetic material for further biological evaluation.  Accordingly, we devised a convergent 
synthetic strategy. 
 
 
Figure 35. Structure of chrysophaentins A-H 
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3.2 1ST GENERATION SYNTHESIS OF CHRYSOPHAENTIN A  
Our first generation retrosynthetic analysis of chrysophaentin A (Figure 36) begins with a 
potentially biomimetic oxidative dimerization of the C1-C16 fragment of chrysophaentin A 3.1.  
Although a biosynthetic pathway for the chrysophaentins has yet to be elucidated, the isolation 
of the ring opened analogue chrysophaentin E (Figure 35) and the highly conserved oxygenation 
pattern suggests a laccase
116
 or other enzyme
117
 may form the diaryl ether linkages.  In addition, 
the key oxidative dimerization would provide rapid access to chrysophaentin A and be amenable 
to the synthesis of the other chrysophaentins.  Although oxidative diaryl ether formation has 
been well studied,
118-125
 an asymmetric oxidative dimerization strategy has yet to be reported.  
Therefore, in order to rapidly access tetraphenol 3.1, we envisioned its construction using a 
potential unselective hydrochlorination of alkyne 3.2.  Alkyne 3.2 could be accessed by 
nucleophilic displacement of benzyl bromide 3.3 with alkyne 3.4.   Finally, benzyl bromide 3.3 
and alkyne 3.4 could be prepared using several functional group interconversions (FGIs) from 
the commercially available benzoic acid 3.5 and dimethyl hydroquinone 3.6 respectively. 
 
 
Figure 36. 1st Generation retrosynthetic analysis of chrysophaentin A 
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In the forward sense, our synthesis begins with preparation of benzyl bromide 3.3 
(Scheme 30).
126
  Reduction of the commercially available 3,5-dimethoxy benzoic acid (3.5) with 
lithium aluminum hydride (LAH) afforded benzyl alcohol 3.7 in excellent yield.  Bromination 
using phosphorous tribromide (PBr3) in dichloromethane gave benzyl bromide 3.3 in 92% yield.  
This route proved both efficient and scalable, permitting the preparation of 20 grams of 3.3. 
 
 
Scheme 30. Synthesis of benzyl bromide 3.3. 
 
Next, we focused on the synthesis of alkyne 3.4 (Scheme 31).  Formylation of the 
commercially available dimethyl chlorohydroquinone 3.6 with hexamethylenetetramine in 
trifluoroacetic acid (TFA) at reflux afforded aldehyde 3.8 in good yield.  Addition of ethynyl 
magnesium bromide to aldehyde 3.8 proceeded smoothly to afford alkyne 3.9 in 94% yield.  
Deoxygenation with TFA and triethylsilane yielded a mixture of the terminally silylated alkyne 
and alkyne 3.4 (~1:5 ratio).  Desilylation of the crude mixture with tetrabutylammonium fluoride 
(TBAF) in the presence of acetic acid, afforded alkyne 3.4 in 98% yield over two steps.  The 
addition of acetic acid proved crucial as in its absence allene formation predominated, most 
likely a result of trace ammonium hydroxide.   
 
 
Scheme 31. Synthesis of alkyne 3.4 
 
Having synthesized both benzyl bromide 3.3 and alkyne 3.4, their coupling in the 
presence of several bases was explored (Table 17).  Addition of lithium hexamethyldisilazide 
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(LHMDS) to a mixture of 3.4 and 3.3 in THF at -78º C resulted in complete decomposition of 
alkyne 3.4 and only benzyl bromide 3.3 was isolated after purification (entry 1, Table 17).  
Treatment of alkyne 3.4 and benzyl bromide 3.3 with potassium hexamethyldisilazide in THF at  
-78 ºC (entry 2, Table 17) provided the unexpected benzylic substitution product tentatively 
assigned by 
1
H NMR as 3.12.   Compound 3.12 potentially arises from formation of a benzylic 
anion followed by displacement of benzyl bromide 3.3.  This result contradicts a first order pka 
analysis, which suggests the terminal alkyne (pka ~25) should be selectively deprotonated in the 
presence of the less acidic benzylic position (pka ~32).  This unusual reactivity was further 
demonstrated when switching to the stronger base n-BuLi.  Addition of n-BuLi to a cooled (-78 
ºC) mixture of 3.4 and 3.3 in THF led to the formation of a complex mixture, determined by 
1
H 
NMR analysis to consist of benzyl bromide 3.3, allene 3.11, and the benzylic displacement 
product 3.12 (entry 3, Table 17). 
  
Table 17.  Nucleophilic displacement of 3.3 with 3.4  
 
 
One explanation for the unusually high reactivity of the benzylic position is that the 
ortho-methoxy group directs deprotonation and stabilizes the resulting benzylic anion via metal 
chelation.  In order to break this potential chelation the use of hexamethylphosphoramide 
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(HMPA) was explored.
127
  Treatment of a cooled (-78 ºC) mixture of 3.4 and 3.3 in THF with n-
BuLi and HMPA followed by warming to 0 ºC resulted in the formation of a complex mixture of 
unidentifiable products (entry 4, Table 17).  Next, activation of the alkyne with copper was 
investigated.  The use of copper iodide, potassium carbonate, and tetrabutylammonium iodide
128
 
resulted in no reaction and only starting material was recovered (entry 5, Table 17).  Moving to a 
stronger base, ethylmagnesium bromide, previously shown to provide superior yields in 
challenging alkyne couplings,
129
 led to no observable reaction (entries 6, Table 17).  
The unusual benzylic reactivity of alkyne 3.4 led us to reevaluate our displacement 
strategy.  Therefore, a reversal of coupling partners was explored (Figure 37).  This coupling 
reversal removes the potential for o-methoxy stabilization of the benzylic anion while decreasing 
the steric encumbrance of the terminal alkyne.   In addition the o-methoxy substituent, now 
located on the benzyl bromide, can conjugatively stabilize the positive charge during the course 
of the reaction (Figure 37). 
 
 
Figure 37. Revised synthesis of 3.10 
 
Benzyl bromide 3.14 was readily prepared from aldehyde 3.8 in two steps.  Reduction of 
aldehyde 3.8 with sodium borohydride followed by a solvent swap and conversion to the 
bromide with hydrobromic acid afforded 3.14 in quantitative yield (Scheme 32).  
  132 
 
 
Scheme 32. Synthesis of benzyl bromide 3.13 
 
Next, we focused on the synthesis of alkyne 3.13. Addition of ethynyl magnesium 
bromide to aldehyde 3.16 afforded benzyl alcohol 3.17 in quantitative yield.  Several attempts to 
deoxygenate 3.17 with TFA and triethylsilane as before were unsuccessful, furnishing only 
polymerized products (Scheme 33).  Fortunately, an alternative approach published by the Wolff 
group
130
 using the direct displacement of benzyl bromide 3.3 with trimethylsilyl ethynyl 
magnesium bromide in the presence of copper bromide afforded alkyne 3.18 in excellent yield.  
Desilylation with TBAF and acetic acid in THF gave the desired alkyne 3.13 in 97% yield.  
 
 
Scheme 33. Synthesis of alkyne 3.13 
 
With a sufficient quantity of benzyl bromide 3.14 and alkyne 3.13 in hand, several basic 
coupling conditions were examined (Table 18).  The use of n-BuLi in THF resulted in the 
isolation of a mixture of recovered starting material (3.13 and 3.14), benzylic homocoupling 
product 3.20, and the benzylic displacement product 3.21.  The formation of the Wurtz coupling 
product 3.14 would suggest either an initial lithium halogen exchange followed by bromide 
displacement or single electron transfer mechanism occurred, not observed in the previous 
coupling studies.  The addition of HMPA to the reaction mixture resulted in complete 
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consumption of the starting material to give a mixture of the homo-coupling product 3.20, 
benzylic displacement product 3.21, and allene 3.11.   Switching to copper-mediated conditions, 
a mixture of recovered starting materials (3.13 and 3.14), nucleophilic aromatic substitution to 
give 3.23, and formation of the Glaser coupling product 3.24 was observed (Table 18).  
Investigating the use of a mesylate electrophile also afforded none of the desired product. 
Mesylate 3.19 proved unstable to isolation and after preparation by addition of methanesulfonyl 
chloride and triethylamine to benzyl alcohol 3.15 was directly subjected to the coupling 
conditions.  In the presence of either KHMDS or n-BuLi, allene formation (3.11) and 
nucleophilic aromatic substitution (3.22) were observed.  The structures of the side-products 
observed during the screen of basic coupling conditions and shown in Table 18 were tentatively 
assigned based solely on 
1
H NMR analysis. 
 
Table 18. Nucleophilic coupling to synthesize 3.10 
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The unusual benzylic reactivity of the both alkyne 3.13 and alkyne 3.4 led us to 
reevaluate our initial retrosynthetic analysis.  A key structural feature of the chrysophaentins is 
the presence of two E-chloroalkenes.  Our initial retrosynthetic analysis proposed their 
installation using a potentially nonselective hydrochlorination.  We envisioned the 
regiochemistry of the chloride would have little effect on the proposed oxidative dimerization 
and that this strategy would provide the most rapid access to tetraphenol 3.1.  Since access to the 
alkyne precursor using the outlined route (Figure 36) was complicated by the unusual benzylic 
reactivity of alkynes 3.13 and 3.4, a different approach to the synthesis of fragment 3.1 was 
needed.  Therefore, we decided to revise our synthetic strategy. 
Interestingly, reports of the stereo- and regio-selective synthesis of dialkyl trisubstituted 
E-chloroalkenes are sparse and often complicated by preferential formation of the Z-
chloroalkene.
131-133
  A survey of the pertinent literature revealed that iodine monochloride (ICl) 
could be used for the stereo- and regio-selective selective iodochlorination of terminal 
alkynes.
134,135
  We envisioned that application of this selective iodochlorination to alkyne 3.13, 
followed by a transition metal catalyzed coupling with benzyl bromide 3.14 would afford the 
desired E-chloroalkene.  Therefore, our efforts were redirected towards the investigation of 
second-generation synthesis of chrysophaentin A. 
 
3.3 2ND GENERATION SYNTHESIS OF CHRYSOPHAENTIN A 
As before, our 2
nd
 generation retrosynthetic analysis (Scheme 34) of chrysophaentin A 
features a key oxidative dimerization of fragment 3.1 to give chrysophaentin A.  Fragment 3.1 
would now be prepared by a Negishi coupling of vinyl-iodide 3.25 and organo-zinc 3.26.  Iodo-
chloroalkene 3.26 could be accessed using a regio- and stereo-selective iodochlorination of 
alkyne 3.13.  Finally, the benzylic zinc species 3.25 could be accessed via metalation of benzyl 
bromide 3.14 (Scheme 34).  In fact, while some modification of protecting groups was required, 
the synthesis of fragment 3.1 could be readily realized employing this strategy. 
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Scheme 34. 2nd Generation retrosynthetic analysis of chrysophaentin A 
 
 Our second-generation synthesis of chrysophaentin A begins with selective 
iodochlorination of alkyne 3.13.  Subjecting alkyne 3.13 to a small excess of iodine 
monochloride (ICl)
135
 in a mixture of dichloromethane and 1,2-dichloroethane afforded 19% of 
the desired product 3.26 as an inseparable mixture with several over-iodinated products (Table 
19).  Screening varying equivalents of ICl, the addition of copper chloride,
134
 and the use of 
different solvents, all led to formation of an inseparable mixture of compounds containing the 
iodochlorinated alkene as well as iodination of the aromatic ring (Table 19).  Using the 
terminally silylated alkyne
136
 3.18 also resulted in non-selective iodination.  The observed 
iodination of the aromatic ring likely results from the presence of two activating, electron 
donating methoxy groups.  Therefore, the use of a different deactivating phenolic protecting 
group was investigated.  
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Table 19. Iodochlorination of alkynes 3.13 and 3.18 
 
  
In order to deactivate the aromatic ring both sterically and electronically, the methyl 
ethers were converted to the corresponding pivalate (Piv) protected phenols (Scheme 35).  
Deprotection of the methyl ethers with boron tribromide (BBr3) in dichloromethane followed by 
re-protection with pivaloyl chloride (PivCl) afforded alkyne 3.27 in 69% yield (2 steps) (Scheme 
35).  Gratifyingly, alkyne 3.27 now underwent selective iodochlorination to provide an 
inseparable mixture of stereo-isomers, iodochloro-alkenes 3.28a and 3.28b.  Changing the 
solvent from dichloromethane to acetonitrile increased stereoselectivity, favoring the desired 
product (3.28a); however, the significant decrease in reaction yield led to the use of 
dichloromethane in future reactions (Scheme 35).  Although the observed improvement in 
stereo-selectivity could result from the increased polarity of acetonitrile relative to 
dichloromethane, the reduction in isolated yield may suggest it could also result from an 
increased rate of decomposition of 3.28b relative to 3.28a.  It is unclear however, why the rate of 
decomposition of the undesired isomer would be preferentially accelerated in acetonitrile. 
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Scheme 35. Synthesis and iodochlorination of alkyne 3.27 
 
The assignment of both the regio- and stereo-chemistry of products 3.28a and 3.28b were 
based on NMR analysis and comparison to the literature.
135
  The regiochemical outcome of the 
reaction corresponded to that predicted by the Markovnikov rule and was established based on 
the different effects exerted by a chlorine and an iodine atom on the chemical shift of the carbon 
to which they are directly bound.  Although the chlorine atom induces a downfield shift due its 
high electronegativity, the iodine atom induces an upfield shift due to the heavy atom effect (i.e., 
increased diamagnetic shielding resulting from the large number electrons introduced by a heavy 
atom).
135
  Attempts to elucidate the stereochemistry of the products by NOE analysis were 
inconclusive.  Direct support for the assignment of stereochemistry can be made by comparison 
of the 
13
C alkene shifts of 3.28a and 3.29b to similar compounds in the literature.
134
  Although 
only a small shift is observed for the terminal vinyl iodide carbon, the large shift of the vinyl 
chloride is consistent with previously reported values.  The trans-substituted iodochloroalkenes 
generally exhibit a vinyl chloride carbon shift of 129-145 ppm depending on substitution while 
cis-substituted iodochloroalkenes exhibit a vinyl chloride carbon shift of 118-125 ppm (Scheme 
35).
134,135,137,138
  Therefore, 3.28a, with the chlorine and iodine trans to one another was assigned 
as the major product.   
Next, the Negishi coupling of iodochloro-alkene 3.28 with benzylic organo-zinc 3.25 was 
investigated.  Initially, conditions recently reported to give increased yields for the 
intermolecular Negishi coupling of alkyl substrates were evaluated.
139
  Formation of organo-zinc 
3.25 in THF with zinc dust and a catalytic amount of iodine, immediately followed by addition 
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of a mixture of 3.28a and 3.28b, tris(dibenyzlideneacetone)dipalladium, and SPhos
140
 in THF 
gave, after stirring overnight at 50 ºC, none of the desired product (Scheme 36).  
 
 
Scheme 36. Synthesis of organo-zinc 3.25 and initial attempt at its Negishi coupling with 3.28 
 
As Negishi couplings often rely on high sample concentrations  ( 1 M), a model Z-vinyl 
iodide was generated in order to rapidly screen conditions while the synthesis of iodochloro-
alkene 3.28 was scaled-up. Generation of iodomethyltriphenylphosphonium iodide 3.30 from 
triphenylphosphine and diiodomethane proceeded in quantitative yield to give 3.30 on 90-gram 
scale.
141
  Z-selective Wittig reaction of iodomethyltriphenylphosphonium iodide (3.30) and the 
commercially available 3-phenyl propionaldehyde (3.31) afforded the desired cis-iodoalkene 
3.32 in quantitative yield.   
 
 
Scheme 37. Synthesis of model vinyl iodide 3.32 
 
 With ample quantities of vinyl iodide 3.32 in hand, we optimized the Negishi coupling of 
organozinc 3.25 and vinyl iodide 3.32 (Table 20).  Benzylic organozinc 3.25, generated with zinc 
dust and catalytic iodine in DMF, was cannulated onto a stirred solution of SPhos, 
tris(dibenyzlideneacetone)dipalladium, and 3.32 in THF.  After stirring overnight at room 
temperature only starting material was recovered. Changing the solvent from THF to 
dimethylformamide (DMF),
142
 the desired product 3.33 was isolated in 43% yield along with 
recovered vinyl iodide (20%) and the proto-demetalated product 3.34 (5%) (entry 2, Table 20). 
Increasing the reaction temperature from room temperature to 60 ºC had little effect on the 
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isolated yield of 3.33 however an increased yield of recovered vinyl iodide 3.32 (30%) and the 
proto-demetalated product 3.34 (15%) was observed.  Next, several palladium catalysts systems 
were evaluated. Palladium acetate and tris(dibenyzlideneacetone)dipalladium were screened 
using either SPhos or tri-o-tolyl phosphine (P(o-Tol)3), which have been shown to improve 
yields in sterically hindered systems
139,140
 (entries 3-8, Table 20).  Although the palladium source 
had little effect on isolated yield, the use of P(o-Tol)3 provided slightly better yields than SPhos.  
In addition, the ratio of ligand:Pd, either 4:1 shown be optimal for the Negishi coupling of alkyl 
halides by Szczepankiewicz et al.
143
 or 2:1 which proved optimal for Jackson et al.
139,144
 was 
investigated.  Although varying the ligand:Pd ratio had little effect on the isolated yield of 3.33, 
the isolated yield of recovered starting material 3.32 decreased.  Finally, doubling the equivalents 
of organo-zinc 3.25 afforded a substantial increase in yield affording 3.33 in 68% isolated yield 
(entry 9, Table 20).  Satisfied with the improvement in yield, the optimized conditions were 
applied to the Negishi coupling of benzyl bromide 3.14 and iodochloroalkenes 3.28a/3.28b. 
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Table 20. Optimization of Negishi coupling in model system 
 
 
A multi-gram synthesis of benzyl bromide 3.14 and iodochloroalkenes 3.28a/3.28b 
proceeded smoothly during the optimization studies (Scheme 38).  Formylation of dimethyl 
hydroquinone 3.7 and subsequent reduction afforded benzylic alcohol 3.15 on 28-gram scale.  
Conversion to benzyl bromide 3.14, as needed, proceeded quantitatively.  The synthesis of 
3.28a/3.28b also proved quite scalable.  Starting from benzoic acid 3.5, reduction, bromination, 
displacement with trimethylsilylacetylene, and silyl deprotection afforded alkyne 3.13 on 17-
gram scale in 72% yield (4 steps).  Deprotection of the methyl ethers, reprotection with PivCl, 
and iodochlorination provided an inseparable mixture of 3.28a/3.28b on a 14-gram scale in 78% 
yield over the three steps.    
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Scheme 38. Scale-up of intermediates 3.14 and 3.28a/3.28b 
 
With sufficient quantities of benzyl bromide 3.14 and iodochloroalkene 3.28 prepared, 
their Negishi coupling to furnish E-chloroalkene 3.35 was investigated (Table 21).  In contrast to 
the model system, initial attempts to couple 3.14 and 3.28 revealed that the removal of excess 
zinc after generation of the organozinc reagent was critical prior to combination with 
3.28a/3.28b.  Any residual zinc metal catalyzes the rapid anti-elimination of the trans-
iodochloro alkene 3.28a, thus returning alkyne 3.27.
135
  Therefore, 3.25 (4 equiv) was generated, 
rapidly filtered, and cannulated into a mixture of tris(dibenyzlideneacetone)dipalladium, tri-o-
tolyl phosphine, and a mixture of 3.28a/3.28b in DMF.  After stirring at room temperature 
overnight, desired product 3.35 (26%), benzylic homo-coupling product 3.20, and the proto-
demetalated product 3.33 were isolated.  
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Table 21. Optimization of Negishi coupling of 3.28a/3.28b and 3.25 
 
 
The use of the more air-stable palladium diacetate provided no significant drop in yield, 
thus it was selected for future optimization (entries 1, 2, Table 21).  A screen of phosphine 
ligands revealed that tributyl phosphine and tri-o-tolyl phosphine provided superior yields.  
Again due to ease of handling, tri-o-tolyl phosphine was selected for future optimization (entries 
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3-7, 10, 11 Table 21).  The use of either nickel (0) or nickel (II) catalysts in dimethyl acetamide 
(DMAC) resulted in no observable reaction and only starting material was recovered (entries 8, 
9, Table 21).  Due to the long reaction times associated with both the room temperature and 
conventional heating procedures (>12 h), microwave irradiation was explored. Gratifyingly, 
microwave irradiation (80 ºC) of the reaction mixture in DMF afforded 3.35 in comparable 
yields after only 25 min. (Table 22). 
Unfortunately, in several solvent systems, 3.35, 3.33, and 3.20 exhibited extremely 
similar retention factors (Rf’s) on silica gel, making reproducible levels of purity challenging to 
obtain.  However, subjecting the impure Negishi coupling mixture to pivalate deprotection with 
cesium carbonate and methanol afforded the more readily separable diphenol 3.36.  Thus, in 
order to obtain more accurate yields, all future optimization studies used the two-step procedure 
of Negishi coupling and deprotection prior to purification. 
Final optimization of the Negishi coupling using microwave irradiation and immediate 
pivalate deprotection led to an optimized procedure (Table 22).  Increasing the reaction 
temperature of the Negishi coupling from 80 ºC to 140 ºC reduced the reaction time from 25 min 
to 2 min, with no observable decrease in yield.  The formation of palladium black during the 
course of the reaction led to the hypothesis that decomposition of the palladium catalyst was 
inhibiting further product formation.  Decreasing the reaction temperature to 120 ºC and 
sequential addition of the palladium catalyst led to an optimized procedure that afforded 3.36 as 
an inseparable mixture of E- and Z-isomers (4:1) in 51% (2 steps) in only 4 minutes.  
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Table 22. Final optimization of the Negishi coupling 
 
  
With an optimized procedure for the Negishi coupling obtained, attention was directed to 
deprotection of the methyl ethers of 3.36 and completion of key fragment 3.1 (Table 23).  
Deprotection of 3.36 (2:1 mixture of E- and Z-isomers) with boron tribromide in 
dichloromethane provided 27% of the desired product 3.1 as an inseparable mixture of E- and Z-
stereoisomers (2:1).  Several other nucleophilic deprotection conditions, as well as elevated 
reaction temperatures, led to decomposition of 3.36 (Table 23).  Fortunately, decreasing the 
concentration of 3.36 (2:1 mixture of E- and Z-isomers) to 0.02 M in the presence of boron 
tribromide (BBr3) afforded the desired tetraphenol 3.1 as an inseparable mixture of E- and Z-
isomers (2:1) in quantitative yield.  Therefore, the tetraphenolic C1-C16 monomer of 
chrysophaentin A 3.1 was synthesized in 10 steps (longest linear sequence) and 24% overall 
yield from commercially available starting materials. 
100 mg of an analytically pure E-isomer of 3.36 was obtained by separation of the 
geometric isomers by supercritical fluid chromatography (SFC) using a semi-prep (250 × 10 
mm) silica column (Rt 5.80 min, 10 mL/min, 15% methanol, 220 nm detection).  Subjecting the 
pure E-isomer of 3.36 to the optimized deprotection conditions provided 3.1 as a single 
geometric isomer (E-isomer) in 96% yield.   40 mg of an analytically pure E-isomer of 3.1 was 
obtained by separation of the geometric isomers by SFC chromatography using a semi-prep (250 
× 10 mm) silica column (Rt 4.68 min, 8 mL/min, 25% methanol, 220 nm detection). 
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Table 23. Optimization of methyl deprotection 
 
 
10 mg of pure E-isomer of both the dimethoxy monomer 3.36 and the tetraphenol 3.1 
were sent to our collaborator Dr. Carole Bewley’s lab at the NIH for evaluation of their 
antimicrobial activities.  The synthesis of 3.36 and 3.1 discussed above and the biological 
evaluation discussed below were recently reported in the Journal of Marine Drugs
145
 and are 
reproduced with permission. 
“The antibacterial activity of the pure E-isomer of 3.36 and 3.1 were evaluated in a 
microbroth dilution assay.  The minimum inhibitory concentration that led a 50% decrease in 
growth (MIC50) was determined using a model curve fit to the data.  The MIC90 was determined 
as the lowest concentration where no visibile growth was observed.  The minimum bactericidal 
concentration (MBC) was determined as the lowest concentration where a plated aliquot of 
treated bacteria led to a three logarithmic decrease in colony forming units (CFU) per milliliter 
relative to the starting inoculum.”  The antibacterial activity of both 3.36 and 3.1 were evaluated 
against five different strains of Staphylococcus aureus including a highly resistant strain, ATCC 
BAA-44 (Table 24).     
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Table 24. Summary of antibacterial activity of chrysophaentin A, 3.36, and 3.1 against five diverse strains of 
Staphylococcus aureus (all values are in µM).  
MIC50 MIC90 MBC
S. aureus 
25923 (µM)
MDRSA 
BAA-44(µM)
S. aureus
 UAMS-1 (µM)
CA-MRSA
USA300-LAC (µM)
MIC50 MIC90 MBC MIC50 MIC90 MIC50 MIC90 MBC MIC50 MIC90 MBC
Chrysophaentin
 A
3.36
3.1
2.7±0.9 9.2a 37a 2.3±1.0 4.6a 37a 1.8±0.5 9.2a 5.1±2.1 9.2a 19a 5.0±2.4 9.2a 19a
12±4.3 34a 68a 11±5.4 34a 68a 13±4.7 34a 20±10 34a 68a 18±8.4 34a 68a
20±5.2 74a 150a 23±9.9 74a 150a 27±9.4 74a 31±13 74a 150a 29±9.9 74a 150a
Compound
MRSA BAA-41
(µM)
 
Strains used: S. aureus ATCC 25923,  clinical isolate from Seattle, 1945; methicillin-resistant S. aureus ATCC 
BAA-41, a hospital-acquired strain isolated in New York City in 1994; multidrug-resistant S. aureus (MDRSA) 
ATCC BAA-44, a hospital-acquired strain isolated in Lisbon, Portugal, with resistance towards ampicillin, 
methicillin, oxacillin, penicillin, erythromycin, gentamicin, tetacycline, azithromycin, amikacin, clindamycin, 
cephalothin, ceftriaxone, imipenem, lincomycin, streptomycin, perfloxacin, rifampin, and neomycin. S. aureus 
UAMS-1, a clinical osteomyelitis isolate; and community-associated methicillin-resistant S. aureus, USA300-LAC.  
aNote: MIC90 and MBC values were determined using a microbroth dilution assay and represent the minimum 
concentration evaluated at which no visible growth of bacteria (MIC90) or a three-fold logarithmic decrease in the 
number of viable bacteria relative to the starting inoculum (MBC) was observed; they are only approximate values. 
 
The monomeric units 3.36 and 3.1 retained the potent antibacterial activity of their parent 
natural product against all five strains of bacteria.  In fact, compound 3.36 proved more potent 
than chrysophaentins D, E, and G.  Since the acyclic variants were still approximately 10-fold 
less potent than chrysophaentin A, attention returned to the completion of the synthesis.  
With a scalable route to monomer 3.1 in hand, investigation of the key oxidative 
dimerization to afford chrysophaentin A began.  Although the desired oxidative addition requires 
the asymmetic formation of two diaryl ether bonds, small quantities of product should be 
identifiable by LCMS analyses.  Isolation by either SFC or HPLC purification will provide 
access to chrysophaentin A, even if the efficiency of the reaction is poor.  Therefore, all reactions 
were conducted using 20 mg of 3.1 and were monitored by LCMS.  When major products were 
observed they were isolated and characterized by NMR analysis to provide insight into the 
inherent reactivity of fragment 3.1. 
First, the use of iron catalysts was investigated (Table 25).
123-125,146-148
  Subjecting 3.1  to 
iron trichloride hexahydrate in either dichloromethane or toluene afforded no reaction after 
stirring at room temperature overnight.  Upon heating the reaction mixtures to 60 ºC, steady 
decomposition of 3.1 was observed.  Switching to the more polar acetonitrile accelerated the 
decomposition process and after 2 h at room temperature only a small portion starting material 
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was recovered.  Using DMF as the solvent led to the formation of an unexpected product in 2 h 
at room temperature.  This product was purified by SFC and tentatively assigned based on 
1
H 
NMR analysis to be tricycle 3.37.  Allowing the reaction mixture to stir for 3 d at room 
temperature afforded 3.37 along with a complex mixture of unidentified products.  Increasing the 
temperature of the reaction led to decomposition of 3.1.  Although 3.37 is not a useful 
intermediate for the total synthesis of chrysophaentin A, this unusual cyclization may warrant 
further exploration in the future.  The use of potassium ferricyanide was also explored (not 
shown).  Unfortunately, in several solvents in the absence of base or in the presence of the weak 
base ammonium acetate no reaction was observed and only starting material was recovered.  
Switching to stronger carbonate bases or potassium hydroxide led to the decomposition of 3.1.   
  
Table 25. Attempted oxidative dimerization of 3.1 
 
 
Next, the use of copper catalysts was explored.
149-152
  Subjecting 3.1  to copper chloride 
in acetonitrile at room temperature resulted in the formation of a small quantity of the oxidized 
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quinone 3.38 (20%) as well as some recovered starting material.  Increasing the reaction 
temperature, only decomposition was observed.  The use of phenyliodine diacetate (PIDA) was 
explored next.
121,122,153,154
  Subjecting to 3.1 to PIDA in acetonitrile provided a complex mixture 
of unidentified products.  Although several other solvents were investigated, again only 
decomposition was observed.  Next, the use of oxidative silver or manganese conditions to affect 
the desired oxidative dimerization were explored.
125,148
  The use of manganese dioxide resulted 
in no observable reaction and only starting material was recovered.  Using freshly prepared silver 
oxide in diethyl ether led to the isolation of a major product, tentatively assigned by 1H NMR 
analysis to be quinone 3.38.  Selective synthesis of quinone 3.38 using DDQ in diethyl ether 
afforded 3.38 in 99% yield.  Attempts to functionalize the rapidly purified quinone 3.38 were 
met with decomposition.  The instability of quinone 3.38 may suggest that some of the 
decomposition observed during the reaction screening was a result of initial formation of the 
quinone followed by a series of undesired side-reactions leading to the observed complex 
mixtures.  
 
Table 26. Attempt to dimerize 3.1 
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Finally we chose to investigate the use of enzymes for the desired oxidation 
dimerization.
116,117,119,120,155-158
  Initially we chose to investigate a commercially available laccase 
from Trametes versicolor.  Laccases are copper-containing enzymes known to catalyze the single 
electron oxidation of variety of organic substrates including the oxidative dimerization of 
polyphenols to afford -hydroxy diaryl ethers.116,155  Subjecting 3.1 to 10 units of the laccase in a 
20 mM acetate buffer (pH = 4.3) afforded only decomposition.  Next, we investigated the use of 
horseradish peroxidase (HRP), a hemoprotein known to oxidatively couple phenols in the 
presence of hydrogen peroxide.
159
  Using a protocol recently used for the oxidative dimerization 
of 17-estradiol, 3.1 was subjected to HRP and hydrogen peroxide in a 0.1 mM phosphate buffer 
(pH = 7.4).
160
  After stirring overnight, only decomposition was observed. These results led us to 
reevaluate our strategy for diaryl ether bond formation.  
Examination of the literature revealed that although a number of different methods exist 
for diaryl ether bond formation, the Ullmann coupling has been refined over the last century and 
has one of the broadest applications of any methods reported so far.
161-164
  Thus, we chose to 
investigate the Ullmann coupling of some simplified variants of chrysophaentin A.  
 
 
Figure 38. Chrysophaentin A ring labeling 
 
Initially, the synthesis of both an aryl iodide and a phenol containing a similar 
substitution pattern to aryl rings D and C of chrysophaentin A was pursued (Figure 38).  Starting 
from the commercially available 3,5-dihydroxy toluene (3.39), selective iodination with iodine 
and sodium bicarbonate in a mixture of THF and water afforded the desired aryl iodide 3.40 in 
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80% yield (Scheme 39). Protection of 3.40 with potassium carbonate and methyl iodide in DMF 
proceeded in 90% yield to provide aryl iodide 3.41.   
 
 
Scheme 39. Synthesis of 3.41 
  
With a sufficient quantity of 3.41 prepared, several Ullmann coupling conditions were 
investigated (Figure 39).  3,5-Dihydroxy toluene (3.39) was chosen as the first phenol as it 
contains a similar 1,3-didroxy substitution to the A and D rings of chrysophaentin A.  3,5-
Dihydroxy toluene (3.39) and aryl iodide 3.41 were combined in the presence of copper iodide, 
cesium carbonate, and N,N-dimethyglycine
165
 and the mixture was heated at 90 ºC in dioxane 
overnight.  Unfortunately, no reaction was observed and only starting material was recovered.  
1,5-Dihydroxy toluene (3.42) was explored next as it contains a similar substitution pattern to the 
A and C rings of chrysophaentin A (Figure 38).  Subjecting a mixture of dihydroxy toluene 
(3.42), aryl iodide 3.41, copper iodide, cesium carbonate, and 1,10-phenanthroline
166
 to either 
microwave irradiation or conventional heating again returned only starting material.  
Investigating the use of a copper triflate toluene complex, reported to provide superior yields 
than copper iodide in the Ullmann coupling,
167
 once again afforded only unreacted starting 
material.  Finally, in order to eliminate any potential steric and electronic effects of either the 
dihydroxy or methyl substituents, phenol (3.43) was evaluated in the Ullmann coupling with aryl 
iodide 3.41.  Screening the use of a copper bromide dimethylsulfide complex,
168
 copper iodide 
and 1,10-phenanthroline, copper chloride and tetramethylheptanedione,
169
 copper oxide in 
pyridine,
168
 and copper iodide and picolinic acid
170
 in the Ullmann coupling under conventional 
heating all returned only starting material.  Based on these results, it was hypothesized that the 
electron rich nature and steric encumbrance of aryl iodide 3.41 was inhibiting oxidative insertion 
and therefore the success of the coupling.   
 
  151 
 
Figure 39. Attempted Ullmann coupling of 3.41 with several phenols 
 
Since sterically hindered electron rich aryl iodides were found to be inefficient for the 
desired Ullmann coupling, the use of sterically encumbered electron rich phenols was evaluated.  
Selectively protected phenols with oxygenation patterns similar to the D ring of chrysophaentin 
A were prepared (Scheme 40, Scheme 41).  Protection of 3,5-dihydroxy toluene (3.39) with 
potassium carbonate and methyl iodide gave 3,5-dimethoxy toluene 3.44 in 98% yield.  Directed 
ortho-metalation
171
 of 3,5-dimethoxy toluene 3.44 with n-butyllithium in the presence of 
tetramethylethylenediamine followed by trapping with dimethylformamide gave aldehyde 3.45 
in 92% yield.  Although our initial attempt at the Dakin oxidation of 3.45 with m-CPBA 
provided a complex mixture, the use of hydrogen peroxide and catalytic diphenyl diselenide
172
 
followed by methanolysis of the resulting ester intermediate afforded phenol 3.46 in 94% yield.  
Subjecting phenol 3.46 and iodobenzene to copper chloride, 2,2,6,6,-tetramethyl-3,5-
heptanedione (TMHD), and cesium carbonate in NMP at 120 ºC overnight provided diaryl ether 
3.48 in 69% yield (Scheme 40).   
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Scheme 40. Synthesis and Ullmann coupling of 3.46 
 
Next, the preparation and Ullmann coupling of phenol 3.50, which contains the 
oxygenation present of the A ring of chrysophaentin A (Figure 38), was investigated (Scheme 
41).  Selective formylation of 3,5-dimethoxy toluene 3.44 with the Vilsmeier-Haack reagent, 
generated in situ from phosphorous oxychloride (POCl3) and DMF, yielded aldehyde 3.49 in 
88% yield.  Dakin oxidation with hydrogen peroxide and catalytic diphenyl diselenide
172
 
proceeded smoothly to give an intermediate ester which was reduced with sodium borohydride to 
provide phenol 3.50 in quantitative yield.  Subjecting phenol 3.50 and iodobenzene (3.47) to the 
previously successful Ullmann conditions afforded the desired diaryl ether 3.51 in 83% yield.  
Bromobenzene (3.52) also proved competent in the Ullmann coupling to give the desired diaryl 
ether 3.51 in slightly improved 91% yield (Scheme 41).   
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Scheme 41. Synthesis and Ullmann coupling of 3.50 
 
Having successfully coupled both 3.46 and 3.50, the use of the fully functionalized 3.55 
in the Ullmann coupling was explored (Table 27).  Bromination of 2-hydroxy-4-chlorobenzoic 
acid (3.54) with bromine and triethylamine
173
 followed by methylation of both the phenol and 
acid with methyl iodide provided aryl bromide 3.55 in 72% yield along with 19% of the 
dibrominated product.  Ullmann coupling of 3.55 with copper iodide and TMHD in NMP 
overnight at 140 ºC provided a complex mixture of products.  Investigating different CuI ligands, 
N,N-dimethyl glycine
165
 or 1,10-phenanthroline
166
 afforded only recovered starting material.  
Varying the copper catalyst to either copper triflate
167
 or copper oxide
174
 resulted in no 
observable reaction and only starting material was recovered.  Moving from conventional 
heating to microwave irradiation, the use of copper iodide and cesium carbonate at 200 ºC for 20 
minutes gave a complex mixture of unidentified products.  Investigating the use of a recently 
reported copper thiophene complex
175,176
 in dimethylformamide under microwave irradiation 
(200 ºC) afforded a mixture of recovered starting material (3.59), the proto-demetalated product 
(3.62), and decomposition.  Decreasing the reaction temperature to 160 ºC, approximately 20% 
of a product tentatively assigned as 3.56 was isolated along with an intractable impurity.  Hoping 
to increase the reactivity of the aryl bromide, we also prepared and evaluated the aryl iodide (not 
shown).  Unfortunately under a variety of copper mediated conditions, none of the desired 
product was isolated. 
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Table 27. Preparation and attempted Ullmann coupling of 3.56 
 
 
Based on the limited success of both the iodo and bromo derivatives, a series of aryl 
iodides were prepared to test which substitutions were inhibiting the Ullmann coupling.  Using 
the commercially available methyl 3,5-dimethoxy-4-hydroxybenzoate, these aryl iodides were 
evaluated under the previously successful reaction conditions of copper chloride, cesium 
carbonate, and TMHD in NMP at 120 ºC.  Iodobenzene afforded the desired Ullmann coupling 
product 3.60 in 44% yield.  Introduction of the o-chloride dramatically reduced the efficiency of 
the reaction and only 20% of a product tentatively assigned as 3.61 containing an intractable 
impurity was isolated.  The presence of a p-methoxy substituent afforded the highest yield of the 
Ullmann coupling product 3.62 (84% yield).  Introduction of a m-ester significantly decreased 
the efficiency of the reaction providing only 4% yield of 3.63.  Although several mechanisms 
have been postulated for the copper mediated Ullmann coupling, a mechanistic consensus has yet 
to be reached.
161,177
   Examination of Table 28 reveals that for the sterically hindered electron 
rich phenol 3.59 the combination of the o-chloride and m-ester are responsible for the 
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inefficiency of the Ullmann coupling.  These studies led us to conclude that further optimization 
of the Ullmann coupling or its application to the fully functionalized fragment 3.1, were not 
worth pursuing.  Therefore, an alternative strategy for diaryl ether formation had to be explored.  
 
Table 28. Investigation of the effect of increasing complexity on the intermolecular Ullmann coupling 
 
 
In a final attempt to form the diaryl ether bond, a recently reported procedure for diaryl 
ether formation using diaryliodonium salts was investigated (Scheme 42).
178
  Synthesis of 
diaryliodonium 3.65 from ester 3.57 was accomplished using the commercially available 
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iodomesitylene diacetate 3.64 in the presence of triflic acid in 74% yield.
179
   Unfortunately, 
several attempts to synthesize diaryl ether 3.66 using t-butoxide in tetrahydrofuran failed to 
afford the desired product 3.66.   
 
 
Scheme 42. Investigation of diaryl ether formation via hypervalent iodonium coupling 
 
3.4 CONCLUSIONS 
Herein, the convergent synthesis of the C1-C16 tetraphenol of chrysophaentin A is reported 
in 10 steps (longest linear sequence) and 24% overall yield.  Our synthetic strategy is highlighted 
by a regio and stero-selective iodochlorination and subsequent Negishi cross-coupling to install 
the E-chloroalkene conserved throughout the chrysophaentins.  After SFC separation of the E- 
and Z-stereoisomers, the pure E-isomer of both fragment 3.1 and the dimethyl variant 3.36 were 
submitted for biological evaluation.   
Through a collaboration with Dr. Bewley and coworkers at the National Institutes of Health, 
the antibacterial activity of both 3.36 and 3.1 was evaluated.  Gratifyingly, 3.36 and 3.1, which 
comprise the conserved portions of the chrysophaentins, retained the potent growth inhibition 
exhibited by their parent natural product for several bacterial strains, including a highly drug 
resistant strain of Staphylococcus aureus (Table 24).
145
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Although the formation of the diaryl ether linkages present in chrysophaentin A has yet to be 
realized, a series of oxidative, Ullmann, and hypervalent iodine conditions were examined and 
provided insight into the reactivity of the fully functionalized phenols. In particular, the fully 
functionalized fragment 3.1 exhibited a propensity to oxidize to the quinone, which could 
undergo a variety of undesired side reactions leading to a mixture of degradation products.  The 
investigation of the Ullmann coupling of a series of model systems revealed that the presence of 
the o-chloride and a m-ester are primarily responsible for the decreased efficiency of the 
Ullmann coupling.   Finally, the use of a hypervalent iodine derivative 3.65 proved inefficent for 
the SNAr type coupling. 
In the future, the formation of the diaryl ether bond must be addressed.  Ideally, diarly ether 
formation will be either the penultimate or final step affording the most convergent synthesis and 
allowing for full use of the described synthesis of fragment 3.1.  A major challenge associated 
with the total synthesis of the chyrsophaentins, the installation of the dialkyl E-chloroalkene, has 
been addressed.  The significant advances in metal mediated coupling made in the last 50 years 
make it likely that this strategy will be amenable to a large variety of substition around the aryl 
rings.  Therefore, it is likely that the Negishi coupling of fragments already containing the diaryl 
ether linkage will be successful.   
3.5 EXPERIMENTAL 
General. All moisture sensitive reactions were performed using syringe-septum techniques under 
an atmosphere of either dry N2 or dry argon unless otherwise noted. All glassware was dried in 
an oven at 140 °C for a minimum of 6 h or flame-dried under an atmosphere of dry nitrogen 
prior to use. Reactions carried out at −78 °C employed a CO2(s)/acetone bath. Et2O and 
tetrahydrofuran were dried by distillation over sodium/benzophenone under an argon 
atmosphere. Dry methylene chloride was purified by filtration through an activated alumina 
column. All degassed solvents were prepared using the freeze/pump/thaw method (3×). 
Methanol, acetonitrile, and N,N-dimethylformamide were stored over molecular sieves (3 Å). 
Deuterated chloroform was stored over anhydrous potassium carbonate. Reactions were 
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monitored by TLC analysis (pre-coated silica gel 60 F254 plates, 250 µm layer thickness) and 
visualized by using UV lamp (254 nm) or by staining with either Vaughn’s reagent (4.8 g of 
(NH4)6Mo7O24·4H2O and 0.2 g of Ce(SO4)2 in 100 mL of a 3.5 N H2SO4) or a potassium 
permanganate solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL of a 0.1% NaOH 
solution). Flash column chromatography was performed with 40–63 µm silica gel (Silicycle). 
Microwave reactions were performed on a Biotage Initiator microwave reactor. Infrared spectra 
were measured on a Smiths Detection IdentifyIR FT-IR spectrometer (ATR). Unless otherwise 
indicated, all NMR data were collected at room temperature in CDCl3 or (CD3)2CO on a 300, 
400, 500, 600, or 700 MHz Bruker instrument. Chemical shifts (δ) are reported in parts per million 
(ppm) with internal CHCl3 (δ 7.26 ppm for 
1
H and 77.00 ppm for 
13C), or internal acetone (δ 2.05 
ppm for 
1
H and 29.85 ppm for 
13
C), as the reference. 
1
H NMR data are reported as follows: 
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, m 
= multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, qd = quartet 
of doublets, sep = septet), integration, and coupling constant(s) (J) in Hertz (Hz). HRMS 
analyses were obtained using either a Q-TOF Ultima API, Micromass UK Limited (ESI) or a VG 
Autospec, FISIONS instrument (EI). 
 
 
 
3,5-Dimethoxy benzyl alcohol (3.7).  To a stirred suspension of lithium aluminum hydride 
(13.1 g, 329 mmol, 2 equiv) in dry THF (400 mL) at 0 °C was added a solution of 3,5-
dimethoxybenzoic acid (30.0 g, 164 mmol, 1 equiv) in dry THF (400 mL) over 45 min. Upon 
completion of the addition, the reaction mixture was diluted with THF (300 mL), warmed to rt, 
stirred for 5 h, and slowly quenched with a saturated aqueous solution of Na/K tartrate. The 
resulting biphasic mixture was stirred at rt. for 1 h, the organic layer was separated, the 
remaining aqueous layer was extracted with EtOAc (x2), and the combined organic layers were 
dried (MgSO4), filtered, and concentrated under reduced pressure to give 3.7 (27.0 g, 97%) as a 
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colorless oil: Rf 0.33 (EtOAc/hexanes, 1:2); IR (CDCl3) 3390, 2937, 1594, 1456, 1428, 1318, 
1294, 1202, 1146, 1057, 829 cm
−1
; 
1
H NMR (600 MHz, CDCl3) δ 6.45 (d, 2 H, J = 2.4 Hz), 6.32 
(d, 1 H, J = 2.4 Hz), 4.50 (d, 2 H, J = 5.4 Hz), 3.71 (s, 6 H), 3.49 (t, 1 H, J = 5.4 Hz); 
13
C NMR 
(150 MHz, CDCl3) δC160.5, 143.3, 104.2, 99.2, 64.5, 55.0.  Characterization matches that 
reported by Weist et al.
180
 
 
 
3,5-Dimethoxybenzyl bromide (3.3).  To a stirred solution of 3.7 (17.5 g, 104 mmol, 1 equiv) in 
CH2Cl2 (500 mL) at 0 °C was added dropwise PBr3 (12.1 mL, 125 mmol, 1.2 equiv). The 
reaction mixture was slowly warmed to rt, stirred for 3 h, quenched with a saturated aqueous 
solution of NaHCO3, and stirred at rt. for 1 h. The organic layer was separated and the aqueous 
layer was extracted with Et2O. The combined organic layers were dried (MgSO4), filtered, and 
concentrated under reduced pressure to give 3.3 (22.2 g, 92%) as a white solid: Rf 0.75 
(EtOAc/hexanes, 1:2); IR (CDCl3) 2999, 2954, 1596, 1458, 1428, 1345, 1323, 1297, 1204, 1152, 
1062, 930 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 6.54 (d, 2 H, J = 2.0 Hz), 6.39 (d, 1 H, J = 2.4 
Hz), 4.42 (s, 2 H), 3.80 (s, 6 H); 
13
C NMR (150 MHz, CDCl3) δ 160.9, 139.7, 107.0, 100.6, 55.4, 
33.6; HRMS (ESI
+
) m/z calcd for C9H12O2Br 231.0021, found 231.0038. Characterization 
matches that reported by Snyder, Scott A.
181
 
 
 
4-Chloro-2,5-dimethoxybenzaldehyde (3.8). To a stirred solution of 2-chloro-1,4-
dimethoxybenzene (25.0 g, 0.145 mol, 1 equiv) and hexamethylenetetramine (20.5 g, 0.145 mol, 
1 equiv) at rt. was carefully added TFA (250 mL). The resulting yellow suspension was heated to 
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95 °C, stirred for 5 h, and the hot brown solution was poured into a 2 L Erlenmeyer flask 
containing approximately 250 g of crushed ice. To the vigorously stirred mixture was slowly 
added solid NaHCO3 (243 g, 2.90 mol, 20 equiv) in 5–10 g portions over two hours. The 
resulting yellow precipitate was filtered through a pad of Celite, washed with water, and 
dissolved in Et2O. The organic layer was washed with water and brine, dried (MgSO4), filtered, 
and concentrated under reduced pressure to give 3.8 yield (29.0 g, 100%) as an off-white solid: 
Rf 0.70 (EtOAc/hexanes, 3:7); IR (neat) 2941, 2874, 1664, 1601, 1575, 1497, 1478, 1461, 1389, 
1269, 1213, 1023, 977 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 10.35 (s, 1 H), 7.33 (s, 1 H), 7.03 (s, 
1 H), 3.87 (s, 6 H); 
13
C NMR (100 MHz, CDCl3) δ 188.4, 156.1, 149.4, 130.4, 123.4, 114.5, 
109.9, 56.5, 56.3; HRMS (EI
+
) m/z calcd for C9H9O3Cl 200.0240, found 200.0238. 
Characterization matches that reported by Bloomer et al.
182
 
 
 
1-(4-Chloro-2,5-dimethoxyphenyl)prop-2-yn-1-ol (3.9).
183
  To a stirred solution of 3.7 (2.50 g, 
12.5 mmol, 1 equiv) in THF (20 mL) at 0 ºC was added dropwise ethynyl magnesium bromide 
(0.5 M in THF; 49.8 mL, 24.9 mmol, 2.0 equiv). The reaction was allowed to stir at 0 ºC for 30 
min, quenched with a saturated aqueous solution of NH4Cl, and extracted with Et2O (x2).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, and concentrated 
under reduced pressure. The crude mixture was purified by chromatography on SiO2 
(EtOAc/hexanes, 1:3) to give 3.9 (2.64 g, 94% yield) as a white solid: Mp 80-81 ºC; Rf 0.24 
(EtOAc/hexanes, 1:3); IR (neat) 3282, 2958, 1491, 1463, 1441, 1388, 1206, 1178, 1031, 982, 
740; 
1
H NMR (300 MHz, CDCl3)  7.21 (s, 1 H), 6.93 (s, 1 H), 5.66 (dd, 1 H, J = 2.1, 5.1 Hz), 
3.87, (s, 3 H), 3.83 (s, 3 H), 3.06 (d, 1 H, J = 5.7 Hz), 2.62 (d, 1 H, J = 2.4 Hz); 
13
C NMR (75 
MHz, CDCl3)  150.5, 149.1, 127.5, 122.6, 113.5, 112.1, 82.6, 74.4, 60.1, 56.7, 56.3; HRMS 
(EI+) m/z calcd for C11H11O3Cl 226.0397, found 226.0395.  
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1-Chloro-2,5-dimethoxy-4-(prop-2-ynyl)benzene (3.4).
184
  To a stirred solution of 3.9 (1.30 g, 
5.74 mmol, 1 equiv) in CH2Cl2 (25 mL) was added triethylsilane (1.85 mL, 11.5 mmol, 2 equiv) 
followed by TFA (1.70 mL, 22.9 mmol, 4 equiv) under a N2 atmosphere.  The dark purple 
solution was stirred at rt for 20 min, quenched with a saturated aqueous solution of NaHCO3, and 
extracted with Et2O (x2).  The combined organic layers were washed with brine, dried (MgSO4), 
filtered, and concentrated under reduced pressure.  The crude residue was dissolved in dry THF 
(20 mL) and AcOH (1 mL) and TBAF (1 M in THF; 11.5 mL, 11.5 mmol, 2 equiv) were added 
sequentially. The reaction mixture was stirred at rt under TLC control.  Once complete, the 
reaction was diluted with Et2O, washed with water (x2), brine, dried (MgSO4), filtered, and 
concentrated under reduced pressure.  The crude mixture was purified by chromatography on 
SiO2 (hexanes/Et2O, 9:1) to give 3.4 (1.18 g, 98% yield) as a colorless oil: Rf 0.66 
(Et2O/hexanes, 1:9); IR (neat) 3277, 2934, 2839, 1497, 1461, 1448, 1409, 1206, 1180, 1032, 818 
cm
-1
; 
1
H NMR (300 MHz, CDCl3)  7.17 (s, 1 H), 6.87 (s, 1 H), 3.89 (s, 6 H), 3.79 (s, 6 H), 3.54 
(dd, 2 H, J = 0.6, 2.7 Hz), 2.21 (t, 1 H, J = 2.7 Hz); 
13
C NMR (75 MHz, CDCl3)  150.8, 149.0, 
123.9, 120.7, 113.7, 112.6, 81.4, 70.9, 56.9, 56.1, 29.7, 22.7, 19.2; HRMS (EI
+
) m/z calcd for 
C11H11O2Cl 210.0448, found 210.0445.  
 
 
(3-(4-Chloro-2,5-dimethoxyphenyl)prop-1-ynyl)triethylsilane: 
1
H NMR (300 MHz, CDCl3)  
7.27 (s, 1 H), 6.85 (s, 1 H), 3.88 (s, 1 H), 3.77 (s, 1 H), 3.60 (d, 2 H, J = 0.6 Hz), 1.02 (t, 9 H, J = 
8.1 Hz), 0.63 (q, 6 H, J = 7.8, 15.6 Hz). 
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1-Chloro-2,5-dimethoxy-4-(propa-1,2-dienyl)benzene (3.11).  To a stirred solution of  (3-(4-
chloro-2,5-dimethoxyphenyl)prop-1-ynyl)triethylsilane (mixture of product and SM, 0.113 g, 
0.348 mmol, 1 equiv) in THF (2 mL) was added TBAF (1 M in THF; 0.696 mL, 0.696 mmol, 2 
equiv).  The reaction was stirred at rt for 1 h.   The amber red reaction mixture was diluted with 
water and extracted with Et2O (x3).  The combined organic layers were washed with water (x2), 
brine, dried (MgSO4), filtered, and concentrated under reduced pressure. The crude mixture was 
purified by chromatography on SiO2 (EtOAc/hexanes, 1:9) to give undesired allene 3.11 (0.060 
g, 82% yield):  Rf 0.5 (EtOAc/hexanes, 1:9); 
1
H NMR (300 MHz, CDCl3)  6.97 (s, 1 H), 6.89 
(s, 1 H), 6.51 (t, 1 H, J = 6.9 Hz), 5.14 (d, 2 H, J = 6.9 Hz), 3.85 (s, 3 H), 3.79 (s, 3 H). 
 
 
(5-Chloro-2-(1-(3,5-dimethoxyphenyl)but-3-yn-2-yl)-4-methoxyphenoxy)methylium (3.12).   
To a stirred solution of 3.4 (0.0500 g, 0.237 mmol, 1 equiv) and 3,5-dimethoxybenzyl bromide 
(0.0679 g, 0.284 mmol, 1.2 equiv) at -78 ºC in THF (1 mL) was added dropwise a solution of 
KHMDS (0.0568 g, 0.284 mmol, 1.2 equiv) in THF (1 mL).  The reaction was stirred at -78 ºC 
for 4 h and quenched with a saturated solution of aqueous NH4Cl.  The aqueous solution was 
extracted with Et2O (x2) and the combined organic layers were washed with brine, dried 
(MgSO4), filtered, and concentrated under reduced pressure. The crude mixture was purified by 
chromatography on SiO2 (EtOAc/hexanes, 1:9) to give 3.12 (0.0856 g, 56% yield) as an oil: Rf 
0.5 (EtOAc/hexanes, 1:9); 
1
H NMR (300 MHz, CDCl3)  7.11 (s, 1 H), 6.89  (s, 1 H), 6.35 (s, 3 
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H), 4.33 (ddd, 1 H, J = 2.4, 4.8, 11.1 Hz), 3.83 (s, 3 H), 3.78 (s, 3 H), 3.75 (s, 3 H), 2.98 (dd, 1 
H, J = 4.8, 12.9 Hz), 2.79 (s, 1 H, J = 8.7, 13.2 Hz), 2.27 (d, 1 H, J = 2.4 Hz); 
13
C NMR (75 
MHz, CDCl3)  160.3, 150.1, 149.0, 141.1, 128.4, 120.9, 113.4, 112.9, 107.5, 98.4, 85.0, 71.9, 
56.8, 56.1, 55.2, 42.7, 33.0. 
 
 
(4-Chloro-2,5-dimethoxyphenyl)methanol (3.15).  To a stirred solution of 3.8 (29.0 g, 145 
mmol, 1 equiv) in absolute ethanol (550 mL) was added sodium borohydride (27.3 g, 723 mmol, 
5 equiv). The reaction mixture was stirred at rt for 6 h, quenched via dropwise addition of 
acetone, diluted with EtOAc, washed with brine (x2), dried (MgSO4), filtered, and concentrated 
under reduced pressure. The crude residue was purified by chromatography on SiO2 
(EtOAc/hexanes, 1:1) to give 3.15 (28.0 g, 96%) as a white solid: Mp 89–90 °C; Rf 0.53 
(EtOAc/hexanes, 1:1); IR (neat) 3258, 2958, 2915, 1495, 1461, 1392, 1204, 1061, 719 cm
−1
; 
1
H 
NMR (300 MHz, CDCl3) δ 6.90 (s, 1 H), 6.80 (s, 1 H), 4.55 (d, 2 H, J = 4.2 Hz), 3.77 (s, 3 H), 
3.71 (s, 3 H), 3.10 (bs, 1 H); 
13
C NMR (75 MHz, CDCl3) δ 150.6, 148.7, 128.4, 120.8, 112.5, 
112.4, 60.3, 56.5, 55.6; HRMS (ESI
+
) m/z calcd for C9H12O3Cl 203.0475, found 203.0465. 
 
 
1-(Bromomethyl)-4-chloro-2,5-dimethoxybenzene (3.14).
185
  To a stirred solution of 3.15 
(5.00 g, 24.7 mmol, 1 equiv) in CH2Cl2 (125 mL) at 0 °C was added dropwise HBr (47–49% 
aqueous solution; 4.13 mL, 74.0 mmol, 3 equiv). The resulting solution was slowly warmed to rt 
and stirred overnight. The following morning a second batch of HBr (47–49% solution; 4.13 mL, 
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74.0 mmol, 3 equiv) was added to the reaction mixture, which was stirred at rt for an additional 4 
h, extracted with Et2O (×2), washed with water, a saturated aqueous solution of NaHCO3, brine, 
dried (MgSO4), filtered, and concentrated under reduced pressure to give 3.14 (6.55 g, 100%) as 
a white solid: Rf 0.31 (EtOAc/hexanes, 3:7); IR (neat) 2962, 2947, 2844, 1732, 1582, 1495, 
1458, 1443, 1389, 1301, 1204, 1182, 1033, 882 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 6.91–6.90 
(m, 2 H), 4.50 (s, 2 H), 3.84 (s, 3 H), 3.82 (s, 3 H); 
13
C NMR (75 MHz, CDCl3) δ 151.3, 148.9, 
125.1, 123.2, 114.6, 113.6, 56.6, 56.2, 28.2. 
 
 
1-(3,5-Dimethoxyphenyl)prop-2-yn-1-ol (3.17).
183,186
  To a stirred solution of 3,5-dimethoxy 
benzaldehyde (0.521 g, 3.14 mmol, 1 equiv) in THF (5 mL) at -78 ºC was added 
ethynylmagnesium bromide (0.5 M in THF; 12.5 mL, 6.27 mmol, 2.0 equiv) in two portions at a 
30 min interval.  After 1 h, the reaction was allowed to warm to 0 ºC and stirred for an additional 
30 min.  The reaction was quenched with a saturated aqueous solution of NH4Cl and extracted 
with Et2O (x2).  The combined organic layers were washed with brine, dried (MgSO4), filtered, 
and concentrated under reduced pressure. The crude residue was purified by chromatography on 
SiO2 (EtOAc/hexanes, 2:8) to give 3.17 (0.600 g, 100% yield) as a colorless oil: Rf 0.4 
(EtOAc/hexanes, 3:7); IR (CDCl3) 3416, 3278, 2937, 2836, 1595, 1457, 1427, 1314, 1292, 1202, 
1150, 1055, 835, 727 cm
-1
; 
1
H NMR (300 MHz, CDCl3)  6.69 (d, 2 H, J = 2.4 Hz), 6.40 (t, 1 H, 
J = 2.4 Hz), 5.36 (dd, 1 H, J = 2.1, 6.0 Hz), 3.77 (s, 6 H), 2.87 (d, 1 H, J = 6.3 Hz), 2.65 (d, 1 H, 
J = 2.4 Hz); 
13
C NMR (75 MHz, CDCl3)  160.8, 142.4, 104.5, 100.4, 83.3, 74.6, 64.2, 55.3; 
HRMS (EI
+
) m/z calcd for C11H12O3 192.0786, found 192.0784. Characterization matches that 
reported by Trepanier et al.
183
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(3-(3,5-Dimethoxyphenyl)prop-1-ynyl)trimethylsilane (3.18).  To a stirred solution of ethynyl 
trimethylsilane (39.1 mL, 277 mmol, 4 equiv) in THF (120 mL) at 0 °C was added 
ethylmagnesium bromide (3.16 M in Et2O; 87.6 mL, 277 mmol, 4 equiv). After stirring for 30 
min CuBr (9.93 g, 69.2 mmol, 1 equiv) followed 15 min later by 3,5-dimethoxybenzyl bromide 
(3.3, 16.0 g, 69.2 mmol, 1 equiv).  The resulting mixture was heated to 66 °C, stirred overnight, 
diluted with Et2O, slowly quenched with brine, and extracted with Et2O (x2). The combined 
organic layers were washed with a saturated aqueous solution of NH4Cl, brine, dried (MgSO4), 
filtered, and concentrated under reduced pressure. The crude mixture was purified by 
chromatography on SiO2 (EtOAc/hexanes, 1:10) to give 3.18 (17.2 g, 100%) as a pale yellow oil: 
Rf 0.41 (EtOAc/hexanes, 1:20); IR (neat) 2956, 2898, 2175, 1754, 1596, 1459, 1428, 1204, 
1156, 1122, 1101, 839 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 6.53 (d, 2 H, J = 2.4 Hz), 6.34 (t, 1 
H, J = 2.4 Hz), 3.79 (s, 6 H), 3.60 (s, 2 H), 0.19 (s, 9 H); 
13
C NMR (100 MHz, CDCl3) δ 160.8, 
138.7, 105.9, 104.0, 98.7, 87.1, 55.3, 26.3, 0.1; HRMS (ESI
+
) m/z calcd for C14H21O2Si 
249.1311, found 249.1287. 
 
 
1,3-Dimethoxy-5-(prop-2-ynyl)benzene (3.13).  To a stirred solution of 3.18 (5.37 g, 21.6 mmol, 
1 equiv) and AcOH (4.99 mL, 86.5 mmol, 4 equiv) in THF (100 mL) was added dropwise TBAF 
(1 M in THF; 86.5 mL, 86.5 mmol, 4 equiv). The resulting reaction mixture was stirred at rt for 
24 h, diluted with Et2O, washed with brine (×2), dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 
1:10) to give 3.13 (3.85 g, 100%) as a colorless oil: Rf 0.36 (EtOAc/hexanes, 1:10); IR (CDCl3) 
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3286, 2999, 2954, 1593, 1457, 1428, 1344, 1323, 1288, 1204, 1154, 1064, 827; 
1
H NMR (400 
MHz, CDCl3) δ 6.53 (d, 2 H, J = 2.4 Hz), 6.35 (t, 1 H, J = 2.4 Hz), 3.79 (s, 6 H), 3.56 (d, 2 H, J 
= 2.8 Hz), 2.20 (t, 1 H, J = 2.8 Hz); 
13
C NMR (100 MHz, CDCl3) δ 160.9, 138.3, 105.9, 98.7, 
81.7, 70.6, 55.3, 25.0; HRMS (EI
+
) m/z calcd for C11H12O2 176.0837, found 176.0834. 
 
 
1,2-Bis(4-chloro-2,5-dimethoxyphenyl)ethane (3.20).  
1
H NMR (400 MHz, CDCl3)  6.86 (s, 1 
H), 6.59  (s, 1 H), 3.78 (s, 3 H), 3.76 (s, 3 H), 2.82 (s, 2 H). 
 
 
1-Chloro-4-(2-(3,5-dimethoxyphenyl)but-3-ynyl)-2,5-dimethoxybenzene (3.21).  
1
H NMR 
(400 MHz, CDCl3)  6.89 (s, 1 H), 6.67 (s, 1 H), 6.49 (d, 2 H, J = 2.4 Hz), 6.34 (t, 1 H, J = 2.4 
Hz), 3.84 (d, 2 H, J = 4 Hz), 3.78 (s, 3 H), 3.77 (s, 9 H), 3.04 (dd, 1 H, J = 6.4, 13.2 Hz), 2.93 
(dd, 1 H, J = 8.8, 13.2 Hz), 2.25 (d, 1 H, J = 2.4 Hz). 
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1,3-Dimethoxy-5-(propa-1,2-dienyl)benzene (3.11).  
1
H NMR (400 MHz, CDCl3)  6.47 (d, 2 
H, J = 2.4 Hz), 6.33 (t, 1 H, J = 2.4 Hz), 6.10 (t, 1 H, J = 6.8 Hz), 5.16 (d, 2 H, J = 6.8 Hz), 3.79 
(s, 6 H). 
 
 
2-(4-Chloro-2,5-dimethoxybenzyl)-1,5-dimethoxy-3-(propa-1,2-dienyl)benzene (3.22).  
1
H 
NMR (400 MHz, CDCl3)  6.86 (s, 1 H), 6.51 (d, 1 H, J = 2.4 Hz), 6.39 (d, 1 H, J = 2.4 Hz), 
6.39 (s, 1 H), 6.26 (t, 1 H, J = 6.8 Hz), 5.06 (d, 2 H, J = 6.8 Hz), 3.95 (s, 2 H), 3.84 (s, 3 H), 3.83 
(s, 3 H), 3.76 (s, 3 H), 3.63 (s, 3 H). 
 
 
2-(4-Chloro-2,5-dimethoxybenzyl)-1,5-dimethoxy-3-(prop-2-ynyl)benzene (3.23).  
1
H NMR 
(400 MHz, CDCl3)  6.86 (s, 1 H), 6.77 (d, 1 H, J = 2.4 Hz), 6.44 (d, 1 H, J = 2.4 Hz), 6.35 (s, 1 
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H), 3.90 (s, 2 H), 3.85 (s, 3 H), 3.84 (s, 3 H), 3.76 (s, 3 H), 3.63 (s, 3 H), 3.44 (d, 2 H, J = 2.8 
Hz), 2.13 (t, 1 H, J = 2.8 Hz). 
 
 
1,6-Bis(3,5-dimethoxyphenyl)hexa-2,4-diyne (3.24).  
1
H NMR (400 MHz, CDCl3)  6.48 (d, 2 
H, J = 2.4 Hz), 6.34 (t, 1 H, J = 2.4 Hz), 3.79 (s, 6 H), 3.62 (s, 2 H). 
  
 
(E)-1-(2-Chloro-3-iodoallyl)-3,5-dimethoxybenzene (3.26).  To a stirred solution of 3.13 
(0.0500 g, 0.284 mmol, 1 equiv) in dry acetonitrile (3 mL) was added ICl (0.015 mL, 0.284 
mmol, 1 equiv).  The resulting mixture was heated to 80 ºC in a sealed vial and stirred at 80 ºC 
for 5 h.  The reaction mixture was cooled, filtered, washing the solid with CH2Cl2, and the 
filtrate was washed with a saturated aqueous solution of sodium thiosulfate, extracted with Et2O, 
dried (MgSO4), filtered, and concentrated under reduced pressure.  The crude mixture was 
purified by chromatography on SiO2 (EtOAc/hexanes, 1:10) to give 3.26 (0.053 g, 55% yield) as 
an impure colorless semi-solid.  The impure solid was resubjected to chromatography on SiO2 
(EtOAc/hexanes, 1:10) to give 0.035 g of a mixture of E- and Z-isomers (3:1) of 3.26  and an 
intractable mixture of over-iodinated products as a semi-pure colorless solid: Characteristic 
signals for the major geometric isomer of 3.26: 
1
H NMR (300 MHz, CDCl3)  6.48 (s, 1 H), 4.46 
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(d, 2 H, J = 1.5 Hz), 6.39 (t, 1 H, J = 1.8 Hz), 3.85 (s, 2 H), 3.79 (s, 6 H); 
13
C NMR (75 MHz, 
CDCl3)  160.9, 137.9, 136.4,106.9, 98.9, 74.1, 55.3, 44.6. LCMS data was obtained using a 
Prevail C18-Select 3µ column (150 x 4.6 mm) (Rt = 13.5 min, 0.50 mL/min, 50% to 80% 
MeCN/H2O with 0.1% TFA, over 30 min): ESI m/z 339 [M+H]
+
. 
 
 
5-(Prop-2-ynyl)-1,3-phenylene bis(2,2-dimethylpropanoate (3.27).  To a stirred solution of 
3.13 (6.50 g, 36.9 mmol, 1 equiv) in CH2Cl2 (1200 mL) at 0 °C was added BBr3 (1 M in CH2Cl2; 
92.2 mL, 92.2 mmol, 5 equiv) over 1 h via an addition funnel. The reaction mixture was warmed 
to rt and stirred overnight. The reaction mixture was slowly quenched with a saturated aqueous 
solution of NaHCO3 (500 mL) and stirred at rt for 4 h. The solution was acidified with HCl, 
extracted with CH2Cl2 and EtOAc, and the combined organic layers were dried (MgSO4), 
filtered, and concentrated under reduced pressure. The crude mixture was dissolved in CH2Cl2 
(180 mL), and triethylamine (20.9 mL, 148 mmol, 4 equiv) and PivCl (11.6 mL, 92.2 mmol, 2.5 
equiv) were added. The resulting solution was stirred at rt for 90 min, diluted with brine, the 
organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined 
organic layers were dried (MgSO4), filtered, and concentrated under reduced pressure. The crude 
mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 1:10) to give 3.27 (9.6 g, 
82%) as a colorless oil: Rf 0.85 (EtOAc/hexanes, 3:7); IR (neat) 3293, 2973, 1806, 1750, 1414, 
1452, 1396, 1366, 1269, 1118, 1098, 1031, 1003 cm
−1
; 
1
H NMR (300 MHz, CDCl3) δ 6.95 (d, 2 
H, J = 1.8 Hz), 6.76 (t, 1 H, J = 1.8 Hz), 3.61 (d, 2 H, J = 2.4 Hz), 2.21 (t, 1 H, J = 2.4 Hz); 
13
C 
NMR (75 MHz, CDCl3) δ 176.6, 151.5, 138.3, 118.3, 113.8, 80.7, 71.2, 39.1, 27.1, 24.5; HRMS 
(EI
+
) m/z calcd for C19H24O4 316.1675, found 316.1670. 
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(E)-5-(2-Chloro-3-iodoallyl)-1,3-phenylene bis(2,2-dimethylpropanoate (3.28a) and (Z)-5-(2-
Chloro-3-iodoallyl)-1,3-phenylene bis(2,2-dimethylpropanoate (3.28b).  To a stirred solution 
of 3.27 (9.50 g, 30.0 mmol, 1 equiv) in dry CH2Cl2 (150 mL) at 0 °C was added ICl (1 M in 
CH2Cl2; 30.0 mL, 30.0 mmol, 1 equiv).  The reaction mixture was warmed to rt, stirred protected 
from light (enclosed in aluminum foil) for 3 h, diluted with Et2O, washed with Na2SO4 (×2), 
brine, dried (MgSO4), filtered, and concentrated under reduced pressure. The crude mixture was 
purified by chromatography on SiO2 (EtOAc/hexanes, 1:10) to give an inseparable 2:1 mixture 
of 3.28a and 3.28b (13.7 g, 95%) as a colorless oil: Rf 0.54 (EtOAc/hexanes, 1:10); IR (neat) 
3277, 2934, 2872, 1746, 1592, 1497, 1461, 1409, 1269, 1207, 1122, 1103, 1032, 975, 723 cm
−1
; 
HRMS (ESI
+
) m/z calcd for C19H24O4NaClI 501.0306, found 501.0308. Characteristic data for 
the major, desired isomer 3.28a: 
1
H NMR (300 MHz, CDCl3) δ 6.87 (d, 2 H, J = 1.5 Hz), 6.80 (t, 
1 H, J = 2.1 Hz), 6.62 (s, 1 H), 3.90 (s, 2 H), 1.35 (s, 18 H); 
13
C NMR (100 MHz, CDCl3) δ 
176.6, 151.6, 137.9, 135.6, 119.0, 114.2, 74.8, 44.2, 39.1, 27.1. Characteristic signals for 3.28b: 
1
H NMR (300 MHz, CDCl3) δ 7.06 (s, 1 H), 3.92 (s, 2 H). 
 
 
(Iodomethyl)triphenylphosphonium iodide (3.31).
141,187
  To a mechanically stirred solution of 
triphenylphosphine (60.0 g, 229 mmol, 1 equiv) in anhydrous toluene (120 mL) was added 
diiodomethane (23.4 mL, 297 mmol, 1.3 equiv).  The reaction was heated to 80 ºC and stirred 
under N2 overnight (~20 h).  The reaction mixture was filtered and washed with anhydrous 
toluene (1 L) until the filtrate was no longer yellow.   The white solid was collected and further 
dried under vacuum to give 3.31 (92 g, 100% yield) as a white solid: 
1
H NMR (400 MHz, 
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CDCl3)  7.94-7.77 (m, 15 H), 5.05 (d, 2 H, J = 8.4 Hz); 
13
C NMR (100 MHz, CDCl3)  135.2, 
135.1, 133.8, 133.8, 130.2, 118.8, 117.9.  
 
 
(Z)-(4-Iodobut-3-enyl)benzene (3.32).
188
  To a stirred solution of 3.31 (26.6 g, 50.3 mmol, 1.5 
equiv) in anhydrous THF (100 mL) at rt was added dropwise a solution of NaHMDS (9.71 g, 
50.3 mmol, 3 equiv) in THF (25 mL) over 15 min.  The reaction was stirred at rt for 10 min, 
cooled to -78 ºC, and a solution of hydrocinnamaldehyde (4.93 mL, 33.5 mmol, 1 equiv) in THF 
(20 mL) was added dropwise over 20 min.  The reaction mixture was stirred at - 78 ºC under N2, 
protected from light, for an additional 10 min, quenched with brine, and allowed to warm to rt.  
The mixture was thoroughly extracted with EtOAc (4 x 250 mL) and the combined organic 
layers were dried (MgSO4), filtered, and concentrated under reduced pressure to give a reddish 
semi-solid.  The semi-solid was dissolved in CH2Cl2 and purified by chromatography on SiO2 
(CH2Cl2) to give 3.32 (8.7 g, 100%) as a colorless oil: Rf 0.67 (EtOAc/hexanes, 1:10); IR (neat) 
3277, 2965, 2841, 1497, 1463, 1448, 1418, 1437, 1387, 1208, 1033, 846, 818, 688 cm
-1
;
 1
H 
NMR (400 MHz, CDCl3)  7.33-7.29 (m, 2 H), 7.24-7.20 (m, 3 H), 6.26-6.19 (m, 2 H), 2.76 (t, 2 
H, J = 8.0 Hz), 2.51-2.46 (m, 2 H); 
13
C NMR (100 MHz, CDCl3)  141.0, 140.2, 128.4, 126.1, 
83.1, 36.3, 34.0; HRMS (EI
+
) m/z calcd for C10H11I 257.9906, found 257.9907. 
 
 
(Z)-1-Chloro-2,5-dimethoxy-4-(5-phenylpent-2-enyl)benzene (3.33).  To a dry flask was 
added zinc dust (1.01 g, 15.5 mmol, 5 equiv) and iodine (0.118 g, 0.464 mmol, 0.15 equiv). Heat 
(Bunsen burner flame) was applied until a purple gas coated the interior of the flask. The sample 
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was allowed to cool under argon and suspended in dry, degassed DMF (1.5 mL).  To the stirred 
solution was added 3.14 (1.24 g, 4.64 mmol, 1.5 equiv) and a second batch of iodine (0.118 g, 
0.464 mmol, 0.15 equiv).  The reaction was stirred at rt for 15 min.  Meanwhile, in a separate, 
dry flask, 3.32 (0.200 g, 0.775 mmol, 1 equiv), Pd2(dba)3 (0.0178 g, 0.0194 mmol, 0.025 equiv) 
and P(o-Tol)3 (0.0243, 0.0775 mmol, 0.1 equiv) were dissolved in dry, deoxygenated DMF (0.4 
mL) and allowed to stir at rt for 10 min.  The activated zinc reagent was then syringed off the 
excess zinc, rinsing with DMF (0.5 mL), and 1 mL of the heterogeneous mixture was added 
dropwise to the stirred solution of vinyl iodide.  The reaction was allowed to stir at rt overnight 
(~16 h) and directly applied to SiO2 for purification by chromatography (EtOAc/hexanes, 1:50) 
to give 3.33 (0.168 g, 68% yield) as well as the quenched organo zinc (0.056 g, 12% yield) and 
P(o-Tol)3 (0.011 g) as an intractable mixture: Rf 0.18 (EtOAc/hexanes, 1:10); Characteristic 
signals for 3.33:
 1
H NMR (400 MHz, CDCl3)  7.37 (d, 2 H, J = 7.2 Hz), 7.30 (t, 3 H, J = 6.4 
Hz), 6.96 (s, 1 H), 6.82 (s, 1 H), 5.72-5.62 (m, 2 H),  3.83 (s, 6 H), 3.42 (d, 2 H, J = 6.0 Hz), 2.82 
(t, 2 H, J = 7.2 Hz) 2.60 (t, 2 H, J = 8.4 Hz); 
13
C NMR (100 MHz, CDCl3)  151.3, 148.8, 141.7, 
130.1, 128.3, 128.1, 127.6, 125.7, 114.0, 112.6, 56.6, 55.8, 35.7, 28.9, 27.4. 
 
 
 
1-Chloro-2,5-dimethoxy-4-methylbenzene (3.34).  Rf 0.18 (EtOAc/hexanes, 1:10); 
1
H NMR 
(400 MHz, CDCl3)  6.94 (s, 1 H), 6.85 (s, 1 H), 3.90 (s, 6 H), 2.31 (s, 3 H). Characterization 
matches that reported by Green et al.
189
 
 
  173 
 
(E)-5-(2-Chloro-4-(4-chloro-2,5-dimethoxyphenyl)but-2-enyl)-1,3-phenylene-bis(2,2-
dimethylpropanoate) (3.35).  A flame-dried flask was charged with a catalytic amount of iodine 
and activated zinc (0.513 g, 7.69 mmol, 8 equiv).  The flask was heated (Bunsen burner) until a 
purple gas coated the interior of the flask. The flask was allowed to cool to rt and dry degassed 
DMF (1 mL) was added followed by 3.14 (1.02 g, 3.84 mmol, 4 equiv) followed by a second 
catalytic amount of iodine the reaction was allowed to stir at rt for 15 min.  A separate dry flask 
was charged with 3.28a/3.28b (0.460 g, 0.961 mmol, 1 equiv), Pd(OAc)2 (0.0108 g, 0.0480 
mmol, 0.05 equiv), dry deoxygenated DMF (0.8 mL), and P(o-Tol)3 (0.0301 g, 0.0961 mmol, 0.1 
equiv).  The mixture was allowed to stir at rt for 10 min. The activated organo-zinc reagent was 
then syringed off the excess Zn, filtered to removed any remaining solid zinc, and cannulated 
onto the vinyl iodide solution mixture.  The resulting solution was heated in the microwave (80 
ºC for 25 min).  The resulting solution was allowed to cool to rt and directly purified by 
chromatography on SiO2 (EtOAc/hexanes, 1:20 to 1:10) to give 3.35 (0.16 g, 33% yield) as a 
colorless oil and an inseparable mixture with the Wurtz coupling product:  Rf 0.37 
(EtOAc/hexanes, 1:10); Characteristic signals for 3.35: 
1
H NMR (600 MHz, CDCl3)  6.89 (s, 1 
H), 6.87 (s, 1 H), 6.80 (d, 2 H, J = 2.4 Hz), 6.76 (t, 1 H, J = 2.4 Hz), 5.94 (t, 1 H, J = 7.8 Hz), 
3.80 (s, 3 H), 3.78 (s, 3 H), 3.74 (s, 2 H), 3.43 (d, 2 H, J = 14.4 Hz), 1.33 (s, 18 H).  
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(E)-5-(2-Chloro-4-(4-chloro-2,5-dimethoxyphenyl)but-2-enyl)benzene-1,3-diol (3.36).  A 
flame-dried microwave vial was charged with a 2:1 mixture of 3.28a and 3.28b (0.520 g, 1.08 
mmol, 1 equiv), Pd(OAc)2 (0.0122 g, 0.0543 mmol, 0.05 equiv), P(o-Tol)3 (0.0341 g (0.109 
mmol, 0.1 equiv), and freshly distilled, dry, degassed DMF (0.8 mL). The reaction mixture was 
stirred at rt. for 10 min. In a separate dry flask, a catalytic amount of iodine (~20 mg) and zinc 
(0.362 g, 5.43 mmol, 5 equiv) were heated (Bunsen burner) until a purple gas coated the interior 
of the flask. The flask was cooled to rt, charged with distilled, dry, degassed DMF (1 mL), and 
benzyl bromide 3.14 (1.15 g, 4.34 mmol, 4 equiv). The mixture was allowed to stir at rt. under 
argon for 6 min. The activated organozinc reagent was filtered through an oven dried fritted 
funnel under an atmosphere of argon and cannulated into the stirred solution of 3.28a and 3.28b. 
The resulting solution was heated in a microwave reactor (2 min, 120 °C), treated with a second 
batch of Pd(OAc)2 (0.0122 g, 0.0543 mmol, 0.05 equiv) and resubjected to the microwave 
conditions (2 min, 120 °C). The crude reaction mixture was directly purified by chromatography 
on SiO2 (EtOAc/hexanes, 1:20) to give a crude yellow oil, which was immediately dissolved in 
MeOH/CH2Cl2 (4 mL, 2:1), and Cs2CO3 (1.67 g, 5.08 mmol, 5 equiv) was added. The reaction 
mixture was stirred at rt. for 6 h, diluted with EtOAc, and acidified with conc. HCl. The organic 
layer was separated, and the acidified aqueous solution was extracted with EtOAc. The 
combined organic layers were washed with brine, dried (MgSO4), filtered, and concentrated 
under reduced pressure. The crude mixture was purified by chromatography on SiO2 
(chloroform/acetone, 8:2) to give a 4:1 mixture (0.192 g, 51%) of 3.36a and the undesired 
regioisomer 3.36b as a yellow oil. Characteristic signals for 3.36a: 
1
H NMR (600 MHz 
(CD3)2CO) δ 8.20 (bs, 2 H), 7.02 (d, 2 H, J = 3.6 Hz), 6.45 (t, 1 H, J = 7.8 Hz), 6.26 (s, 3 H), 3.84 
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(app s, 5 H), 3.81 (s, 3 H), 3.50 (d, 2 H, J = 7.8 Hz); 
13
C NMR (150 MHz, CDCl3) δ 159.5, 
152.3, 150.0, 141.5, 140.7, 127.7, 120.9, 115.6, 113.8, 108.1, 101.9, 101.7, 56.9, 56.5, 45.1. 
An analytically pure sample of 3.36 for biological evaluation and characterization was 
obtained via SFC chromatography using a semi-prep (250 × 10 mm) silica column (Rt 5.80 min, 
10 mL/min, 15% methanol, 220 nm detection): Rf 0.48 (acetone/chloroform, 2:8); IR (acetone) 
3375, 3001, 2952, 1696, 1599, 1495, 1463, 1387, 1212, 1156, 1034, 1010 cm
−1
; 
1
H NMR (600 
MHz (CD3)2CO) δ 8.18 (bs, 2 H), 7.02 (s, 1 H), 6.99 (s, 1 H), 6.30 (s, 2 H), 6.25 (s, 1 H), 5.88 (t, 1 
H, J = 7.8 Hz), 3.84 (s, 3 H), 3.81 (s, 3 H), 3.73 (s, 2 H), 3.51 (d, 2 H, J = 7.8 Hz); 
13
C NMR (150 
MHz, CDCl3) δ 159.5, 152.3, 150.0, 140.6, 133.7, 128.1, 128.1, 120.8, 115.5, 113.8, 108.0, 
101.8, 56.9, 56.5, 40.2, 29.5; HRMS (ES
−
) [M + Cl]
−
 m/z calcd for C18H18O4Cl3 403.0271, found 
403.0295. 
 
 
(E)-5-(2-Chloro-4-(4-chloro-2,5-dihydroxyphenyl)but-2-enyl)benzene-1,3-diol (3.1).  A 
stirred solution of 3.36 (pure E-isomer; 0.0500 g, 0.135 mmol, 1 equiv) in CH2Cl2 (7 mL) was 
enclosed in aluminum foil and cooled to 0 °C. To the stirred solution was added dropwise BBr3 
(1 M in CH2Cl2; 0.677 mL, 0.677 mmol, 5 equiv). The resulting solution was slowly warmed to 
rt. and stirred overnight. The reaction mixture was quenched with a saturated aqueous solution of 
NaHCO3 (8 mL) and stirred at rt. for an additional hour. The solution was acidified with HCl, 
extracted with EtOAc (x2) and the combined organic layers were dried (MgSO4), filtered, and 
concentrated under reduced pressure. The crude product was purified by chromatography on 
SiO2 (chloroform/acetone, 3:1) to give a single geometric isomer of 3.1 (0.0462 g, 96%) as a 
slightly yellow film. Before submission for biological testing, a sample of 3.1 was further 
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purified via SFC chromatography using a semi-prep (250 × 10 mm) silica column (Rt 4.68 min, 8 
mL/min, 25% methanol, 220 nm detection): Rf 0.15 (acetone/chloroform, 2:8); IR (neat) 3343, 
1692, 1599, 1495, 1417, 1329, 1184, 1143, 1005, 822 cm
−1
; 
1
H NMR (600 MHz (CD3)2CO) δ 8.17 
(bs, 4 H), 6.86 (s, 1 H), 6.84 (s, 1 H), 6.29 (d, 2 H, J = 2.4 Hz), 6.24 (t, 1 H, J = 2.4 Hz), 5.89 (t, 
1 H, J = 7.8 Hz), 3.69 (s, 2 H), 3.47 (d, 2 H, J = 7.8 Hz); 
13
C NMR (150 MHz, CDCl3) δ 159.5, 
149.0, 146.9, 140.5, 133.8, 128.0, 127.0, 118.5 (2C), 116.7, 108.0, 101.8, 40.2, 29.5; HRMS 
(ES
−) [2M − H]− m/z calcd for C32H27O8Cl4 679.0460, found 679.0482. 
The demethylation reaction was also performed on a 2:1 mixture of 3.36a and 3.36b, 
resulting in a 2:1 mixture of 3.1 and its (Z)-diastereomer. Characteristic signals for the (Z)-
diastereomer: 
1
H NMR (400 MHz (CD3)2CO) δ 6.85 (s, 1 H), 6.48 (t, 1 H, J = 7.6 Hz), 3.81 (s, 2 
H), 3.46 (d, 2 H, J = 7.6 Hz). 
 
 
2-Chloro-5-(3-chloro-5,7-dihydroxynaphthalen-1-yl)cyclohexa-2,5-diene-1,4-dione (3.37). 
To a stirred solution of 3.1 (0.0300 g, 0.0879 mmol, 1 equiv) in dry DMF (0.90 mL) was added 
ferric chloride hexahydrate (0.119 g, 0.440 mmol, 5 equiv). The reaction mixture was stirred at rt 
for 3 d and then heated to 60 ºC for 18 h. The reaction mixture was allowed to cool to rt, diluted 
with EtOAc, washed with brine, dried (MgSO4), filtered, and concentrated under reduced 
pressure. The crude mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 1:20) to 
give a semi-pure compound. An analytically pure sample was obtained via SFC chromatography 
using the semi-prep (250 x 10 mm) silica column (RT = 6.48 min, 9 mL/min, 15% methanol, 220 
nm detection) to give 0.010 g (40%) of the unexpected ring system 3.37: 
1
H NMR (400 MHz, 
CD3OD)  7.36 (d, 1 H, J = 1.6 Hz), 7.31 (s, 1 H), 7.26 (d, 1 H, J = 1.6 Hz), 6.60 (d, 1 H, J = 2.0 
Hz), 6.50 (d, 1 H, J = 2.0 Hz).  
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(E)-2-Chloro-5-(3-chloro-4-(3,5-dihydroxyphenyl)but-2-en-1-yl)cyclohexa-2,5-diene-1,4-
dione (3.38).  To a stirred solution 3.1 (0.0150 g, 0.0440 mmol, 1 equiv) in Et2O (0.5 mL) was 
added DDQ (0.0130 g, 0.0571 mmol, 1.3 equiv).  The reaction was stirred at rt for 5 min, diluted 
with Et2O, washed with sodium thiosulfate (x2), dried (MgSO4), filtered, and concentrated under 
reduced pressure to give 3.38 (0.012 g, 80%) as a reddish yellow film: Rf = 0.5 (EtOAc/hexanes, 
1:1); 
1
H NMR (400 MHz, (CD3)2CO)  8.16 (s, 1 H), 7.18 (s, 1 H), 6.81 (t, 1 H, J = 1.6 Hz), 6.25 
(d, 2 H, J = 2.0 Hz), 5.85 (t, 1 H, J = 8.0 Hz), 3.66 (s, 2 H), 3.40 (dd, 2 H, J = 1.2, 7.6 Hz).  
 
 
2-Iodo-5-methylresorcinol (3.40).
190
  To a vigorously stirred solution of 3,5-dihydroxytoluene 
(2.00 g, 16.1 mmol, 1 equiv) and I2 (4.09 g, 16.1 mmol, 1 equiv) in a mixture of THF/H2O (1:1, 
200 mL) at 0 ºC was slowly added NaHCO3 (1.35 g, 16.1 mmol, 1 equiv) in portions.  The 
reaction mixture was warmed to rt, stirred for 10 min, diluted with EtOAc, washed with brine, 
dried (MgSO4), filtered, and concentrated under reduced pressure. The crude mixture was 
purified by chromatography on SiO2 (EtOAc/hexanes, 1:9 to 2:8) to give 3.40 (3.2 g, 79%) along 
with recovered starting material (0.3 g, 15%): Rf = 0.24 (EtOAc/hexanes, 1.5:8.5); Characteristic 
signals for 3.40: 
1
H NMR (400 MHz, CDCl3)  6.40 (s, 2 H), 5.41 (bs, 2 H), 2.40 (s, 3 H). 
Characterization matches that reported by Srebnik et al.
190
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1,3-Dihydroxy-2-iodo-5-methylbenzene (3.41).
190
 To a stirred solution of 2-iodo-5-
methylresorcinol (0.100 g, 0.400 mmol, 1 equiv) in DMF (2 mL) was added K2CO3 (0.276 g, 
2.00 mmol, 5 equiv) and MeI (0.124 mL, 2.00 mmol, 5 equiv).  The reaction mixture was stirred 
at rt for 3 h, diluted with EtOAc, washed with brine, dried (MgSO4), filtered, and concentrated 
under reduced pressure. The crude mixture was purified by chromatography on SiO2 
(EtOAc/hexanes, 1.5:8.5) to give 3.41 (0.102 g, 92%) as a pale yellow oil: Rf = 0.66 
(EtOAc/hexanes, 1.5:8.5); 
1
H NMR (400 MHz, CDCl3)  6.40 (s, 2 H), 3.87 (s, 6 H), 2.35 (s, 3 
H); 
13
C NMR (100 MHz, CDCl3)  159.2, 140.4, 105.2, 73.6, 56.5, 22.0. Characterization 
matches that reported by Srebnik et al.
190
 
 
 
1,3-Dimethoxy-5-methylbenzene (3.44).
191
 To a stirred heterogeneous solution of 3,5-
dihydroxytoluene (2.00 g, 16.1 mmol, 1 equiv) and 3 Å molecular sieves in acetone (30 mL) was 
added K2CO3 (22.3 g, 161 mmol, 10 equiv) and MeI (10.0 mL, 161 mmol, 10 equiv).  The 
reaction mixture was stirred at 60 ºC overnight, diluted with EtOAc, washed with 1 M aqueous 
NaOH (x3), dried (MgSO4), filtered, and concentrated under reduced pressure to give 3.44 (2.40 
g, 98%) as a pale yellow oil: Rf = 0.58 (EtOAc/hexanes, 1:10); IR (CDCl3) 2995, 2937, 1593, 
1458, 1424, 1320, 1202, 1146, 1068 cm
-1
; 
1
H NMR (400 MHz, CDCl3)  6.36 (bs, 2 H), 6.31 
(bs, 1 H), 3.79 (s, 6 H), 2.33 (s, 3 H); 
13
C NMR (100 MHz, CDCl3)  160.7, 140.2, 107.0, 97.5, 
55.2, 21.8; HRMS (ESI
+
) m/z calcd for C9H12O2 152.0837, found 152.0878. 
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2,6-Dimethoxy-4-methylbenzaldehyde (3.45).
171
  To a stirred solution of 3.44 (0.600 g, 3.94 
mmol, 1 equiv) in Et2O (10 mL) at 0 ºC was added TMEDA (1.19 mL, 7.88 mmol, 2 equiv) and 
n-butyllithium (1.4 M in hexanes; 4.22 mL, 5.91 mmol, 1.5 equiv).  The resulting yellow slurry 
was heated at reflux for 3 h, cooled to 0 ºC, and DMF (1.85 mL, 19.7 mmol, 5 equiv) was added.  
The reaction mixture was slowly warmed to rt, stirred for an additional 2 h, quenched with water 
(10 mL), and extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried 
(MgSO4), filtered, and concentrated under reduced pressure.  The crude mixture was purified by 
chromatography on SiO2 (EtOAc/hexanes, 2:8 to 1:1) to give 3.45 (0.65 g, 92%) as a white 
solid:  Rf = 0.42 (EtOAc/hexanes, 1:1); 
1
H NMR (400 MHz, CDCl3)  10.44 (s, 1 H), 6.38 (s, 2 
H), 3.87 (s, 6 H), 2.37 (s, 3 H). Characterization matches that reported by Trost et al.
171
  
 
 
2,6-Dimethoxy-4-methylphenol (3.46).  To a stirred solution of 3.45 (0.540 g, 3.00 mmol, 1 
equiv) in CH2Cl2 (24 mL) was added (PhSe)2 (0.0266 g, 0.120 mmol, 0.04 equiv), and H2O2 
(30% aqueous solution; 0.918 mL, 8.99 mmol, 3 equiv). The reaction mixture was stirred at rt for 
18 h, diluted with EtOAc, washed with brine, dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude oil was resuspended in MeOH (25 mL) and KOH (0.841 g, 15.0 
mmol, 5 equiv) was added.  The reaction mixture was stirred at rt for 3 h, acidified with HCl, 
extracted with EtOAc, washed with brine, dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude reaction mixture was purified by chromatography on SiO2 
(EtOAc/hexanes, 4:6) to give 3.46 (0.475 g, 94%) as a yellow oil: Rf = 0.27 (EtOAc/hexanes, 
2:8); IR (CDCl3) 3502, 2937, 2857, 1608, 1515, 1463, 1327, 1211, 1111 cm
-1
; 
1
H NMR (400 
MHz, CDCl3)  6.39 (s, 2 H), 5.37 (s, 1 H), 3.86 (s, 6 H), 2.29 (s, 3 H); 
13
C NMR (100 MHz, 
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CDCl3)  146.8, 132.3, 128.7, 105.5, 56.1, 21.5; HRMS (ESI
+
) m/z calcd for C9H13O3 [M+H]
+
 
169.0865, found 169.0889. Characterization matches that reported by Steinbess.
192
 
 
 
1,3-Dimethoxy-5-methyl-2-phenoxybenzene (3.48). To a stirred solution of 3.46 (0.100 g, 
0.595 mmol, 1 equiv), iodobenzene (0.135 mL, 1.19 mmol, 2 equiv), Cs2CO3 (0.387 g, 1.19 
mmol, 2 equiv), and THMD (0.0125 mL, 0.0595 mmol, 0.1 equiv) in dry, degassed NMP (1 mL) 
was added CuCl (0.0310 g, 0.297 mmol, 0.5 equiv).  The reaction mixture was stirred overnight 
120 ºC, diluted with EtOAc, washed with 1 M aqueous NaOH (x2), dried (MgSO4), filtered, and 
concentrated under reduced pressure. The crude mixture was purified by chromatography on 
SiO2 (EtOAc/hexanes, 1:10) to give 3.48 (0.092 g, 63%) as a white solid: Mp = 93.5-94.2 ºC; Rf 
= 0.35 (EtOAc/hexanes, 1:10); IR (CDCl3) 2935, 2839, 1590, 1488, 1463, 1336, 1228, 1126, 749 
cm
-1
; 
1
H NMR (400 MHz, CDCl3)  7.52 (t, 2 H, J = 7.6 Hz), 7.24 (t, 1 H, J = 7.2 Hz), 7.17 (d, 2 
H, J = 8.4 Hz), 6.76 (s, 2 H), 4.02 (s, 6 H), 2.66 (s, 3 H); 
13
C NMR (100 MHz, CDCl3)  158.5, 
153.0, 135.4, 129.6, 129.1, 121.2, 114.6, 106.0, 56.0, 21.9; HRMS (ESI
+
) m/z calcd for 
C15H16O3, 244.1099 found 244.1118. 
 
 
2,4-Dihydroxy-6-methylbenzaldehyde (3.49).
193
  To a stirred solution of DMF (0.5 mL) at 0 ºC 
was added POCl3 (0.147 mL, 1.58 mmol, 1.2 equiv), the reaction mixture was warmed to rt and 
stirred for 15 min.  In a separate flask, 3.44 (0.200 g, 1.31 mmol, 1 equiv) was dissolved in DMF 
(2.5 mL) and warmed to 120 ºC. The Vilsmeier-Hack reagent was added dropwise to the stirred 
solution of 3.44 at 120 ºC and allowed to stir at 120 ºC for 2 h.  The reaction mixture was cooled 
to rt, quenched with a saturated aqueous solution of NaHCO3, extracted with EtOAc, dried 
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(MgSO4), filtered, and concentrated under reduced pressure. The crude mixture was purified by 
chromatography on SiO2 (EtOAc/hexanes, 1:9) to give 3.49 (0.208 g, 87%) as a white solid: Rf = 
0.37 (EtOAc/hexanes, 2:8); 
1
H NMR (400 MHz, CDCl3)  10.49 (s, 1 H), 6.33 (s, 2 H), 3.88 (s, 3 
H), 3.86 (s, 3 H), 2.59 (s, 3 H). Characterization matches that reported by Wang et al.
193
  
 
 
2,4-Dimethoxy-6-methylphenyl (3.50).
194
  To a stirred solution of 3.49 (0.200 g, 1.11 mmol, 1 
equiv) in CH2Cl2 (12 mL) was added (PhSe)2 (0.0246 g, 0.111 mmol, 0.1 equiv), and H2O2 (30% 
aqueous solution; 0.340 mL, 3.33 mmol, 3 equiv). The reaction mixture was stirred at rt for 18 h, 
diluted with EtOAc, washed with 1 M aqueous NaOH, brine, dried (MgSO4), filtered, and 
concentrated under reduced pressure. A portion of the crude formate (50 mg) was dissolved 
EtOH (1 mL) and sodium borohydride (0.210 g, 5.55 mmol, 5 equiv) was added. The reaction 
mixture was stirred at rt for 5 h, diluted with EtOAc, quenched with 1 M aqueous HCl, extracted 
with EtOAc, dried (MgSO4), filtered, and concentrated under reduced pressure to give 3.50 
(0.0465 g, 100%) as an off-white solid: Mp = 102-103 ºC; Rf = 0.41 (EtOAc/hexanes, 2:8); IR 
(CDCl3) 3431, 2956, 1614, 1499, 1451, 1427, 1234, 1199, 1150, 1089, 1055, 913, 831 cm
-1
; 
1
H 
NMR (400 MHz, CDCl3)  6.37 (d, 1 H, J = 2.4 Hz), 6.30 (d, 1 H, J = 2.0 Hz), 5.37 (s, 1 H), 
3.85 (s, 3 H), 3.76 (s, 3 H), 2.26 (s, 3 H); 
13
C NMR (100 MHz, CDCl3)  152.6, 146.6, 137.8, 
123.7, 106.5, 96.7, 55.9, 55.7, 15.7; HRMS (ESI
+
) m/z calcd for C9H12O3 168.0786, found 
168.0806. 
 
 
1,5-Dimethoxy-3-methyl-2-phenoxybenzene (3.51).  To a stirred solution of 3.50 (0.0600 g, 
0.357 mmol, 1 equiv), iodobenzene (0.0811 mL, 0.713 mmol, 2 equiv), Cs2CO3 (0.232 g, 0.713 
mmol, 2 equiv), and THMD (0.00750 mL, 0.0357 mmol, 0.1 equiv) in dry, degassed NMP (1 
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mL) was added CuCl (0.0372 g, 0.357 mmol, 1 equiv). The reaction mixture was stirred 
overnight at 120 ºC, diluted with EtOAc, washed with brine, dried (MgSO4), filtered, and 
concentrated under reduced pressure. The crude mixture was purified by chromatography on 
SiO2 (EtOAc/hexanes, 1:20) to give 3.51 (0.0725 g, 83%) as a colorless oil: Rf = 0.46 
(EtOAc/hexanes, 1:10); IR (CDCl3) 2950, 2837, 1601, 1487, 1348, 1219, 1200, 1150, 1094, 854 
cm
-1
; 
1
H NMR (400 MHz, CDCl3)  7.28 (t, 2 H, J = 7.6 Hz), 7.00 (t, 1 H, J = 7.2 Hz), 6.86 (d, 2 
H, J = 8.0 Hz), 6.47 (d, 1 H, J = 2.0 Hz), 6.42 (d, 1 H, J = 2.0 Hz), 3.85 (s, 3 H), 3.77 (s, 3 H), 
2.18 (s, 3 H); 
13
C NMR (100 MHz, CDCl3)  158.5, 157.0, 153.1, 135.3, 133.0, 129.3, 121.2, 
114.5, 106.2, 97.9, 55.8, 55.4, 16.4; HRMS (ESI
+
) m/z calcd for C15H17O3 [M+H]
+
 245.1178, 
found 245.1201.  
 
 
5-Bromo-4-chloro-2-methoxy-benzoic acid.  To a stirred solution of 4-chlorosalicylic acid 
(10.0 g, 58.0 mmol, 1 equiv) in CH2Cl2 (250 mL) was added triethylamine (9.77 mL, 69.5 mmol, 
1.2 equiv).  The mixture was cooled to -78 ºC and bromine (2.98 mL, 69.5 mmol, 1 equiv) was 
added to the solution. The reaction mixture was stirred at -78 ºC for 5 h, quenched with a 
saturated aqueous solution of NaHCO3 (70 mL), acidified with 1 M aqueous HCl, extracted with 
Et2O, dried (MgSO4), filtered, and concentrated under reduced pressure to give 5-Bromo-4-
chloro-2-methoxy-benzoic acid (15.0 g of an inseparable mixture (9:1 ratio of the desired 
product and the undesired debrominated compound). The reaction mixture was directly carried 
onto the next step without further purification. Characteristic signals for the desired product: 
1
H 
NMR (400 MHz, (CD3)2CO)  8.20 (s, 1 H), 7.23 (s, 1 H); Characteristic data for the undesired 
debrominated product: 7.90 (d, 1 H, J = 8.0 Hz), 7.1-6.9 (m, 2 H). The characterization matches 
that reported by Mizufune et al.
173
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Methyl 5-bromo-4-chloro-2-methoxybenzoate (3.55).  To a stirred solution of 5-Bromo-4-
chloro-2-methoxybenzoic acid (15.0 g, 59.6 mmol, 1 equiv) in acetone (200 mL) was added 
K2CO3 (82.4 g, 597 mmol, 10 equiv) and MeI (26.0 mL, 417 mmol, 7 equiv). The reaction 
mixture was stirred at 60 ºC overnight (~16 h), cooled to rt, diluted with EtOAc, washed with 
brine, dried (MgSO4), filtered, and concentrated under reduced pressure.  The crude mixture was 
purified by chromatography on SiO2 (EtOAc/hexanes, 1:10 to 2:8) to give 3.55 (12.0 g, 72%) as 
an inseparable mixture (4:1 ratio of the desired product to the undesired debrominated product) 
as a white solid: Mp = 86-87 ºC; Rf = 0.51 (EtOAc/hexanes, 2:8); IR (CDCl3) 2947, 1728, 1709, 
1586, 1552, 1478, 1431, 1368, 1234, 1090, 900 cm
-1
; HRMS (ESI
+
) m/z calcd for C9H9O3ClBr 
[M+H]
+
 278.9424, found 278.9463; Characteristic data for 3.55:
 1
H NMR (400 MHz, CDCl3)  
8.01 (s, 1 H), 7.05 (s, 1 H), 3.88 (s, 3 H), 3.86 (s, 3 H); 
13
C NMR (100 MHz, CDCl3)  164.4, 
158.6, 139.3, 136.0, 119.7, 114.2, 112.4, 56.4, 52.3; Characteristic data for the undesired 
debrominated product: 
1
H NMR (400 MHz, CDCl3)  7.72 (d, 1 H, J = 8.8 Hz), 6.94-6.92 (m, 2 
H); 
13
C NMR (100 MHz, CDCl3)  165.6, 159.7, 134.1, 132.7, 120.3, 118.2, 112.6, 56.2, 52.0. 
 
 
Methyl 5-iodo-2-methoxybenzoate (3.58).  To a stirred solution of 5-iodosalicylic acid (1.00 g, 
3.78 mmol, 1 equiv) in dry acetone (40 mL) was added K2CO3 (4.19 g, 30.3 mmol, 8 equiv) and 
MeI (1.18 mL, 18.9 mmol, 5 equiv).  The reaction mixture was heated to 56 ºC, stirred overnight, 
filtered through a pad of Celite, concentrated under reduced pressure, and purified by 
chromatography on SiO2 (EtOAc/hexanes, 2:8) to give 3.58 (1.06 g, 96%) as a white solid:  Rf = 
0.16 (EtOAc/hexanes, 1:9); 
1
H NMR (400 MHz, CDCl3)  8.07 (d, 1 H, J = 2.0 Hz), 7.72 (dd, 1 
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H, J = 2.0, 8.8 Hz) 6.75 (d, 1 H, J = 8.8 Hz), 3.88 (s, 6 H);
 13
C NMR (100 MHz, CDCl3)  165.1, 
158.9, 141.9, 140.0, 122.1, 114.3, 81.7, 56.1, 52.2. Characterization matches reported data.
195
 
 
 
Methyl 3,5-dimethoxy-4-phenoxybenzoate (3.60). To a stirred solution of methyl 3,5-
dimethoxy-4-hydroxybenzoate (0.100 g, 0.471 mmol, 1 equiv), iodobenzene (0.105 mL, 0.943 
mmol, 2 equiv), Cs2CO3 (0.307 g, 0.942 mmol, 2 equiv), and THMD (0.00970 mL, 0.0471 
mmol, 0.1 equiv) in dry, degassed NMP (1 mL) was added CuCl (0.0233 g, 0.236 mmol, 0.5 
equiv). The reaction mixture was heated to 120 ºC, stirred overnight, diluted with EtOAc, 
washed with 1 M NaOH (x2), brine, dried (MgSO4), filtered, and concentrated under reduced 
pressure. The crude mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 2:8) to 
give 3.60 (0.060 g, 44%) as an inseparable mixture with methylated methyl 3,5-dimethoxy-4-
hydroxybenzoate (5:1): Rf = 0.51 (EtOAc/hexanes, 3:7); Characteristic data for the 3.60: 
1
H 
NMR (400 MHz, CDCl3)  7.33 (s, 2 H), 7.30 (t, 2 H, J = 7.6 Hz), 6.95 (t, 1 H, J = 7.2 Hz), 6.80 
(d, 2 H, J = 8.0 Hz), 3.90 (s, 3 H), 3.78 (s, 6 H); 
13
C NMR (100 MHz, CDCl3)  166.5, 157.9, 
153.2, 129.3, 127.1, 121.8, 114.8, 106.8, 55.3, 52.3; HRMS (ESI+) m/z calcd for C16H16O5, 
288.0998 found 288.1001. 
 
 
Methyl 4-(2-chlorophenoxy)-3,5-dimethoxybenzoate (3.61).  To a stirred solution of methyl 
3,5-dimethoxy-4-hydroxybenzoate (0.100 g, 0.471 mmol, 1 equiv), 2-chloro-iodobenzene (0.115 
mL, 0.943 mmol, 2 equiv), Cs2CO3 (0.307 g, 0.942 mmol, 2 equiv), and TMHD (0.00970 mL, 
0.0471 mmol, 0.1 equiv) in dry, degassed NMP (1 mL) was added CuCl (0.02330 g, 0.236 
mmol, 0.5 equiv). The reaction mixture was heated to 120 ºC, stirred overnight, diluted with 
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EtOAc, washed with 1 M NaOH (x2), brine, dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 
2:8) to give 3.61 (0.030 g, 20%) as an inseparable mixture: Rf = 0.21 (EtOAc/hexanes, 3:7); 3.61 
was tentatively assigned based on the following data: 
1
H NMR (400 MHz, CDCl3)  7.81 (dd, 2 
H, J = 1.6, 8.0 Hz), 7.41 (dd, 2 H, J = 1.2, 8.0 Hz), 7.22 (s, 2 H), 3.90 (s, 3 H), 3.78 (s, 6 H); 
13
C 
NMR (100 MHz, CDCl3)  166.7, 153.0, 152.9, 140.3, 129.4, 127.9, 127.3, 125.2, 122.6, 106.8, 
56.2, 52.2; HRMS (ESI+) m/z calcd for C16H15O5Cl, 322.0608 found 322.0658. 
 
 
Methyl 3,5-dimethoxy-4-(4-methoxyphenoxy)benzoate (3.62).  To a stirred solution of methyl 
3,5-dimethoxy-4-hydroxybenzoate (0.120 g, 0.565 mmol, 1.2 equiv), 4-iodoanisole (0.221, 0.942 
mmol, 2 equiv), Cs2CO3 (0.307 g, 0.942 mmol, 2 equiv), and TMHD (0.0970 mL, 0.471 mmol, 1 
equiv) in dry, degassed NMP (1 mL) was added CuCl (0.0233 g, 0.236 mmol, 0.5 equiv). The 
reaction mixture was heated to 120 ºC, stirred overnight, diluted with EtOAc, washed with 1 M 
NaOH (x2), brine, dried (MgSO4), filtered, and concentrated under reduced pressure. The crude 
mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 1:10 to 2:8) to give 3.62 
(0.166 g, 84%) as an inseparable mixture of and methylated methyl 3,5-dimethoxy-4-
hydroxybenzoate (5:1): Mp = 92-99 ºC; Rf = 0.46 (EtOAc/hexanes, 3:7); IR (neat) 2947, 2835, 
1711, 1590, 1499, 1433, 1336, 1215, 1128, 1109, 999 cm
-1
; Characteristic data for 3.62: 
1
H 
NMR (400 MHz, CDCl3)  7.36 (s, 2 H), 6.78 (s, 4 H), 3.92 (s, 3 H), 3.82 (s, 6 H), 3.74 (s, 3 H); 
13
C NMR (100 MHz, CDCl3)  160.5, 154.5, 153.2, 152.9, 152.1, 125.1, 115.6, 114.3, 106.8, 
56.3, 55.6, 52.1. 
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Methyl 3,5-dimethoxy-4-(4-methoxy-3-(methoxycarbonyl)phenoxy)benzoate (3.63). To a 
stirred solution of methyl 3,5-dimethoxy-4-hydroxybenzoate (0.100 g, 0.471 mmol, 1 equiv), 
3.63 (0.138, 0.943 mmol, 2 equiv), Cs2CO3 (0.307 g, 0.942 mmol, 2 equiv), and TMHD 
(0.00970 mL, 0.0471 mmol, 0.1 equiv) in dry, degassed NMP (1 mL) was added CuCl (0.0233 g, 
0.236 mmol, 0.5 equiv). The reaction mixture was heated to 120 ºC, stirred overnight, diluted 
with EtOAc, washed with 1 M NaOH (x2), brine, dried (MgSO4), filtered, and concentrated 
under reduced pressure. The crude mixture was purified by chromatography on SiO2 
(EtOAc/hexanes, 2:8) to give 3.63 (0.0063 g, 4%) as a colorless film: Rf = 0.37 (EtOAc/hexanes, 
2:8); 
1
H NMR (400 MHz, CDCl3)  7.37 (s, 2 H), 7.26 (d, 1 H, J = 3.2 Hz), 7.00 (dd, 1 H, J = 
3.2, 9.2 Hz), 6.87 (d, 1 H, J = 9.2 Hz), 3.94 (s, 3 H), 3.86 (s, 3 H), 3.84 (s, 3 H), 3.83 (s, 6 H); 
HRMS (ESI+) m/z calcd for C19H21O8 [M+H]
+
 377.1236 found 377.1242. 
 
 
(2-Chloro-4-methoxy-5-(methoxycarbonyl)phenyl)(mesityl)iodonium (3.65). To a stirred 
solution of iodomesitylene diacetate (3.20 g, 8.79 mmol, 1 equiv) and 3.57 (3.52 g, 17.6 mmol, 2 
equiv) in CH2Cl2 (20 mL) at 0 ºC was added triflic acid (0.936 mL, 10.5 mmol, 1.2 equiv). The 
reaction mixture was slowly warmed to rt, stirred overnight, concentrated under reduced 
pressure, resuspended in dry Et2O and placed in the -20 ºC freezer overnight. The reaction 
mixture was filtered and the precipitate was washed with cold Et2O (x3) to give 3.65 (2.90 g, 
74%) as an off-white (tannish) solid: Mp = 170-172 ºC; IR (neat) 1743, 1730, 1577, 1549, 1461, 
1352, 1284, 1230, 1168, 1092, 1020 cm
-1
; 
1
H NMR (400 MHz, CDCl3)  7.95 (s, 1 H), 7.19 (s, 1 
H), 7.10 (s, 2 H), 3.93 (s, 3 H), 3.84 (s, 3 H), 2.65 (s, 6 H), 2.35 (s, 3 H);
 13
C NMR (100 MHz, 
CDCl3)  163.4, 162.4, 144.6, 142.4, 141.6, 138.6, 130.6, 122.0, 121.8, 114.9, 101.6, 56.9, 52.7, 
26.9, 21.0; HRMS (ESI+) m/z calcd for C18H19O3ClI [M-OTf]
+
 445.0067 found 445.0066. 
 
  187 
4.0  SYNTHESIS OF BONT/A LC INHIBITORS 
4.1 INTRODUCTION 
Botulinum neurotoxins (BoNTs) are the most toxic proteins known.
196
  First described in 
the 1820’s as “sausage poisoning”, the term botulinum is derived from the Latin word botulus, 
meaning sausage. In 1895, Emile Pierre Marie van Ermengem discovered the bacteria 
responsible for the production of the toxin.
197
  Today, seven biochemically and serologically 
distinct botulinum neurotoxins (designated BoNT/A to BoNT/G) have been characterized from 
the anaerobic spore-forming bacteria of the genus Clostridium.
196
  Of the seven, BoNT A, B, E, 
and rarely F are responsible for human intoxication.  The most lethal, BoNT/A, exhibits an LD50 
in humans of approximately 1 ng kg
-1
 of body mass, approximately one hundred thousand times 
more potent than sarin and one hundred billion times more potent than cyanide.
198
   
BoNTs exist as progenitor toxins composed of inactive chains and accessory proteins.  
The accessory proteins protect the toxin as it passes through the digestive system to the small 
intestine where it is absorbed into the blood stream, subsequently making its way to the 
cholinergic presynaptic terminals.
198
  The active form of BoNT consists of three domains: the C-
terminal domain, which is responsible for specific synaptic binding, the N-terminal domain, a 
zinc dependent endopeptidase, and the middle domain, which mediates translocation into the 
cytosol of the nerve.  The C-terminal and middle domains combine to make a 100 kD subunit 
known as the heavy-chain (HC), which is connected to the N-terminal domain, a 50 kD subunit, 
known as the light chain (LC), via a disulfide bond (Figure 40). 
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Figure 40. Ribbon representation of the three domains of botulinum neurotoxin serotype A adapted from PDB 
structure 3BTA199 (The N-terminal domain (BoNT LC) is represented in red with the catalytic Zn ion in magenta, 
the middle domain (BoNT HC-N) is represented in blue, and the C-terminal domain (BoNT HC-C) is represented in 
green.   
 
When an action potential from motor neurons arrives at the neuromuscular junction, the 
entry of calcium through a voltage-gated channel triggers the fusion of synaptic vesicles 
containing acetylcholine to the presynaptic membrane.  Acetylcholine is subsequently released 
into the synaptic cleft and diffuses to the acetylcholine receptors located on the surface of the 
muscle fiber.  Once bound, the acetylcholine causes a depolarization and the action potential 
travels throughout the length of the muscle cell triggering muscle contraction.
198
 This union of 
the synaptic vesicles to the presynaptic membrane is mediated by several proteins, which act 
together to form a synaptic fusion complex.  These proteins are collectively known as SNARE 
(soluble NSF-attachment protein receptors; NSF is N-ethylmaleimide-sensitive fusion protein) 
proteins and include SNAP-25 (synaptosomal-associate protein-25 kD), syntaxin, and 
synaptobrevin.  BoNTs act by disrupting the fusion complex, thereby inhibiting the release of 
acetylcholine into the presynaptic cleft. 
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Figure 41. Cartoon representation of I) Normal neurotransmitter release. II) Individual stages of BoNT-intoxication 
including: A) neurotoxin binding to cell-surface receptors, B) endocytosis into an intracellular vesicle, C) HC-
mediated translocation of the LC into the cytosol, and D) proteolytic cleavage of specific SNARE proteins. BoNT/B, 
/D, /F, and /G cleave synaptobrevin; BoNT/A, /C, and /E cleave SNAP25; BoNT/C also cleaves syntaxin. 
Reproduced with permission from ref.200 
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BoNT’s mechanism of action consists of four sequential steps (Figure 41).200  The first 
stage involves binding to the specific cholinergic nerve terminal membrane followed by 
internalization inside a vesicle endowed with an ATPase proton pump.  Membrane translocation 
is triggered by acidification of the vesicular lumen, which causes a structural rearrangement, 
insertion of the toxin, and translocation of the light chain into the cytosol.  Finally, expression of 
the light chain and proteolytic activity leads to disruption of the fusion complex.  Consequently, 
the toxins interfere with the transmission of nerve impulse and cause muscle paralysis.  The 
different BoNTs target different proteins in the complex (Figure 41); however, the most lethal, 
BoNT/A, targets the SNAP-25 protein.
196
   
Once intoxicated, the facial and throat muscles are the first to become progressively 
paralyzed, causing diplopia, ptosis, dysphagia, and facial paralysis.  The paralysis gradually 
descends to affect muscles of the trunk, including the respiratory and cardiac muscles.  Death 
usually results from either respiratory failure or cardiac arrest.  Concurrently, dysfunctions of the 
autonomic nervous systems develop, which result in reduced salivation, lacrimation, nausea, 
vomiting, and abdominal pain.
196
   
Interestingly, due its ability to decrease muscle activity, BoNT/A has received attention 
in the medical community.  A localized injection of BoNT/A, known as BOTOX, renders 
muscles unable to contract for approximately 3-4 months.  As such, BOTOX is commonly used 
to treat a variety of disorders associated with the hyperactivity of specific muscles, as well as for 
cosmetic purposes. The increasingly widespread use of BoNT as therapeutic and cosmetic agents 
is paralleled by an increased risk of accidental overdosing.  Additionally, BoNT’s ease of 
production, potent toxicity, ubiquitous nature, chemical and physical resistance, as well as their 
ability to be delivered via aerosol medium, has caused them to be considered Category A 
bioterror agents by the Center for Disease Control and Prevention.
201
  
Current treatment involves passive administration of equine antibodies.  Although 
broadly effective, administration of the antibodies can cause sickness or anaphylaxis.  
Additionally, these antitoxins are only capable of sequestering freely circulating BoNT, 
rendering them useless once the toxin has entered the neuronal cells.  The onset of botulism is 
very rapid with initial symptoms appearing within two hours of ingestion; thus current 
therapeutics have a very short window of application.  In most cases, even with therapeutic 
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intervention, intubation and mechanical respiration of patients is required for upwards of 6 
months.  Currently there are no drugs approved for the treatment of botulism.202  Therefore, there 
is an urgent need for therapeutic strategies to counter BoNT intoxication.  
4.2 DESIGN OF INHIBITORS 
The structural basis for the rational design of BoNT/A inhibitors can be better 
understood in the context of the current model for its proteolytic activity, as well as through the 
examination of other known inhibitors.  Thus, one must focus on the details of the proteolytic 
interaction of BoNT/A with SNAP-25 and the different mechanisms of inhibition that have 
previously been described.  
The proteolytic cleavage of the Gln197-Arg198 peptide bond in SNAP-25 involves four 
distinct stages (Scheme 43).  In the first stage, prior to entrance of the substrate, the catalytic zinc 
ion of BoNT/A is tetracoordinated to Glu262, His223, His227, and Glu224 via H-bonding 
through a water molecule (Scheme 43, panel I).  As the substrate enters the active site, the 
Michaelis complex is formed via anchoring of the P1 (Arg198) residue of SNAP-25 into the 
active site.  Upon entering, the substrate elicits a conformational change of Asp370 with a 
concomitant formation of a salt bridge, along with cation-π interactions with Phe194 of the toxin.  
Further stabilization is achieved through polar contacts, via the displacement of a water molecule 
on Tyr363 by the carbonyl oxygen of P1 (Gln197) as well as favorable ionic interactions with 
Glu164 and Arg363 of the toxin (Scheme 43, panel II).  Ionization of the catalytic water 
molecule H-bonded to Glu224, followed by nucleophilic attack at the P1 carbonyl leads to the 
formation of the tetrahedral intermediate.  The resulting oxyanion is stabilized by both H-
bonding interactions with Tyr366 and coordination to the zinc ion (Scheme 43, panel III).  
Breakdown of the tetrahedral intermediate is facilitated by the transfer of two protons by Glu224 
to the P1 residue in the substrate.  Thus, the stabilized amino group leaves the catalytic site of 
the BoNT/A LC and proteolysis is complete (Scheme 43, panel IV).  Because of its crucial role 
in channeling these protons from the nucleophilic water molecule to the substrate, Glu224 in 
BoNT/A LC is often described as the general base or “proton shuttle”. 
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Scheme 43. Schematic representation of the proteolytic cleavage of the Gln197-Arg198 peptide bond in SNAP-25 
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Non-peptidic inhibitors of both BoNT/A HC and LC have been identified.  In 2003, the 
first small molecule inhibitors (Michellamine B, Q2-12 and NSC 357736; Figure 42) were 
reported.
203
  In addition,  zinc-coordinating hydroxamic acids (2,4-dichlorocinnamoyl-
hydroxamic acid; Figure 42) represent another class of LC inhibitors.  
 
 
Figure 42. Small molecule inhibitors of the BoNT/A LC 
 
These and other inhibitors containing zinc-coordinating moieties tend to exhibit mediocre 
selectivity, making them poor therapeutic leads.
204
  More recently, the Wipf group has focused 
on elaborating the indole bis-amidine containing compounds (NSC 357756; Figure 42) and 
through collaborations have successfully elucidated some structural requirements for binding.
205
 
A more in depth discussion of the development of small-molecule inhibitors in included 
immediately preceding the discussion of our own work in this area. 
Another approach to address the need for potent and effective inhibitors is the use of 
peptide-like molecules (PLMs).  Over the past decade, a large number of PLM inhibitors have 
been investigated and have provided valuable information regarding substrate specificity, 
substrate recognition, and structural requirements.
202
  Therefore, in parallel to our exploration of 
small molecule inhibitors of BoNT/A, we sought to expand our investigation to include PLM 
inhibitors.   
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 Most PLM inhibitors share some fundamental contacts.  All non-zinc-chelating BoNT/A 
peptide inhibitors reported to date orient their amino terminal group to contact the Glu224 
carboxylate group, effectively displacing the catalytic water molecule and shutting down the 
“proton shuttle”.  In addition, all of these structures exhibit substrate-like interactions between 
the P1 carbonyl and both the Tyr366 residue as well as the zinc ion of BoNT/A LC.   
In 2008, Zuniga et al. published a series of SAR studies that led to the discovery of a 
potent PLM inhibitor, I1 (Figure 43), along with a crystal structure of the I1 inhibitor bound to 
the active site of BoNT/A.
204
  The I1 inhibitor is the most-potent non-zinc chelating, non-
hydroxamate based antagonist reported to date with a Ki = 41 nM.
204
  This inhibitor mimics the 
7-residue QRATKML sequence of the native 206-residue, SNAP-25 protein (Figure 43).  
   
 
Figure 43. Structure of the 7-residue sequence of SNAP-25 and its peptidomimetic inhibitor I1 
 
Examination of the crystal structure containing the bound inhibitor revealed I1 inhibited 
protease activity via displacement of the catalytic water molecule on Glu224 with the terminal 
amine group of I1 (Figure 44), as observed in previous non-zinc chelating PLM inhibitors.
204
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Figure 44. Coordination of the zinc ion bound to the 1I inhibitor204 
 
Zuniga et al.’s SAR studies revealed that replacement of the P1, P2, and P4 residues of 
the native 7-residue QRATKML sequence had the greatest effect on inhibitor binding affinity.
204
  
Specifically, replacing the native P1 arginine with 4-(2,4-dinitrophenylamino)-2-aminobutanoate 
(DNP-DAB) provided a 10-fold increase in the binding affinity of the inhibitor relative to an 
identical inhibitor containing a phenylalanine at the P1 position.
204
  The increased potency is 
primarily attributed to the polar nitro and butanoic acid groups of the DNP-DAB residue, which 
play a critical role in stabilizing the bound inhibitor via a network of polar interactions (Figure 
45).  Replacing the native P2 alanine with a tryptophan residue also significantly reduced the 
inhibitor’s Ki, suggesting favorable hydrophobic interactions were effectively “locking” the 
inhibitor into place.  Finally, the P4 (Arg) position was replaced with 2,4-diaminobutanoic acid 
(DAB), which crystal structural analysis revealed provided a strong hydrogen bonding 
interaction of its free terminal amine with Q162 of BoNT/A LC.  Examination of the crystal 
structure revealed that when bound to the active site, the C-terminal residues of the I1 inhibitor 
adopt a 310-helical conformation (Figure 45). 
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Figure 45. Crystal structure of previously synthesized inhibitor I1 (left), and polar interactions of the DNP-DAB 
residue bound within the active site (right, I1 shown in magenta, H-bonding shown in yellow, and the Zn ion shown 
in red). 
 
The goal of our study was to further refine the I1 inhibitor to increase its drug-like 
character while retaining potency and its 310-helical conformation.   Replacing the redox-active 
DNP-DAB group was instrumental to our goal in moving toward a more drug-like compound. 
Thus, in order to maintain potency, new electrostatic interactions must be accessed.  In 2008, 
Kumaran et al. described four tetrameric peptide inhibitors (RRGC, RRGL, RRGI, and RRGM) 
with submicromolar activity.
201
  The authors were able to obtain crystallographic data for each of 
the four tetrapeptides individually bound to the BoNT/A LC.  In each of these structures, the 
guanidinium group of the P1 Arg exhibited strong electrostatic interactions with the toxin, while 
maintaining the previously described mechanism of inhibition.
201
  Substituting the redox active 
DNP-DAP group with an arginine should allow access to these electrostatic interactions, thus 
compensating for the loss of the DNP-DAB residue. 
The importance of an Arg at the P1 position has been established and is hypothesized to 
be necessary for efficient docking into the S1 pocket of the toxin.206  Zuniga et al.’s SAR 
revealed that the presence of a large aromatic residue at the P2 position induced a conformation 
of the active site, which provided favorable hydrophobic interactions as well as potential π-
stacking interactions (Figure 46).  In addition, the presence of an aromatic residue directly 
preceding the N-terminus of a 310-helix is known to have a stabilizing effect.
207
  Consequently, 
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we sought to further probe the effects of substitution of different aromatic residues at this 
position.  Initially, three variants at the P2 were proposed to modulate the aromatic hydrophobic 
interactions by generating the sterically and electronically diverse benzyl, CH2-naphthyl, and 
CH2-indolyl analogues.   
 
 
Figure 46. Trp residue bound in the active site (the I1 inhibitor is shown in purple) 
 
 Moreover, to further stabilize the 310-helical nature of the C-terminus of the inhibitor, an 
α-aminoisobutryic acid (AIB) residue, known to stongly favor the 310-helix
208,209
 was 
incoroporated.  Based on the chemical and electronic environments of the remaining amino 
acids, it became apparent that the Thr position immediately following the aromatic P2 residue 
would be the best site for replacement.  The Thr residue benefits from favorable electrostatic 
interactions with both the backbone nitrogen and carboxylic acid side chain of Asp307 (Figure 
47), however it exhibits no strong hydrophobic interactions.   
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Figure 47. Polar contacts of the Thr residue of I1 (magenta) with Asp307 of BoNT/A LC 
 
Low level (PM5) CACHE calculations for the heat of formation revealed that by 
replacing the Thr residue with an AIB residue in the conformation exhibited in the crystal 
structure, an increase in thermodynamic stability was observed (-240.799 kJ/mol for the structure 
containing the Thr residue vs. -342.1377 kJ/mol for the strucuture containing the AIB 
replacement). 
The next residue in the I1 inhibitor, a DAB, exhibits favorable electrostatic interactions 
and previous SAR analysis revealed that replacement with other residues led to a decreased Ki.
204
  
However, to increase the hydrophobicity of the C-terminus, the DAB residue was replaced with 
an Ala, which is commonly overrepresented in the 310-helix.
207
 
The final two residues of the inhibitor, which correspond to the native substrate are 
located in a more solvent exposed cavity and do not exhibit strong electrostatic or hydrophobic 
interactions in the crystal structure of the bound inhibitor.  As such, they were left as Met and 
Leu, respectively.  Therefore, three PLMs were selected for an initial screening (JTH-NB72-35, 
JTH-NB72-38, JTH-NB72-39; Figure 48) and were synthesized via the previously optimized 
microwave solid phase peptide synthesis protocol (vide supra).  
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Figure 48.  Structure of I1 and analogous PLM structures 
4.3 SYNTHESIS OF INHIBITORS 
The desired heptameric peptides were synthesized via microwave assisted solid phase 
peptide synthesis using Fmoc protected amino acids and Rink amide SS resin (Figure 3).  After 
swelling the resin in CH2Cl2 for 30 min, the synthesis was initiated by removal of the Fmoc 
protecting group from the Rink amide resin with a solution of 20% piperidine in DMF.  The 
newly afforded free amine was then coupled to the protected amino acid, which had been 
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preactivated with the Goodman reagent (DEPBT), corresponding to the C-terminus of the 
desired heptamer.  With the first amino acid successfully coupled to the Rink resin, the Fmoc 
group was once again removed and the subsequent activated amino acid was coupled to the 
freshly deprotected growing peptide chain.  This process of deprotection and coupling was 
repeated until the N-terminal residue of the desired heptamer had been coupled (Scheme 44, 
Scheme 45, and Scheme 46).  Following the final Fmoc deprotection, the peptide was cleaved 
from the solid support by stirring in a modified version of Reagent K, (87.5% TFA, 3.6% 
thioanisole, 2.3% EDT, 3.7% phenol, 1.8% H2O, 1.1% triisopropylsilane) for 2 h at rt.  The resin 
was filtered and washed with a small quantity of cleavage cocktail.  The crude peptide was 
precipitated with ice-cold diethyl ether, collected via centrifugation, dissolved in deionized 
water, and lyophilized.  The crude peptides were purified by preparative RP HPLC to afford 
approximately 35 mg of each of the desired peptides (JTH-NB72-35, JTH-NB72-38, and JTH-
NB72-39; Figure 48).  
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Scheme 44. Synthesis of RR(1-Nap)(AIB)AML (JTH-NB72-35) 
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Scheme 45. Synthesis of RRW(AIB)AML (JTH-NB72-38) 
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Scheme 46. Synthesis of RRF(AIB)AML (JTH-NB72-39) 
4.4 RESULTS AND DISCUSSION 
The desired peptides were successfully synthesized in moderate yields (34-41%) after 
purification by reverse phase HPLC (Table 29).  25 mg of each of the newly synthesized 
peptides were sent to our collaborators Dr. Johnathan Nuss and Dr. Sina Bavari of the 
Department of Immunology, Target Identification, and Translational Research, Division of 
Bacteriology, at the United States Army Medical Research Institute of Infectious Diseases, for 
BoNT/A LC inhibition studies and all three compounds were found to possess sub-µM activity 
(Table 29).  Although the inhibitors did not possess the potency of I1, the overall drug-like 
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nature of the molecule was increased both by removing the redox-active DNP-DAB group as 
well as increasing by the overall hydrophobicity of the molecule (Table 29) while maintaining 
sub µM potency. 
 
Table 29. BoNT/A LC inhibitor summary. 
 
aYields are determined assuming the initial loading of the resin to be 0.7 mmol/g. bAll kinetic analysis was obtained 
through a collaboration with Dr. Johnathan Nuss and Dr. Sina Bavari at the Department of Immunology, Target 
Identification, and Translational Research, Division of Bacteriology, United States Army Medical Research Institute 
of Infectious Diseases using previously described assays.204  ccLogP data was generated using QikProp software 
from Schrödinger. 
 
In addition, through the tireless efforts of our collaborators Jorge Zuniga and Dr. Axel 
Brunger of the Howard Hughes Medical Institute and Departments of Molecular and Cellular 
Physiology, Neurology, and Neurological Science, Structural Biology, and Photon Science, at 
Stanford University, the three dimensional structure of the BoNT/A LC:JTH-NB72-39 complex 
was solved at 2.4 Å resolution by X-ray crystallography (Figure 49). 
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Figure 49. Crystal structure with JTH-NB72-35 (in magenta) bound to the BoNT/A LC. 
 
Structural comparison of the bound I1 inhibitor and bound JTH-NB72-39 revealed that 
although substantial replacements were made to the I1 inhibitor, the overall conformation of the 
molecule as well as integrity of 310-helix were successfully maintained (Figure 50).  
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Figure 50. Comparison of I1 (top left) and JTH-NB72-39 (top right) bound to the active site of BoNT/A LC as well 
as both a front (bottom left) and back (bottom right) view of an overlay (JTH-NB72-39 carbons are magenta while 
I1 carbons are green). 
 
Further examination of the crystal structure revealed that the majority of the 
toxin:inhibitor interactions occur along residues 1 through 4 (P1-P3), while the last three 
residues have a less conspicuous electron density indicating the disordered nature of their 
binding.  True to its design, JTH-NB72-39 was able to exploit the electrostatic surface and 
hydrophobic interactions that had been previously established as binding surfaces for two 
different kinds of inhibitors.
201,204
   
In the BoNT/A LC:JTH-NB72-39 complex, the backbone groups in the P1 Arg in the 
inhibitor established two crucial interactions that effectively impair the catalytic machinery of 
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the BoNT/A LC; first, the terminal amino group of the P1 Arg has displaced the catalytic water 
molecule normally observed at H-bond distance from Glu224, and second, this amino group is 
associated with the negative head group of the Glu224 side chain.  In this way, the catalytic 
center of BoNT/A is deprived of the nucleophilic water molecule necessary for proteolytic bond-
cleavage.  Concurrently, JTH-NB72-39 is exerting a “lock” effect in this “proton shuttle” of the 
active site.  The inhibitor also displays substrate-like interactions by placing the carbonyl group 
of P1 2.4 Å away from the zinc ion and forming a H-bond with Tyr366 (Figure 51).  
Although removing the DNP-DAP residue led to the loss of several strong electrostatic 
interactions, its replacement in JTH-NB72-39 with an Arg led to the formation of new 
electrostatic interactions.  The Arg (P1) of JTH-NB72-39 forms a salt bridge with Glu164 and 
an H-bond with the carbonyl group of Cys165 in the toxin.  The P1 Arg also possesses a salt 
bridge with the carboxylate group of Asp370 as well as cation-π interactions of the guanidinium 
with Phe194 of the toxin (Figure 51), as previously described.
201
 
 
 
Figure 51.  Panoramic view of the JTH-NB72-39 inhibitor bound to BoNT/A LC active site210 
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The P2 residue, a Phe, successfully exploits the hydrophobic interactions described as 
crucial for proper “locking” of the I1 inhibitor.204  Phe369 and Leu367 are responsible for the 
bulk of the hydrophobic interactions and have undergone a significant reorientation as compared 
to the free form of BoNT/A LC.  However, both Phe369 and Leu367 exhibit stronger 
hydrophobic interactions with previously described I1 inhibitor, which may suggest that Trp is a 
better anchor than Phe in this inhibitor.  Interestingly, the inhibitor containing the larger Trp 
residue at the P2 position (JTH-NB72-38) exhibited the highest Ki (990.5116.9 nM).  One 
explanation is that due to the different mode of binding exhibited by JTH-NB72-39, the ability 
for electrostatic interactions of the indole nitrogen described by Zuniga et al. has been removed 
and the presence of a polar atom decreases the residue’s overall affinity toward the hydrophobic 
pocket.  This theory is supported by the increase in the activity of the analogue containing the 1-
naphthyl residue.  It is clear that hydrophobic interactions play a large role in modulating the 
affinity of the BoNT inhibitors and hydrophobicity is an important interaction that could be 
further optimized in future inhibitors. 
Incorporation of the AIB residue successfully stabilized the 310-helix; however, AIB did 
not participate in any strong hydrophobic or electrostatic interactions.  As previously mentioned, 
the last three residues are not as tightly bound to the toxin as the first four.  Although several 
hydrophobic interactions are observed, they are likely transient.  
4.5 CONCLUSIONS 
The rational design and synthesis of three PLM inhibitors of BoNT/A LC have been 
described.  Through collaboration with Dr. Johnathan Nuss and Dr. Sina Bavari of the 
Department of Immunology, Target Identification, and Translational Research, Division of 
Bacteriology, at the United States Army Medical Research Institute of Infectious Diseases, all 
three compounds have been tested in a biological assay for inhibition of BoNT/A LC, and found 
to possess sub-µM activity (Table 29).  The drug-like character of I1 was increased by removing 
the redox active DNP-DAB residue and increasing the hydrophobic nature of the C-terminus by 
replacing Thr with AIB and DAB with Ala residues, while maintaining the 310-helix.  In 
addition, through a collaboration with Jorge Zuniga and Dr. Axel Brunger of the Howard Hughes 
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Medical Institute and Departments of Molecular and Cellular Physiology, Neurology, and 
Neurological Science, Structural Biology, and Photon Science, at Stanford University, the 
BoNT/A LC:JTH-NB72-39 complex was solved at 2.4 Å resolution by X-ray crystallography.  
This crystal structure revealed that, true to its design, the inhibitor exhibited hydrophobic and 
electrostatic interactions previously described for two different inhibitors.
201,204
  Thus, the next 
stage of this project would be to use the information gained from the crystal structure to develop 
an even more drug-like molecule by decreasing the size of the inhibitor as well as removing the 
peptide bonds, which lead to the short in vivo lifetimes exhibited by peptidic inhibitors.     
4.6 DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF BONT/A LC 
In addition to PLM inhibitors of BoNT/A LC, our group has focused on the identification 
and preparation of small-molecule inhibitors.  Our collaborators, Gussio and coworkers 
conducted a high-throughput screen of the National Cancer Institute’s (NCI) diversity set, which 
identified several non-peptidic small-molecule inhibitors of the BoNT LC.
211
  In particular this 
screen led to the identification of Michellamine B, Q2-15, and NSC 357736 (Figure 42).  Based 
on the newly identified inhibitors, iterative comformational anaylses, and molecular docking 
studies, the authors were able to develop a refined pharmacophore (Figure 52).
211,212
 
The refined pharmacophore, shown in Figure 52, is composed of two planar components (A 
and B), one of which contains a heteroatom atom thought to engage with the catalytic zinc either 
through direct contacts or by replacing the water molecule responsible for hydrolysis of the 
substrate peptide.  Components C and D represent lipophilic portions of the inhibitors, which are 
placed into hydophobic pockets of the active site.  Finally, Component E represents the the polar, 
ionizable center, thought to be involved with electrostatic or water mediated interactions with the 
polar residues of the active site.
212
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Figure 52.  Refined pharmacophore for BoNT/A LC inhibition.  Planar components A and B are represented as blue 
dashed rectangles. The dashed circle in plane A represents a heteroatom.  Hydrophobic components C and D are 
shown as light blue circles.  The positive ionizable component of E of the pharmacophore is shown as a red circle.  
Residues that remained consistent when docking inhibitors predicted binding subsites of both dynamic and 
molecular mechanics “only” refined models are shown as grey spheres.  Residues E36, V67, and E170 are shown as 
gray spheres with dashed black boarders—to indicate that these amino acids were found to participate when docking 
inhibitors in dynamic structures.  Note this figure and caption were reproduced with permission from Burnett and 
coworkers.212 
 
Based on this pharmacophore as well as data generated from some peptidic inhibitors, 
Burnett and coworkers generated a series of queries searching the NCI’s Open Repository.213  
This set of queries led to the identication of several hits, which were assayed for inhibition of 
BoNT/LC A.  These inhibition studies led to the identification of four potent inhibitors (Figure 
53).  Of the four newly identified inhibitors, NSC 240898 showed a dose-dependant inhibition of 
SNAP-25 proteolysis and displayed no cellular toxicity up to 40 µM concentration.
213
 The 
molecular docking study for NSC 240898, shown in Figure 53, revealed that the indole nitrogen 
is positioned to interfere with the catalytic zinc in the active site while maintaining several 
stabilizing polar and hydrophobic contacts.
213
  The potent activity and limited toxicity of NSC 
240898 led our group to choose it as a lead for a structure-activity relationship (SAR) study 
aimed at generating more potent analogues (Figure 54).
205
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Figure 53. (A) Structures of the four most potent BoNT/A LC inhibitors screened. (B) Docking of NSC 240898 fit 
with good steric and hydropathic complementarity in the BoNT/A LC substrate binding cleft. Reproduced with 
permission from ref.213 
 
The synthetic modifications made during our initial SAR study are highlighted in Figure 
54.
205
  Specifically our SAR studies focused on replacing the two polar terminal amidines, 
moving the indole amidine from the indole C5 to the indole C6 carbon, and a variety of 
substitutions.  The incorporation of heteroarenes (pink Z) were investigated to improve solubility 
properties while decreasing the potential for metablolism.  Different heteroatomic linkers (X = 
O, N, S) were also investigated.  Finally, substitution of the central phenyl ring was done to 
explore the electronic and steric requirements of the active site.  These SAR studies revealed that 
substitution of the bis-amidines with imidazolines led to more pharmacologically relevent 
inhibitors without a significant decrease in potency.  In addition, the SAR revealed the presence 
of additional polar atoms led to decreased potency, however switching to a softer sulfur linker 
improved activity.  Ultimately our SAR studies led to the identification of CWD-021, a more 
potent NSC 240989 analogue.
205
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Figure 54.  Structure of potent small-molecule inhibitors of BoNT/A LC and SAR studies of NSC240898 to yield 
CWD-021 
  
As a part of an ongoing research program seeking to further elucidate the SAR of the 
BoNT/A LC small-molecule inhibitors, the synthesis of a set of structurally rigidified eight-
membered ring analogues containing either an amide or amine was pursued (4.1-4.5, Figure 55). 
 
 
Figure 55. Proposed rigidified small-molecule inhibitors of BoNT/A LC 
 
I was charged with continuing the efforts of a former postdoctoral scholar in our group, Dr. 
Igor Opsenica.  Dr. Opsenica had successfully prepared both the amide derivatives 4.1 and 4.3 
however, was unable to complete the thioamides 4.2 and 4.4, as well as the amine derivative 4.5 
prior to completion of his postdoctoral studies.  My own synthetic work started from 
intermediate 4.13, which was prepared by Dr. Opsenica according to the sequence outlined in 
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Scheme 47.  Dr. Opsenica’s synthesis of 4.13 began from aniline 4.6.  Diazotization of 4.6, 
displacement with thioacetate, hydrolysis with sodium hydroxide, and conversion to the methyl 
ester in acidic methanol afforded 4.7 in 58% yield over the four steps.  Thiophenol 4.7 was 
coupled with the commerically available 2-fluoro-5-cyano-benzaldehyde 4.8 in the presence of 
potassium carbonate to yield diaryl thiol 4.9 in 55% yield.  Selective reduction of the aldehyde 
with sodium borohydride, followed by conversion to the meslate and displacement with sodium 
azide afforded the benzyl azide 4.11 in 53% yield over three steps.  Hydrolysis of the ester 
followed by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) mediated penta-
fluorophenol (Pfp) ester fomation afforded 4.12 in 60% yield over two steps. Staudinger 
reduction and subsequent amide formation provided 4.13 in moderate yield.  
 
 
Scheme 47. Dr. Igor Opsenica’s synthesis of 4.13 
 
Following Dr. Opsenica’s previously optimized proceedures, my own synthetic work began 
with the Stille coupling of the eight-membered lactam 4.13 with the readily available stannane 
4.14.  The Stille coupling proceeded smoothly in the presence of an N-heterocyclic carbene 
copper chloride catalyst ((IPr)CuCl)
214
 and bis(triphenylphosphine)palladium(II) chloride to 
afford 4.15 in 43% yield.  Removal of the indole t-butyloxycarbonyl (Boc) protecting group with 
TFA in dichloromethane gave the free indole 4.16 in good yield.  Conversion of the nitriles to 
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imidazolines was accomplished using 1,2-diaminoethane in the presence of sulfur to give 4.3 in 
52% yield.  After some optimization, it was found that heating 4.3 with phosphorous 
pentasulfide and pyridine in dimethyl sulfone overnight at 120 ºC provided the desired thioamide 
4.4 in excellent yield (Scheme 48).  The use of dimethyl sulfone, which remains a solid below 
110 ºC, proved crucial for solubilizing 4.3 and providing reproducible levels of reactivity.   
 
 
Scheme 48. Synthesis of thioamide 4.4 
 
Next, we focused on the preparation of thiomide 4.2 (Scheme 49, Scheme 50).  Starting 
from the commercially available 2-fluoro-5-cyanobenzoic acid 4.17, Fischer esterification 
proceeded smoothly to afford methly ester 4.18 in good yield.  Nucleophilic aromatic 
substitution with thioacetic acid and subsequent hydrolysis afforded thiophenol 4.19 in 34% 
yield.  Unfortunately, attempts to increase the yield of the substitution using different thiol 
sources as well as screening several bases proved unsuccessful.  Thiophenol 4.19 was coupled 
with the commerically available 2-fluoro-5-bromo-benzaldehyde 4.20 in the presence of 
tetramethyl guanidine, which proved superior to potassium carbonate, to yield diaryl thiol 4.21 in 
47%.  Selective reduction of the aldehyde with sodium borohydride afforded benzyl alcohol 
4.22.  Conversion to the meslate and displacement with sodium azide proceeded in excellent 
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yield to afford the benzyl azide 4.23.  Saponification of the methyl ester followed by formation 
of the penta-fluorophenol (Pfp) ester afforded 4.24 in 62% yield over two steps. Staudinger 
reduction and subsequent amide formation provided the eight-membered lactam 4.25 in 48% 
yield.  
 
 
Scheme 49. Synthesis of the eight-membered lactam 4.25 
 
Completion of thioamide 4.2 following a similar sequence used in the preparation of 
thioamide 4.4 proceeded in comparable yields (Scheme 50).  Stille coupling of eight-membered 
lactam 4.25 with the readily accessible cyano-indole 4.14 gave 4.26 in 40% yield.  Removal of 
the t-butyloxycarbonyl (Boc) group with TFA proceeded in quantitative yield to afford the free 
indole 4.27.  Converion of both nitriles to imidazolines in the microwave with 1,2-diaminoethane 
and sulfur provided 4.1 in 56% yield.  Thioamide formation proceeded this time in moderate 
yield in the presence of phosphorous pentasulfide and pyridine in dimethyl sulfone to give 
thioamine 4.2 in 58% yield.  
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Scheme 50.  Completion of thioamide 4.2 
 
 Next, the preparation of the final amino analogue 4.5 was investigated.  Initial attempts to 
de-sulfurize thioamide 4.2 to give the desired product directly were unsuccessful (Table 30).  
The use of various equivalents of Raney-Ni in several solvent systems provided no reaction and 
only starting material was observed by LCMS analysis.   The observed lack of reactivity is most 
likely a result of the poor solubility of 4.2 even in DMSO at elevated temperatures.  
Consumption of 4.2 was only observed with in situ prepared nickel borohydride and with 
Schwartz reagent (Cp2ZrHCl); however in neither case was the desired product observed by 
LCMS analysis.  These initial attempts to directly reduce the thioamide present in 4.2 were not 
promising and when coupled with a rapidly diminishing supply of 4.2 led us to re-evaluate our 
synthetic strategy.  Therefore, focus was shifted to the installation of the amine prior to Stille 
coupling. 
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Table 30. Attempts to synthesize 4.5 via direct de-sulfurization of 4.2 
 
 
 Next, the intramolecular Staudinger-aza-Wittig (SAW) reaction to close the eight-
membered ring was investigated (Scheme 51).  To this end azido-ester 4.22 was reduced with 
lithium borohydride to provide benzyl alcohol 4.28 in 80% yield.  Oxidation of 4.28 with MnO2 
provided unsatisfactorily low yields; however, switching to barium permanganate afforded the 
desired benzyl aldehyde 4.29 in 74% yield.  Subjecting 4.29 to triphenylphosphine in THF, either 
at room temperature or 66 ºC overnight, proved ineffective and only starting material was 
recovered.  Switching to 1,2-bis(diphenylphosphino)ethane, after stirring with 4.29 in THF 
overnight at room temperature afforded a product tentatively assigned as 4.30 in 76% yield. 
Reduction of the product tentatively assigned as 4.30 with lithium borohydride, however, yielded 
a product assigned by HRMS analysis to be the dimeric product 4.32 (Scheme 51).  Based on 
this result it is apparent that the desired intermolecular SAW reaction to form the eight-
membered had not occurred; instead a bimolecular SAW reaction to form the symmetric dimer 
3.31 had proceeded.  Investigating more dilute conditions (c = 0.005 M) afforded none of the 
desired imine 4.30, and only the dimeric 4.32 was observed.  Therefore, an alternative approach 
to the synthesis of the amino derivative 4.5 is needed.  
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Scheme 51. Attempted synthesis of 4.30 
 
4.7 CONCLUSIONS AND FUTURE DIRECTIONS 
Herein, the synthesis of several non-peptidic small-molecule inhibitors of BoNT/A LC is 
described.  Successful preparation of amides 4.1 and 4.3 according to Dr. Igor Opsenica’s 
previously optimized route allowed for the syntheses of the corresponding thioamides 4.2 and 
4.4.  All four eight-membered ring analogues were sent to our collaborators Dr. Johnathan Nuss 
and Dr. Sina Bavari of the Department of Immunology, Target Identification, and Translational 
Research, Division of Bacteriology, at the United States Army Medical Research Institute of 
Infectious Diseases, for BoNT/A LC inhibition assays.  Attempts to synthesize 4.5 by either de-
sulfurization of 4.2 or an intramolecular Staudinger-aza-Wittig reaction of 4.29 proved 
unsuccessful.  The future goal of this project is the completion of the amino derivative.  We 
envision that selective reduction of the amide of 4.25 to the amine, followed by protection and an 
analogous reaction sequence used in the preparation of 4.1 and 4.3 will afford access to the 
desired amino derivative 4.5. 
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4.8 EXPERIMENTAL FOR PEPTIDIC INHIBITORS 
N,N-Diisopropylethylamine was sequentially distilled from ninhydrin then KOH and 
stored under argon.   Piperidine was distilled from CaH2 and stored under argon.  Phenol was 
purified by dissolving the solid in diethyl ether, washing with a saturated aqueous solution of 
NaHCO3 (3x), extracting with aqueous NaOH (0.1 M) (3x), acidifying with 0.1 N HCl, 
extracting with Et2O (3x), concentrating under reduced pressure, and the dry solid was stored 
under argon. N,N-dimethylformamide was purchased from Alfa Aesar as anhydrous and amine 
free in 4 L quantities and stored in 1 L amber bottles (dried overnight in an oven at 140 ºC) over 
activated 4 Å molecular sieves and under argon.  Trifluoroacetic acid (biochemical grade, 
99.5+% pure) was purchased from Alfa Aesar and used as received.  Methanol (HPLC grade), 
water (HPLC grade), and thioanisole (99% purity) were purchased from Aldrich and used as 
received.  Triisopropylsilane (99% pure) was purchased from Acros and used as received.  1,2-
ethanedithiol (>98% pure) was purchased from Fluka and used as received.  All natural Fmoc-
protected amino acids and 3-(diethoxy-phosphoryloxy)-3H-benzo[d][1,2,3] triazin-4-one were 
purchased from either Peptides International or Advanced Automated Peptide Protein 
Technologies (AAPPTEC) and used as received.  Unnatural Fmoc protected amino acids and 
Rink Amide Resin SS, 100-200 mesh, 1% DVB (catalogue #: SA5030) were purchased from 
Advanced Chemtech and used as received.  BD Falcon BlueMax 50 mL Graduated tubes and 25 
mm syringe filters with a 0.45 µm nylon frit were purchased from Fischer Scientific.   
The Fmoc-solid phase peptide syntheses were performed on a CEM Discover manual 
microwave peptide synthesizer fitted with a fiber-optic temperature probe.  Solid phase peptide 
syntheses were performed in a 25 mL polypropylene reaction vessel.  The 25 mL polypropylene 
reaction vessel was constructed by inserting a Teflon ring (0.4 mm height, 2.1 mm outer 
diameter, 1.8 mm inner diameter) into a capped 25 mL SPE reservoir purchased from Grace 
Davison Discovery Science (Catalogue #: 210425) containing a frit purchased from Grace 
Davison Discovery Science (Catalogue #: 211416) (Figure 56).  
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Figure 56. Diagram of assembled 25 mL polypropylene reaction vessel 
 
Preparative reverse phase HPLC purifications were performed on a Gilson HPLC system 
with 220 and 254 nm UV detection, using a Phenomenex Luna 5µ C18(2) 100 Å, AX (75 x 30.0 
mm) column at a flow rate of 10 mL/min.  Unless otherwise noted, all preparative runs used 
linear gradients of 30-60% buffer B in A (A: water containing 0.1% TFA, B: CH3CN containing 
0.1% TFA) over 30 min.  Analytical HPLC traces of final products were performed on a Gilson 
HPLC system with 220 and 254 nm UV detection, using a Varian Microsorb 100-3 C18 (100 x 
4.6 mm) column at a flow rate of 0.7 mL/min.  Unless otherwise noted, all analytical runs used 
linear gradients of 30-100% buffer B in A (A: water containing 0.1% TFA, B: MeOH) over 70 
min.  CD Spectra were recorded on a Jasco J-815 Circular Dichroism Spectrometer.  Unless 
otherwise noted, all CD spectra were recorded in MeOH at a concentration of 0.5 mmol, at 298 
K, over a range of 300-200 nm, at a scan rate of 50 nm/min.  Mass spectra were obtained using 
an ABI 4800 MALDI TOF/TOF instrument with 2,5-dihydroxybenzoic acid as the matrix in the 
positive ion mode.  Lyophilization was accomplished using a Labconco FreeZone 4.5 liter 
benchtop freeze dry system.   
Proton and carbon NMR spectra were recorded using a Bruker Avance spectrometer at 
600 MHz/150 MHz (
1
H NMR/
13
C NMR) in D2O (298 K), unless otherwise noted.  Chemical 
shifts (δ) are reported in parts per million (ppm) using MeOH solvent peaks as an internal 
reference (referenced to 3.34 ppm (
1
H) and 49.5 ppm (
13
C)).  
1
H NMR data are reported as 
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follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, qd = quartet 
of doublets), coupling constants (J) in Hertz (Hz), and integration.  
13
C NMR spectra were 
obtained using a proton-decoupled pulse sequence with d1 of 6 sec, and are tabulated by 
observed peak. 
A stock solution of the coupling base was prepared by dissolving DIPEA (1.74 mL, 1.00 
mmol) in DMF (5.00 mL) to give a 0.148 M solution.  A stock solution of the Fmoc-cleavage 
base was prepared by dissolving piperidine (1.00 mL, 10.1 mmol) in DMF (4.00 mL) to give a 
2.02 M solution.  A stock solution of the resin cleavage cocktail was prepared by combining 
TFA (5.07 g, 44.5 mmol), PhSCH3 (0.210 g, 1.69 mmol), PhOH (0.215 g, 2.28 mmol), TIPSH 
(0.0620 g, 0.392 mmol), 1,2-EDT (0.135 g, 1.43 mmol) and H2O (0.100 g, 5.56 mmol).  All 
stock solutions were freshly prepared prior to use.   
4.8.1 General Procedure A: Solid Phase Peptide Synthesis.   
To a polypropylene reaction vessel (25 mL) charged with a Teflon stir bar (10 x 3 mm) 
was added the Rink Amide resin (0.143 g, 0.100 mmol, loading 0.700 mmol/g, 1.00 equiv). The 
resin was washed with MeOH (2 x 5 mL), CH2Cl2 (3 x 10 mL) and DMF (3 x 10 mL), suspended 
in CH2Cl2 (5 mL) and allowed to swell at room temperature for 20 min.  The resin was filtered 
and washed with DMF (3 x 10 mL). The reaction vessel was fitted with the fiber optic 
temperature probe and the Fmoc group was cleaved by heating the resin in the Fmoc-cleavage 
base stock solution (1 mL) in the microwave (35 W, 78 ºC, 3 min).  The resin was filtered and 
washed with DMF (3 x 10 mL), CH2Cl2 (3 x 10 mL) and DMF (3 x 10 mL).  The first Fmoc 
protected amino acid was coupled to the resin by heating in a pre-mixed solution of amino acid 
(0.350 mmol, 3.50 equiv), DEPBT (0.105 g, 0.350 mmol, 3.50 equiv), DMF (0.800 mL), and 
Fmoc-coupling base stock solution (0.750 mL) in the microwave (25 W, 80 ºC, 5 min).  The 
resin was filtered and washed with DMF (3 x 10 mL), CH2Cl2 (3 x 10 mL) and DMF (3 x 10 
mL).  The Fmoc group was cleaved by heating the resin in Fmoc-cleavage base stock solution (1 
mL) in the microwave (35 W, 78 ºC, 3 min).  The resin was filtered and washed with DMF (3 x 
10 mL), CH2Cl2 (3 x 10 mL) and DMF (3 x 10 mL).  The second Fmoc protected amino acid was 
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coupled to the resin by heating in a pre-mixed solution of amino acid (0.350 mmol, 3.50 equiv), 
DEPBT (0.105 g, 0.350 mmol, 3.50 equiv), DMF (0.800 mL), and Fmoc-coupling base stock 
solution (0.750 mL) in the microwave (25 W, 80 ºC, 5 min).  This process of Fmoc cleavage and 
amino acid coupling was repeated for each additional amino acid.  After the final Fmoc cleavage, 
the resin was washed with DMF (30 mL) and CH2Cl2 (20 mL).  The protecting groups were 
cleaved by treatment of the dry resin with the resin cleavage cocktail stock solution (2.50 mL) 
for 2 h at room temperature with vigorous stirring.  The resin was filtered and rinsed with the 
remaining resin cleavage cocktail stock solution (1.50 mL) and TFA (1.50 mL), collecting the 
filtrate and rinses in a BD Falcon tube (50 mL).  The sample was concentrated to a 
heterogeneous mixture (approximately 0.2 mL) under a stream of argon for 30 min.  Cold diethyl 
ether (45 mL) was added to precipitate the crude peptide.  The sample was centrifuged (3200 
rpm, -8 ºC, 15 min) and the supernatant was discarded.  The crude peptide was transferred to a 
scintillation vial (20 mL) with approximately 5 mL of a mixture of H2O/CH3CN (9:1) and 
lyophilized overnight.  The crude peptide was dissolved in H2O containing 0.1% TFA (5.00 mL) 
and filtered through a 0.45 µm nylon syringe filter.  The filtrate was purified by preparative RP 
HPLC.  
 
 
RR(1-Nal)(AIB)AML (JTH-NB72-35).  Prepared according to general procedure A utilizing 
the following amino acid sequence: Fmoc-L-Leu-OH (0.124 g, 0.350 mmol, 3.50 equiv), Fmoc-
L-Met-OH (0.130 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ala-OH (0.115 g, 0.350 mmol, 3.50 
equiv), Fmoc-AIB-OH (0.114 g, 0.350 mmol, 3.50 equiv), Fmoc-L-1-Nal-OH (0.153 g, 0.350 
mmol, 3.50 equiv), Fmoc-L-Arg(Pbf)-OH (0.227 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Arg(Pbf)-
OH (0.227 g, 0.350 mmol, 3.50 equiv).  JTH-NB72-35 (0.0399 g, 40%) was obtained as a white 
powder: The product was characterized by 
1
H NMR (Table 31); 
13
C NMR (Table 31); DEPT-
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135; COSY; HMBC; HMQC; HPLC RT 5.7 min, HRMS (MALDI
+
) m/z calcd for C43H71N14O7S 
[M+H]
+
 927.5351, Found 927.5355. 
 
Table 31. 
1H and 13C NMR Data for JTH-NB72-35 (600 MHz/150 MHz) in D2O (298 K) with MeOH as an internal 
reference (referenced to 3.34 ppm (1H) and 49.5 ppm (13C)). 
Residue 
# 
 
Resonance 1H δ [ppm] 
13C 
δ [ppm] Amino Acid (N->C) 
1 Arginine CO  169.7 
  CαH 3.97 (t, J = 6.4 Hz, 1 H) 53.1 
  CβH 1.86-1.76 (m, 2 H) 28.7 
  CγH 1.51-1.42 (m, 2 H) 23.8 
  CδH 
3.03 (dt, J = 6.3, 12.7 Hz, 1 H), 
41.0 3.00 (dt, J = 6.3, 12.7 Hz, 1 H) 
  Cζ  157.1 
2 Arginine CO  173.3 
  CαH 4.35 (t, J = 7.2 Hz, 1 H) 53.8 
  CβH 1.72-1.62 (m, 2 H) 28.9 
  CγH 1.62-1.53 (m, 2 H) 25.2 
  CδH 
3.14 (dt, J = 6.7, 13.8 Hz, 1 H), 
41.2 3.1 (dt, J = 6.7, 13.8 Hz, 1 H) 
  Cζ  157.3 
3 
3-(1-Naphthyl)-
alanine CO  172.7 
  CαH 4.73 (t, J = 7.8 Hz, 1 H) 55.2 
  CβH 
3.59 (dd, J = 7.1, 14.1 Hz, 1 H), 
34.5 3.50 (dd, J = 8.6, 14.1 Hz, 1 H) 
  Cγ  132.7 
  Cδ1H 7.42 (d, J = 6.9 Hz, 1 H) 128.6 
  Cδ2  132.1 
  Cε1H 7.48 (t, J = 7.6 Hz, 1 H) 126.4 
  Cε2H 8.15 (d, J = 8.5 Hz, 1 H) 124.0 
  Cζ1H 7.86 (d, J = 8.2 Hz, 1 H) 128.5 
  Cζ2H 7.63 (t, J = 7.6 Hz, 1 H) 127.3 
  Cη1  134.2 
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  Cη2H 7.57 (t, J = 7.5 Hz, 1 H) 126.8 
  CθH 7.95 (d, J = 8.1 Hz, 1 H) 129.5 
4 
α-Aminoisobutyric 
acid CO  177.7 
  Cα  57.2 
  CβH 1.31 (s, 3 H), 1.28 (s, 3 H) 
24.6, 
25.0 
5 Alanine CO  176.2 
  CαH 4.22 (q, J = 7.3 Hz, 1 H) 51.1 
  CβH 1.38 (d, J = 7.3 Hz, 3 H) 16.8 
6 Methionine CO  174.3 
  CαH 4.35 (dd, J = 4.8, 9.6 Hz, 1 H) 52.8 
  CβH 2.12-1.95 (m, 2 H) 30.0 
  CγH 2.57-2.45 (m, 2 H) 30.6 
  CδH 2.02 (s, 3 H) 14.8 
7 Leucine CO  178 
  CαH 4.28 (dd, J = 3.9, 10.3 Hz, 1 H) 53.7 
  CβH 1.72-1.62 (m, 2 H) 40.2 
  CγH 1.63-1.58 (m, 1 H) 24.6 
  CδH 
0.89 (d, J = 5.8 Hz, 3 H), 22.9 
21.0 0.83 (d, J = 5.7 Hz, 3 H) 
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Figure 57. CD spectrum of JTH-NB72-35 (0.5 mmol) in MeOH. 
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Figure 58. Analytical HPLC trace of JTH-NB72-35 using a linear gradient of 30-100% buffer B in A (A: water 
containing 0.1% TFA, B: MeOH) over 70 min with UV detection at 220 nm. 
 
 
RRW(AIB)AML (JTH-NB72-38).  Prepared according to general procedure A utilizing the 
following amino acid sequence: Fmoc-L-Leu-OH (0.124 g, 0.350 mmol, 3.50 equiv), Fmoc-L-
Met-OH (0.130 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ala-OH (0.115 g, 0.350 mmol, 3.50 equiv), 
Fmoc-AIB-OH (0.114 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Trp(Boc)-OH (0.185 g, 0.350 mmol, 
3.50 equiv), Fmoc-L-Arg(Pbf)-OH (0.227 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Arg(Pbf)-OH 
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(0.227 g, 0.350 mmol, 3.50 equiv).  JTH-NB72-38 (0.0415 g, 41%) was obtained as a white 
powder: The product was characterized by 
1
H NMR (Table 32); 
13
C NMR (Table 32); DEPT-
135; COSY; HMBC; HMQC; HPLC RT 5.7 min, HRMS (MALDI
+
) m/z calcd for C41H70N15O7S 
[M+H]
+
 916.5303, Found 916.5461. 
 
Table 32. 
1H and 13C NMR Data for JTH-NB72-38 (600 MHz/150 MHz) in D2O (298 K) with MeOH as an internal 
reference (referenced to 3.34 ppm (1H) and 49.5 ppm (13C)). 
Residue 
# 
 
Resonance 1H δ ppm 
13C 
δ ppm 
Amino Acid  
(N->C) 
1 Arginine CO  169.8 
  CαH 3.99 (t, J = 6.5 Hz, 1 H) 53.1 
  CβH 1.88-1.77 (m, 2 H) 28.7 
  CγH 1.52-1.42 (m, 2 H) 23.9 
  CδH 
3.05 (dt, J = 7.1, 13.5 Hz, 1 H), 
41.0 3.00 (dt, J = 7.1, 13.6 Hz, 1 H) 
  Cζ  157.2 
2 Arginine CO  173.3 
  CαH 4.40 (t, J = 7.3 Hz, 1 H) 53.8 
  CβH 1.75-1.64 (m, 2 H) 28.9 
  CγH 1.52-1.42 (m, 2 H) 25.1 
  CδH 
3.15 (dt, J = 6.8, 13.5 Hz, 1 H), 
41.2 3.11 (dt, J = 6.9, 13.5 Hz, 1 H) 
  Cζ  157.3 
3 Tryptophan CO  173.2 
  CαH 4.64 (t, J = 7.5 Hz, 1 H) 55.2 
  CβH 
3.29 (dd, J =7.0, 14.6 Hz, 1 H), 
27.5 3.22 (dd, J = 8.0, 14.7 Hz, 1 H) 
  Cγ  109.4 
  Cδ1H 7.26 (s, 1 H) 125 
  Cδ2  127.4 
  Cε  136.8 
  Cε2H 7.66 (d, J = 7.9 Hz, 1 H) 119.1 
  Cζ1H 7.48 (d, J = 8.2 Hz, 1 H) 112.5 
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  Cζ2H 7.15 (t, J = 7.4 Hz, 1 H) 120.0 
  CηH 7.23 (t, J = 7.6 Hz, 1 H) 122.7 
4 
α-Aminoisobutyric 
acid CO  178.0 
  Cα  57.2 
  CβH 1.31 (s, 6 H) 
24.7, 
24.5 
5 Alanine CO  176.2 
  CαH 4.19 (q, J = 7.3 Hz, 1 H) 51.1 
  CβH 1.33 (d, J = 7.3 Hz, 3 H) 16.7 
6 Methionine CO  174.3 
  CαH 4.34 (dd, J = 9.3, 5.0 Hz, 1 H) 53.9 
  CβH 2.10-2.0 (m, 2 H) 30.7 
  CγH 2.60-2.55 (m, 1 H), 2.53-2.49 (m, 1 H) 30.0 
  CδH 2.05 (s, 3 H) 14.7 
7 Leucine CO  177.8 
  CαH 4.28 (dd, J = 10.5, 3.9 Hz, 1 H) 52.9 
  CβH 1.75-1.53 (m, 2 H) 40.2 
  CγH 1.75-1.53 (m, 1 H) 25.1 
  CδH 
0.90 (d, J = 5.9 Hz, 3 H), 22.9 
 21.0 0.84 (d, J = 5.9 Hz, 3 H) 
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Figure 59. CD spectrum of JTH-NB72-38 (0.5 mmol) in MeOH 
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Figure 60. Analytical HPLC trace of JTH-NB72-38 using a linear gradient of 30-100% buffer B in A (A: water 
containing 0.1% TFA, B: MeOH) over 70 min with UV detection at 220 nm at a flow rate of 0.7 mL/min. 
 
 
RRF(AIB)AML (JTH-NB72-39).  Prepared according to general procedure A utilizing the 
following amino acid sequence: Fmoc-L-Leu-OH (0.124 g, 0.350 mmol, 3.50 equiv), Fmoc-L-
Met-OH (0.130 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ala-OH (0.115 g, 0.350 mmol, 3.50 equiv), 
Fmoc-AIB-OH (0.114 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Phe-OH (0.136 g, 0.350 mmol, 3.50 
equiv), Fmoc-L-Arg(Pbf)-OH (0.227 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Arg(Pbf)-OH (0.227 
g, 0.350 mmol, 3.50 equiv).  JTH-NB72-39 (0.0318 g, 34%) was obtained as a white powder: 
The product was characterized by 
1
H NMR (Table 33); 
13
C NMR (Table 33); DEPT-135; COSY; 
HMBC; HMQC; HPLC RT 5.6 min, HRMS (MALDI
+
) m/z calcd for C39H68N14NaO7S [M+Na]
+
 
899.5014, Found 899.5021. 
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Table 33. 
1H and 13C NMR Data for JTH-NB72-39 (600 MHz/150 MHz) in D2O (298 K) with MeOH as an internal 
reference (referenced to 3.34 ppm (1H) and 49.5 ppm (13C)). 
Residue 
# 
 
Resonance 1H δ [ppm] 
13C 
δ [ppm] 
Amino Acid  
(N->C) 
1 Arginine CO  169.1 
  CαH 4.00 (t, J = 6.5 Hz, 1 H) 53.1 
  CβH 1.90-1.83 (m, 2 H) 29.0 
  CγH 1.60-1.47 (m, 2 H) 24.1 
  CδH 3.16 (t, J = 6.8 Hz, 2 H) 41.1 
  Cζ  157.3 
2 Arginine CO  173.3 
  CαH 4.29 (dd, J = 7.5, 10.7 Hz, 1 H) 53.9 
  CβH 1.77-1.65 (m, 2 H) 28.7 
  CγH 1.60-1.47 (m, 2 H) 25.1 
  CδH 3.16 (t, J = 6.8 Hz, 2 H) 41.2 
  Cζ  157.3 
3 Phenylalanine CO  172.8 
  CαH 4.55 (t, J = 7.6 Hz, 1 H) 55.7 
  CβH 
3.11 (dd, J = 7.0, 13.9 Hz, 1 H), 
37.5 3.05 (dd, J = 8.3, 13.8 Hz, 1 H) 
  Cγ  136.7 
  CδH 7.36 (t, J = 7.4 Hz, 2 H) 129.4 
  CεH 7.28 (d, J = 7.5 Hz, 2 H) 130.0 
  CζH 7.31 (t, J = 7.4 Hz, 1 H) 127.8 
4 
α-Aminoisobutyric 
acid CO  178 
  Cα  57.3 
  CβH 1.35 (s, 3 H), 1.34 (s, 3 H) 25.0, 24.3 
5 Alanine CO  176.1 
  CαH 4.22 (q, J = 7.2 Hz, 1 H) 51.0 
  CβH 1.37 (d, J = 7.3 Hz, 3 H) 16.8 
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6 Methionine CO  174.2 
  CαH 4.39 (dd, J = 7.5, 9.3 Hz, 1 H) 52.9 
  CβH 2.18-1.99 (m, 2 H) 30.1 
  CγH 2.65-2.51 (m, 2 H) 30.7 
  CδH 2.10 (s, 3 H) 14.9 
7 Leucine CO  177.7 
  CαH 4.36 (t, J = 7.4 Hz, 1 H) 53.7 
  CβH 1.75-1.59 (m, 2 H) 40.3 
  CγH 1.75-1.59 (m, 1 H) 25.0 
  CδH 
0.92 (d, J = 5.8 Hz, 3 H), 
22.9, 21.0 0.86 (d, J = 5.6 Hz, 3 H) 
 
 
 
Figure 61. CD spectrum of JTH-NB72-39 (0.5 mmol) in MeOH. 
 
  233 
 
Figure 62. Analytical HPLC trace of JTH-NB72-39 using a linear gradient of 30-100% buffer B in A (A: water 
containing 0.1% TFA, B: MeOH) over 70 min with UV detection at 220 nm at a flow rate of 0.7 mL/min. 
 
4.9 EXPERIMENTAL FOR SMALL-MOLECULE INHIBITORS 
General. All moisture sensitive reactions were performed using syringe-septum techniques 
under an atmosphere of either dry nitrogen or dry argon unless otherwise noted. All glassware 
was dried in an oven at 140 ºC for a minimum of 6 h or flame-dried under an atmosphere of dry 
nitrogen prior to use. Reactions carried out at -78 ºC employed a CO2(s)/acetone bath. Et2O and 
tetrahydrofuran were dried by distillation over sodium/benzophenone under an argon 
atmosphere. Dry methylene chloride was purified by filtration through an activated alumina 
column. All degassed solvents were prepared using the freeze/pump/thaw method (3x). 
Methanol, acetonitrile, and N,N-dimethylformamide were stored over molecular sieves (3Å).  
Deuterated chloroform was stored over anhydrous potassium carbonate. Reactions were 
monitored by TLC analysis (pre-coated silica gel 60 F254 plates, 250 µm layer thickness) and 
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visualized by using UV lamp (254 nm) or by staining with either Vaughn’s reagent (4.8 g of 
(NH4)6Mo7O24•4 H2O and 0.2 g of Ce(SO4)2 in 100 mL of a 3.5 N H2SO4) or a potassium 
permanganate solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL of a 0.1% NaOH 
solution). Flash column chromatography was performed with 40-63 µm silica gel (Silicycle). 
Microwave reactions were performed on a Biotage Initiator microwave reactor. Infrared spectra 
were measured on a Smiths Detection IdentifyIR FT-IR spectrometer (ATR). Unless otherwise 
indicated, all NMR data was collected at room temperature in CDCl3, (CD3)2SO, or (CD3)2CO on 
a 300, 400, 500, 600, or 700 MHz Bruker instrument. Chemical shifts (δ) are reported in parts 
per million (ppm) with internal CHCl3 ( 7.26 ppm for 
1
H and 77.00 ppm for 
13
C), internal 
acetone ( 2.05 ppm for 1H and 29.85 ppm for 13C), or internal DMSO ( 2.50 ppm for 1H and 
39.52 for 
13
C) as the reference. 
1
H NMR data are reported as follows: chemical shift, multiplicity 
(s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of 
doublets, dt = doublet of triplets, td = triplet of doublets, qd = quartet of doublets, sep = septet), 
integration, and coupling constant(s) (J) in Hertz (Hz).  HRMS analyses were obtained using 
either a Q-TOF Ultima API, Micromass UK Limited (ESI) or a VG Autospec, FISIONS 
instrument (EI). 
 
 
tert-Butyl-6-cyano-2-(9-cyano-5-oxo-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocin-3-yl)-1H-
indole-1-carboxylate (4.15).  To a stirred solution of 4.13 (0.250 g, 0.724 mmol, 1 equiv) and 
4.14 (0.352 g, 0.869 mmol, 1.2 equiv) in sparged (30 min) DMA (3 mL) at rt was added 
Pd(Ph3P)2Cl2 (0.0254 g, 0.0362 mmol, 0.05 equiv) and (IPr)CuCl (0.0265 g, 0.0543 mmol, 0.075 
equiv).  The reaction was heated to 80 °C and monitored by TLC.  Upon completion of the 
reaction (22 h), the reaction was diluted with ethyl acetate (100 mL), washed with water (x2), 
brine, dried (Na2SO4), filtered, and concentrated under reduced pressure.  The crude residue was 
purified by chromatography on SiO2 (acetone/CH2Cl2, 5:95) to give 4.15 (0.195 g, 43%) as a 
pale yellow solid: Mp 215 
o
C (decomp.); IR (ATR): 3176, 3057, 2982, 2937, 2222, 1737, 1655, 
1474, 1424, 1316, 1297, 1226 cm
-1
; 
1H NMR (400 MHz, DMSO) δ 8.50-8.45 (m, 1 H), 8.48-
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8.42 (m, 1 H), 7.90-7.65 (m, 8 H), 7.07-7.02 (m, 1 H), 4.22 (bs, 2 H), 1.33 (s, 9 H); 
13
C NMR 
(125 MHz, DMSO) δ 170.8, 148.6, 142.1, 141.6, 139.9, 137.1, 136.4, 136.0, 135.8, 134.1, 132.1, 
131.7, 131.7, 130.7, 127.3, 126.2, 124.2, 122.3, 119.7, 119.0, 118.2, 110.9, 109.5, 106.4, 85.3, 
45.0, 26.9. Note: characterization taken from Igor Opsenica’s final postdoctoral report. 
 
 
9-(6-Cyano-1H-indol-2-yl)-7-oxo-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine-3-carbonitrile 
(4.16).  To a solution of 4.15 (0.180 g, 0.355 mmol, 1 equiv) in degassed CH2Cl2 (3.5 mL) at rt 
was added TFA (0.792 mL, 10.7 mmol, 30 equiv).  The reaction was stirred at rt for 14 h, poured 
onto a saturated aqueous solution of NaHCO3, and extracted with EtOAc (600 mL). The organic 
layer was washed with brine, dried (Na2SO4), filtered, and concentrated under reduced pressure 
to give 4.16 (0.144 g, 100%) as a white solid.  The crude reaction mixture was directly used in 
next reaction: Mp >250 
o
C; IR (ATR): 3334, 2231, 2209, 1650, 1618, 1594, 1472, 1452, 1418, 
1385, 1355, 1340, 1320, 1282 cm
-1
;
 1
H NMR (400 MHz, DMSO) δ 12.39 (s, 1 H), 8.50-8.45 (m, 
1 H), 8.16-8.10 (m, 2 H), 7.90-7.88 (m, 1 H), 7.84 (d, J = 8.0 Hz, 1 H), 7.79-7.72 (m, 3 H), 7.69 
(d, J = 8.0 Hz, 1 H), 7.38 (dd, 1 H, J = 8.4, 1.2 Hz), 7.33-7.30 (m, 1 H), 4.25-4.20 (m, 2 H); 
13
C 
NMR (100 MHz, DMSO) δ 171.0, 143.2, 140.1, 139.7, 137.2, 136.9, 136.2, 134.2, 134.2, 131.7, 
131.5, 130.5, 128.3, 123.9, 123.8, 122.4, 121.6, 120.5, 118.2, 116.2, 109.5, 103.5, 101.5, 45.1. 
Note: characterization taken from Igor Opsenica’s final postdoctoral report. 
 
 
9-(4,5-Dihydro-1H-imidazol-2-yl)-3-(6-(4,5-dihydro-1H-imidazol-2-yl)-1H-indol-2-yl)-6,7-
dihydro-5H-dibenzo[b,g][1,5]thiazocin-5-one (4.3).  To a stirred solution of 4.16 (0.0800 g, 
0.197 mmol, 1 equiv) in ethylenediamine (2 mL) was added sulfur (0.126 g, 0.394 mmol, 2 
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equiv) in one portion. The reaction was irradiated in the microwave (110 ºC, 80 min), poured 
onto water, filtered, and the resulting solid was washed with water and toluene to give 4.3 (0.050 
g, 52% yield) as a brown solid: Mp >250 
o
C; IR (ATR): 3258, 2932, 2863, 1636, 1599, 1554, 
1443, 1334, 1273 cm
-1
; 
1H NMR (400 MHz, DMSO) δ 12.00 (s, 1 H), 8.50-8.44 (m, 1 H), 8.10-
8.05 (m, 2 H), 7.92-7.88 (m, 1 H), 7.81-7.77 (m, 1 H), 7.73-7.70 (m, 1 H), 7.67-7.64 (m, 1 H), 
7.60-7.55 (m, 2 H), 7.54 (d, J = 8.0 Hz, 1 H), 7.17 (s, 1 H), 4.20 (bs, 2 H), 3.65 (s, 4 H), 3.60 (s, 
4 H), 3.36 (bs, 2 H); 
13
C NMR (125 MHz, DMSO) δ 171.2, 164.6, 162.6, 143.5, 137.6, 136.9, 
136.7, 135.7, 135.5, 134.5, 129.9, 129.6, 129.5, 129.4, 127.6, 126.7, 124.4, 123.8, 123.2, 119.9, 
119.2, 110.6, 100.9, 49.3, 45.9; HRMS (ESI) m/z calcd for C28H25N6OS [M+H]
+
 493.1811, 
found 493.1828. LC-MS Purity: >95%. Note: characterization taken from Igor Opsenica’s final 
postdoctoral report. 
 
 
9-(4,5-Dihydro-1H-imidazol-2-yl)-3-(6-(4,5-dihydro-1H-imidazol-2-yl)-1H-indol-2-yl)-6,7-
dihydro-5H-dibenzo[b,g][1,5]thiazocine-5-thione (4.4).  To a stirred solution of 4.3 (0.0220 g, 
0.0447 mmol, 1 equiv) in distilled pyridine (4 mL) was added P4S10 (0.198 g, 0.447 mmol, 10 
equiv).  The reaction was stirred at 120 ºC for 1 h, Dimethyl sulfone (12 g) was added and 
stirring was continued overnight at 120 ºC. The reaction mixture was cooled to rt, aqueous 
NaHCO3 was added, and the yellow solution was stirred 3 h at rt.  The resulting precipitate was 
filtered, washed with water (30 mL), toluene (20 mL), CH2Cl2 (20 mL), and THF (20 mL) to 
give 4.4 (0.022 g, 97%) as a yellow solid: Mp = >260 ºC; IR (neat) 3105, 2974, 1597, 1545, 
1366, 1137, 1012, 701; 
1H NMR (700 MHz, DMSO) δ 12.22 (s, 1 H), 10.85 (s, 1 H), 8.07 (s, 2 
H), 7.98 (s, 1 H), 7.75-7.66 (m, 4 H), 7.55 (bs, 2 H), 7.19 (s, 1 H), 4.34 (bs, 2 H), 3.80 (s, 4 H), 
3.60 (s, 4 H); 
13C NMR (176 MHz, DMSO) δ 200.3, 165.2, 162.5, 148.6, 139.0, 136.8, 136.7, 
136.2, 134.1, 133.3, 131.3, 130.0, 129.6, 129.0, 127.8, 127.0, 124.1, 121.9, 120.4, 119.2, 111.7, 
101.1, 67.0, 50.3; HRMS (ESI
+
) m/z calcd for C28H25N6S2 [M+H]
+
 509.1577, found 509.1563.  
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Methyl 5-cyano-2-fluorobenzoate (4.17).  To a stirred solution of 5-cyano-2-fluorobenzoic acid 
(15.0 g, 89.0 mmol, 1 equiv) in MeOH (125 mL) was added 96% H2SO4 (4.96 mL, 89.0 mmol, 1 
equiv).  The reaction mixture was stirred at reflux overnight, the solvent was evaporated, and the 
crude residue was diluted with water (100 mL) and EtOAc (150 mL).  The aqueous layer was 
separated and extracted with EtOAc (2 x 50 mL). The combined organic phases were washed 
with a saturated aqueous solution of NaHCO3 (2 x 100 mL), dried (Na2SO4), filtered, and 
concentrated under reduced pressure to give 4.17 (15.0 g, 94%) as a white solid.  The crude 
product was carried onto the next reaction without further purification: Mp 76-77 
o
C; IR (ATR): 
3116, 3088, 3068, 3059, 3021, 2962, 2237, 1724, 1715, 1607, 1491, 1444, 1435, 1407, 1308, 
1288, 1252, 1236, 1198, 1187, 1174, 1141, 1092, 982, 937, 842 cm
-1
;
 1
H NMR (400 MHz, 
CDCl3) δ 8.30 (dd, 1 H, J = 6.4, 2.0 Hz), 7.83 (ddd, 1 H, J = 8.4, 4.0, 2.0 Hz), 7.29 (dd, 1 H, J = 
9.6, 8.8 Hz), 3.98 (s, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 164.0 (d, J = 268 Hz), 162.8 (d, J = 4 
Hz), 137.9 (d, J = 10 Hz), 136.8 (d, J = 2 Hz), 120.2 (d, J = 11 Hz), 118.7 (d, J = 24 Hz), 117.0, 
108.9 (d, J = 4 Hz), 52.9; HRMS (ESI) m/z calcd for C9H7FNO2 [M+H]
+
 180.0461, found 
180.0434. Note: characterization taken from Igor Opsenica’s final postdoctoral report. 
 
 
Methyl 5-cyano-2-mercaptobenzoate (4.18).  To a stirred solution of thioacetic acid (6.82 mL, 
93.5 mmol, 2.5 equiv) in dry DMF (130 mL) at rt was added cesium carbonate (30.8 g, 93.5 
mmol, 2.5 equiv).  After 10 min, a solution of the 4.17 (6.7 g, 37.4 mmol, 1 equiv) in dry DMF 
(40 mL) was added dropwise (over the course of 45 min using a syringe pump) and the reaction 
mixture was stirred at rt for 14 h.  The reaction mixture was diluted with H2O (300 mL), 
carefully adjusted to a pH~1.0 with conc. HCl (~14 mL) and stirred at rt for 10 min.  The 
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aqueous layer was extracted with EtOAc (300 mL x 3) and the combined organic layers were 
dried (MgSO4), filtered, and concentrated under reduced pressure.  The crude mixture was 
purified by chromatography on SiO2 (EtOAc/hexanes, 2:8 to 3:7) to give 4.18 (3.06 g, 34%) as a 
brown solid: Mp 114-115 
o
C; IR (ATR): 3098, 3059, 2954, 2473, 2227, 1715, 1690, 1597, 1543, 
1469, 1431, 1316, 1247, 1213, 1195, 1111, 1059, 964, 898, 889, 848, 839, 781 cm
-1
; 
1
H NMR 
(500 MHz, CDCl3) δ 8.32 (d, 1 H, J = 2.0 Hz), 7.54 (dd, 1 H, J = 8.0, 2.0 Hz), 7.42 (d, 1 H, J = 
8.0 Hz), 5.19 (s, 1 H), 3.97 (s, 3 H); 
13
C NMR (125 MHz, CDCl3) δ 165.5, 145.7, 135.5, 134.3, 
131.5, 126.2, 117.7, 108.4, 52.8; HRMS (ESI) m/z calcd for C9H8NO2S [M+H]
+
 194.0276, found 
194.0268. Note: characterization taken from Igor Opsenica’s final postdoctoral report. 
 
 
Methyl 5-cyano-2-mercaptobenzoate (4.19).  To a stirred solution of thioacetic acid (6.82 mL, 
93.5 mmol, 2.5 equiv) in dry DMF (130 mL) at rt was added cesium carbonate (30.8 g, 93.5 
mmol, 2.5 equiv).  After stirring at rt for 10 min, a solution of the 4.18 (6.7 g, 37.4 mmol, 1 
equiv) in dry DMF (40 mL) was added dropwise (over 45 min using a syringe pump) and the 
reaction mixture was stirred at rt for 14 h. The reaction mixture was diluted with H2O (300 mL), 
the pH was carefully adjusted to a ~1.0 with conc. HCl (~14 mL) and stirred at rt for 10 min.  
The mixture was extracted with EtOAc (300 mL x 3) and the combined organic layers were dried 
(MgSO4), filtered, and concentrated under reduced pressure. The crude mixture was purified by 
chromatography on SiO2 (EtOAc/hexanes, 2:8 to 3:7) to give 4.19 (3.06 g, 34%) as a brown 
solid: Mp 114-115 
º
C; IR (ATR): 3098, 3059, 2954, 2473, 2227, 1715, 1690, 1597, 1543, 1469, 
1431, 1316, 1247, 1213, 1195, 1111, 1059, 964, 898, 889, 848, 839, 781 cm
-1
; 
1
H NMR (500 
MHz, CDCl3) δ 8.32 (d, 1 H, J = 2.0 Hz), 7.54 (dd, 1 H, J = 8.0, 2.0 Hz), 7.42 (d, 1 H, J = 8.0 
Hz), 5.19 (s, 1 H), 3.97 (s, 3 H); 
13
C NMR (125 MHz, CDCl3) δ 165.5, 145.7, 135.5, 134.3, 
131.5, 126.2, 117.7, 108.4, 52.8; HRMS (ESI) m/z calcd for C9H8NO2S [M+H]
+
 194.0276, found 
194.0268. Note: characterization taken from Igor Opsenica’s final postdoctoral report. 
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Methyl 2-((4-bromo-2-formylphenyl)thio)-5-cyanobenzoate (4.21).  To a stirred solution of 
4.19 (0.200 g, 1.04 mmol, 1 equiv) and 5-bromo-2-fluorobenzaldehyde (0.147 mL, 1.24 mmol, 
1.2 equiv) in degassed CH3CN (3 mL) was added TMG (0.156 mL, 1.24 mmol, 1.2 equiv).  The 
reaction mixture was stirred overnight (~16 h) at 70 ºC, cooled to rt, and diluted with EtOAc.  
The organic layer was washed with 1 M aqueous HCl, saturated aqueous NaHCO3, dried 
(MgSO4), filtered, and concentrated under reduced pressure.  The crude mixture was purified by 
chromatography on SiO2 (EtOAc/hexanes, 2:8) to give 4.21 (0.23 g, 80% pure; 47%) as a foam: 
IR (ATR): 3072, 3001, 2950, 2852, 2227, 1713, 1689, 1594, 1569, 1547, 1461, 1456, 1433, 
1377, 1308, 1284, 1243, 1195, 1182, 1107, 1083, 1042, 973, 893, 874, 826 cm
-1
; 
1
H NMR (400 
MHz, CDCl3) δ 10.35 (s, 1 H), 8.34 (d, 1 H, J = 1.6 Hz), 8.21 (d, 1 H, J = 2.4 Hz), 7.84 (dd, 1 H, 
J = 8.4, 2.0 Hz), 7.52 (d, 1 H, J = 8.0 Hz), 7.50 (dd, 1 H, J = 8.4, 2.0 Hz), 6.72 (d, 1 H, J = 8.8 
Hz), 4.02 (s, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 189.8, 164.8, 148.4, 139.1, 139.0, 138.3, 
135.1, 135.1, 132.8, 132.7, 127.6, 127.0, 126.0, 117.4, 108.9, 53.0; HRMS (ESI) m/z calcd for 
C16H10BrNO3S [M]
+
 374.9565, found 374.9602. Note: characterization taken from Igor 
Opsenica’s final postdoctoral report. 
 
 
Methyl 2-((4-bromo-2-(hydroxymethyl)phenyl)thio)-5-cyanobenzoate (4.22).  To a stirred 
solution of 4.19 (impure from last reaction; 1.00 g, 2.66 mmol, 1 equiv) in dry MeOH (30 mL) 
was added NaBH4 (0.201 mg, 5.32 mmol. 2 equiv).  The reaction mixture was stirred at rt for 2 
h, the solvent was removed and the residue was diluted with EtOAc.  The organic layer was 
washed with 1M aqueous HCl, brine, dried (NaSO4), filtered, and concentrated under reduced 
pressure.  The crude mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 8:2) to 
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give 4.22 (0.780 g, 78% yield) as a slightly off-white foam: IR (ATR): 3493, 3424, 3079, 2949, 
2921, 2848, 2229, 1715, 1594, 1575, 1551, 1461, 1435, 1310, 1282, 1245, 1197, 1107, 1085, 
1060, 1048, 1034, 975, 852 cm
-1
;
 1
H NMR (400 MHz, CDCl3) δ 8.32 (d, 1 H, J = 1.6 Hz), 7.90-
7.86 (m, 1 H), 7.55 (dd, 1 H, J = 8.4, 2.0 Hz), 7.45 (dd, 1 H, J = 8.4, 2.0 Hz), 7.41 (d, 1 H, J = 
8.4 Hz), 6.69 (d, 1 H, J = 8.8 Hz), 4.72 (d, 2 H, J = 5.6 Hz), 4.01 (s, 3 H), 2.10-2.00 (m, 1 H); 
13
C NMR (100 MHz, CDCl3) δ 165.0, 149.0, 147.3, 138.6, 135.1, 134.8, 132.3, 131.9, 126.6, 
126.6, 126.0, 117.7, 108.2, 62.4, 52.8; 
13
C NMR (125 MHz, CDCl3) δ 165.0, 149.0, 147.3, 138.6, 
135.1, 134.8, 132.3, 131.9, 126.8, 126.7, 126.0, 117.7, 108.2, 62.4, 52.8; HRMS (ESI) m/z calcd 
for C16H12BrNO3S [M]
+
 376.9721, found 376.9762. Note: characterization taken from Igor 
Opsenica’s final postdoctoral report. 
 
 
Methyl 2-((2-(azidomethyl)-4-bromophenyl)thio)-5-cyanobenzoate (4.23).  To a stirred 
solution of the 4.22 (0.760 g, 2.01 mmol, 1 equiv) in CH2Cl2 (30 mL) at 0 ºC was added 
triethylamine (0.570 mL, 4.02 mmol, 2 equiv) and methanesulfonyl chloride (0.234 mL, 3.01 
mmol, 1.5 equiv).  The reaction mixture was stirred at 0 ºC for 10 min, warmed to rt, and stirred 
for 1 h.  The reaction mixture was diluted with CH2Cl2, washed with brine, and the aqueous layer 
was extracted with CH2Cl2.  The combined organic layers were dried (NaSO4), filtered, and 
concentrated under reduced pressure to give a slight off-white solid.  The crude mesylate was 
dissolved in DMF (5 mL) and sodium azide (0.660 g, 9.91 mmol, 5 equiv) was added.  The 
reaction mixture was stirred at rt for 1.5 h, diluted with EtOAc, washed with brine, dried 
(Na2SO4) and concentrated under reduced pressure.  The crude mixture was purified by 
chromatography on SiO2 (EtOAc/hexanes, 15:85) to give 4.23 (0.746 g, 92%) as a yellow oil: IR 
(ATR): 2950, 3094, 3074, 2229, 2101, 1715, 1596, 1577, 1551, 1461, 1435, 1387, 1338, 1308, 
1284, 1245, 1195, 1107, 1088, 1053, 1044, 826, 783 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 8.34 
(d, 1 H, J = 2.0 Hz), 7.79-7.76 (m, 1 H), 7.61 (dd, 1 H, J = 8.0, 2.0 Hz), 7.50-7.45 (m, 2 H), 6.64 
(d, 1 H, J = 8.4 Hz), 4.51 (s, 2 H), 4.02 (s, 3 H);
 13
C NMR (100 MHz, CDCl3) δ 164.9, 148.8, 
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142.5, 139.1, 135.2, 134.9, 133.1, 133.1, 128.2, 126.7, 126.6, 126.0, 117.7, 108.4, 52.9, 52.2; 
HRMS (ESI) m/z calcd for C16H12BrN2O2S (M–N2+H) 374.9803, found 374.9835. Note: 
characterization taken from Igor Opsenica’s final postdoctoral report. 
 
 
Perfluorophenyl 2-((2-(azidomethyl)-4-bromophenyl)thio)-5-cyanobenzoate (4.24).  To a 
stirred solution of 4.23 (0.900 g, 2.23 mmol, 1 equiv) in MeOH/THF (1:1, 50 mL) was added 1M 
aqueous NaOH (23 mL).  The solution was stirred at rt for 4 h and concentrated under reduced 
pressure.  The remaining aqueous solution was acidified  (pH~2) with 1M aqueous HCl, 
extracted with EtOAc (100 mL), dried (Na2SO4), and concentrated under reduced pressure.  To a 
stirred solution of crude acid (0.800 g, 2.06 mmol, 1 equiv) in CH2Cl2 (125 mL) at 0 °C was 
added EDCI (0.591 g, 3.08 mmol, 1.5 equiv), Pfp-OH (0.378 g, 2.05 mmol, 1 equiv), and DMAP 
(0.00254 g, 0.206 mmol, 0.1 equiv).  The mixture was warmed to rt, stirred for 2 h, poured onto 
water and extracted with CH2Cl2. The organic layer was washed with brine, dried (Na2SO4), and 
concentrated under reduced pressure. The crude mixture was purified by chromatography on 
SiO2 (EtOAc/hexanes, 1:9) to give 4.24 (0.71 g, 62%): IR (ATR): 2231, 2106, 1754, 1519, 1459, 
1294, 1286, 1228, 1182, 1087, 1077, 1031, 1008, 995, 986 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 
8.59 (d, 1 H, J = 2.0 Hz), 7.82-7.78 (m, 1 H), 7.64 (dd, 1 H, J = 8.4, 2.0 Hz), 7.61 (dd, 1 H, J = 
8.8, 2.0 Hz), 7.50 (d, 1 H, J = 8.4 Hz), 6.75 (d, 1 H, J = 8.4 Hz), 4.52 (s, 2 H);
 19
F NMR (376 
MHz, CDCl3) δ -152.4 (d, J = 19 Hz), -156.9 (t, J = 23 Hz), -162.0 (t, J = 19 Hz); 
13
C NMR (125 
MHz, CDCl3) δ 160.2, 151.1, 142.6, 142.3 (m, C-F coupling), 141.0 (m, C-F coupling), 140.3 
(m, C-F coupling), 139.1, 139.0 (C-F coupling), 137.0 (m, C-F coupling), 136.2, 136.2, 133.4, 
133.4, 127.2, 127.1, 126.5, 124.6 (m, C-F coupling), 123.3, 117.2, 108.9, 52.3; HRMS (ESI) m/z 
calcd for C21H9BrF5N4O2S  [M+H]
+
 554.9550, found 554.9520. Note: characterization taken 
from Igor Opsenica’s final postdoctoral report. 
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9-Bromo-5-oxo-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine-3-carbonitrile (4.25).  To a 
stirred solution of 4.24 (0.700 g, 1.26 mmol, 1 equiv) in CH3CN/H2O (4:1, 80 mL) at rt was 
added PPh3 (0.401 g, 1.51 mmol, 1.2 equiv). The mixture was stirred at 50 ºC for 6 h, filtered, 
and the solid product separated.  The filtrate was diluted with EtOAc (100 mL), washed with 
brine, dried (Na2SO4), filtered, and concentrated under reduced pressure.  The crude mixture was 
purified by chromatography on SiO2 (acetone/CH2Cl2, 5:95) to give 0.125 g as a white solid 
which was combined with the filtered product (85 mg) to give 4.25 (0.21 g, 48% yield) as a 
white solid: Mp >250 
o
C; IR (ATR): 3290, 3277, 3202, 3081, 2930, 2229, 1653, 1594, 1452, 
1416, 1366, 1342, 1284, 1269, 1202, 1184, 1102, 1087, 1046, 958, 900 cm
-1
; 
1
H NMR (400 
MHz, DMSO) δ 8.55-8.48 (m, 1 H), 8.06-8.01 (m, 2 H), 7.92-7.88 (m, 1 H), 7.55-7.42 (m, 3 H), 
4.15-4.05 (m, 2 H); 
13C NMR (125 MHz, DMSO) δ 169.7, 143.9, 138.4, 137.1, 135.1, 133.4, 
132.3, 131.5, 131.2, 130.6, 130.4, 120.6, 117.6, 114.2, 44.9; HRMS (ESI) m/z calcd for 
C15H9BrN2OS [M]
+
 343.9619, found 343.9645. Note: characterization taken from Igor 
Opsenica’s final postdoctoral report. 
 
 
tert-Butyl 6-cyano-2-(9-cyano-7-oxo-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocin-3-yl)-1H-
indole-1-carboxylate (4.26).  To a stirred solution of 4.25 (0.120 g, 0.348 mmol, 1 equiv) and 
4.8 (0.169 g, 0.417 mmol, 1.2 equiv) in degassed DMA (1.5 mL) at rt was added Pd(Ph3P)2Cl2 
(0.0122 g, 0.0174 mmol, 0.05 equiv) and (IPr)CuCl (0.0127 g, 0.0261 mmol, 0.075 equiv). The 
reaction was heated to 80 °C and monitored by TLC.  Upon completion (22 h), the reaction was 
diluted with ethyl acetate (100 mL), washed with water (x2), brine, dried (Na2SO4), and 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
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(acetone/CH2Cl2, 3:97) to give 4.26 (0.070 g, 40%) as a off-white film: IR (ATR): 3215, 3088, 
2982, 2932, 2222, 1735, 1670, 1472, 1458, 1435, 1370, 1361, 1325, 1294, 1228, 1161, 1150, 
1133, 1053, 1042, 1029, 846, 833, 839 cm
-1
; 
1
H NMR (400 MHz, DMSO) δ 8.68-8.62 (m, 1 H), 
8.44 (s, 1 H), 8.08-8.01 (m, 2 H), 7.91 (d, 1 H, J = 8.0 Hz), 7.84 (d, 1 H, J = 8.0 Hz), 7.69 (dd, 1 
H, J = 8.0, 1.6 Hz), 7.61 (d, 1 H, J = 8.4 Hz), 7.46 (dd, 1 H, J = 8.0, 2.0 Hz), 7.40-7.38 (m, 1 H), 
6.88 (s, 1 H), 4.18 (bs, 2 H), 1.29 (s, 9 H); 
13
C NMR (125 MHz, DMSO) δ 169.9 148.7, 144.0, 
142.4, 136.9, 135.7, 135.7, 135.0, 132.5, 132.2, 132.2, 130.9, 130.8, 130.7, 130.3, 128.6, 126.2, 
122.1, 119.8, 118.9, 117.7, 114.1, 109.9, 106.1, 84.9, 45.4, 27.0. Note: characterization taken 
from Igor Opsenica’s final postdoctoral report. 
  
 
9-(6-Cyano-1H-indol-2-yl)-5-oxo-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine-3-carbonitrile 
(4.27).  To a stirred solution of 4.26 (0.0650 g, 0.128 mmol) in CH2Cl2 (4 mL, degassed) at rt 
was added TFA (0.286 mL, 1.53 mmol, 30 equiv). The reaction was stirred at rt for 14 h, 
carefully poured onto saturated aqueous NaHCO3, and extracted with EtOAc (50 mL).  The 
organic layer was washed with brine, dried (Na2SO4), filtered, and concentrated under reduced 
pressure to give 0.053 g (100%) of 4.27.  The crude compound was used in next reaction.  
 
 
3-(4,5-Dihydro-1H-imidazol-2-yl)-9-(6-(4,5-dihydro-1H-imidazol-2-yl)-1H-indol-2-yl)-6,7-
dihydro-5H-dibenzo[b,g][1,5]thiazocin-5-one (4.1). To a stirred solution of crude 4.21 (0.0600 
g, 0.148 mmol, 1 equiv) in ethylenediamine (4 mL) was added sulfur (0.00947 g, 0.295 mmol, 2 
equiv).  The reaction was irradiated in the microwave (110 ºC, 80 min), poured onto water, and 
filtered.  The solid was washed with water, toluene, THF, and CH2Cl2 to give 4.1 (0.041 g, 56% 
yield): Compound is partially soluble (suspension) in DMSO (<1 mg/0.6 mL). Better solubility 
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(partially suspension) in the presence of d3-AcOH. 
1
H NMR (400 MHz, DMSO) δ 11.84 (s, 1 H), 
8.52-8.47 (m, 1 H), 8.02-7.98 (m, 1 H), 7.97-7.95 (m, 1 H), 7.88 (s, 1 H), 7.86-7.82 (m, 1 H), 
7.81-7.77 (m, 1 H), 7.76-7.73 (m, 1 H), 7.60-7.54 (m, 3 H), 7.02-7.00 (m, 1 H), 4.20-4.17 (m, 2 
H), 3.90-3.60 (m, 8 H).
 1
H NMR (400 MHz, DMSO+ d3-AcOH) δ 8.16-8.13 (m, 1 H), 8.13-8.09 
(m, 1 H), 8.06-8.02 (m, 2 H), 7.94-7.90 (m, 1 H), 7.83 (s, 1 H), 7.80-7.75 (m, 1 H), 7.68-7.64 (m, 
1 H), 7.59-7.55 (m, 1 H), 7.13 (s, 1 H), 4.23 (bs, 2 H), 4.05-4.02 (m, 8 H).HRMS (ESI
+
) m/z 
calcd for C28H25ON6S [M+H]
+
 493.1805, found 493.1805. Note: characterization taken from 
Igor Opsenica’s final postdoctoral report. 
 
 
3-(4,5-Dihydro-1H-imidazol-2-yl)-9-(6-(4,5-dihydro-1H-imidazol-2-yl)-1H-indol-2-yl)-6,7-
dihydro-5H-dibenzo[b,g][1,5]thiazocin-5-one-bis(2,2,2-trifluoroacetate) (IMO-27).  A 
solution of TFA in THF (100 μL, 3.20 M) was added to a stirred suspension of 4.1 (40.0 mg, 
0.0812 mmol) in THF (0.5 mL) and the reaction mixture was vigorously stirred over night at rt. 
The reaction mixture was evaporated to dryness, and co-evaporated with PhMe to provide the 
bis-TFA salt of 4.1 (0.0560 g, 96%) as a yellow solid: Mp >250 
o
C; IR (ATR): 3184, 3114, 
2969, 2919, 2718, 1763, 1672, 1616, 1599, 1459, 1413, 1364, 1288, 1167, 1124, 1031, 814 cm
-1
;
 
1H NMR (500 MHz, DMSO) δ 12.38-12.34 (m, 1 H), 10.78 (s, 2 H), 10.40 (s, 2 H), 8.74-8.68 
(m, 1 H), 8.15-8.13 (m, 1 H), 8.13-8.10 (m, 1 H), 8.08-8.05 (m, 1 H), 8.04 (s, 1 H), 7.96-7.92 (m, 
1 H), 7.87-7.85 (m, 1 H), 7.80-7.77 (m, 1 H), 7.68-7.65 (m, 1 H), 7.59-7.55 (m, 1 H), 7.17-7.15 
(m, 1 H), 4.23 (bs, 2 H), 4.06 (s, 4 H), 4.04 (s, 4 H), 3.64-3.60 (m, 2 H, 0.5 eq THF), 1.79-1.76 
(m, 2 H, 0.5 eq THF); 
13C NMR (125 MHz, DMSO, without TFA peaks) δ 170.2, 165.8, 163.7, 
143.7, 141.4, 137.1, 136.6, 136.2, 133.0, 132.3, 131.8, 131.1, 131.0, 130.4, 128.9, 128.2, 128.1, 
127.0, 124.8, 120.7, 114.5, 112.4, 100.2, 67.0 (THF), 45.7, 44.6, 44.2, 25.1 (THF); HRMS (ESI) 
m/z calcd for C28H25N6OS [M+H]
+
 493.1811, found 493.1802. LC-MS Purity: >95%. According 
to 1H NMR there is 0.5 molecule of THF (complex).  
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Sample (5 mg) was dissolved in MeOH, and evaporated. NMR was taken in CD3OD.
 1
H 
NMR (400 MHz, CD3OD) δ 8.07-8.04 (m, 3 H), 8.01-7.99 (m, 1 H), 7.87-7.83 (m, 1 H), 7.80-
7.76 (m, 1 H), 7.74-7.71 (m, 1 H), 7.69-7.65 (m, 1 H), 7.53-7.48 (m, 1 H), 7.07 (s, 1 H), 4.36 (s, 
2 H), 4.18 (s, 4 H), 4.13 (s, 4 H); 
13
C NMR (125 MHz, CD3OD) δ 174.3, 169.7, 167.6, 145.9, 
144.1, 139.6, 138.9, 138.2, 136.2, 135.7, 135.0, 133.5, 133.4, 133.3, 130.1, 128.7, 127.6, 127.4, 
123.1, 120.8, 116.7, 114.1, 102.3, 48.4, 47.1, 46.6. Note: characterization taken from Igor 
Opsenica’s final postdoctoral report. 
 
 
3-(4,5-Dihydro-1H-imidazol-2-yl)-9-(6-(4,5-dihydro-1H-imidazol-2-yl)-1H-indol-2-yl)-6,7-
dihydro-5H-dibenzo[b,g][1,5]thiazocine-5-thione (4.2).  To a stirred solution of 4.1 (0.0280 g, 
0.0568 mmol, 1 equiv) in distilled pyridine (4 mL) was added P4S10 (0.253 g, 0.568 mmol, 10 
equiv).  The reaction was stirred at 110 ºC for 1 h, dimethyl sulfone (12 g) was added and the 
mixture was stirred overnight at 120 ºC.  The reaction mixture was cooled to rt, diluted with a 
saturated aqueous solution of NaHCO3 (60 mL), and the yellow solution was stirred at rt for 2 h. 
The reaction mixture was filtered (slowly), washed with water (5 mL), toluene (5 mL), and 
CH2Cl2 (5 mL). This provided a brown solid (0.023 g, 80%), which did not meet purity 
standards, thus the solid was washed with CH2Cl2 (15 mL), toluene (15 mL), and CH2Cl2 (15 
mL) to give 4.2 (0.0168 g, 58%) as slightly green solid: Mp >260 ºC; IR (neat) 3269, 2898, 
1597, 1539, 1361, 1172, 815 cm
-1
; 
1H NMR (600 MHz, DMSO) δ 11.80 (s, 1 H), 10.88 (dd, 1 H, 
J = 4.8, 8.4 Hz), 8.01 (d, 1 H, J = 1.8 Hz), 7.93 (dd, 1 H, J = 2.4, 8.4 Hz), 7.86-7.84 (m, 2 H), 
7.77 (s, 1 H), 7.74 (d, 1 H, J = 8.4 Hz), 7.59 (d, 1 H, 8.4 Hz), 7.53 (s, 2 H), 7.15 (bs, 1 H), 6.99 
(s, 1 H), 4.36 (dd, 1 H, J = 4.8, 16.2 Hz), 4.30 (dd, 1 H, J = 9.0, 15.6 Hz), 3.84 (bs, 2 H), 3.70-
3.50 (m, 4 H), 3.50-3.41 (m, 2 H); 
13C NMR (176 MHz, DMSO) δ 199.7, 165.6, 162.9, 148.2, 
141.1, 136.5, 136.3, 134.2, 133.0, 132.7, 130.6, 130.3, 130.1, 128.4, 126.8, 126.6, 125.7, 120.3, 
118.8, 114.3, 113.6, 99.7, 50.2, 44.3; HRMS (ESI
+
) m/z calcd for C28H25N6S2 [M+H]
+
 509.1577, 
found 509.1571.  Determined to be 99.1% pure by ELS.   
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4-((2-(Azidomethyl)-4-bromophenyl)thio)-3-(hydroxymethyl)benzonitrile (4.28). To a stirred 
solution of 4.22 (0.100 g, 0.248 mmol, 1 equiv) in THF (2 mL) was added LiBH4 (2 M in THF; 
0.0620 mL, 0.124 mmol, 0.5 equiv). After stirring at rt for 5 h, a second batch of LIBH4 (2 M in 
THF; 0.0620 mL, 0.124 mmol, 0.5 equiv) was added and the reaction was stirred at rt overnight.  
The reaction mixture was carefully quenched with sequential addition of EtOAc, acetone, and 1 
M aqueous HCl. The quenched mixture was diluted with EtOAc, washed with 1 M aqueous. 
HCl, dried (MgSO4), filtered, and concentrated under reduced pressure.  The crude mixture was 
purified by chromatography on SiO2 (EtOAc/hexanes, 3:7) to give 4.28 (0.060 g, 64%) as a 
colorless film: Rf = 0.16 (EtOAc/hexanes, 2:8); IR (CDCl3) 3464, 2918, 2227, 2101, 1593, 1459, 
1338, 1087, 1036 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.80 (s, 1 H), 7.69 (d, 1 H, J = 2.0 Hz), 
7.51 (dd, 1 H, J = 2.0, 8.4 Hz), 7.38 (dd, 1 H, J = 1.2, 8.0 Hz), 7.30 (d, 1 H, J = 8.4 Hz), 6.79 (d, 
1 H, J = 8.4 Hz), 4.82 (s, 2 H), 4.46 (s, 2 H); 
13
C NMR (100 MHz, CDCl3) δ 140.9, 140.8, 139.2, 
133.0, 132.9, 131.4, 130.7, 128.8, 127.8, 124.66, 118.5, 109.8, 61.8, 52.3; HRMS (ESI) [M-
N2+H] m/z calcd for C15H12N2OSBr  calcd 346.9854, found 346.9871. 
 
 
4-((2-(Azidomethyl)-4-bromophenyl)thio)-3-formylbenzonitrile (4.29).  To a stirred solution 
of 4.28 (0.110 g, 0.293 mmol, 1 equiv) in CH2Cl2 (3 mL) was added BaMnO4 (0.376 g, 1.47 
mmol, 5 equiv).  The reaction mixture was stirred overnight at rt, diluted with CH2Cl2, filtered, 
washing the solid with CH2Cl2. The filtrate was concentrated under reduced pressure and 
purified by chromatography on SiO2 (EtOAc/hexanes, 2:8) to give 4.29 (0.021 g, 74%) as a 
colorless film: Rf = 0.45 (EtOAc/hexanes, 2:8); IR (CDCl3) 3090, 2849, 2229, 2102, 1696, 1681, 
1597, 1459, 1286, 1219, 1089, 762 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 10.2 (s, 1 H), 8.1 (d, 1 
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H, J = 1.2 Hz), 7.75 (d, 1 H, J = 1.6 Hz), 7.60 (dd, 1 H, J = 2.0, 8.0 Hz), 7.54 (dd, 1 H, J = 1.6, 
8.4 Hz), 7.44 (d, 1 H, J = 8.4 Hz), 6.72 (d, 1 H, J = 8.4 Hz), 4.49 (d, 2 H); 
13
C NMR (100 MHz, 
CDCl3) δ 189.3, 147.9, 142.1, 138.6, 137.5, 135.9, 133.2, 133.2, 132.2, 127.2, 127.0, 125.9, 
117.3, 109.0, 52.2; HRMS (ESI) [M-N2+H] m/z calcd for C15H10N2OSBr 344.9697, found 
344.9714. 
 
 
(11E,23E)-8,20-Dibromo-10H,22H-
tetrabenzo[b,g,j,o][1,9]dithia[5,13]diazacyclohexadecine-2,14-dicarbonitrile (4.31). To a 
stirred solution of 4.29 (0.0200 g, 0.0534 mmol, 1 equiv) in THF (2 mL) was added DPPE 
(0.0427 g, 0.107 mmol, 2 equiv).  The reaction mixture was stirred at rt for 18 h, diluted with 
EtOAc, washed with 1 M KOH, dried (MgSO4), filtered, and concentrated under reduced 
pressure.  The crude mixture was purified by chromatography on SiO2 (0.5% MeOH/CH2Cl2) to 
give 4.31 (0.0134 g, 76%) as a white solid: Rf = 0.23 (0.5% MeOH/CH2Cl2); 
1
H NMR (300 
MHz, CDCl3) δ 8.86 (s, 1 H), 7.49 (d, 2 H, J = 1.8 Hz), 7.71 (s, 1 H), 7.58 (dd, 1 H, J = 2.1, 8.4 
Hz), 7.42 (dd, 1 H, J = 1.8, 8.4 Hz), 7.33 (d, 1 H, J = 8.4 Hz), 6.86 (d, 1 H, 8.4 Hz), 4.83 (s, 2 H); 
HRMS (ESI) [(M+2H2O)/2+H] m/z calcd for C15H12N2OSBr 346.9848, found 346.9837. 
 
 
8,20-Dibromo-11,12,23,24-tetrahydro-10H,22H-
tetrabenzo[b,g,j,o][1,9]dithia[5,13]diazacyclohexadecine-2,14-dicarbonitrile (4.32).  To a 
stirred solution of 4.31 (0.0100 g, 0.0304 mmol, 1 equiv) in dry THF (3 mL) was added LiBH4 (2 
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M in THF; 0.0228 mL, 0.0456 mmol, 1.5 equiv).  The reaction mixture was stirred overnight at 
room temperature, quenched sequentially with EtOAc, acetone, and 1 M aqueous HCl. The 
reaction mixture was diluted with EtOAc, washed with 1 M aqueous HCl, dried (MgSO4), 
filtered, and concentrated under reduced pressure.  Analysis of the crude mixture by HRMS 
revealed the presence of 4.32: HRMS (ESI) [(M+H] m/z calcd for C30H23Br2N4S2 660.9731, 
found 660.9723. 
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APPENDIX A 
 
 
Table 34. Crystal data and structure refinement for 2.3 
Identification code  2.3 
Empirical formula  C33H31NO10 
Formula weight  601.59 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 8.4680(10) Å a= 90°. 
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 b = 10.7412(12) Å b= 90°. 
 c = 32.884(4) Å g = 90°. 
Volume 2991.0(6) Å3 
Z 4 
Density (calculated) 1.336 Mg/m3 
Absorption coefficient 0.099 mm-1 
F(000) 1264 
Crystal size 0.35 x 0.08 x 0.04 mm3 
Theta range for data collection 1.99 to 25.00°. 
Index ranges -10<=h<=10, -12<=k<=12, -39<=l<=38 
Reflections collected 20924 
Independent reflections 3015 [R(int) = 0.0642] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3015 / 0 / 401 
Goodness-of-fit on F2 0.896 
Final R indices [I>2sigma(I)] R1 = 0.0371, wR2 = 0.0954 
R indices (all data) R1 = 0.0504, wR2 = 0.1026 
Absolute structure parameter -0.1(12) 
Largest diff. peak and hole 0.173 and -0.157 e.Å-3 
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Table 35. Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2x103) for 2.3.  U(eq) is 
defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
N 1108(3) 7423(2) 8622(1) 31(1) 
C(1) 1683(4) 7095(2) 6681(1) 32(1) 
O(1) -1180(2) 7124(2) 6887(1) 38(1) 
C(2) 257(4) 7823(2) 6819(1) 33(1) 
O(2) 860(3) 5119(2) 7043(1) 36(1) 
C(3) -399(3) 7682(3) 7229(1) 32(1) 
O(3) -834(2) 6171(2) 7757(1) 33(1) 
C(4) 399(3) 6855(3) 7535(1) 28(1) 
O(4) -1670(3) 5901(2) 8392(1) 39(1) 
C(5) 1482(3) 5893(2) 7360(1) 29(1) 
O(5) 1471(3) 6691(2) 6269(1) 42(1) 
C(6) 2092(4) 6006(2) 6948(1) 31(1) 
O(6) 3356(2) 8274(2) 7094(1) 40(1) 
C(7) -826(4) 6431(2) 8157(1) 31(1) 
O(7) 186(3) 9319(2) 8809(1) 51(1) 
C(8) 250(3) 7532(2) 8237(1) 28(1) 
O(8) 1774(3) 8295(2) 9227(1) 48(1) 
C(9) 1253(3) 7655(3) 7855(1) 31(1) 
O(9) 1932(3) 5530(2) 8404(1) 42(1) 
C(10) 3112(4) 7962(3) 6680(1) 36(1) 
O(10) 2904(3) 6306(2) 8988(1) 58(1) 
C(11) 4664(4) 9062(3) 7174(1) 45(1) 
C(12) 3908(4) 10016(3) 7846(1) 38(1) 
C(13) 3851(4) 9993(3) 8266(1) 42(1) 
C(14) 4647(4) 9077(3) 8478(1) 44(1) 
C(15) 5514(4) 8197(3) 8267(1) 45(1) 
C(16) 5577(4) 8221(3) 7847(1) 40(1) 
C(17) 4769(3) 9137(3) 7631(1) 37(1) 
C(18) 972(4) 8430(3) 8890(1) 32(1) 
C(19) 1609(6) 9299(3) 9520(1) 61(1) 
C(20) 1454(6) 7661(4) 10060(1) 66(1) 
C(21) 1759(6) 7239(4) 10447(1) 74(1) 
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C(22) 2618(5) 7946(5) 10710(1) 68(1) 
C(23) 3178(5) 9080(5) 10590(1) 65(1) 
C(24) 2884(5) 9509(4) 10198(1) 58(1) 
C(25) 2010(5) 8800(3) 9933(1) 47(1) 
C(26) 2004(4) 6330(3) 8659(1) 36(1) 
C(27) 3777(5) 5146(3) 9065(1) 67(1) 
C(28) 3040(6) 4558(4) 9771(1) 74(1) 
C(29) 2212(7) 3853(5) 10051(2) 90(2) 
C(30) 1168(7) 2958(4) 9922(2) 95(2) 
C(31) 993(8) 2764(4) 9516(2) 111(2) 
C(32) 1841(7) 3458(4) 9233(2) 92(2) 
C(33) 2881(5) 4365(3) 9360(1) 63(1) 
________________________________________________________________________________ 
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 Table 36. Bond lengths [Å] and angles [°] for 2.3. 
_____________________________________________________  
N-C(18)  1.399(3) 
N-C(26)  1.403(4) 
N-C(8)  1.463(3) 
C(1)-O(5)  1.432(3) 
C(1)-C(6)  1.504(4) 
C(1)-C(2)  1.508(4) 
C(1)-C(10)  1.526(4) 
O(1)-C(3)  1.435(3) 
O(1)-C(2)  1.448(3) 
C(2)-C(3)  1.465(4) 
C(2)-H(2A)  0.9900 
O(2)-C(5)  1.433(3) 
O(2)-C(6)  1.448(3) 
C(3)-C(4)  1.504(4) 
C(3)-H(3A)  0.9900 
O(3)-C(7)  1.344(3) 
O(3)-C(4)  1.471(3) 
C(4)-C(5)  1.497(4) 
C(4)-C(9)  1.539(4) 
O(4)-C(7)  1.197(3) 
C(5)-C(6)  1.456(4) 
C(5)-H(5A)  0.9900 
O(5)-H(5O)  0.87(4) 
C(6)-H(6A)  0.9900 
O(6)-C(11)  1.419(4) 
O(6)-C(10)  1.419(3) 
C(7)-C(8)  1.516(4) 
O(7)-C(18)  1.194(3) 
C(8)-C(9)  1.522(4) 
C(8)-H(8A)  0.9900 
O(8)-C(18)  1.311(3) 
O(8)-C(19)  1.451(4) 
C(9)-H(9A)  0.9800 
C(9)-H(9B)  0.9800 
O(9)-C(26)  1.202(3) 
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C(10)-H(10A)  0.9800 
C(10)-H(10B)  0.9800 
O(10)-C(26)  1.322(3) 
O(10)-C(27)  1.471(4) 
C(11)-C(17)  1.506(4) 
C(11)-H(11A)  0.9800 
C(11)-H(11B)  0.9800 
C(12)-C(13)  1.381(4) 
C(12)-C(17)  1.387(4) 
C(12)-H(12A)  0.9400 
C(13)-C(14)  1.381(4) 
C(13)-H(13A)  0.9400 
C(14)-C(15)  1.384(4) 
C(14)-H(14A)  0.9400 
C(15)-C(16)  1.380(4) 
C(15)-H(15A)  0.9400 
C(16)-C(17)  1.394(4) 
C(16)-H(16A)  0.9400 
C(19)-C(25)  1.499(4) 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(20)-C(25)  1.376(5) 
C(20)-C(21)  1.378(5) 
C(20)-H(20A)  0.9400 
C(21)-C(22)  1.360(6) 
C(21)-H(21A)  0.9400 
C(22)-C(23)  1.365(6) 
C(22)-H(22A)  0.9400 
C(23)-C(24)  1.390(5) 
C(23)-H(23A)  0.9400 
C(24)-C(25)  1.375(5) 
C(24)-H(24A)  0.9400 
C(27)-C(33)  1.492(6) 
C(27)-H(27A)  0.9800 
C(27)-H(27B)  0.9800 
C(28)-C(33)  1.372(5) 
C(28)-C(29)  1.383(7) 
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C(28)-H(28A)  0.9400 
C(29)-C(30)  1.373(7) 
C(29)-H(29A)  0.9400 
C(30)-C(31)  1.358(7) 
C(30)-H(30A)  0.9400 
C(31)-C(32)  1.392(8) 
C(31)-H(31A)  0.9400 
C(32)-C(33)  1.378(6) 
C(32)-H(32A)  0.9400 
C(18)-N-C(26) 129.5(2) 
C(18)-N-C(8) 116.2(2) 
C(26)-N-C(8) 114.3(2) 
O(5)-C(1)-C(6) 110.2(2) 
O(5)-C(1)-C(2) 110.0(2) 
C(6)-C(1)-C(2) 114.3(2) 
O(5)-C(1)-C(10) 106.4(2) 
C(6)-C(1)-C(10) 107.0(2) 
C(2)-C(1)-C(10) 108.6(2) 
C(3)-O(1)-C(2) 61.08(17) 
O(1)-C(2)-C(3) 59.01(17) 
O(1)-C(2)-C(1) 116.8(2) 
C(3)-C(2)-C(1) 121.9(2) 
O(1)-C(2)-H(2A) 115.7 
C(3)-C(2)-H(2A) 115.7 
C(1)-C(2)-H(2A) 115.7 
C(5)-O(2)-C(6) 60.71(17) 
O(1)-C(3)-C(2) 59.90(17) 
O(1)-C(3)-C(4) 119.0(2) 
C(2)-C(3)-C(4) 120.5(2) 
O(1)-C(3)-H(3A) 115.4 
C(2)-C(3)-H(3A) 115.4 
C(4)-C(3)-H(3A) 115.4 
C(7)-O(3)-C(4) 112.2(2) 
O(3)-C(4)-C(5) 106.3(2) 
O(3)-C(4)-C(3) 108.0(2) 
C(5)-C(4)-C(3) 115.1(2) 
O(3)-C(4)-C(9) 105.85(19) 
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C(5)-C(4)-C(9) 111.2(2) 
C(3)-C(4)-C(9) 109.9(2) 
O(2)-C(5)-C(6) 60.16(16) 
O(2)-C(5)-C(4) 117.1(2) 
C(6)-C(5)-C(4) 121.2(2) 
O(2)-C(5)-H(5A) 115.6 
C(6)-C(5)-H(5A) 115.6 
C(4)-C(5)-H(5A) 115.6 
C(1)-O(5)-H(5O) 106(2) 
O(2)-C(6)-C(5) 59.13(16) 
O(2)-C(6)-C(1) 118.2(2) 
C(5)-C(6)-C(1) 121.8(2) 
O(2)-C(6)-H(6A) 115.3 
C(5)-C(6)-H(6A) 115.3 
C(1)-C(6)-H(6A) 115.3 
C(11)-O(6)-C(10) 115.7(2) 
O(4)-C(7)-O(3) 122.0(3) 
O(4)-C(7)-C(8) 128.1(2) 
O(3)-C(7)-C(8) 109.6(2) 
N-C(8)-C(7) 112.7(2) 
N-C(8)-C(9) 116.3(2) 
C(7)-C(8)-C(9) 105.0(2) 
N-C(8)-H(8A) 107.4 
C(7)-C(8)-H(8A) 107.4 
C(9)-C(8)-H(8A) 107.4 
C(18)-O(8)-C(19) 115.4(3) 
C(8)-C(9)-C(4) 104.7(2) 
C(8)-C(9)-H(9A) 110.8 
C(4)-C(9)-H(9A) 110.8 
C(8)-C(9)-H(9B) 110.8 
C(4)-C(9)-H(9B) 110.8 
H(9A)-C(9)-H(9B) 108.9 
O(6)-C(10)-C(1) 105.0(2) 
O(6)-C(10)-H(10A) 110.8 
C(1)-C(10)-H(10A) 110.8 
O(6)-C(10)-H(10B) 110.8 
C(1)-C(10)-H(10B) 110.8 
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H(10A)-C(10)-H(10B) 108.8 
C(26)-O(10)-C(27) 116.6(2) 
O(6)-C(11)-C(17) 105.2(2) 
O(6)-C(11)-H(11A) 110.7 
C(17)-C(11)-H(11A) 110.7 
O(6)-C(11)-H(11B) 110.7 
C(17)-C(11)-H(11B) 110.7 
H(11A)-C(11)-H(11B) 108.8 
C(13)-C(12)-C(17) 121.1(3) 
C(13)-C(12)-H(12A) 119.5 
C(17)-C(12)-H(12A) 119.5 
C(14)-C(13)-C(12) 120.0(3) 
C(14)-C(13)-H(13A) 120.0 
C(12)-C(13)-H(13A) 120.0 
C(13)-C(14)-C(15) 119.5(3) 
C(13)-C(14)-H(14A) 120.2 
C(15)-C(14)-H(14A) 120.2 
C(16)-C(15)-C(14) 120.5(3) 
C(16)-C(15)-H(15A) 119.7 
C(14)-C(15)-H(15A) 119.7 
C(15)-C(16)-C(17) 120.3(3) 
C(15)-C(16)-H(16A) 119.8 
C(17)-C(16)-H(16A) 119.8 
C(12)-C(17)-C(16) 118.5(3) 
C(12)-C(17)-C(11) 120.9(3) 
C(16)-C(17)-C(11) 120.0(3) 
O(7)-C(18)-O(8) 124.4(3) 
O(7)-C(18)-N 121.7(2) 
O(8)-C(18)-N 113.9(2) 
O(8)-C(19)-C(25) 108.2(3) 
O(8)-C(19)-H(19A) 110.0 
C(25)-C(19)-H(19A) 110.0 
O(8)-C(19)-H(19B) 110.0 
C(25)-C(19)-H(19B) 110.0 
H(19A)-C(19)-H(19B) 108.4 
C(25)-C(20)-C(21) 120.6(4) 
C(25)-C(20)-H(20A) 119.7 
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C(21)-C(20)-H(20A) 119.7 
C(22)-C(21)-C(20) 120.3(4) 
C(22)-C(21)-H(21A) 119.9 
C(20)-C(21)-H(21A) 119.9 
C(21)-C(22)-C(23) 120.0(4) 
C(21)-C(22)-H(22A) 120.0 
C(23)-C(22)-H(22A) 120.0 
C(22)-C(23)-C(24) 120.1(4) 
C(22)-C(23)-H(23A) 119.9 
C(24)-C(23)-H(23A) 119.9 
C(25)-C(24)-C(23) 120.1(4) 
C(25)-C(24)-H(24A) 120.0 
C(23)-C(24)-H(24A) 120.0 
C(24)-C(25)-C(20) 119.0(3) 
C(24)-C(25)-C(19) 120.0(3) 
C(20)-C(25)-C(19) 121.0(3) 
O(9)-C(26)-O(10) 125.8(3) 
O(9)-C(26)-N 120.7(3) 
O(10)-C(26)-N 113.6(2) 
O(10)-C(27)-C(33) 109.4(3) 
O(10)-C(27)-H(27A) 109.8 
C(33)-C(27)-H(27A) 109.8 
O(10)-C(27)-H(27B) 109.8 
C(33)-C(27)-H(27B) 109.8 
H(27A)-C(27)-H(27B) 108.2 
C(33)-C(28)-C(29) 121.5(4) 
C(33)-C(28)-H(28A) 119.2 
C(29)-C(28)-H(28A) 119.2 
C(30)-C(29)-C(28) 120.2(5) 
C(30)-C(29)-H(29A) 119.9 
C(28)-C(29)-H(29A) 119.9 
C(31)-C(30)-C(29) 118.8(5) 
C(31)-C(30)-H(30A) 120.6 
C(29)-C(30)-H(30A) 120.6 
C(30)-C(31)-C(32) 121.2(5) 
C(30)-C(31)-H(31A) 119.4 
C(32)-C(31)-H(31A) 119.4 
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C(33)-C(32)-C(31) 120.3(5) 
C(33)-C(32)-H(32A) 119.8 
C(31)-C(32)-H(32A) 119.8 
C(28)-C(33)-C(32) 117.9(5) 
C(28)-C(33)-C(27) 120.4(4) 
C(32)-C(33)-C(27) 121.6(4) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms  
  260 
Table 37. Anisotropic displacement parameters (Å2x103) for 2.3.  The anisotropic displacement factor exponent 
takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
N 39(1)  26(1) 26(1)  1(1) -3(1)  1(1) 
C(1)43(2)  28(1) 24(1)  -1(1) 0(1)  -5(1) 
O(1)36(1)  39(1) 39(1)  1(1) -8(1)  -6(1) 
C(2)38(2)  25(1) 36(2)  4(1) -8(1)  -4(1) 
O(2)50(1)  25(1) 35(1)  -3(1) 0(1)  -5(1) 
C(3)31(2)  28(1) 36(1)  -4(1) -2(1)  2(1) 
O(3)35(1)  34(1) 30(1)  -3(1) 1(1)  -11(1) 
C(4)29(2)  30(1) 26(1)  -1(1) 2(1)  -6(1) 
O(4)44(1)  37(1) 38(1)  3(1) 6(1)  -8(1) 
C(5)36(2)  23(1) 29(1)  1(1) -6(1)  -2(1) 
O(5)60(2)  39(1) 27(1)  -3(1) -2(1)  -11(1) 
C(6)33(2)  26(1) 33(1)  -3(1) 0(1)  1(1) 
O(6)41(1)  46(1) 33(1)  -3(1) 0(1)  -16(1) 
C(7)32(2)  28(1) 32(2)  1(1) 1(1)  2(1) 
O(7)85(2)  33(1) 36(1)  -4(1) -10(1)  15(1) 
C(8)31(1)  26(1) 27(1)  2(1) -2(1)  2(1) 
O(8)66(2)  46(1) 31(1)  -11(1) -13(1)  13(1) 
C(9)33(2)  29(1) 31(1)  -3(1) -1(1)  -4(1) 
O(9)50(1)  31(1) 46(1)  -7(1) -7(1)  9(1) 
C(10)41(2)  34(2) 32(1)  0(1) 3(1)  -2(1) 
O(10)71(2)  45(1) 57(1)  -8(1) -31(1)  19(1) 
C(11)43(2)  48(2) 43(2)  1(1) -2(2)  -18(2) 
C(12)34(2)  31(2) 50(2)  6(1) -9(2)  -6(1) 
C(13)35(2)  41(2) 49(2)  -6(1) 1(2)  -1(2) 
C(14)38(2)  54(2) 41(2)  4(2) -2(2)  -7(2) 
C(15)35(2)  44(2) 57(2)  9(2) -5(2)  -1(2) 
C(16)30(2)  35(2) 56(2)  -5(1) 2(2)  -3(1) 
C(17)29(2)  37(2) 45(2)  0(1) -1(1)  -8(1) 
C(18)41(2)  29(2) 26(1)  3(1) 1(1)  0(1) 
C(19)99(3)  48(2) 36(2)  -17(1) -15(2)  13(2) 
C(20)89(3)  70(3) 40(2)  -7(2) -16(2)  -4(3) 
C(21)102(3)  78(3) 42(2)  4(2) 2(2)  -1(3) 
C(22)68(3)  100(3) 35(2)  0(2) -2(2)  31(3) 
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C(23)53(2)  103(3) 39(2)  -24(2) -13(2)  7(3) 
C(24)53(2)  73(3) 47(2)  -13(2) -5(2)  -2(2) 
C(25)57(2)  52(2) 33(2)  -12(2) -3(2)  10(2) 
C(26)39(2)  30(2) 38(2)  3(1) -1(1)  4(1) 
C(27)75(3)  53(2) 74(2)  -4(2) -31(2)  31(2) 
C(28)74(3)  62(3) 85(3)  -5(2) -28(3)  1(2) 
C(29)91(4)  78(3) 101(4)  1(3) -24(3)  7(3) 
C(30)91(4)  61(3) 133(4)  22(3) -31(4)  2(3) 
C(31)140(5)  50(3) 144(5)  16(3) -65(4)  -25(3) 
C(32)128(5)  45(2) 102(3)  4(2) -64(3)  0(3) 
C(33)70(3)  35(2) 84(3)  -1(2) -41(2)  16(2) 
______________________________________________________________________________ 
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Table 38.   Hydrogen coordinates (x104) and isotropic displacement parameters (Å2x103) for 2.3 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2A) 121 8652 6693 39 
H(3A) -917 8433 7341 38 
H(5A) 2187 5473 7557 35 
H(5O) 830(50) 6060(40) 6278(11) 75(13) 
H(6A) 3153 5644 6903 37 
H(8A) -424 8283 8255 33 
H(9A) 2325 7345 7903 37 
H(9B) 1313 8525 7767 37 
H(10A) 4040 7539 6567 43 
H(10B) 2898 8709 6518 43 
H(11A) 4494 9890 7057 53 
H(11B) 5635 8710 7060 53 
H(12A) 3354 10637 7704 46 
H(13A) 3271 10601 8407 50 
H(14A) 4599 9051 8763 53 
H(15A) 6065 7577 8410 54 
H(16A) 6168 7617 7707 48 
H(19A) 523 9615 9518 73 
H(19B) 2322 9985 9449 73 
H(20A) 861 7166 9880 79 
H(21A) 1372 6460 10531 89 
H(22A) 2827 7653 10974 81 
H(23A) 3763 9571 10772 78 
H(24A) 3283 10285 10115 70 
H(27A) 4824 5340 9175 81 
H(27B) 3918 4688 8809 81 
H(28A) 3727 5183 9864 88 
H(29A) 2365 3986 10330 108 
H(30A) 585 2488 10110 114 
H(31A) 287 2149 9425 133 
H(32A) 1703 3308 8954 110 
________________________________________________________________________________   
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APPENDIX B 
 
Table 39.  Crystal data and structure refinement for 2.37 
Identification code  2.37 
Empirical formula  C21H18Br2O4S2 
Formula weight  558.29 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  Cc 
Unit cell dimensions a = 15.9415(18) Å = 90°. 
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 b = 14.7510(17) Å = 99.907(2)°. 
 c = 9.2139(11) Å  = 90°. 
Volume 2134.4(4) Å3 
Z 4 
Density (calculated) 1.737 Mg/m3 
Absorption coefficient 4.019 mm-1 
F(000) 1112 
Crystal size 0.28 x 0.23 x 0.20 mm3 
Theta range for data collection 1.89 to 32.24°. 
Index ranges -23<=h<=22, -21<=k<=21, -13<=l<=13 
Reflections collected 12944 
Independent reflections 6478 [R(int) = 0.0214] 
Completeness to theta = 32.24° 94.7 %  
Absorption correction multi-scan 
Max. and min. transmission 0.5003 and 0.3991 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6478 / 3 / 275 
Goodness-of-fit on F2 0.668 
Final R indices [I>2sigma(I)] R1 = 0.0304, wR2 = 0.0792 
R indices (all data) R1 = 0.0380, wR2 = 0.0849 
Absolute structure parameter 0.000(6) 
Largest diff. peak and hole 0.832 and -0.304 e.Å-3 
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Table 40.  Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2x103) for 2.37.  U(eq) is 
defined as one third of  the trace of the orthogonalized Uij tensor 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Br(1) 3894(1) 1914(1) 8392(1) 46(1) 
Br(2) -1565(1) 2296(1) 8844(1) 46(1) 
S(1) 3281(1) 3720(1) 10086(1) 34(1) 
S(2) -88(1) 3919(1) 9128(1) 29(1) 
O(1) 1555(1) 3478(1) 10525(2) 33(1) 
O(2) 1757(1) 4484(1) 5024(2) 32(1) 
O(3) 924(1) 5092(1) 7274(2) 27(1) 
O(4) 558(2) 1956(1) 8675(3) 42(1) 
C(1) 4378(2) 3076(2) 8275(3) 30(1) 
C(2) 5016(2) 3162(2) 7432(3) 40(1) 
C(3) 5384(2) 4007(3) 7330(4) 52(1) 
C(4) 5122(2) 4745(2) 8049(5) 52(1) 
C(5) 4482(2) 4655(2) 8883(4) 44(1) 
C(6) 4096(2) 3809(2) 9010(3) 32(1) 
C(7) 2377(2) 3715(2) 8664(3) 27(1) 
C(8) 1570(1) 3583(2) 9223(3) 25(1) 
C(9) 745(1) 3560(2) 8079(3) 24(1) 
C(10) 2377(2) 3840(2) 7230(3) 28(1) 
C(11) 1578(2) 3856(2) 6084(3) 26(1) 
C(12) 821(1) 4186(2) 6778(2) 24(1) 
C(13) 1371(2) 2916(2) 5434(3) 33(1) 
C(14) 1209(2) 2233(2) 6597(3) 35(1) 
C(15) 556(2) 2575(2) 7502(3) 32(1) 
C(16) -1658(2) 3337(2) 7616(3) 33(1) 
C(17) -2406(2) 3430(2) 6597(4) 40(1) 
C(18) -2517(2) 4171(3) 5673(4) 46(1) 
C(19) -1880(2) 4840(2) 5788(4) 42(1) 
C(20) -1140(2) 4749(2) 6816(3) 34(1) 
C(21) -1005(2) 3981(2) 7739(3) 29(1) 
________________________________________________________________________________ 
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Table 41. Bond lengths [Å] and angles [°] for 2.37 
_____________________________________________________  
Br(1)-C(1)  1.891(3) 
Br(2)-C(16)  1.898(3) 
S(1)-C(6)  1.770(3) 
S(1)-C(7)  1.773(2) 
S(2)-C(21)  1.772(3) 
S(2)-C(9)  1.849(2) 
O(1)-C(8)  1.214(3) 
O(2)-C(11)  1.411(3) 
O(2)-H(2O)  0.75(4) 
O(3)-C(12)  1.413(3) 
O(3)-H(3O)  0.71(4) 
O(4)-C(15)  1.415(4) 
O(4)-H(4O)  0.77(2) 
C(1)-C(2)  1.387(4) 
C(1)-C(6)  1.390(4) 
C(2)-C(3)  1.387(5) 
C(2)-H(2A)  0.9400 
C(3)-C(4)  1.377(6) 
C(3)-H(3A)  0.9400 
C(4)-C(5)  1.385(5) 
C(4)-H(4A)  0.9400 
C(5)-C(6)  1.406(4) 
C(5)-H(5A)  0.9400 
C(7)-C(10)  1.334(3) 
C(7)-C(8)  1.480(3) 
C(8)-C(9)  1.538(3) 
C(9)-C(12)  1.534(3) 
C(9)-C(15)  1.558(3) 
C(10)-C(11)  1.508(3) 
C(10)-H(10A)  0.9400 
C(11)-C(13)  1.523(4) 
C(11)-C(12)  1.539(3) 
C(12)-H(12A)  0.9900 
C(13)-C(14)  1.525(4) 
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C(13)-H(13A)  0.9800 
C(13)-H(13B)  0.9800 
C(14)-C(15)  1.528(4) 
C(14)-H(14A)  0.9800 
C(14)-H(14B)  0.9800 
C(15)-H(4O)  1.72(5) 
C(15)-H(15A)  0.9900 
C(16)-C(17)  1.392(4) 
C(16)-C(21)  1.399(4) 
C(17)-C(18)  1.378(5) 
C(17)-H(17A)  0.9400 
C(18)-C(19)  1.407(5) 
C(18)-H(18A)  0.9400 
C(19)-C(20)  1.386(4) 
C(19)-H(19A)  0.9400 
C(20)-C(21)  1.410(4) 
C(20)-H(20A)  0.9400 
C(6)-S(1)-C(7) 99.63(12) 
C(21)-S(2)-C(9) 102.42(11) 
C(11)-O(2)-H(2O) 105(3) 
C(12)-O(3)-H(3O) 110(3) 
C(15)-O(4)-H(4O) 99(5) 
C(2)-C(1)-C(6) 122.1(3) 
C(2)-C(1)-Br(1) 117.4(2) 
C(6)-C(1)-Br(1) 120.5(2) 
C(1)-C(2)-C(3) 118.7(3) 
C(1)-C(2)-H(2A) 120.7 
C(3)-C(2)-H(2A) 120.7 
C(4)-C(3)-C(2) 120.7(3) 
C(4)-C(3)-H(3A) 119.6 
C(2)-C(3)-H(3A) 119.6 
C(3)-C(4)-C(5) 120.3(3) 
C(3)-C(4)-H(4A) 119.9 
C(5)-C(4)-H(4A) 119.9 
C(4)-C(5)-C(6) 120.5(3) 
C(4)-C(5)-H(5A) 119.8 
C(6)-C(5)-H(5A) 119.8 
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C(1)-C(6)-C(5) 117.8(3) 
C(1)-C(6)-S(1) 123.1(2) 
C(5)-C(6)-S(1) 119.1(2) 
C(10)-C(7)-C(8) 120.8(2) 
C(10)-C(7)-S(1) 126.37(19) 
C(8)-C(7)-S(1) 112.83(17) 
O(1)-C(8)-C(7) 121.8(2) 
O(1)-C(8)-C(9) 121.0(2) 
C(7)-C(8)-C(9) 117.2(2) 
C(12)-C(9)-C(8) 110.45(18) 
C(12)-C(9)-C(15) 109.31(19) 
C(8)-C(9)-C(15) 110.30(18) 
C(12)-C(9)-S(2) 113.34(16) 
C(8)-C(9)-S(2) 103.99(15) 
C(15)-C(9)-S(2) 109.34(16) 
C(7)-C(10)-C(11) 123.4(2) 
C(7)-C(10)-H(10A) 118.3 
C(11)-C(10)-H(10A) 118.3 
O(2)-C(11)-C(10) 104.33(19) 
O(2)-C(11)-C(13) 112.4(2) 
C(10)-C(11)-C(13) 111.2(2) 
O(2)-C(11)-C(12) 110.2(2) 
C(10)-C(11)-C(12) 110.06(19) 
C(13)-C(11)-C(12) 108.6(2) 
O(3)-C(12)-C(9) 109.69(18) 
O(3)-C(12)-C(11) 112.19(19) 
C(9)-C(12)-C(11) 107.88(19) 
O(3)-C(12)-H(12A) 109.0 
C(9)-C(12)-H(12A) 109.0 
C(11)-C(12)-H(12A) 109.0 
C(11)-C(13)-C(14) 112.1(2) 
C(11)-C(13)-H(13A) 109.2 
C(14)-C(13)-H(13A) 109.2 
C(11)-C(13)-H(13B) 109.2 
C(14)-C(13)-H(13B) 109.2 
H(13A)-C(13)-H(13B) 107.9 
C(13)-C(14)-C(15) 112.2(2) 
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C(13)-C(14)-H(14A) 109.2 
C(15)-C(14)-H(14A) 109.2 
C(13)-C(14)-H(14B) 109.2 
C(15)-C(14)-H(14B) 109.2 
H(14A)-C(14)-H(14B) 107.9 
O(4)-C(15)-C(14) 106.9(2) 
O(4)-C(15)-C(9) 111.5(2) 
C(14)-C(15)-C(9) 112.6(2) 
O(4)-C(15)-H(4O) 26.4(13) 
C(14)-C(15)-H(4O) 133.0(13) 
C(9)-C(15)-H(4O) 98.5(19) 
O(4)-C(15)-H(15A) 108.6 
C(14)-C(15)-H(15A) 108.6 
C(9)-C(15)-H(15A) 108.6 
H(4O)-C(15)-H(15A) 92.7 
C(17)-C(16)-C(21) 121.8(3) 
C(17)-C(16)-Br(2) 116.9(2) 
C(21)-C(16)-Br(2) 121.4(2) 
C(18)-C(17)-C(16) 120.0(3) 
C(18)-C(17)-H(17A) 120.0 
C(16)-C(17)-H(17A) 120.0 
C(17)-C(18)-C(19) 119.7(3) 
C(17)-C(18)-H(18A) 120.2 
C(19)-C(18)-H(18A) 120.2 
C(20)-C(19)-C(18) 120.1(3) 
C(20)-C(19)-H(19A) 119.9 
C(18)-C(19)-H(19A) 119.9 
C(19)-C(20)-C(21) 120.9(3) 
C(19)-C(20)-H(20A) 119.6 
C(21)-C(20)-H(20A) 119.6 
C(16)-C(21)-C(20) 117.5(2) 
C(16)-C(21)-S(2) 122.2(2) 
C(20)-C(21)-S(2) 119.9(2) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table 42. Anisotropic displacement parameters (Å2x 103) for 2.37.  The anisotropic displacement factor exponent 
takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Br(1)48(1)  30(1) 60(1)  -1(1) 10(1)  -3(1) 
Br(2)42(1)  48(1) 52(1)  6(1) 19(1)  -12(1) 
S(1)26(1)  49(1) 24(1)  0(1) 0(1)  6(1) 
S(2)25(1)  37(1) 28(1)  -6(1) 9(1)  -2(1) 
O(1)34(1)  40(1) 26(1)  5(1) 8(1)  8(1) 
O(2)31(1)  44(1) 21(1)  4(1) 2(1)  -4(1) 
O(3)32(1)  27(1) 23(1)  1(1) 6(1)  -1(1) 
O(4)48(1)  29(1) 56(1)  3(1) 25(1)  -1(1) 
C(1)27(1)  30(1) 34(1)  5(1) 2(1)  2(1) 
C(2)34(1)  44(2) 42(2)  4(1) 10(1)  11(1) 
C(3)37(1)  60(2) 60(2)  21(2) 16(1)  1(1) 
C(4)44(2)  42(2) 70(2)  11(2) 7(2)  -12(1) 
C(5)38(1)  39(1) 51(2)  -1(1) -1(1)  1(1) 
C(6)23(1)  38(1) 32(1)  5(1) -1(1)  2(1) 
C(7)23(1)  32(1) 26(1)  1(1) 2(1)  2(1) 
C(8)24(1)  23(1) 27(1)  1(1) 5(1)  3(1) 
C(9)23(1)  26(1) 25(1)  -3(1) 8(1)  0(1) 
C(10)23(1)  35(1) 25(1)  -1(1) 4(1)  1(1) 
C(11)24(1)  34(1) 22(1)  -1(1) 5(1)  -1(1) 
C(12)22(1)  28(1) 21(1)  -2(1) 3(1)  0(1) 
C(13)31(1)  40(1) 30(1)  -11(1) 10(1)  -2(1) 
C(14)36(1)  28(1) 46(1)  -9(1) 18(1)  -2(1) 
C(15)31(1)  26(1) 41(1)  -7(1) 13(1)  -2(1) 
C(16)28(1)  36(1) 38(1)  -9(1) 13(1)  -6(1) 
C(17)26(1)  46(2) 49(2)  -13(1) 9(1)  -6(1) 
C(18)27(1)  59(2) 50(2)  -10(2) 5(1)  5(1) 
C(19)34(1)  45(2) 50(2)  5(1) 11(1)  9(1) 
C(20)28(1)  32(1) 44(1)  -3(1) 12(1)  3(1) 
C(21)23(1)  34(1) 33(1)  -7(1) 11(1)  -1(1) 
______________________________________________________________________________  
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Table 43.   Hydrogen coordinates (x104) and isotropic displacement parameters (Å2x103) for 2.37. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2O) 1400(30) 4440(30) 4390(40) 40(10) 
H(3O) 1100(20) 5360(30) 6760(40) 35(10) 
H(4O) 170(30) 2140(40) 8990(70) 84(19) 
H(2A) 5195 2658 6941 48 
H(3A) 5817 4076 6763 62 
H(4A) 5378 5313 7974 63 
H(5A) 4306 5162 9368 53 
H(10A) 2903 3923 6917 33 
H(12A) 293 4139 6037 28 
H(13A) 1846 2704 4976 40 
H(13B) 865 2954 4664 40 
H(14A) 1746 2106 7259 42 
H(14B) 1005 1664 6111 42 
H(15A) -14 2565 6873 38 
H(17A) -2834 2988 6539 48 
H(18A) -3016 4229 4969 55 
H(19A) -1956 5350 5167 51 
H(20A) -723 5205 6898 41 
________________________________________________________________________________  
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APPENDIX C 
Selected NMR Spectra: 
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